SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K38/09,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Not Yet Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Completed,,BACTEREMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Unknown status,NCT00493194,"KIDNEY FAILURE, CHRONIC|TRANSPLANTATION|IMMUNOSUPPRESSION|INTERSTITIAL FIBROSIS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Antwerp, Edegem, Antwerp, Belgium|University Hospital Brussels, Brussels (Jette), Brabant, Belgium|University Hospital Gent, Gent, Oost-Vlaanderen, Belgium",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00106,__ABARELIX,5843901,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.8242674387564,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,1416.09,424.98,16.0,13.0,6.0,149.31,373.91,38.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
N[C@@H](Cc1c[nH]cn1)C(=O)O,1,DB00117,__HISTIDINE,3943038,Terminated,,CANCER-RELATED MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N1/38,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,155.1546,92.0,4.0,3.0,1.0,14.67,38.06,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0
N[C@@H](Cc1c[nH]cn1)C(=O)O,1,DB00117,__HISTIDINE,3943038,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N1/38,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,155.1546,92.0,4.0,3.0,1.0,14.67,38.06,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0
N[C@@H](Cc1ccccc1)C(=O)O,1,DB00120,__PHENYLALANINE,3930948,Terminated,,CANCER-RELATED MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,19521.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,165.1891,63.32,3.0,2.0,1.0,17.03,45.12,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccccc1)C(=O)O,1,DB00120,__PHENYLALANINE,3930948,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,19521.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,165.1891,63.32,3.0,2.0,1.0,17.03,45.12,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Completed,NCT01469364,COMPLICATION OF TRANSPLANTED LUNG,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Duke University Medical Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Completed,NCT02178293,PHARYNGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Terminated,,CANCER-RELATED MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
NCCCC[C@H](N)C(=O)O,1,DB00123,__L-LYSINE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,146.1876,89.34,4.0,3.0,0.0,15.84,37.81,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Completed,NCT01332578,INFLUENZA|COMMON COLD,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"BIO-IMAGES Research Ltd., Glasgow, Scotland, United Kingdom",7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Completed,,COLONOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,1,DB00126,__ASCORBIC_ACID,7169381,Completed,,COMMON COLD,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Unknown status,NCT00712205,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Medicine, Bruderholz, Baselland, Switzerland",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,1,DB00146,__CALCIFEDIOL,6582727,Completed,NCT02805907,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Servicio Murciano de Salud, Murcia, Spain",A61K9/4816,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,19.4829462617302,571.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.71,400.6371,40.46,2.0,2.0,3.0,50.32,125.06,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
N[C@@H](CS)C(=O)O,1,DB00151,__CYSTEINE,10478453,Not yet recruiting,NCT03900988,INFLUENZA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,11.0,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.6,121.15799999999999,63.32,3.0,3.0,0.0,11.41,28.22,2.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
N[C@@H](CS)C(=O)O,1,DB00151,__CYSTEINE,10478453,Recruiting,NCT03364218,BRONCHIOLITIS ACUTE,All,up to 2 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carilion Clinic, Roanoke, Virginia, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,11.0,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.6,121.15799999999999,63.32,3.0,3.0,0.0,11.41,28.22,2.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,1,DB00159,__ICOSAPENT,4377526,Recruiting,NCT04505098,COVID19|ATHEROSCLEROSIS|CARDIOVASCULAR DISEASES|UPPER RESPIRATORY TRACT INFECTIONS,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Kaiser Permanente Northern California, Oakland, California, United States",C07C67/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,15.310375983079698,4159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.53,302.45099999999996,37.3,2.0,1.0,0.0,35.93,101.07,13.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Completed,NCT00712647,LUNG CANCER,All,"45 Years to 69 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Completed,NCT00228254,PNEUMONIA|DIARRHEA|ACUTE UPPER RESPIRATORY TRACT INFECTIONS,All,6 Months to 36 Months   (Child),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention,"Tufts University School of Medicine, Boston, Massachusetts, United States|Corporacion Ecuatoriana de Biotecnologia, Quito, Pinchincha, Ecuador",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Withdrawn,NCT01416701,CHRONIC OBSTRUCTIVE LUNG DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hvidovre University Hospital, Department of Respiratory Medicine, Hvidovre, Denmark|Medical Unit, Hvidovre University Hospital, Hvidovre, Denmark",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Unknown status,NCT02507843,BRONCHIECTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shanghai Pulmonary Hospital , Tongji University, Shanghai, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Recruiting,NCT04335786,ACUTE RESPIRATORY DISTRESS SYNDROME|SARS-COV-2|COVID|COVID-19|SEVERE ACUTE RESPIRATORY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Terminated,NCT02058823,HYPOXIA|SLEEP APNEA|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Laboratoire EFCR - Functional Cardio-respiratory Exploration Laboratory, La Tronche, Isère, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00409487,"HYPERTENSION,|OBSTRUCTIVE SLEEP APNEA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Grenoble, Grenoble, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CC(N)Cc1ccccc1,1,DB00182,__AMPHETAMINE,6322819,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,37.22458366701571,874.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.85,135.2062,26.02,1.0,1.0,1.0,16.17,43.71,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Completed,NCT00628225,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"35 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Completed,NCT00365508,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States|Hematology Oncology Associates of Central New York, PC - Northeast Center, East Syracuse, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Nashville General Hospital at Meharry, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Suspended,NCT00701207,PULMONARY SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Recruiting,NCT03315910,SMOKING CESSATION,All,"55 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Southern California, Los Angeles, California, United States|John Muir Health, Walnut Creek, California, United States|WellStar Health System, LaGrange, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Riverside Healthcare, Kankakee, Illinois, United States|St. Mary Medical Center, Community Healthcare System, Crown Point, Indiana, United States|Maine Medical Center Cancer Institute, Scarborough, Maine, United States|NYU Winthrop Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Carolinas Healthcare System Blue Ridge, Morganton, North Carolina, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Legacy Health, Portland, Oregon, United States|Temple University, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Recruiting,NCT03611881,"SMOKING, TOBACCO",All,"55 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Terminated,NCT03110900,"AGITATION,PSYCHOMOTOR|HALOPERIDOL CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LORAZEPAM CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LOXAPINE CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,AGITATION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,"SURGERY, CARDIAC",,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Not Yet Recruiting,,INTRAOPERATIVE AWARENESS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Recruiting,NCT03454217,SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lausanne University Hospital, Lausanne, Vaud, Switzerland",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",A61K9/2081,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Unknown status,NCT03067103,"SLEEP DISORDER; BREATHING-RELATED|PAIN, POSTOPERATIVE|CHILD, ONLY",All,3 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Juliana Alves de Sousa Caixeta, Anápolis, GO, Brazil",A61K9/2081,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02964416,BRAIN NEOPLASM,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aga Khan University, Karachi, Sindh, Pakistan",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2081,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT00841971,"MYCOSES|FUNGEMIA|CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS|LUNG DISEASES, FUNGAL",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","UCLA Medical Cente, Los Angeles, California, United States|University of Miami, Miami, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Terminated,NCT02663674,COCCIDIOIDOMYCOSIS,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix, Phoenix, Arizona, United States|St Josephs Hospital and Medical Center - Center for Liver Disease and Transplantation - Phoenix, Phoenix, Arizona, United States|Mayo Clinic, Phoenix - Infectious Diseases, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale - Infectious Diseases, Scottsdale, Arizona, United States|The University of Arizona - Banner University Medical Center Tucson Campus - Tucson, Tucson, Arizona, United States|Kaiser Permanente Chester Avenue Medical Offices - Pulmonology, Bakersfield, California, United States|Kern Medical Center - Medicine, Bakersfield, California, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|Kaiser Permanente Antelope Valley Medical Offices - Infectious Diseases, Lancaster, California, United States",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Completed,NCT02609399,INFLUENZA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maricopa Integrated Health System, Phoenix, Arizona, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Not yet recruiting,NCT04183725,INFLUENZA IN CHILDREN,All,2 Years to 14 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D309/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Terminated,NCT01690637,INFLUENZA|HUMAN INFLUENZA,All,up to 9 Years   (Child),U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Nacional San Juan de Dios de San Miguel, San Miguel, El Salvador|Hospital Nacional San Juan de Dios de Santa Ana, Santa Ana, El Salvador|Hospital Jose Domingo de Obaldia, David, Panama|Hospital de Especialidades Pediátricas Omar Torrijos Herrera, Panama City, Panama|Hospital Del Nino, Panama City, Panama",C07D309/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Completed,NCT01052961,INFLUENZA|RESPIRATORY TRACT INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Chinese University of Hong Kong, Prince of Wales Hospital and Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hksar, Hong Kong",C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Completed,NCT01248715,INFLUENZA|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jewish Hospital, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Rex Robley VA Medical Center, Louisville, Kentucky, United States|Baptist Hospital East, Louisville, Kentucky, United States",C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Recruiting,NCT04255017,2019-NCOV,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department and Institute of Infectious Disease, Wuhan, Hubei, China",C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Withdrawn,NCT02282384,PULMONARY DISEASE|INFLUENZA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",,C07D309/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,NCT00368342,ASTHMA,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1694,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,NCT00367419,BRONCHIOLITIS OBLITERANS|ACUTE OBLITERATING BRONCHIOLITIS,Male,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Baqiyatallah Medical Sciences University, Tehran, Iran, Islamic Republic of",A61K9/1694,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,PANCREATITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,NCT01402089,NON SMALL-CELL LUNG CANCER|RENAL-CELL CANCER|GASTROINTESTINAL STROMA TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St.Gallen, St.Gallen, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,NCT01466348,COMMON COLD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Common Cold Centre, Cardiff, Wales, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Recruiting,NCT03086473,BPD - BRONCHOPULMONARY DYSPLASIA|APNEA OF PREMATURITY|HEMODYNAMIC INSTABILITY|INTUBATION,All,up to 1 Day   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Hollywood Presbyterian Medical Center, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,NCT00809055,APNEA OF PREMATURITY|INTRAVENTRICULAR HEMORRHAGE|BRAIN INJURY,All,24 Weeks to 30 Weeks   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","St. Louis Children's Hospital, St. Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,"INTUBATION, ENDOTRACHEAL",,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00617305,PULMONARY ARTERIAL HYPERTENSION,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|West Los Angeles Healthcare Center, Los Angeles, California, United States|Harbor - UCLA, Torrance, California, United States|Cleveland Clinic, Ft. Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Orlando Heart Center, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|BACH Cardiology, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical Center, New York, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00862043,PULMONARY HYPERTENSION|VALVULAR HEART DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Universitario Alava, Vitoria, Alava, Spain|Hospital German Trias y Pujol, Badalona, Barcelona, Spain|Hospital de la Santa Creu y San Pau, Barcelona, Barcelon, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital de Galdakao, Galdakao, Vizcaya, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Juan Canalejo, La Coruna, Spain|Hospital de Leon, Leon, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico de Valladolid, Valladolid, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT03431649,PEDIATRIC PULMONARY HYPERTENSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00627965,HIGH ALTITUDE PULMONARY EDEMA|ACUTE MOUNTAIN SICKNESS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01757782,MECONIUM ASPIRATION SYNDROME|PERSISTENT PULMONARY HYPERTENSION OF NEWBORN,All,up to 12 Hours   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"NICU, Pediatrics department, SirTakhtasinhjiGH, Bhavnagar, Gujarat, India",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Unknown status,NCT01449253,PULMONARY HYPERTENSION SECONDARY TO LUNG DISEASE AND/OR HYPOXIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"All India Institute Of Medical Sciences, New Delhi, Delhi, India",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Unknown status,NCT03053739,ASSOCIATED PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr Preksha Dwivedi, Chandigarh, India",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Recruiting,NCT03402191,THALASSEMIA,All,"6 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sherief Abd-Elsalam, Tanta, Egypt",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Withdrawn,NCT00625079,PULMONARY ARTERIAL HYPERTENSION|IDIOPATHIC PULMONARY FIBROSIS|INTERSTITIAL LUNG DISEASE|PULMONARY HYPERTENSION,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","David Geffen School of Medicine UCLA, Los Angeles, California, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Terminated,NCT00133679,"HERNIA, DIAPHRAGMATIC|HYPERTENSION, PULMONARY|HYPOPLASIA, PULMONARY",All,up to 42 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California San Francisco Children's Hospital, San Francisco, California, United States|Children's Memorial Hospital, Chicago, Illinois, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Terminated,NCT02304705,HEART FAILURE WITH REACTIVE PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Kentucky Medical Center, Lexington, Kentucky, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01060020,AORTIC STENOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01800292,"HYPERTENSION, PULMONARY ARTERY|VENTRICULAR DYSFUNCTION, LEFT",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Arizona Medical Center, Tucson, Arizona, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT02378649,PULMONARY HYPERTENSION|MITRAL VALVE SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cardiac Surgical Department, Leviev Heart Center, Ramat Gan, Tel Hashomer, Israel",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01642407,"PULMONARY ARTERIAL HYPERTENSION|HYPERTENSION, PULMONARY",All,1 Year to 17 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan|Shizuoka Children's Hospital, Shizuoka, Japan",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01889966,PULMONARY HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kerckhoff Heart Center, Bad Nauheim, Germany",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT01055405,COPD|PULMONARY HYPERTENSION,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Clinic, Barcelona, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Not yet recruiting,NCT04538976,ACUTE EXACERBATION OF COPD,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bispebjerg University Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00491803,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|PULMONARY HYPERTENSION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital clinic, Barcelona, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Unknown status,NCT01382368,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|IDIOPATHIC PULMONARY FIBROSIS,All,"30 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT03733470,EMPHYSEMA,All,30 Years to 60 Years   (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Iowa, Iowa City, Iowa, United States",C07D487/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,,HIGH ALTITUDE PULMONARY EDEMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1,1,DB00204,__DOFETILIDE,4959366,Completed,,PAROXYSMAL ATRIAL FIBRILLATION,,,,,"FISABIO, Elche, Alicante, Spain",C07D295/192,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,48.0,40.9043306844083,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,441.565,104.81,6.0,2.0,2.0,46.03,113.27,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Unknown status,NCT01661985,URETHRITIS|CERVICITIS|GENITAL MYCOPLASMA INFECTION|CHLAMYDIA TRACHOMATIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00883818,OVERACTIVE BLADDER SYNDROME,Female,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inha University College of Medicine, Inchon, Korea, Republic of|Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of",A61K9/0048,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02677701,CYSTIC FIBROSIS,All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital and Health Center at the University of California San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|The Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Saint Luke's Cystic Fibrosis Center of Idaho, Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Saint Francis Medical Center, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Maine Medical Partners Pediatric Specialty Care, Portland, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|The Minnesota Cystic Fibrosis Center, Minneapolis, Minnesota, United States|Children's Mercy Kansas City, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|Children's Hospital of New York, New York, New York, United States|University of Rochester Medical Center Strong Memorial, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center/Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|Hershey Medical Center Pennsylvania State University, Hershey, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Intermountain Cystic Fibrosis Center, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT00132951,RESPIRATORY TRACT INFECTIONS|CHRONIC BRONCHITIS|PNEUMONIA,All,18 Years to 35 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Québec, Canada",A61K9/0048,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Withdrawn,NCT00245453,"PNEUMONIA, BACTERIAL|BRONCHITIS, CHRONIC",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Western Kentucky Pulmonary Clinic, Louisville, Kentucky, United States|Northshore Research Associates, Slidell, Louisiana, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT00237445,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Sanofi-Aventis, Bridgewater, New Jersey, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT00245440,MAXILLARY SINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01009619,BRONCHIOLITIS OBLITERANS SYNDROME|GRAFT REJECTION|LYMPHOCYTIC BRONCHIOLITIS|RESPIRATORY INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Katholieke Universiteit Leuven and University Hospital Gasthuisberg, Leuven, Belgium",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00599079,MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT00598962,MYCOBACTERIUM AVIUM COMPLEX,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02414399,PNEUMONIA|DIARRHEA|MALARIA|CO-INFECTION|DEATH|MALNUTRITION,All,1 Month to 59 Months   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kisii Teaching and Referral Hospital, Homa Bay District Hospital, St. Paul's Mission Hospital, Kisii And Homa Bay Counties, Kenya",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02972957,INFLUENZA,All,24 Months to 59 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Medical Research Council unit The Gambia, Banjul, Gambia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Enrolling by invitation,NCT02048007,CHILDHOOD MORTALITY,All,"1 Month and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Proctor Foundation, San Francisco, California, United States|Johns Hopkins University, Baltimore, Maryland, United States|College of Medicine at the University of Malawi, Blantyre, Blantyre, Malawi|The Carter Center, Niger, Niamey, Niger|Kongwa Trachoma Project, Kongwa, Tanzania|London School of Hygiene & Tropical Medicine, London, United Kingdom",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT04481555,COPD|INHALED CORTICOSTEROID|AZITHROMYCIN|COPD EXACERBATION|PNEUMONIA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bispebjerg Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark|Gentofte Hospital, Hellerup, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Næstved-Slagelse-Ringsted Sygehus, Næstved, Denmark|Roskilde Sygehus, Roskilde, Denmark",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02307825,CHRONIC RHINOSINUSITIS|HIGH-RISK PATIENT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT01109160,LYMPHOCYTIC BRONCHI(OLI)TIS POST-LUNG TRANSPLANTATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Gasthuisberg, Leuven, Vlaams-Brabant, Belgium",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Recruiting,NCT04319705,"ASTHMA|COPD|EXACERBATION COPD|ASTHMA; EOSINOPHILIC|BRONCHIAL DISEASES|LUNG DISEASES, OBSTRUCTIVE|LUNG DISEASES|IMMUNE SYSTEM DISEASES",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT03485703,BRONCHOPULMONARY DYSPLASIA,All,up to 72 Hours   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT02003911,ASTHMA,All,4 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital at Montefiore, Bronx, New York, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Unknown status,NCT00132860,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Odense University Hospital, Odense, Denmark",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Not yet recruiting,NCT04339270,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospitals of Bordeaux, Bordeaux, France|University Hospitals of Montpellier, Montpellier, France|University Hospitals of Toulouse, Toulouse, France",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Completed,NCT02107274,BRONCHIECTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Respiratory Unit, Taiping Hospital, Taiping, Perak, Malaysia",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Completed,NCT02467621,GASTROINTESTINAL BLEEDING|STRESS ULCERS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark|Dept. of Intensive Care, Århus University Hospital Nørrebrogade, Aarhus, Denmark|Dept. of Intensive Care, Århus University Hospital Skejby, Arhus, Denmark|Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Neurointensive Care, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Intensive Care, Herning Hospital, Herning, Denmark|Dept. of Intensive Care, Hillerød Hospital, Hillerød, Denmark|Dept. of Intensive Care, Hjørring Hospital, Hjørring, Denmark|Dept. of Intensive Care, Holbæk Hospital, Holbæk, Denmark|Dept. of Intensive Care, Holstebro Hospital, Holstebro, Denmark|Dept. of Intensive Care, Køge University Hospital, Køge, Denmark|Dept. of Intensive Care, Nykøbing Falster Sygehus, Nykøbing Falster, Denmark|Dept. of Intensive Care, Randers Hospital, Randers, Denmark|Dept. of Intensive Care, Roskilde Hospital, Roskilde, Denmark|Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark|Dept. of Intensive Care, Vejle Hospital, Vejle, Denmark|Dept. of Intensive Care, Viborg Hospital, Viborg, Denmark|Dept. of Intensive Care, Helsinki University Hospital, Helsinki, Finland|Dept. of Intensive Care, Kuopio University Hospital, Kuopio, Finland|Dept. of Intensive Care, Oulu University Hospital, Oulu, Finland|Dept. of Intensive Care, Tampere University Hospital, Tampere, Finland|Dept. of Intensive Care, Turku University Hospital, Turku, Finland|Dept. of Intensive Care, University Medical Center Groningen, Groningen, Netherlands|Dept. of Intensive Care, Heerlen Hospital, Heerlen, Netherlands|Dept. of Intensive Care, Bergen University Hospital, Bergen, Norway|Dept. of Intensive Care, Akershus University Hospital, Lørenskog, Norway|Dept. of Intensive Care, Oslo University Hospital, Oslo, Norway|Dept. of Intensive Care, Stavanger University Hospital, Stavanger, Norway|Dept. of Intensive Care, Basel University Hospital, Basel, Switzerland|Dept. of Intensive Care, Bern University Hospital, Bern, Switzerland|Dept. of Intensive Care, University Hospital of Wales, Cardiff, United Kingdom",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC,1,DB00213,__PANTOPRAZOLE,4758579,Completed,NCT00307944,ACID REFLUX DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"University Ear, Nose and Throat Specialists, Cincinnati, Ohio, United States",C07D317/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,14.718988069570198,416.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,383.37,86.33,6.0,1.0,3.0,35.17,90.05,7.0,0.0,1.0,0.0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00493038,SINUSITIS|BACTERIAL INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Benedetto del Tronto, Ascoli Piceno, Italy|Esine, Brescia, Italy|Lamezia Terme, Catanzaro, Italy|Cesena, Forlì, Italy|Sestri Ponente, Genova, Italy|Monza, Monza-Brianza, Italy|Comiso, Ragusa, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Bolzano, Italy|Caserta, Italy|Catania, Italy|Catania, Italy|Firenze, Italy|Foggia, Italy|Lecce, Italy|Lecco, Italy|Matera, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Torino, Italy|Treviso, Italy|Udine, Italy",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Terminated,NCT00887276,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Charité - Universitätsmedizin Berlin ,Campus Virchow-Klinikum ,Medizinische Klinik : Infektiologie u. Pneumologie, Berlin, Germany|HELIOS-Klinikum Emil von Behring ,Lungenklinik Heckeshorn, Berlin, Germany|Klinikum der Ruhr Universität , Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Medizinische Klinik III, Bochum, Germany|Medizinische Hochschule Hannover, Abteilung für Pneumologie, Hannover, Germany|Universitätsklinikum-Schleswig-Holstein, Campus Lübeck, Zentralklinikum, MK III, Studienzentrum Pneumologie-Infektiologie-Onkologie,, Lübeck, Germany|Brüderkrankenhaus St. Josef , Innere Abteilung, Paderborn, Germany|Diakoniekrankenhaus Rotenburg gGmbH, Lungenklinik Unterstedt , Zentrum für Pneumologie, Rotenburg, Germany|Universitätsklinikum Ulm Sektion Pneumologie/Klinik für Innere Medizin II, Ulm, Germany",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,Completed,NCT01091493,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Miquel Servet, Zaragoza, Aragon, Spain|Fundacio Clinic Per la Recerca Biomèdica - Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain|Fundació La Fe- Hospital La Fe, Valencia, Comunitat Valenciana, Spain|Hospital Clínica Platón, Barcelona, Spain",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,1,DB00235,__MILRINONE,4313951,Not yet recruiting,NCT04484675,PULMONARY HYPERTENSION DUE TO LEFT HEART DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",,C07D213/75,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,15.4417955194151,576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,211.2194,65.78,3.0,1.0,2.0,21.46,61.14,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,1,DB00235,__MILRINONE,4313951,Completed,NCT03207165,LOW CARDIAC OUTPUT SYNDROME|CARDIOGENIC SHOCK|ACUTE CORONARY SYNDROME|PULMONARY EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",C07D213/75,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,15.4417955194151,576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,211.2194,65.78,3.0,1.0,2.0,21.46,61.14,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,1,DB00243,__RANOLAZINE,6303607,Completed,NCT02133352,PULMONARY HYPERTENSION|DIASTOLIC LEFT VENTRICULAR DYSFUNCTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boston University Medical Center, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,1,DB00243,__RANOLAZINE,6303607,Completed,NCT01721967,HYPERTROPHIC CARDIOMYOPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Duke University Medical Center, Durham, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,1,DB00243,__RANOLAZINE,6303607,Completed,NCT02829034,PULMONARY HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,Active Not Recruiting,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Unknown status,NCT02550080,ALLERGIC CUTANEOUS VASCULITIS|URTICARIA|PSORIASIS|ACNE|BULLOUS SKIN DISEASES|STERILE PUSTULOSIS|LEPROSY|PNEUMOCYSTIS PNEUMONIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China",A61K9/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Withdrawn,,PNEUMOCYSTIS JIROVECII PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,NCT00366067,BRONCHIAL ASTHMA,All,4 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"""Rea"" Rehabilitation Centre, Tbilisi, Georgia",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Unknown status,NCT01661985,URETHRITIS|CERVICITIS|GENITAL MYCOPLASMA INFECTION|CHLAMYDIA TRACHOMATIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Withdrawn,NCT00952861,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Odense University Hospital, Odense, Denmark",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00883818,OVERACTIVE BLADDER SYNDROME,Female,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inha University College of Medicine, Inchon, Korea, Republic of|Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Terminated,NCT02623959,ADVANCED CANCERS|MALIGNANT PLEURAL EFFUSIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01323101,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00170222,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Medisch centrum Alkmaar, Alkmaar, Noord-holland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Unknown status,NCT00857038,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|INFLAMMATION|PULMONARY EMPHYSEMA,All,"41 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical Center Alkmaar, Alkmaar, Noord-Holland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(=O)NCNCCCC[C@H](N)C(=O)O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00256,__LYMECYCLINE,5021407,Unknown status,NCT01661985,URETHRITIS|CERVICITIS|GENITAL MYCOPLASMA INFECTION|CHLAMYDIA TRACHOMATIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,61.76718207766071,141.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.27,602.6328,242.98,13.0,9.0,4.0,62.48,154.51,10.0,1.0,0.0,0.0,1,1,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1
CC(=O)[O-].CC(=O)[O-].[Ca+2],1,DB00258,__CALCIUM_ACETATE,6576665,Completed,,CARDIOVASCULAR EVENTS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,26.2181974989219,5.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.24,158.166,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,1,DB00263,__SULFISOXAZOLE,3962436,Recruiting,,PNEUMOCYSTIS JIROVECII PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.5528039590135,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.14,267.30400000000003,98.22,4.0,2.0,2.0,26.93,67.92,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Withdrawn,NCT00384566,HEART FAILURE|CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alfred Hospital, Melbourne, Victoria, Australia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Recruiting,NCT03566667,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital of Örebro, Örebro, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Enrolling by Invitation,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT02261727,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The George Institute for Global Health, Sydney, New South Wales, Australia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT01769898,BRONCHIECTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT00440960,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment,"Hospital Pompeia, Caxias do Sul, RS, Brazil|Hospital Medianeira, Caxias do Sul, RS, Brazil|General Hospital of Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01990781,"POSTOPERATIVE SORE THROAT, COUGH, HOARSENESS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Koshi, Nepal",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03905837,"LUNG DISEASES|LUNG INFLAMMATION|LUNG INJURY, ACUTE|POSTOPERATIVE COMPLICATIONS",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital Gregorio Maranon, Madrid, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01827020,"NOSE DEFORMITIES, ACQUIRED",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turgut Ozal Medical Center, Malatya, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02952157,SORE THROAT,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03031808,INTUBATION COMPLICATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ostfold Hospital Trust, Moss, Grålum, Ostfold, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03731429,LIDOCAINE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Fernandez, Capital federal, Buenos Aires, Argentina",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01252225,CHRONIC COUGH,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Hospital of South Manchester, Manchester, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,Completed,NCT02714400,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Diego, San Diego, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,Unknown status,NCT02924090,DEPRESSION,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Health Sciences Centre, Winnipeg, Manitoba, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,"Active, not recruiting",NCT02643381,CARDIOPULMONARY ARREST|RESPIRATORY ARREST,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Parkland Hospital, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Withdrawn,NCT03282669,"PAIN, POSTOPERATIVE|OBESITY|RESPIRATORY INSUFFICIENCY",Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Prentice Womens Hospital, Chicago, Illinois, United States",A61K9/5078,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02622022,INTERSTITIAL LUNG DISEASE|DYSPNEA|MORPHINE,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aarhus University Hospital, Aarhus C, Denmark",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Recruiting,NCT03834363,COPD,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wilhelmina Ziekenhuis Assen, Assen, Drenthe, Netherlands|Ommelander Ziekenhuis Groningen, Scheemda, Groningen, Netherlands|Elkerliek Ziekenhuis, Helmond, Noord-Brabant, Netherlands|Noordwest Ziekenhuisgroep Alkmaar, Alkmaar, Noord-Holland, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Noord-Holland, Netherlands|Spaarne Gasthuis, Haarlem, Noord-Holland, Netherlands|Medisch Spectrum Twente, Enschede, Overijssel, Netherlands|Isala Klinieken, Zwolle, Overijssel, Netherlands|Ikazia Ziekenhuis, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02566226,SLEEP APNEA,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Lausanne University Hospital, Lausanne, Switzerland",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Unknown status,NCT03013075,RIGHT VENTRICULAR DYSFUNCTION,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"PGIMER, Chandigarh, India",A61K9/5078,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT00338481,DYSPNEA|LUNG NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Sankt Lukas Hospice, Copenhagen, Hellerup, Denmark",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Recruiting,NCT02856698,ACUTE PULMONARY EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Reina Sofía de Córdoba, Córdoba, Andalucía, Spain|Hospital Comarcal de la Axarquía, Málaga, Andalucía, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Cataluña, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital General Universitario Reina Sofía, Murcia, Spain|Hospital Comarcal de Axarquia, Málaga, Spain",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT01236495,SOLITARY MASS|LUNG DISEASES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02429050,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ciro centre of expertise for chronic organ failure, Horn, Netherlands",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT01740453,RESPIRATORY DEPRESSION|ANESTHESIA MORBIDITY|BLOCK,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre hospitalier La Pitié Salpetriere, Paris, Ile de France, France",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Withdrawn,NCT03302221,LUNG CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the First Hospital of China Medical University, Shenyang, Liaoning, China",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT02523755,PREGNANCY|ATELECTASIS,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Universitair Ziekenhuis Brussel, Jette, Vlaams Brabant, Belgium",C07D211/60,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,"Active, not recruiting",NCT02359175,LUNG NEOPLASMS|PAIN|IMMUNE SUPPRESSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Odense University Hospital, Odense C, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,"Active, not recruiting",NCT03305666,"DRUG EFFECT|RIB FRACTURES|RIB TRAUMA|SURGICAL PROCEDURE, UNSPECIFIED|PAIN; CATHETER (OTHER)|NERVE PAIN|LOCAL INFILTRATION|ANESTHESIA, LOCAL|INTERCOSTAL RIB|OPIOID DEPENDENCE|CHEST INJURY TRAUMA|PNEUMONIA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Denver Health, Denver, Colorado, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02444533,TONSILLECTOMY|TONSILLITIS|POST-OPERATIVE PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02566226,SLEEP APNEA,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Lausanne University Hospital, Lausanne, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT03642457,LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mount Sinai St. Luke's Hospital, New York, New York, United States|Mount Sinai West Hospital, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Unknown status,NCT03013075,RIGHT VENTRICULAR DYSFUNCTION,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"PGIMER, Chandigarh, India",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT03360045,TRANEXAMIC ACID|EPISTAXIS|NASAL PACKING,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Keçiören Training and Research Hospital, Ankara, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Withdrawn,NCT02644473,PULMONARY EMBOLISM|DEEP VEIN THROMBOSIS|STROKE|MYOCARDIAL INFARCTION,All,"50 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,1,DB00303,__ERTAPENEM,5478820,Recruiting,NCT03891433,"URINARY TRACT INFECTIONS|ENTEROBACTERIACEAE INFECTIONS|INFECTION DUE TO ESBL BACTERIA|CARBAPENEM|ESCHERICHIA COLI INFECTION|KLEBSIELLA PNEUMONIAE INFECTION|CLINICAL TRIAL|DRUG RESISTANCE, BACTERIAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,1,DB00303,__ERTAPENEM,5478820,Completed,NCT01723150,"LIVER ABSCESS, PYOGENIC",All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT02244437,"ACUTE MOUNTAIN SICKNESS, BLOOD OXYGEN SATURATION, HEADACHE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Buddha Basnyat, MD, Kathmandu, Nepal",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Terminated,NCT01019980,FEVER,All,2 Years to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de niños ""J. M. de los Rios"", Distrito Metropolitano, Caracas, Venezuela|Ciudad Hospitalaria Enrique Tejera, Valencia, Estado Carabobo, Venezuela",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT03323047,TONSILLITIS,All,3 Years to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Children's Hospital, London, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01721486,TONSILLITIS|AIRWAY OBSTRUCTION|DIFFICULTY SWALLOWING,All,5 Years to 13 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Beaumont Health System, Royal Oak, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Withdrawn,NCT02056678,CHOLECYSTITIS|CHOLELITHIASIS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University Health System, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01783236,LUNG TUMOR,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Weill Cornell Medical College, New York City, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00377364,ASTHMA|RHEUMATIC DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,DB00317,__GEFITINIB,5457105,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,DB00317,__GEFITINIB,5457105,Terminated,NCT02299765,NON-SMALL CELL LUNG CANCER METASTATIC|EGFR ACTIVATING MUTATION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"China West Hospital, Chengdu, Sichuan, China",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,DB00317,__GEFITINIB,5457105,Completed,NCT00608868,NON SMALL CELL LUNG CARCINOMA,All,"19 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Daegu, Korea, Republic of",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,DB00317,__GEFITINIB,5457105,Terminated,NCT00536107,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Taipei, Taiwan",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,DB00317,__GEFITINIB,5457105,Completed,NCT01203917,CAUCASIAN PATIENTS WITH EGFR MUTATION POSITIVE ADVANCED NSCLC,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, ANGERS Cedex 9, France|Research Site, Saint Herblain Cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Edelény, Hungary|Research Site, Győr, Hungary|Research Site, Mosdós, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ancona, Italy|Research Site, Carpi, Italy|Research Site, Livorno, Italy|Research Site, Perugia, Italy|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Trondheim, Norway|Research Site, Gdańsk, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Szczecin, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Lugo, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Basel, Switzerland|Research Site, Chur, Switzerland|Research Site, Rapperswil-Jona, Switzerland|Research Site, Sursee, Switzerland|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Burnley, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Wolverhampton, United Kingdom",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,14.2590196923961,1102.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.02,446.902,68.74,7.0,1.0,4.0,46.11,117.51,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Completed,NCT01760109,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chongqing Red Cross hospital, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Unknown status,NCT01667094,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Alfred Hospital, Melbourne, Victoria, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Recruiting,NCT03891433,"URINARY TRACT INFECTIONS|ENTEROBACTERIACEAE INFECTIONS|INFECTION DUE TO ESBL BACTERIA|CARBAPENEM|ESCHERICHIA COLI INFECTION|KLEBSIELLA PNEUMONIAE INFECTION|CLINICAL TRIAL|DRUG RESISTANCE, BACTERIAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,1,DB00319,__PIPERACILLIN,6207661,Recruiting,NCT03262142,COPD|RESPIRATORY TRACT INFECTIONS|PSEUDOMONAS AERUGINOSA,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Herlev and Gentofte Hospital, Hellerup, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Withdrawn,NCT03282669,"PAIN, POSTOPERATIVE|OBESITY|RESPIRATORY INSUFFICIENCY",Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Prentice Womens Hospital, Chicago, Illinois, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown status,NCT02901288,"TUBERCULOSIS, PULMONARY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Completed,NCT00367913,PULMONARY DISEASES,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Llandough Hospital, Penarth, Vale of Glamorgan, United Kingdom",A61K9/0014,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown Status,,PULMONARY TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0014,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown Status,,REINFECTION PULMONARY TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0014,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01247870,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","North Tees and Hartlepool NHS Trust, Hartlepool, Cleveland, United Kingdom|University Hospitals of Morecambe Bay NHS Trust, Lancaster, Cumbria, United Kingdom|East Sussex Healthcare NHS Trust, Hastings, East Sussex, United Kingdom|Blackpool Teaching Hospitals NHS Trust, Blackpool, Lancashire, United Kingdom|Lancashire Teaching Hospitals NHS Trust, Preston, Lancashire, United Kingdom|Sherwood Forest Hospitals NHS Trust, Sutton-in-Ashfield, Nottinghamshire, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT01415518,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Beijing, Beijing, China|Research Site, Foshan, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Zhongshan, Guangdong, China|Research Site, Haikou, Hainan, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Tangshan, Hebei, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Qingdao, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Tianjin, Tianjin, China|Research Site, Chengdu, China|Research Site, Chongqin, China|Research Site, Da Lian, China|Research Site, Ha'er BING, China|Research Site, Huhehaote, China",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Recruiting,NCT03738917,ACUTE BRONCHITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nova Lloreda Health Center, Badalona, Catalonia, Spain|Martí i Julià Health Center, Badalona, Catalonia, Spain|Balaguer Health Center, Balaguer, Catalonia, Spain|Via Roma Health Centre, Barcelona, Catalonia, Spain|La Marina Health Center, Barcelona, Catalonia, Spain|CAP Passeig Maragall (EAP Camp de l'Arpa), Barcelona, Catalonia, Spain|Cornellà - La Gavarra Health Center, Cornellà De Llobregat, Catalonia, Spain|Pineda de Mar Health Center, Pineda De Mar, Catalonia, Spain|Ca n'OriacHealth Center, Sabadell, Catalonia, Spain|Molí Nou Health Center, Sant Boi De Llobregat, Catalonia, Spain|Singuerlin Health Center, Santa Coloma De Gramenet, Catalonia, Spain|CAP Jaume I, Tarragona, Catalonia, Spain",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Recruiting,NCT04101500,ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT01943552,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"244.2514.86008 Boehringer Ingelheim Investigational Site, Chengdu, China|244.2514.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86007 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86010 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86009 Boehringer Ingelheim Investigational Site, Hangzhou, China|244.2514.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|244.2514.86002 Boehringer Ingelheim Investigational Site, Tianjin, China|244.2514.86011 Boehringer Ingelheim Investigational Site, Wuhan, China|244.2514.86012 Boehringer Ingelheim Investigational Site, Wuhan, China",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT00911651,COPD,All,"40 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antwerp University Hospital, Antwerp, Belgium",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,COLD,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,EXERCISE-INDUCED BRONCHOSPASM,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Not Yet Recruiting,,ASTHMA IN CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,,CANCER OF HEAD AND NECK,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Recruiting,NCT03571126,CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING|LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China|Afﬁliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00337,__PIMECROLIMUS,5912238,Terminated,NCT00124709,ATOPIC DERMATITIS,All,3 Months to 18 Months   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabama Allergy and Asthma Center, Birmingham, Alabama, United States|Northwest Arkansas Pediatric Clinic, P.A., Fayetteville, Arkansas, United States|The Children's Clinic of Jonesboro, Jonesboro, Arkansas, United States|Southern California Research, Mission Viejo, California, United States|Children's Hospital of Orange County, Orange, California, United States|Stanford Dermatology Clinic and Clinical Trials Dept, Redwood City, California, United States|Capital Allergy Respiratory Disease Center, Sacramento, California, United States|Children's Hospital San Diego, San Diego, California, United States|Allergy and Asthma Medical Group of Diablo Valley, Inc./ Clinical Research Division, Walnut Creek, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Dermatology Associates and Research, Coral Gables, Florida, United States|Emerald Coast Clinical Research, Pensacola, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Indiana University Outpatient Clinical Research, Indianapolis, Indiana, United States|Central Kentucky Research Associates, Lexington, Kentucky, United States|Dermatology Specialists, Louisville, Kentucky, United States|Rx R & D, Metarie, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Children's Hospital - Boston, Boston, Massachusetts, United States|Dermatology, PLLC, Ann Arbor, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Central Dermatology, St Louis, Missouri, United States|Skin Specialists, P.C., Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center/Dermatology Section, Lebanon, New Hampshire, United States|Children's Medical Group, Hopewell Junction, New York, United States|Dermatology Associates of St. Luke's - Roosevelt, New York, New York, United States|Calcagno Research and Development, Gresham, Oregon, United States|Oregon Health Science University - Dermatology Dept., Portland, Oregon, United States|The Childrens' Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Clinical Research Center, Nashville, Tennessee, United States|Texas Children's Hospital, BCM, Houston, Texas, United States|Alpine Medical Group, LLC, Salt Lake City, Utah, United States|Granger Medical Clinic, West Valley City, Utah, United States|Virginia Clinical Research, Norfolk, Virginia, United States|Asthma Inc, Seattle, Washington, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,58.9088071623647,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,810.46,158.13,10.0,2.0,4.0,87.79,214.03,6.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT03086070,LARYNGOPHARYNGEAL REFLUX|CHRONIC RHINOSINUSITIS (DIAGNOSIS),All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Terminated,NCT01777854,LARYNGOPHARYNGEAL REFLUX|THROAT PAIN,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,CLOSTRIDIUM DIFFICILE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,FOOD ALLERGY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown status,NCT02901288,"TUBERCULOSIS, PULMONARY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown status,NCT01395654,"HEPATITIS|TUBERCULOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chest Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown Status,,PULMONARY TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown Status,,REINFECTION PULMONARY TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00561717,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02543346,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Biogenics Research Chamber, San Antonio, Texas, United States|Kingston General Hospital, Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01916226,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT03192488,"HYPOXIA, ALTITUDE",All,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Indiana University, Bloomington, Indiana, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ALLERGIES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,PERENNIAL ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
Nc1ccc(C(=O)NCC(=O)O)cc1,1,DB00345,__AMINOHIPPURIC_ACID,4292154,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N27/44747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,194.1873,92.42,4.0,3.0,1.0,19.13,50.82,3.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,1,DB00346,__ALFUZOSIN,4661491,Completed,,BENIGN PROSTATIC HYPERTROPHY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,11.039241052177598,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,389.4488,111.83,8.0,2.0,3.0,42.71,107.11,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],1,DB00355,__AZTREONAM,7214364,Completed,NCT01469364,COMPLICATION OF TRANSPLANTED LUNG,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Duke University Medical Center, Durham, North Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,46.1611121378262,1204.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.04,435.43300000000005,206.03,10.0,3.0,2.0,39.94,102.09,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],1,DB00355,__AZTREONAM,7214364,Unknown status,NCT03158116,TRACHEOSTOMY INFECTION,All,"7 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital Oakland, Oakland, California, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,46.1611121378262,1204.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.04,435.43300000000005,206.03,10.0,3.0,2.0,39.94,102.09,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc([NH3+])n2)C(=O)N1S(=O)(=O)[O-],1,DB00355,__AZTREONAM,7214364,Completed,NCT02894684,CYSTIC FIBROSIS|INFECTION|PSEUDOMONAS,Male,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom",3,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,46.1611121378262,1204.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.04,435.43300000000005,206.03,10.0,3.0,2.0,39.94,102.09,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,1,DB00361,__VINORELBINE,4307100,Completed,NCT01196078,NON SMALL CELL LUNG CANCER,All,70 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taipei, Taiwan",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,1,DB00361,__VINORELBINE,4307100,Completed,NCT01848613,NON-SMALL CELL LUNG CANCER METASTATIC,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Irccs Irst, Meldola (FC), FC, Italy|U.O. Oncologia Ospedale Civile degli Infermi, Faenza, RA, Italy|U.O. Oncologia Ospedale Civile Umberto I, Lugo, RA, Italy|UO Oncologia Medica, Ospedale S.Maria delle Croci, Ravenna, RA, Italy|U.O. Oncologia Ospedale Cervesi, Cattolica, RN, Italy|U.O. Oncologia ed Ematologia Oncologica ULSS 13 MIRANO, Mirano, VE, Italy|U.O. Oncologia Medica ULSS 1 Belluno, Belluno, Italy|U.O. Oncologia Ospedale degli Infermi, Rimini, Italy",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1,1,DB00362,__ANIDULAFUNGIN,5965525,Completed,NCT00841971,"MYCOSES|FUNGEMIA|CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS|LUNG DISEASES, FUNGAL",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","UCLA Medical Cente, Los Angeles, California, United States|University of Miami, Miami, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,52.633524302347,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1140.2369,377.42,17.0,14.0,7.0,122.78,292.29,14.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0
O.O=S(=O)(OC[C@H]1O[C@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O,1,DB00364,__SUCRALFATE,,Completed,NCT00702871,VENTILATOR ASSOCIATED PNEUMONIA|ETIOLOGICAL ORGANISMS|ANTIMICROBIAL DRUG SUSCEPTIBILITY PATTERN|STRESS ULCER PROPHYLAXIS,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.74,1558.67,772.17,35.0,16.0,2.0,107.19,180.03,37.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,1,DB00369,__CIDOFOVIR,5142051,Completed,NCT00205374,RECURRENT RESPIRATORY PAPILLOMATOSIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07F9/6512,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,61.3072137004866,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,279.187,145.68,8.0,4.0,1.0,24.44,60.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
CN1CCN2c3ncccc3Cc3ccccc3C2C1,1,DB00370,__MIRTAZAPINE,5178878,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1
CN1CCN2c3ncccc3Cc3ccccc3C2C1,1,DB00370,__MIRTAZAPINE,5178878,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,1,DB00374,__TREPROSTINIL,5153222,Terminated,NCT00643604,"HYPERTENSION, PULMONARY",All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,1,DB00374,__TREPROSTINIL,5153222,Terminated,NCT00439946,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco (UCSF) Medical Center, San Francisco, California, United States|THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center, New York, New York, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,1,DB00374,__TREPROSTINIL,5153222,Completed,NCT00373360,PULMONARY HYPERTENSION,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Foundation, Cleveland, Ohio, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,1,DB00374,__TREPROSTINIL,5153222,Completed,NCT00058929,PULMONARY ARTERIAL HYPERTENSION|PULMONARY HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|The Rush Heart Institute Center for Pulmonary Heart Disease, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|LDS Hospital, Salt Lake City, Utah, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.770344360253803,26.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.53,390.5131,86.99,5.0,3.0,3.0,45.74,108.0,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Terminated,NCT02058823,HYPOXIA|SLEEP APNEA|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Laboratoire EFCR - Functional Cardio-respiratory Exploration Laboratory, La Tronche, Isère, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CNC[C@H](O)c1cccc(O)c1,1,DB00388,__PHENYLEPHRINE,8173707,Completed,NCT01332578,INFLUENZA|COMMON COLD,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"BIO-IMAGES Research Ltd., Glasgow, Scotland, United Kingdom",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,24.1154849175547,908.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.69,167.205,52.49,3.0,3.0,1.0,18.2,47.25,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,1,DB00394,__BECLOMETHASONE_DIPROPIONATE,5776432,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,37.22458366701571,676.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.69,521.0419999999998,106.97,5.0,1.0,4.0,54.41,134.79,8.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,1,DB00394,__BECLOMETHASONE_DIPROPIONATE,5776432,Completed,NCT00395408,ASTHMA,All,6 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,37.22458366701571,676.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.69,521.0419999999998,106.97,5.0,1.0,4.0,54.41,134.79,8.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Not yet recruiting,NCT02480634,NON-SMALL CELL LUNG CANCER|BONE METASTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00099541,"NON-SMALL-CELL LUNG CANCER|PLEURAL EFFUSION, MALIGNANT",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States|Hembree Cancer Center-St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States|Pacific Cancer Medical Center Inc., Anaheim, California, United States|Bay Area Cancer Research Group, Concord, California, United States|Fresno Hem/Onc Medical Group, Fresno, California, United States|Beaver Med Group, Highland, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Stockton Hem. Onc., Stockton, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Greeley Medical Clinic, Greeley, Colorado, United States|Western Hematology/Oncology, Lakewood, Colorado, United States|Hematology Oncology PC, Stamford, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Gainesville Hematology Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Center for Cancer Care & Research, Lakeland, Florida, United States|Lake Heart & Cancer Center, Leesburg, Florida, United States|Melbourne Internal Medicine Assoc (MIMA) Century Research, Melbourne, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Mid- Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States|Space Coast Medical, Titusville, Florida, United States|Vero Beach Hematology/Oncology, Vero Beach, Florida, United States|Hematology & Oncology of N.E. GA, Athens, Georgia, United States|Augusta Onc. Associates, Augusta, Georgia, United States|Suburban Hematology-Oncology, Snellville, Georgia, United States|Regional Cancer Center, Danville, Illinois, United States|The Cancer Institute at Alexian Brothers, Elk Grove Village, Illinois, United States|Lekha Babu M.D Ltd., Flossmoor, Illinois, United States|Joliet Oncology Hematology Associates, Ltd, Joliet, Illinois, United States|LaGrange Oncology Associates, LaGrange, Illinois, United States|Northwest Medical Specialists, Niles, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Medical Consultants, PC, Muncie, Indiana, United States|Kentuckiana Cancer Center, PLLC, Louisville, Kentucky, United States|W. Kentucky Hematology's Oncology Group, PSC, Paducah, Kentucky, United States|Cabrini Center for Cancer Care, Alexandria, Louisiana, United States|Louisiana Oncology Associates, Lafayette, Louisiana, United States|Hematology and Oncology Specialists, Metairie, Louisiana, United States|Highland Clinic, APMC, Shreveport, Louisiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States|David H. Smith, MD, Chestertown, Maryland, United States|Oncology-Hematology Associates, PA, Clinton, Maryland, United States|Maryland Oncology, Columbia, Maryland, United States|St. Joseph Medical Center, Towson, Maryland, United States|Caritas Holy Family Hospital, Methuen, Massachusetts, United States|Fallon Clinic, Worcester, Massachusetts, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Singh & Arora Hematology/Oncology, Flint, Michigan, United States|Hubert Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Heartland Hematology/Oncology Associates Inc., Kansas City, Missouri, United States|St. Joseph Onocology, Inc., St. Joseph, Missouri, United States|University Hematology Oncology, Inc., St. Louis, Missouri, United States|St. John's Mercy Medical Center, St. Louis, Missouri, United States|Sierra Nevada Oncology Care, Carson City, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|US Oncology, Las Vegas, Nevada, United States|Center For Cancer & Hematologic Disease, Cherry Hill, New Jersey, United States|HOANNJ/Carol G. Simon Cancer Center, Morristown, New Jersey, United States|Medical Hematology/Oncology, Somerset, New Jersey, United States|Hematology-Oncology Associates of CNY, East Syracuse, New York, United States|Huntington Medical Group, Huntington Station, New York, United States|Broome Oncology, Johnson City, New York, United States|Kin Yui Lam, MD, New York, New York, United States|Alamance Regional Medical Ctr. Cancer Ctr., Burlington, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Summa Health System, Akron, Ohio, United States|OHCI, Cincinnati, Ohio, United States|Mukesh Bhatt, MD, Medina, Ohio, United States|Lawrence M. Stallings, MD, LLC, Wooster, Ohio, United States|M. Farouk Kanaa, MD, Inc., Oklahoma City, Oklahoma, United States|Cancer Treatment Center, Tulsa, Oklahoma, United States|Oncology-Hematology of Lehigh Valley PC, Bethlehem, Pennsylvania, United States|Paul V. Woolley MD PC, Johnstown, Pennsylvania, United States|Chester County Hematology/Oncology Services, West Chester, Pennsylvania, United States|South Carolina Oncology Assoc., PA, Columbia, South Carolina, United States|Palmetto Hematology Oncology, P.C, Spartanburg, South Carolina, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|The Family Cancer Center, PLLC, Collierville, Tennessee, United States|McLeod Cancer & Blood Center, Johnson City, Tennessee, United States|Kingsport Hematology-Oncology, Kingsport, Tennessee, United States|Eastern Connecticut Hematology/Oncology, Memphis, Tennessee, United States|Oncology Hematology of South Florida, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|St. Joseph Regional Cancer Ctr., Bryan, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Center for Oncology Research and Treatment, PA, Dallas, Texas, United States|Oncology Consultants P.A., Houston, Texas, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Cancer Outreach, Abingdon, Virginia, United States|Lynchburg Oncology, Lynchburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Oncology/Hematology Association of SW VA, Roanoke, Virginia, United States|Western WA Med. Grp. Oncology, Everett, Washington, United States|Western Washington Oncology, Lacey, Washington, United States|Swedish Health Services, Seattle, Washington, United States|Oncology Alliance, S.C., Glendale, Wisconsin, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Withdrawn,NCT01702415,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Papworth Hospital NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,NCT00612157,OBSTRUCTIVE SLEEP APNEA,All,18 Years to 64 Years   (Adult),U.S. Fed|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Walter Reed Army Medical Center, Washington, District of Columbia, United States",C07D487/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,PANIC DISORDER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,1,DB00408,__LOXAPINE,7537009,Terminated,NCT03110900,"AGITATION,PSYCHOMOTOR|HALOPERIDOL CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LORAZEPAM CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LOXAPINE CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,84.4370520955255,687.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,327.80800000000005,28.07,3.0,0.0,4.0,34.99,95.11,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1,1,DB00408,__LOXAPINE,7537009,Recruiting,NCT02525991,AGITATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ferrer Internacional S.A., Barcelona, Spain",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,84.4370520955255,687.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,327.80800000000005,28.07,3.0,0.0,4.0,34.99,95.11,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Active Not Recruiting,,STAPHYLOCOCCUS AUREUS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,,CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Terminated,NCT00887276,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Charité - Universitätsmedizin Berlin ,Campus Virchow-Klinikum ,Medizinische Klinik : Infektiologie u. Pneumologie, Berlin, Germany|HELIOS-Klinikum Emil von Behring ,Lungenklinik Heckeshorn, Berlin, Germany|Klinikum der Ruhr Universität , Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Medizinische Klinik III, Bochum, Germany|Medizinische Hochschule Hannover, Abteilung für Pneumologie, Hannover, Germany|Universitätsklinikum-Schleswig-Holstein, Campus Lübeck, Zentralklinikum, MK III, Studienzentrum Pneumologie-Infektiologie-Onkologie,, Lübeck, Germany|Brüderkrankenhaus St. Josef , Innere Abteilung, Paderborn, Germany|Diakoniekrankenhaus Rotenburg gGmbH, Lungenklinik Unterstedt , Zentrum für Pneumologie, Rotenburg, Germany|Universitätsklinikum Ulm Sektion Pneumologie/Klinik für Innere Medizin II, Ulm, Germany",C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,NCT00137007,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,NCT04083417,SORE THROAT|TONSILLITIS,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vårdcentralen Rosenhälsan, Jönköping, Sweden|Vårdcentralen Kärna, Linköping, Sweden|Vårdcentralen Lundbergsgatan, Malmö, Sweden|Mariehems hälsocentral, Umeå, Sweden|Ålidhems hälsocentral, Umeå, Sweden|Vårdcentralen Skärvet, Växjö, Sweden",C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Completed,NCT02712307,TONSILLITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alvesta vårdcentral, Alvesta, Sweden|Närhälsan Bollebygd vårdcentral, Bollebygd, Sweden|Capio Citykliniken Bunkeflo Hyllie, Bunkeflostrand, Sweden|Vårdcentralen Tåbelund, Eslöv, Sweden|Närhälsan Fristad vårdcentral, Fristad, Sweden|Vårdcentralen Lessebo, Lessebo, Sweden|Capio Citykliniken Malmö Limhamn, Limhamn, Sweden|Löddeköpinge vårdcentral, Löddeköpinge, Sweden|Vårdcentralen Sorgenfrimottagningen, Malmö, Sweden|Vårdcentralen Lundbergsgatan, Malmö, Sweden|Närhälsan Sandared vårdcentral, Sandared, Sweden|Vårdcentrlaen Sjöbo, Sjöbo, Sweden|Närhälsan Billingen vårdcentral, Skövde, Sweden|Närhälsan Norrmalm vårdcentral, Skövde, Sweden|Närhälsan Södra Ryd, Skövde, Sweden|Vårdcentrlaen Strandbjörket, Växjö, Sweden|Capio vårdcentralen Hovshaga, Växjö, Sweden",C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,,SORE THROAT,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Terminated,NCT02253394,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Brigham & Women's Hospital, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Not yet recruiting,NCT04205136,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","The University of Michigan, Ann Arbor, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Suspended,NCT03344159,"CHRONIC RIGHT-SIDED HEART FAILURE|PULMONARY ARTERIAL HYPERTENSION|PULMONARY HYPERTENSION, PRIMARY, 2|PULMONARY HYPERTENSION, PRIMARY, 3|PULMONARY HYPERTENSION, PRIMARY, 4|CARDIOMYOPATHY RIGHT VENTRICULAR",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Unknown status,NCT01468571,PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Baylor College of Medicine, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Not yet recruiting,NCT04345887,"RESPIRATORY DISTRESS SYNDROME, ADULT",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Istanbul University-Cerrahpaşa, Istanbul, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/585,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2,1,DB00424,__HYOSCYAMINE,4443428,Unknown Status,,BRADYCARDIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2095,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.8813527998521,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.74,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,NCT00086281,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|London Health Sciences Centre, Victoria Campus, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,COGNITION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O,1,DB00438,__CEFTAZIDIME,7112592,Unknown status,NCT01044719,CYSTIC FIBROSIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom",C07D487/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,62.0957309184993,211.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,546.576,191.22,10.0,3.0,4.0,51.06,143.88,9.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O,1,DB00438,__CEFTAZIDIME,7112592,Terminated,NCT00333385,CYSTIC FIBROSIS|PSEUDOMONAS AERUGINOSA|PULMONARY EXACERBATION,All,"8 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Grenoble, Grenoble, France|Centre hospitalier Dr Schaffner, Lens, France|Hopital Albert Calmette, Lille, France|Hopital Jeanne de Flandre, Lille, France|Hopital Sainte Marguerite, Marseille, France|Assistance Publique des hopitaux de paris, Hopital Trousseau, Paris, France|Assistance Publique des Hopitaux de Paris, Hopital Cochin, Paris, France|Assistance Publique des Hopitaux de Paris, Hopital Necker, Paris, France|Assistance Publique des Hopitaux de Paris, Hopital Robert Debré, Paris, France|Hopital Sud, Rennes, France|Centre Héliomarin, Roscoff, France|Hopital Hautepierre, Strasbourg, France|Hopital Foch, Suresnes, France|Hopital Larrey, Toulouse, France|Hopital de Brabois, Vandoeuvre-les-Nancy, France",C07D487/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,62.0957309184993,211.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,546.576,191.22,10.0,3.0,4.0,51.06,143.88,9.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,1,DB00440,__TRIMETHOPRIM,5763449,Completed,NCT01723150,"LIVER ABSCESS, PYOGENIC",All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Terminated,NCT02299765,NON-SMALL CELL LUNG CANCER METASTATIC|EGFR ACTIVATING MUTATION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"China West Hospital, Chengdu, Sichuan, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Not yet recruiting,NCT04331626,NON-SMALL CELL LUNG CANCER METASTATIC,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,"Active, not recruiting",NCT02996214,SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Unknown status,NCT01028729,NON SMALL CELL LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00963573,RHINITIS,All,6 Years to 12 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Unknown status,NCT02978976,NEONATAL RESPIRATORY DISTRESS,Female,28 Years to 38 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","11562, Cairo, Egypt",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Terminated,NCT00295464,RESPIRATORY DISTRESS SYNDROME|INTRAVENTRICULAR HAEMORRHAGE,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Helsinki University Central Hospital, Finland, Helsinki, Finland|Joensuu Central Hospital, Joensuu, Finland|Jyväskylä Central Hospital, Jyväskylä, Finland|Kuopio University Central Hospital, Kuopio, Finland|Lahti Central Hospital, Lahti, Finland|Oulu University Hospital, Oulu, Finland|Central Hospital of Pori, Pori, Finland|Seinäjoki Central Hospital, Seinäjoki, Finland|Tampere University Hospital, Tampere, Finland|Turku Central Hospital, Turku, Finland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00446953,NEONATAL DISTRESS,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Le Parc Centre pour la Mère et l'Enfant, Colmar, France|Centre Hospitalier de Haguenau, Haguenau, France|Hôpital de Hasenrain, Mulhouse, France|Cmco-Sihcus, Schiltigheim, France|Hôpital de Hautepierre, Strasbourg, France",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Unknown status,NCT02278081,RHINITIS|NASAL OBSTRUCTION|GERD,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT00369265,LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States|American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States|Cornell University, Van Lawrence Voice Center, Houston, Texas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT00637416,DYSPHONIA,All,"3 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT00708149,RESPIRATORY FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Far Eastern Memorial Hospital, Taipei, Taiwan",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT00730912,PERENNIAL ALLERGIC RHINITIS,All,"3 Years to 64 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,1,DB00457,__PRAZOSIN,4130647,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,17.380233680363,616.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,383.4011,106.95,7.0,1.0,4.0,40.49,104.5,4.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Recruiting,NCT03467750,OBSTRUCTIVE SLEEP APNEA,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care,"Childrens Healthcare of Atlanta, Atlanta, Georgia, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,1,DB00468,__QUININE,3960559,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",H01L23/291,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,1,DB00469,__TENOXICAM,4636498,Unknown Status,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,16.953120187272805,1159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,337.37,99.6,5.0,2.0,3.0,31.96,83.93,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00534976,EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB),All,4 Years to 14 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00488176,SEASONAL ALLERGIC RHINITIS,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland, Lodz, Poland",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00912171,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,2 Years to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department if Pediatrics, Hospital S. Orsola-Malpighi , University of Bologna, Bologna, Italy",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00092092,BRONCHIAL ASTHMA,All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00295022,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston, Ontario, Canada",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00189475,UPPER RESPIRATORY INFECTIONS,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allegheny General Hospital, Pittsburgh, Pennsylvania, United States",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT01279668,PERSISTENT COUGH|WHOOPING COUGH,All,"16 Years to 49 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Oxford, Oxford, Oxfordshire, United Kingdom",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00406094,RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bernstein Allergy Group, Cincinnati, Ohio, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01211509,BRONCHIOLITIS OBLITERANS|LUNG TRANSPLANTATION|GRAFT REJECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UZ Gasthuisberg, Leuven, Belgium",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00590772,PERENNIAL ALLERGIC RHINITIS,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT03380975,ASTHMA AND ALLERGIC RHINITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dr. Faisal Faiyaz Zuberi, Karachi, Sindh, Pakistan",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT03369119,ACUTE ASTHMA|ACUTE WHEEZY BRONCHITIS,All,6 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Keçiören, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00559546,SEASONAL ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS|ATOPIC ECZEMA|ASTHMA,All,18 Years to 40 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT01121016,NONASTHMATIC EOSINOPHILIC BRONCHITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT01027806,OBSTRUCTIVE SLEEP APNEA,All,2 Years to 10 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00299910,SLEEP DISORDERED BREATHING,All,2 Years to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pediatric Sleep Center, Soroka University Medical Center, Beer-Sheva, Israel",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01618929,BRONCHIAL ASTHMA|FOOD ALLERGY|CHILDREN,All,"6 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cansin Sackesen, Ankara, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01304901,ASTHMA|ACUTE ASTHMA,All,6 Months to 5 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Keçiören, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01147510,PERSISTENT ASTHMA|ELDERLY,All,"60 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ajou University Medical Center, Suwon, Korea, Republic of",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01011452,ACUTE ASTHMA EXACERBATION,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Norfolk and Norwich University Hospital, Norwich, United Kingdom",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00935415,EXERCISE-INDUCED ASTHMA|ASTHMA,All,6 Years to 14 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pediatric Dept Hospital of Bolzano, Bolzano, Italy",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00934713,"LUNG DISEASE, OBSTRUCTIVE|SIGNS AND SYMPTOMS, RESPIRATORY",All,6 Months to 24 Months   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, P.O.Box 160, Finland",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT02655562,COUGH,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mingming Jiang, Beijing, China",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00453765,COUGH|BRONCHIAL HYPERREACTIVITY,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Isala Klinieken, Zwolle, Netherlands",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Active Not Recruiting,,BRONCHIOLITIS ACUTE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,1,DB00474,__METHOHEXITAL,4126684,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,204.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.43,262.3043,66.48,3.0,1.0,1.0,27.4,71.51,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,NCT00445094,INFECTIONS|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Unknown status,NCT02509091,BRONCHIECTASIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,NCT02081963,NON-CYSTIC FIBROSIS BRONCHIECTASIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital of Shandong University, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Unknown Status,,BURN PATIENTS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Recruiting,NCT04147013,CHRONIC RHINOSINUSITIS WITH NASAL POLYPS|ASPIRIN-EXACERBATED RESPIRATORY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Joseph's Healthcare London, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,COLPOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,1,DB00485,__DICLOXACILLIN,4199566,Unknown Status,,BACTEREMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,914.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,470.32599999999996,112.74,5.0,2.0,4.0,42.86,111.44,3.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,1,DB00490,__BUSPIRONE,3976776,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,1,DB00490,__BUSPIRONE,3976776,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1
CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,1,DB00492,__FOSINOPRIL,5006344,Completed,NCT01014338,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royal Brompton Hospital, London, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,9.42935173206841,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.71,563.672,110.21,5.0,1.0,3.0,61.83,149.12,15.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1,1,DB00493,__CEFOTAXIME,WO-2004058695-A1,Completed,NCT01559753,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,C07C303/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,455.465,173.51,9.0,3.0,3.0,41.78,105.11,8.0,0.0,1.0,0.0,1,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Recruiting,NCT03454217,SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lausanne University Hospital, Lausanne, Vaud, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1,1,DB00502,__HALOPERIDOL,3947579,Terminated,NCT03110900,"AGITATION,PSYCHOMOTOR|HALOPERIDOL CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LORAZEPAM CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE|LOXAPINE CAUSING ADVERSE EFFECTS IN THERAPEUTIC USE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.8813527998521,629.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,375.86400000000003,40.54,3.0,1.0,3.0,39.15,102.59,6.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT04252885,CORONAVIRUS INFECTIONS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,1,DB00507,__NITAZOXANIDE,5387598,Recruiting,NCT04406246,CORONAVIRUS INFECTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,9.856465225158619,123.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.14,307.282,114.11,5.0,1.0,2.0,27.54,73.89,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Unknown status,NCT02478710,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Miami Valley Hospital, Dayton, Ohio, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Completed,NCT00445094,INFECTIONS|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Completed,NCT01645735,INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Phoenix, Arizona, United States|Investigational Site, Sylmar, California, United States|Investigational Site, DeLand, Florida, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Kansas City, Kansas, United States|Investigational Site, Royal Oak, Michigan, United States|Investigational Site, Minneapolis, Minnesota, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Omaha, Nebraska, United States|Investigational Site, Laconia, New Hampshire, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Lima, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tbilisi, Georgia|Investigational Site, Matrahaza, Hungary|Investigational Site, Lodz, Poland|Investigational Site, Lublin, Poland|Investigational Site, Wilkowice-Bystra, Poland|Investigational Site, Craiova, Dolj, Romania|Investigational Site, Bucharest, Romania|Investigational Site, Iasi, Romania|Investigational Site, Moscow, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, Yaroslavl, Russian Federation|Investigational Site, Alicante, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Dnipropetrovsk, Ukraine|Investigational Site, Ivano-Frankivsik, Ukraine|Investigational Site, Kharkiv, Ukraine|Investigational Site, Kyiv, Ukraine|Investigational Site, Zaporizhzhya, Ukraine",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Completed,NCT00084266,METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Brandon, Florida, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jackson, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, North Chicago, Illinois, United States|Pfizer Investigational Site, Oak Park, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, New Albany, Indiana, United States|Pfizer Investigational Site, Hazard, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, St. Loius, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Hackensack, New Jersey, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Greensboro, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Sylvania, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Abington, Pennsylvania, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Irving, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Marcos, Texas, United States|Pfizer Investigational Site, Sequin, Texas, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Murray, Utah, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Winchester, Virginia, United States|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Brugge, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Liege 1, Belgium|Pfizer Investigational Site, Salvador, BA, Brazil|Pfizer Investigational Site, Sao Jose do Rio Preto, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Santiago, Región Metropolitana, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Bogota. DC, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Ibague, Tolima, Colombia|Pfizer Investigational Site, Paris, Cedex 18, France|Pfizer Investigational Site, Marseille Cedex 20, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Saint Etienne Cedex 02, France|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Kifisia, Athens, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Crete, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Monterrey/Col. Mitras Centro, Nuevo Léon, Mexico|Pfizer Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Pfizer Investigational Site, Bytom, Poland|Pfizer Investigational Site, Katowice, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Almada, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Senhora da Hora, Portugal|Pfizer Investigational Site, Ponce, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, Moscow, Russia, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Auckland Park, South Africa|Pfizer Investigational Site, Bloefontein, South Africa|Pfizer Investigational Site, Soweto, South Africa|Pfizer Investigational Site, Badalona, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Pan-Chiao, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Recruiting,NCT03738917,ACUTE BRONCHITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nova Lloreda Health Center, Badalona, Catalonia, Spain|Martí i Julià Health Center, Badalona, Catalonia, Spain|Balaguer Health Center, Balaguer, Catalonia, Spain|Via Roma Health Centre, Barcelona, Catalonia, Spain|La Marina Health Center, Barcelona, Catalonia, Spain|CAP Passeig Maragall (EAP Camp de l'Arpa), Barcelona, Catalonia, Spain|Cornellà - La Gavarra Health Center, Cornellà De Llobregat, Catalonia, Spain|Pineda de Mar Health Center, Pineda De Mar, Catalonia, Spain|Ca n'OriacHealth Center, Sabadell, Catalonia, Spain|Molí Nou Health Center, Sant Boi De Llobregat, Catalonia, Spain|Singuerlin Health Center, Santa Coloma De Gramenet, Catalonia, Spain|CAP Jaume I, Tarragona, Catalonia, Spain",A61K47/6903,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Terminated,NCT01257542,"COMMON COLD|INFECTIONS, UPPER RESPIRATORY TRACT",All,6 Years to 11 Years   (Child),Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DMI Research, Pinellas, Florida, United States|Concentrics Center for Research, Indianapolis, Indiana, United States|Cyn3rgy Research, Gresham, Oregon, United States|Clinical Research Associates Incorporated, Nashville, Tennessee, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Completed,NCT02062710,COUGH REFLEX SENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Einstein Division/Montefiore Medical Center, Bronx, New York, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Terminated,NCT02651116,COUGH,All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Avail Clinical Research, LLC, DeLand, Florida, United States|Clinical Associates of Orlando LLC, Orlando, Florida, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States|All Children Pediatrics, Louisville, Kentucky, United States|Bluegrass Clinical Research, Inc, Louisville, Kentucky, United States|MedPharmics, LLC, Metairie, Louisiana, United States|Midwest Children's Health Research Institute, Lincoln, Nebraska, United States|Meridian Clinical Research LLC, Omaha, Nebraska, United States|Rapid Medical Research, Inc, Cleveland, Ohio, United States|Coastal Pediatric Associates, Charleston, South Carolina, United States|Coastal Pediatric Associates, Mount Pleasant, South Carolina, United States|Carolina Ear, Nose & Throat Clinic/CENTRI Inc., Orangeburg, South Carolina, United States|Meridian Clinical Research, LLC, Dakota Dunes, South Dakota, United States|Texas Health Care, PLLC, Fort Worth, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,1,DB00520,__CASPOFUNGIN,5378804,Recruiting,NCT03978559,PNEUMOCYSTIS PNEUMONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MICU of Peking Union Medical College, Beijing, China",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.618513727181202,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,1093.3131,412.03,18.0,16.0,4.0,117.52,278.78,23.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0
CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O,1,DB00520,__CASPOFUNGIN,5378804,Unknown status,NCT01499433,INVASIVE PULMONARY ASPERGILLOSIS|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Institute of Respiratory Diseases, Guangzhou, Guangdong, China",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.618513727181202,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,1093.3131,412.03,18.0,16.0,4.0,117.52,278.78,23.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Terminated,NCT03460678,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"King Hussein Cancer Center (KHCC), Amman, Jordan|American University of Beirut Medical Center, Beirut, Lebanon",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Completed,NCT01402089,NON SMALL-CELL LUNG CANCER|RENAL-CELL CANCER|GASTROINTESTINAL STROMA TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St.Gallen, St.Gallen, Switzerland",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Suspended,NCT01320501,NON-SMALL CELL LUNG CANCER METASTATIC,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"King Abdul Aziz Medical City for National Guard Health Affairs, Riyadh, Saudi Arabia",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Completed,NCT01066884,NON-SQUAMOUS NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Balashikha, Russian Federation|Krasnoyarsk, Russian Federation",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Unknown status,NCT02399566,LUNG ADENOCARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,1,DB00530,__ERLOTINIB,5747498,Completed,NCT04145570,LUNG CANCER,All,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07D491/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Completed,NCT02891915,PNEUMONIA,All,6 Months to 71 Months   (Child),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama - Children's of Alabama - Infectious Diseases/Virology, Birmingham, Alabama, United States|Arkansas Children's Hospital - Infectious Diseases, Little Rock, Arkansas, United States|University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States|Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States|Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Completed,NCT00147914,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1,1,DB00535,__CEFDINIR,4935507,Unknown status,NCT03400735,ACUTE EXACERBATION OF CHRONIC BRONCHITIS|COMMUNITY-ACQUIRED PNEUMONIAE,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erzincan University Mengücek Gazi Training and Research Hospital, Erzincan, Turkey|Yedikule Chest Diseases Training and Research Hospital, İstanbul, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,22.3413211770262,724.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.02,395.414,158.21,8.0,4.0,3.0,36.12,94.34,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT01400750,CYSTIC FIBROSIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of pediatrics, CF center Uuiversity Hospital Leuven, Leuven, Belgium",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Recruiting,NCT03262142,COPD|RESPIRATORY TRACT INFECTIONS|PSEUDOMONAS AERUGINOSA,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Herlev and Gentofte Hospital, Hellerup, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT01723150,"LIVER ABSCESS, PYOGENIC",All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT00367913,PULMONARY DISEASES,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Llandough Hospital, Penarth, Vale of Glamorgan, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,ANTIBIOTIC RESISTANT INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,MENINGOCOCCAL MENINGITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1,1,DB00545,__PYRIDOSTIGMINE,3931205,Unknown Status,,MUSCLE RELAXANTS,,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,1,DB00555,__LAMOTRIGINE,5698226,Completed,NCT00153244,BRONCHIAL ASTHMA,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,18.333025318795,193.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,256.091,90.71,5.0,2.0,2.0,23.1,66.62,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,NAUSEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Terminated,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO,1,DB00558,__ZANAMIVIR,5360817,Completed,NCT00980109,INFLUENZA,All,"20 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Faculty of Medicine Siriraj Hospital, Bangkok, Bangkoknoi, Thailand|Hospital for Tropical Diseases, Bangkok, Thailand",C07D309/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,23.688371424464503,834.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,332.3098,200.72,10.0,7.0,1.0,31.24,76.19,6.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,1,1,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,NCT00323297,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","West Los Angeles VA Healthcare, Pulmonary Hypertension Program, Los Angeles, California, United States|Henry Ford Hospital, Detroit, Michigan, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|St. Vincents Hospital, Darlinghurst, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czech Republic|Institut klinicke a experimentalni mediciny, Klinika kardiologie, Praha 4, Czech Republic|Clinique des Maladies Respiratoires, Lille, France|Hopital Claude Huriez, Lille, France|Hopital Adules Brabois, Vandoeuvre Les Nancy, France|Unfallkrankenhaus Berlin, Klinik fuer Innere Medizin, Berlin, Germany|II. Medizinische Klinik, Kardiologie, Angiologie und Pneumologie, Coburg, Germany|Universitaetsklinikum Essen, Zentrum fuer Innere Medizin, Klinik fuer Kardiologie, Essen, Germany|Universitaetsklinikum Giessen und Marburg GmbH, Standort Giessen, Giessen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum des Saarlandes, Innere Medizin V, Homburg, Germany|Medizinische Klinik und Poliklinik I, Universitaetsklinikum Leipzig, Leipzig, Germany|Med. Klinik u. Poliklinik I der LMU Muenchen, Klinikum Grosshadern, Muenchen, Germany|Praxis fuer Innere Medizin, Kardiologie und Angiologie, Nuernberg, Germany|Missionsaerztliche Klinik Wuerzburg, Gemeinnuetzige Gesellschaft mbH, Wuerzburg, Germany|Attikon Hospital, Haidari, Athens, Greece|Rambam Medical Center, Haifa, Israel|Rabin Medical Centre, Petach Tikva, Israel|Cardiologia, Azienda Ospedaliera Monaldi, Seconda Università di Napoli, Napoli, Italy|Unita' di Ipertensione Polmonare, Dipartimento di Scienze Respiratorie e Cardiovascolari, Roma, Italy|Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan|PVDU, Papworth Everard, Cambridgeshire, United Kingdom",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Unknown status,NCT00637065,PULMONARY HYPERTENSION|INTERSTITIAL LUNG DISEASE|IDIOPATHIC PULMONARY FIBROSIS|NONSPECIFIC INTERSTITIAL PNEUMONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St George's Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Unknown status,NCT01449253,PULMONARY HYPERTENSION SECONDARY TO LUNG DISEASE AND/OR HYPOXIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"All India Institute Of Medical Sciences, New Delhi, Delhi, India",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Withdrawn,NCT00625469,PULMONARY ARTERIAL HYPERTENSION|IDIOPATHIC PULMONARY FIBROSIS,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine UCLA, Los Angeles, California, United States|Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA, Los Angeles, California, United States",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,NCT00266162,EISENMENGER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kinderkardiologie Universitätsklinikum Freiburg, Freiburg, Baden-Wuerttemberg, Germany|Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany|Universitätsklinikum Giessen and Marburg, Giessen, Hesse, Germany|Herz-und Diabeteszentrum NRW, Bad Oeynhausen, North Rhine-Westphalia, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, North Rhine-Westphalia, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg, Halle, Saxony-Anhalt, Germany|Deutsches Herzzentrum Berlin, Berlin, Germany",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,NCT00317486,PULMONARY ARTERIAL HYPERTENSION RELATED TO EISENMENGER PHYSIOLOGY,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"BACH Pulmonary Hypertension Service, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States|Royal Prince Alfred Hospital - Central Clinical School, Camperdown, Australia|The Royal Melbourne Hospital, Victoria, Australia|Universitatsklinikum fur Innere Medizin II, Wien, Austria|UZ Gasthuisberg, Leuven, Belgium|The Peter Lougheed Centre, Calgary, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Hospital Necker-Enfants Malades, Paris, France|Herzzentrum NRW, Bad Oeynhausen, Germany|Deutsches Herzzentrum Munchen, Munchen, Germany|University of Bologna, Bologna, Italy|San Matteo Hospital, Pavia, Italy|Academisch Ziekenhuis Groningen, Groningen, Netherlands|Unidad Medico Quirurgica de Cardiologia - Edificio General, Madrid, Spain|Scottish Vascular Unit - Western Infirmary, Glasgow, United Kingdom|Royal Brompton Hospital, London, United Kingdom",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Unknown status,NCT03053739,ASSOCIATED PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr Preksha Dwivedi, Chandigarh, India",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,NCT00595049,"HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Prince Alfred Hospital, Camperdown, Australia",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Terminated,NCT00679068,PULMONARY HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Respiratory Unit, Fondazione S.Maugeri, Pavia, PV, Italy",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,"SCLERODERMA, SYSTEMIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,1,DB00560,__TIGECYCLINE,RE40183,Recruiting,NCT04489459,TREATMENT OF BLOOD STREAM INFECTIONS DUE TO MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Qasr El Ainy, Cairo, Egypt",C07D333/34,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,33.7091110700425,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.66,585.6487,205.76,11.0,7.0,4.0,61.56,159.34,7.0,1.0,0.0,0.0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,1,DB00560,__TIGECYCLINE,RE40183,Unknown Status,,ANTIBIOTIC RESISTANT INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,33.7091110700425,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.66,585.6487,205.76,11.0,7.0,4.0,61.56,159.34,7.0,1.0,0.0,0.0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0
CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O,1,DB00561,__DOXAPRAM,5811547,Completed,NCT00389909,PREMATURE INFANTS|APNEA,All,up to 3 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Maternite Regionale Universitaire, Nancy, France|Hopital des Enfants, Toulouse, France",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,39.4587157847183,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.65,378.5072,32.78,3.0,0.0,4.0,43.02,112.85,6.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04356118,LEPTOMENINGEAL METASTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04356222,LEPTOMENINGEAL METASTASIS|DURVALUMAB,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT02748785,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Hospital, Seoul, Korea, Republic of",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Skåne University Hospital, Department of Rheumatology, Lund, Skåne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, Göteborg, Västra Götaland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
NC(=O)N1c2ccccc2C=Cc2ccccc21,1,DB00564,__CARBAMAZEPINE,5284662,Completed,NCT00207428,BRONCHIAL ASTHMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.7910840058317,220.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1,236.2686,46.33,1.0,1.0,3.0,25.0,71.89,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,1,DB00565,__CISATRACURIUM,5453510,Completed,NCT03337373,"CRITICAL ILLNESS|RESPIRATORY DISTRESS SYNDROME, ADULT|NEUROMUSCULAR BLOCKADE|RESPIRATORY FAILURE|PARALYSIS|ARDS, HUMAN",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand",C07D217/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,38.5387790303702,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.41,929.16,126.44,10.0,0.0,6.0,104.19,280.68,26.0,1.0,0.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,0,1
COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC,1,DB00565,__CISATRACURIUM,5453510,Completed,NCT00299650,ARDS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Réanimation polyvalente, Aix en Provence, France|Réanimation Polyvalente, Avignon, France|Hôpital Jean Minjoz - Réanimation médicale, Besancon, France|Hôpital Pellegrin - Réanimation médicale, Bordeaux, France|Réanimation médicale, Brest, France|Réanimation chirurgicale, Clermont-Ferrand, France|Hôpital de la Tronche - Réanimation médicale, Grenoble, France|Hôpital de la croix rousse - Réanimation médicale, Lyon, France|Hôpital Ambroise Paré - Réanimation, Marseille, France|Hôpital Sainte-Marguerite - Réanimation médicale, Marseille, France|Réanimation Polyvalente - Hôpital Sainte-Marguerite, Marseille, France|Hôpital Nord - Réanimation, Marseille, France|Réanimation chirurgicale, Montpellier, France|Réanimation médicale, Nice, France|Réanimation chirurgicale, Nimes, France|Réanimation Médicale, Nimes, France|Hôpital Saint-Louis - Réanimation médicale, Paris, France|Hôpital Pontchaillou - Réanimation médicale, Rennes, France|Hôpital Bellevue - Réanimation Médicale, Saint-Etienne, France|Réanimation polyvalente, Toulon, France",C07D217/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,38.5387790303702,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.41,929.16,126.44,10.0,0.0,6.0,104.19,280.68,26.0,1.0,0.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,1,DB00569,__FONDAPARINUX,,"Active, not recruiting",NCT01727401,MEDICAL PATIENT|THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Marcello Di Nisio, Chieti, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,1508.263,805.48,44.0,19.0,5.0,122.56,255.85,27.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O,1,DB00569,__FONDAPARINUX,,Withdrawn,NCT00377091,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Mary's Medical Center, Duluth, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,1508.263,805.48,44.0,19.0,5.0,122.56,255.85,27.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00570,__VINBLASTINE,3932417,Completed,NCT03092986,"CARCINOMA, NON-SMALL-CELL LUNG",All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Oncology,Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,15409.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,810.9741,154.1,9.0,3.0,9.0,87.46,222.42,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT01070225,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Unviersity of Dundee, Dundee, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Completed,NCT00575523,ARRHYTHMIA|RESPIRATORY ARREST,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Div. of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Unknown status,NCT01075490,SPINAL ANESTHESIA|NEONATES,All,up to 60 Weeks   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHU de Montpellier, Montpellier, France",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,1,DB00582,__VORICONAZOLE,5116844,Recruiting,NCT02283905,BLASTOMYCOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Boniface General Hospital, Winnipeg, Manitoba, Canada",C07D233/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,1,DB00582,__VORICONAZOLE,5116844,Unknown status,NCT02234739,INVASIVE PULMONARY ASPERGILLOSIS|COPD,All,"30 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China",C07D233/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Terminated,NCT01019980,FEVER,All,2 Years to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de niños ""J. M. de los Rios"", Distrito Metropolitano, Caracas, Venezuela|Ciudad Hospitalaria Enrique Tejera, Valencia, Estado Carabobo, Venezuela",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Withdrawn,NCT01257126,UPPER RESPIRATORY INFECTIONS,All,3 Years to 7 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00975195,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","352.2046.61006 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia|352.2046.61001 Boehringer Ingelheim Investigational Site, Glebe, New South Wales, Australia|352.2046.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia|352.2046.61004 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia|352.2046.61003 Boehringer Ingelheim Investigational Site, Toorak Gardens, South Australia, Australia|352.2046.61005 Boehringer Ingelheim Investigational Site, Woodville, South Australia, Australia|352.2046.32002 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32016 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32015 Boehringer Ingelheim Investigational Site, Eupen, Belgium|352.2046.32017 Boehringer Ingelheim Investigational Site, Gilly, Belgium|352.2046.32014 Boehringer Ingelheim Investigational Site, Herentals, Belgium|352.2046.32006 Boehringer Ingelheim Investigational Site, Jambes, Belgium|352.2046.32008 Boehringer Ingelheim Investigational Site, Lebbeke, Belgium|352.2046.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|352.2046.32004 Boehringer Ingelheim Investigational Site, Middelheim, Belgium|352.2046.32010 Boehringer Ingelheim Investigational Site, Montigny-le-Tilleul, Belgium|352.2046.32013 Boehringer Ingelheim Investigational Site, Turnhout, Belgium|352.2046.55005 Boehringer Ingelheim Investigational Site, Goiania, Brazil|352.2046.55002 Boehringer Ingelheim Investigational Site, Goiânia, Brazil|352.2046.55001 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55006 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55003 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|352.2046.35905 Boehringer Ingelheim Investigational Site, Bourgas, Bulgaria|352.2046.35902 Boehringer Ingelheim Investigational Site, Rousse, Bulgaria|352.2046.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35906 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35907 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35908 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35903 Boehringer Ingelheim Investigational Site, Stara Zagora, Bulgaria|352.2046.35909 Boehringer Ingelheim Investigational Site, Veliko Tarnovo, Bulgaria|352.2046.86002 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86003 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86006 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86008 Boehringer Ingelheim Investigational Site, Chongqing, China|352.2046.86001 Boehringer Ingelheim Investigational Site, Guangzhou, China|352.2046.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86005 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86007 Boehringer Ingelheim Investigational Site, Wuhan, China|352.2046.45001 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|352.2046.45003 Boehringer Ingelheim Investigational Site, København NV, Denmark|352.2046.45002 Boehringer Ingelheim Investigational Site, Odense C, Denmark|352.2046.3317A Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317B Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317C Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3320A Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320B Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320C Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3335A Boehringer Ingelheim Investigational Site, Clermont Ferrand cedex 1, France|352.2046.3314A Boehringer Ingelheim Investigational Site, Forbach, France|352.2046.3301A Boehringer Ingelheim Investigational Site, Marseille cedex 20, France|352.2046.3333A Boehringer Ingelheim Investigational Site, Marseille, France|352.2046.3326A Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3326C Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3325A Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325C Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325D Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3334A Boehringer Ingelheim Investigational Site, Nantes, France|352.2046.3324A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332B Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332C Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3331A Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331B Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331C Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3329A Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3329B Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3302A Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302B Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302C Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302D Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3336A Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336B Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336C Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3337A Boehringer Ingelheim Investigational Site, Toulouse, France|352.2046.49012 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49020 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49021 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49008 Boehringer Ingelheim Investigational Site, Bochum, Germany|352.2046.49019 Boehringer Ingelheim Investigational Site, Cottbus, Germany|352.2046.49002 Boehringer Ingelheim Investigational Site, Donaustauf, Germany|352.2046.49023 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|352.2046.49013 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49025 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49024 Boehringer Ingelheim Investigational Site, Geesthacht, Germany|352.2046.49022 Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|352.2046.49001 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany|352.2046.49006 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|352.2046.49014 Boehringer Ingelheim Investigational Site, Immenhausen, Germany|352.2046.49016 Boehringer Ingelheim Investigational Site, Kiel, Germany|352.2046.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|352.2046.49004 Boehringer Ingelheim Investigational Site, Mainz, Germany|352.2046.49005 Boehringer Ingelheim Investigational Site, Marburg, Germany|352.2046.49015 Boehringer Ingelheim Investigational Site, München, Germany|352.2046.30003 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30004 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30005 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30007 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30008 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30011 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30012 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30006 Boehringer Ingelheim Investigational Site, Heraklion, Greece|352.2046.30009 Boehringer Ingelheim Investigational Site, Larisa, Greece|352.2046.30001 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.30002 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.36003 Boehringer Ingelheim Investigational Site, Cegled, Hungary|352.2046.36002 Boehringer Ingelheim Investigational Site, Deszk, Hungary|352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary|352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary|352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary|352.2046.36005 Boehringer Ingelheim Investigational Site, Szazhalombatta, Hungary|352.2046.36011 Boehringer Ingelheim Investigational Site, Szigetszentmiklos, Hungary|352.2046.39002 Boehringer Ingelheim Investigational Site, Catania, Italy|352.2046.39007 Boehringer Ingelheim Investigational Site, Cona, Italy|352.2046.39005 Boehringer Ingelheim Investigational Site, Foggia, Italy|352.2046.39003 Boehringer Ingelheim Investigational Site, Modena, Italy|352.2046.39006 Boehringer Ingelheim Investigational Site, Montescano (pv), Italy|352.2046.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|352.2046.39004 Boehringer Ingelheim Investigational Site, Sesto S. Giovanni (mi), Italy|352.2046.39008 Boehringer Ingelheim Investigational Site, Tradate (va), Italy|352.2046.31004 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands|352.2046.31001 Boehringer Ingelheim Investigational Site, Leeuwarden, Netherlands|352.2046.31003 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|352.2046.31002 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands|352.2046.64007 Boehringer Ingelheim Investigational Site, Auckland NZ, New Zealand|352.2046.64003 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand|352.2046.64004 Boehringer Ingelheim Investigational Site, Dunedin, New Zealand|352.2046.64006 Boehringer Ingelheim Investigational Site, Hamilton, New Zealand|352.2046.64001 Boehringer Ingelheim Investigational Site, Newtown Wellington NZ, New Zealand|352.2046.64005 Boehringer Ingelheim Investigational Site, Otahuhu New Zealand, New Zealand|352.2046.64002 Boehringer Ingelheim Investigational Site, Tauranga, New Zealand|352.2046.63001 Boehringer Ingelheim Investigational Site, Caloocan, Philippines|352.2046.63003 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63004 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63009 Boehringer Ingelheim Investigational Site, Muntinlupa, Philippines|352.2046.63006 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63008 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63005 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.63007 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.48006 Boehringer Ingelheim Investigational Site, Bytom, Poland|352.2046.48003 Boehringer Ingelheim Investigational Site, Ostrow Wielkopolska, Poland|352.2046.48001 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48002 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48009 Boehringer Ingelheim Investigational Site, Rzeszow, Poland|352.2046.48011 Boehringer Ingelheim Investigational Site, Tarnowskie Gory, Poland|352.2046.48005 Boehringer Ingelheim Investigational Site, Warsaw, Poland|352.2046.48007 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|352.2046.07011 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|352.2046.07006 Boehringer Ingelheim Investigational Site, Ivanovo, Russian Federation|352.2046.07008 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07009 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07002 Boehringer Ingelheim Investigational Site, Samara, Russian Federation|352.2046.07003 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|352.2046.07001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|352.2046.07004 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.07005 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.27006 Boehringer Ingelheim Investigational Site, Amanzimtoti, South Africa|352.2046.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa|352.2046.27001 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27003 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27007 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|352.2046.27005 Boehringer Ingelheim Investigational Site, Somerset West, South Africa|352.2046.27004 Boehringer Ingelheim Investigational Site, Tygerberg, South Africa|352.2046.34008 Boehringer Ingelheim Investigational Site, Badajoz, Spain|352.2046.34002 Boehringer Ingelheim Investigational Site, Barakaldo (Bilbao), Spain|352.2046.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34004 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34009 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat, Spain|352.2046.34006 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|352.2046.34010 Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón, Spain|352.2046.34013 Boehringer Ingelheim Investigational Site, Salt (Girona), Spain|352.2046.34011 Boehringer Ingelheim Investigational Site, Sevilla, Spain|352.2046.88606 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|352.2046.88604 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|352.2046.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88607 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.88608 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.2161A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2162A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2165A Boehringer Ingelheim Investigational Site, Sfax, Tunisia|352.2046.2164A Boehringer Ingelheim Investigational Site, Sousse, Tunisia|352.2046.2163A Boehringer Ingelheim Investigational Site, Tunis, Tunisia|352.2046.90009 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90019 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90016 Boehringer Ingelheim Investigational Site, Bursa, Turkey|352.2046.90010 Boehringer Ingelheim Investigational Site, Denizli, Turkey|352.2046.90003 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90004 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90006 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90008 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90012 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90017 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90011 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90014 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90018 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90005 Boehringer Ingelheim Investigational Site, Izmit, Turkey|352.2046.90007 Boehringer Ingelheim Investigational Site, Kayseri, Turkey|352.2046.90001 Boehringer Ingelheim Investigational Site, Mersin, Turkey|352.2046.90002 Boehringer Ingelheim Investigational Site, Samsun, Turkey|352.2046.38007 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk, Ukraine|352.2046.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|352.2046.38003 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|352.2046.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38006 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38005 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|352.2046.38001 Boehringer Ingelheim Investigational Site, Vinnytsya, Ukraine|352.2046.44008 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow, United Kingdom|352.2046.44009 Boehringer Ingelheim Investigational Site, Barnsley, United Kingdom|352.2046.44018 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom|352.2046.44010 Boehringer Ingelheim Investigational Site, Birmingham, United Kingdom|352.2046.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom|352.2046.44026 Boehringer Ingelheim Investigational Site, Chertsey, United Kingdom|352.2046.44006 Boehringer Ingelheim Investigational Site, Chesterfield, United Kingdom|352.2046.44012 Boehringer Ingelheim Investigational Site, Cottingham, Hull, United Kingdom|352.2046.44028 Boehringer Ingelheim Investigational Site, Inverness, United Kingdom|352.2046.44016 Boehringer Ingelheim Investigational Site, Isleworth, United Kingdom|352.2046.44002 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|352.2046.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom|352.2046.44017 Boehringer Ingelheim Investigational Site, Norwich, United Kingdom|352.2046.44021 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom|352.2046.44019 Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom|352.2046.44025 Boehringer Ingelheim Investigational Site, Windsor, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00184977,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|LUNG DISEASES, OBSTRUCTIVE|BRONCHITIS, CHRONIC",All,"30 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Department of Family Medicine, University of Maastricht, Maastricht, Netherlands|Department of Family Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT01554488,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT02338362,"OCULAR HYPERTENSION|GLAUCOMA, OPEN-ANGLE",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT01845025,PERSISTENT ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Avondale, Arizona, United States|Novartis Investigative Site, North Hollywood, California, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Conyers, Georgia, United States|Novartis Investigative Site, Stone Mountain, Georgia, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Gaithersburg, Maryland, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, North Massapequa, New York, United States|Novartis Investigative Site, Elizabeth City, North Carolina, United States|Novartis Investigative Site, Winston Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oaks, Pennsylvania, United States|Novartis Investigative Site, East Greenwich, Rhode Island, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Saint George, Utah, United States|Novartis Investigative Site, Mequon, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00692978,HEALTHY|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Asthma Lab, Royal Brompton Hospital, London, United Kingdom|Department of Nuclear Medicine, Royal Brompton Hospital, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00864812,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|Inje university Pusan Paik hospital, Busan, Korea, Republic of|Chonbuk national university hospital, Chunbuk, Korea, Republic of|Chungbuk national university hospital, Chungbuk, Korea, Republic of|Chungnam National University Hospital, Chungnam, Korea, Republic of|Keimyung university dongsan medical center, Daegu, Korea, Republic of|Kyungpook national university hospital, Daegu, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Hallym University scared heart hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Hospital, Inchon, Korea, Republic of|Incheon St. Mary's Hospital, Inchon, Korea, Republic of|Inha university Hospital, Inchon, Korea, Republic of|Gyeongsang national university hospital, Jinju, Korea, Republic of|Kyunghee university east-west neo medical center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Boramae Medical Center, Seoul, Korea, Republic of|Ewha womans university mokdong hospital, Seoul, Korea, Republic of|Hanyang University Hospital, Seoul, Korea, Republic of|Inje university Seoul Paik Hospital, Seoul, Korea, Republic of|Kangdong Scared heart Hospital, Seoul, Korea, Republic of|Kangnam St. Mary's Hospital, Seoul, Korea, Republic of|Konkuk university hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kyunghee university medical center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Soonchunhyang University hospital, Seoul, Korea, Republic of|St. Paul's Hospital, Seoul, Korea, Republic of|Ajou university hospital, Suwon, Korea, Republic of|Uijeongbu St. Mary's Hospital, Uijeongbu, Korea, Republic of|Wonju Christian Hospital, Wonju, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00995475,COPD,,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT02136875,COPD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Chest Institute, Montreal, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,1,DB00590,__DOXAZOSIN,4188390,Completed,NCT01946035,ALLERGIC RHINITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brian Lipworth, Dundee, United Kingdom",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.8360541284215,320.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,451.4751,112.27,9.0,1.0,5.0,47.17,121.64,4.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,Completed,NCT00084266,METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Newark, Delaware, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Brandon, Florida, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jackson, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Honolulu, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, North Chicago, Illinois, United States|Pfizer Investigational Site, Oak Park, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, New Albany, Indiana, United States|Pfizer Investigational Site, Hazard, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Springfield, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Saint Louis, Missouri, United States|Pfizer Investigational Site, St. Loius, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Reno, Nevada, United States|Pfizer Investigational Site, Hackensack, New Jersey, United States|Pfizer Investigational Site, Albany, New York, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Greensboro, North Carolina, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Fargo, North Dakota, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Sylvania, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Toledo, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Abington, Pennsylvania, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Sioux Falls, South Dakota, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Irving, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Marcos, Texas, United States|Pfizer Investigational Site, Sequin, Texas, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Murray, Utah, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Winchester, Virginia, United States|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Brugge, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Liege 1, Belgium|Pfizer Investigational Site, Salvador, BA, Brazil|Pfizer Investigational Site, Sao Jose do Rio Preto, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Santiago, Región Metropolitana, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, Chile|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Bogota. DC, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Ibague, Tolima, Colombia|Pfizer Investigational Site, Paris, Cedex 18, France|Pfizer Investigational Site, Marseille Cedex 20, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Saint Etienne Cedex 02, France|Pfizer Investigational Site, Goettingen, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Kifisia, Athens, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Crete, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Monterrey/Col. Mitras Centro, Nuevo Léon, Mexico|Pfizer Investigational Site, Ciudad Madero, Tamaulipas, Mexico|Pfizer Investigational Site, Bytom, Poland|Pfizer Investigational Site, Katowice, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Almada, Portugal|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Senhora da Hora, Portugal|Pfizer Investigational Site, Ponce, Puerto Rico|Pfizer Investigational Site, San Juan, Puerto Rico|Pfizer Investigational Site, Moscow, Russia, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Auckland Park, South Africa|Pfizer Investigational Site, Bloefontein, South Africa|Pfizer Investigational Site, Soweto, South Africa|Pfizer Investigational Site, Badalona, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Pan-Chiao, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Plymouth, Devon, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,Completed,NCT00572559,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, North East Atlanta, Georgia, United States|Pfizer Investigational Site, North East Atlanta, Georgia, United States|Pfizer Investigational Site, North East Atlanta, Georgia, United States|Pfizer Investigational Site, Ewa Beach, Hawaii, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Peoria, Illinois, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Cortland Manor, New York, United States|Pfizer Investigational Site, Jamaica, New York, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Morgantown, West Virginia, United States|Pfizer Investigational Site, San Juan, Puerto Rico",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,Unknown status,NCT01805284,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Ghent University Hospital, Ghent, Belgium",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,GASTROESOPHAGEAL REFLUX,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Not yet recruiting,NCT04286503,NOVEL CORONAVIRUS INFECTIOUS DISEASE (COVID-19),All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Recruiting,NCT04331600,COVID-19,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Recruiting,NCT04346667,SARS-COV-2|CORONAVIRUS INFECTION|ASYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Recruiting,NCT04351191,SARS-COV2|SYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Recruiting,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,1,DB00612,__BISOPROLOL,4258062,Completed,NCT02380053,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom",C07D303/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.8156430316844,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,325.443,59.95,5.0,2.0,1.0,38.5,92.15,12.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Completed,NCT00598962,MYCOBACTERIUM AVIUM COMPLEX,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Completed,NCT00598897,MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Unknown Status,,REINFECTION PULMONARY TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,1,DB00618,__DEMECLOCYCLINE,3966922,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT02877485,NASAL OBSTRUCTION,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford Hospital and Clinics, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01420471,SINUSITIS,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","E.N.T. Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Withdrawn,NCT00671541,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Lahey Clinic, Inc, Burlington, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Completed,,URINARY TRACT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,CYSTIC FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT03312413,ANESTHESIA COMPLICATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","China,Chongqing The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02203019,SEPSIS|RESPIRATORY FAILURE|AGITATION,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center, Lubbock, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT03091894,OBSTRUCTIVE SLEEP APNEA OF ADULT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zagazig university, Zagazig, Sharkia, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Not yet recruiting,NCT03892122,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"U.O.C. Otorinolaringoiatria Ospedale Di Barletta, Barletta, BAT, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01344759,"SLEEP APNEA, OBSTRUCTIVE",All,"12 Months to 25 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT03570645,LUNG CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Anesthesiology, the First Hospital of China Medical University, Shenyang, Liaoning, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01158820,SEDATION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT00654511,TONSILLITIS,All,2 Years to 12 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,"Active, not recruiting",NCT01050699,CRITICAL ILLNESS|SLEEP|ACUTE LUNG INJURY|ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Southern Arizona VA Health Care System, Tucson, Arizona, United States|University Medical Center, Tucson, Arizona, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT03394430,INHALATION ANESTHESIA,All,1 Year to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Shanghai Ninth People's Hospital,Affililated to Shanghai Jiaotong University School of Medicine, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Withdrawn,NCT04350086,COVID-19 INFECTION|SARS-COV-2|RESPIRATORY FAILURE|PALLIATIVE SITUATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Limoges, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Terminated,NCT02162433,ADENOTONSILLAR HYPERTROPHY|OBSTRUCTIVE SLEEP APNEA|TONSILLITIS|ADENOIDITIS,All,3 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MEEI, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT02958150,ACUTE RESPIRATORY FAILURE,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Araba University Hospital, Vitoria, Álava, Spain",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02843698,RESTRICTIVE LUNG DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cairo University, Cairo, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01774305,COUGH,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Gangnam severance hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02261727,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The George Institute for Global Health, Sydney, New South Wales, Australia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02115997,WEGENER'S GRANULOMATOSIS OR MICROSCOPIC POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Sir Gangaram Hospital, New Delhi, Delhi, India|Medanta-The Medicity, Gurgaon, Haryana, India|Fortis Memorial Research Instititute, Gurgaon, Haryana, India|Apollo BGS Hospitals, Mysuru, Karnataka, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India|Manipal Hospital, Bangalore, India|St. John's Medical College Hospital; Rheumatology, Bangalore, India|Chanre Rheumatology and Immunology Center and Research, Bangalore, India|MULJIBHAI PATEL UROLOGICAL HOSPITAL; Nephrology, Gujarat, India|Medica Superspeciality Hospital, Kolkata, India|Jasleen Hospital, Nagpur, India|Max Super Speciality Hospital, New Delhi, India|All India Institute of Medical Sciences (AIIMS); Rheumatology, New Delhi, India|Indraprastha Apollo Hospitals; Department of Rheumatology, New Delhi, India|Fortis Hospital, Noida, India|Christian Med Clg & Hspt, Vellore, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04276233,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01042145,CROUP,All,1 Year to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, St. Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02237820,HEART FAILURE|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Terminated,NCT02780479,ASTHMA|STATUS ASTHMATICUS|WHEEZES,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wolfson Children Hospital, Jacksonville, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01241006,ASTHMA|REACTIVE AIRWAY DISEASE,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alameda County Medical Center, Oakland, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04534478,COVID-19 PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT03121690,PNEUMONIA HOSPITAL ACQUIRED,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT02119273,CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Loma Linda Sinus and Allergy Center, Redlands, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT00841802,CHRONIC SINUSITIS|RHINOSINUSITIS|NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03424733,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Holy Name Medical Center, Teaneck, New Jersey, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02330952,PULMONARY DISEASE|CHRONIC OBSTRUCTIVE (MESH),All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Assistance Publique - Hopitaux Paris, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03981081,COPD EXACERBATION ACUTE|MECHANICAL VENTILATION,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Arrazi, Marrakech, Morocco|CHU Ibn Cina, Rabat, Morocco|CHU Tahar Sfar, Mahdia, Tunisia|CHU Fattouma Bourguiba, Monastir, Tunisia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
OC[C@H]1O[C@H](O[C@]2(CO[C@]3(CO[C@]4(CO[C@]5(CO[C@]6(CO[C@]7(CO[C@]8(CO[C@]9(CO[C@]%10(CO[C@]%11(CO[C@]%12(CO[C@]%13(CO[C@]%14(CO[C@]%15(CO[C@]%16(CO[C@]%17(CO[C@]%18(CO[C@]%19(CO[C@]%20(CO[C@]%21(CO[C@]%22(CO[C@]%23(CO[C@]%24(CO[C@]%25(CO[C@]%26(CO[C@]%27(CO[C@]%28(CO[C@]%29(CO[C@]%30(CO[C@]%31(CO[C@]%32(CO[C@]%33(CO[C@]%34(CO[C@]%35(CO[C@]%36(CO[C@]%37(CO[C@]%38(CO)O[C@H](CO)[C@@H](O)[C@@H]%38O)O[C@H](CO)[C@@H](O)[C@@H]%37O)O[C@H](CO)[C@@H](O)[C@@H]%36O)O[C@H](CO)[C@@H](O)[C@@H]%35O)O[C@H](CO)[C@@H](O)[C@@H]%34O)O[C@H](CO)[C@@H](O)[C@@H]%33O)O[C@H](CO)[C@@H](O)[C@@H]%32O)O[C@H](CO)[C@@H](O)[C@@H]%31O)O[C@H](CO)[C@@H](O)[C@@H]%30O)O[C@H](CO)[C@@H](O)[C@@H]%29O)O[C@H](CO)[C@@H](O)[C@@H]%28O)O[C@H](CO)[C@@H](O)[C@@H]%27O)O[C@H](CO)[C@@H](O)[C@@H]%26O)O[C@H](CO)[C@@H](O)[C@@H]%25O)O[C@H](CO)[C@@H](O)[C@@H]%24O)O[C@H](CO)[C@@H](O)[C@@H]%23O)O[C@H](CO)[C@@H](O)[C@@H]%22O)O[C@H](CO)[C@@H](O)[C@@H]%21O)O[C@H](CO)[C@@H](O)[C@@H]%20O)O[C@H](CO)[C@@H](O)[C@@H]%19O)O[C@H](CO)[C@@H](O)[C@@H]%18O)O[C@H](CO)[C@@H](O)[C@@H]%17O)O[C@H](CO)[C@@H](O)[C@@H]%16O)O[C@H](CO)[C@@H](O)[C@@H]%15O)O[C@H](CO)[C@@H](O)[C@@H]%14O)O[C@H](CO)[C@@H](O)[C@@H]%13O)O[C@H](CO)[C@@H](O)[C@@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB00638,__INULIN,,Recruiting,NCT04118010,CYSTIC FIBROSIS|DYSBIOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Emory Clinic, Atlanta, Georgia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-62.0,6179.3581,3038.93,191.0,116.0,38.0,44.7137,1251.4,149.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,1,DB00640,__ADENOSINE,5731296,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Withdrawn,NCT00946166,COMMUNITY ACQUIRED PNEUMONIA|CARDIOVASCULAR RISK FACTORS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Audie L Murphy Memorial Veterans Hospital, San Antonio, Texas, United States",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT01151306,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"45 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nottingham Respiratory Biomedical Research Unit, Nottingham, United Kingdom",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT00680641,COPD|EMPHYSEMA,All,"45 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CRTU University of East Anglia, Norwich, Norfolk, United Kingdom|CRTU Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Terminated,NCT03460678,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"King Hussein Cancer Center (KHCC), Amman, Jordan|American University of Beirut Medical Center, Beirut, Lebanon",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Unknown status,NCT02399566,LUNG ADENOCARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Not yet recruiting,NCT03792503,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xinqiao Hospital of Chongqing, Chongqing, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Recruiting,NCT03768037,ADVANCED NON-SQUAMOUS NSCLC,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Chest Hospital, Beijing, Beijing, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Recruiting,NCT03655834,NON SMALL CELL LUNG CANCER|MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Antoni van Leeuwenhoek, Amsterdam, Netherlands|Maastricht University Medical centre, Maastricht, Netherlands|Radboud university medical centre, Nijmegen, Netherlands|Erasmus University Medical Centre, Rotterdam, Netherlands",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,1,DB00642,__PEMETREXED,5344932,Unknown status,NCT02804646,ADENOCARCINOMA OF LUNG,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui provincial hospital, Hefei, Anhui, China",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Recruiting,NCT04497766,ASTHMA IN CHILDREN,All,2 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"King edward medical university/mayo hospital lahore, Lahore, Punjab, Pakistan",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Withdrawn,NCT02498496,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,1,DB00656,__TRAZODONE,6607748,Completed,NCT04162743,SLEEP APNEA SYNDROMES|CEREBRAL INFARCTION,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chang Gung Memorial Hospital, Keelung, Keelung, Taiwan",A61K9/2059,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,37.651697160105904,222.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.68,371.86400000000003,42.39,4.0,0.0,4.0,40.12,105.88,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,1,DB00656,__TRAZODONE,6607748,Recruiting,NCT02922894,SLEEP APNEA|SPINAL CORD INJURY,All,"18 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,"John D. Dingell VA Medical Center, Detroit, Michigan, United States",A61K9/2059,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,43.0,37.651697160105904,222.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.68,371.86400000000003,42.39,4.0,0.0,4.0,40.12,105.88,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",A61M5/31511,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT01834820,BRONCHIOLITIS,All,2 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Distrito Federal, Mexico",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Terminated,NCT00361452,RSV BRONCHIOLITIS,All,up to 1 Year   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pediatric Ward, Rambam Medical Centre, Haifa, Israel",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,"Active, not recruiting",NCT03228914,ENDOSCOPIC SINUS SURGERY|NASAL POLYPS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT01871857,ACUTE BRONCHIOLITIS,All,6 Weeks to 2 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Le Bonheur Children's Hospital, Memphis, Tennessee, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Unknown status,NCT01664507,"CROUP|EPINEPHRINE, ADMINISTRATION, INHALATION",All,6 Months to 5 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Korea, Republic of",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT01705964,ASTHMA,All,6 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Kosair Children's Hospital, Louisville, Kentucky, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Terminated,NCT00588835,TUMOR,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Groningen, Groningen, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,NCT00999921,BENIGN BREAST DISEASE|FIBROCYSTIC DISEASE OF BREAST|FIBROADENOMA|MASTALGIA,Female,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department of Surgery, Medical College, Kolkata, Kolkata, West Bengal, India",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BENIGN BREAST DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Recruiting,NCT04340557,SARS-COV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Terminated,NCT02416102,COPD|CHRONIC BRONCHITIS,All,"35 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Miami, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00720226,COPD|EMPHYSEMA|CHRONIC BRONCHITIS|SMOKING,All,"40 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT03335904,SLEEP DISORDERED BREATHING|HYPOXIA|RESPIRATION; SLEEP DISORDER|CHEMORECEPTOR APNEA,All,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of British Columbia, Kelowna, British Columbia, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00701428,HYPERTENSION|SLEEP APNEA,All,"50 Years to 69 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skaraborg Hospital, Skoevde, West Gotaland, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,"Active, not recruiting",NCT02696564,EMPHYSEMA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|University of California at San Diego, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Hospitals, Chicago, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|St. Louis University School of Medicine, Saint Louis, Missouri, United States|St. Louis Asthma Clinical Research Center - Washington University School of Medicine, Saint Louis, Missouri, United States|New York University School of Medicine, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at The University of Vermont, Colchester, Vermont, United States|Pacific Northwest Airways - VA Puget Sound Healthcare System, Seattle, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Unknown status,NCT00986713,INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing, Beijing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Completed,,"OBESITY, MORBID",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Completed,,INVASIVE ASPERGILLOSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,NCT02161965,PERMANENT ATRIAL FIBRILLATION|VENOUS THROMBOSIS|PULMONARY EMBOLISM|ANTICOAGULATION TREATMENT AT LEAST > OR = TO 12-MONTH,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University Hospital Angers, Angers, France",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Recruiting,NCT02810704,PULMONARY EMBOLISM|VENOUS THROMBOSIS,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA, Los Angeles, California, United States|Stanford University Hospital, Stanford, California, United States|Arthritis Surgery Research Foundation, South Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|New York University, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State Hershey Med Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lifespan Health, East Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Anderson Orthopaedic Institute (VA), Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Unknown status,NCT02979561,ANGIOGRAPHICALLY CONFIRMED ACUTE MASSIVE PULMONARY EMBOLISM TREATED WITH ENDOVASCULAR MECHANICAL FRAGMENTATION AND THROMBOLYTIC THERAPY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Unknown status,NCT01610141,ATRIAL FIBRILLATION|DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM|HEART VALVE DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of geriatric Cardiology, General Hospital of People's Liberation Army, Beijing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,NCT00511173,ATRIAL FIBRILLATION|PULMONARY EMBOLISM|DEEP VEIN THROMBOSIS,All,"19 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,NCT00365950,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM|DEEP VEIN THROMBOSIS WITH PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Chest Medicine, Llandough Hospital, Cardiff, Wales, United Kingdom|Department of Chest Medicine, Llandough Hospital,, Cardiff, Wales, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT01402089,NON SMALL-CELL LUNG CANCER|RENAL-CELL CANCER|GASTROINTESTINAL STROMA TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St.Gallen, St.Gallen, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT00440960,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment,"Hospital Pompeia, Caxias do Sul, RS, Brazil|Hospital Medianeira, Caxias do Sul, RS, Brazil|General Hospital of Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT02166853,ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Clermont-Ferrand, Clermont-Ferrand, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT01158820,SEDATION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,"Active, not recruiting",NCT01050699,CRITICAL ILLNESS|SLEEP|ACUTE LUNG INJURY|ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Southern Arizona VA Health Care System, Tucson, Arizona, United States|University Medical Center, Tucson, Arizona, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Recruiting,NCT02856698,ACUTE PULMONARY EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Reina Sofía de Córdoba, Córdoba, Andalucía, Spain|Hospital Comarcal de la Axarquía, Málaga, Andalucía, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Cataluña, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital General Universitario Reina Sofía, Murcia, Spain|Hospital Comarcal de Axarquia, Málaga, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Recruiting,NCT04273035,PERIOPERATIVE ANXIETY|PREANESTHETIC MEDICATION|INHALATION ANESTHESIA|AMBULATORY SURGERY|TONSILLECTOMY|CIRCUMCISION|DENTAL CARE,All,1 Year to 8 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitair Ziekenhuis Brussel (UZ Brussel), Jette, Belgium",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Unknown status,NCT03394430,INHALATION ANESTHESIA,All,1 Year to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Shanghai Ninth People's Hospital,Affililated to Shanghai Jiaotong University School of Medicine, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,ANAESTHESIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,"OBESITY, MORBID",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,NCT01559753,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Unknown status,NCT02440828,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Netherlands|Hospital Clinic, Barcelona, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,NCT01844778,CYSTIC FIBROSIS,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Southampton, Hampshire, United Kingdom|Novartis Investigative Site, Penarth, Vale of Glamorgan, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Unknown status,NCT01677403,BRONCHIECTASIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shandong University, Jinan, Shandong, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,,FEVER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00687,__FLUDROCORTISONE,4041055,Withdrawn,,ADRENAL INSUFFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Active Not Recruiting,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,1,DB00695,__FUROSEMIDE,3939713,Completed,NCT00652652,CONGESTIVE HEART FAILURE|CHRONIC HEART FAILURE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G01N30/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,1,DB00695,__FUROSEMIDE,3939713,Completed,NCT02531581,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU de Nice, Nice, France",G01N30/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,1,DB00700,__EPLERENONE,6410524,Completed,NCT03186742,"HYPERTENSION,ESSENTIAL|OBSTRUCTIVE SLEEP APNEA|LEFT VENTRICULAR HYPERTROPHY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
CC(=O)N=c1sc(S(N)(=O)=O)nn1C,1,DB00703,__METHAZOLAMIDE,,Completed,NCT02760121,"ALTITUDE SICKNESS|HYPERTENSION, PULMONARY",Male,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of British Columbia, Kelowna, British Columbia, Canada",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.2,236.26,105.19,6.0,1.0,1.0,20.99,51.3,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0
CC(=O)N=c1sc(S(N)(=O)=O)nn1C,1,DB00703,__METHAZOLAMIDE,,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.2,236.26,105.19,6.0,1.0,1.0,20.99,51.3,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0
CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,1,DB00708,__SUFENTANIL,8202535,Unknown status,NCT02205580,SLEEP BREATHING DISORDERS|TONSILLITIS|ADENOID HYPERTROPHY,All,5 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,65.4469290950532,1368.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.4,386.551,32.78,3.0,0.0,3.0,43.85,111.42,8.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Terminated,NCT00492843,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Sun Yat-sen University Cancer Center, Guangzhou, China|The Tumor Hospital of Harbin Medical University, Harbin, China|Shanghai Chest Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|General Hospital of Tianjin Medical University, Tianjin, China",C07F9/405,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,1,DB00712,__FLURBIPROFEN,3973037,Terminated,NCT03200600,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY--COMPLICATIONS|DEXAMETHASONE|FLUBIPROFEN AXETIL|DELIRIUM",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.840202057537102,2498.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.57,244.2609,37.3,2.0,1.0,2.0,25.23,67.29,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,1,DB00712,__FLURBIPROFEN,3973037,Terminated,NCT03172988,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY|DEXAMETHASONE|FLUBIPROFEN AXETIL|LONG-TERM EFFECTS SECONDARY TO CANCER THERAPY IN ADULTS",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.840202057537102,2498.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.57,244.2609,37.3,2.0,1.0,2.0,25.23,67.29,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,1,DB00715,__PAROXETINE,5811436,Completed,NCT00100464,OBSTRUCTIVE SLEEP APNEA,All,"16 Years to 60 Years   (Child, Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Malcolm Randall VA Medical Center, Gainesville, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,25.692519353580106,485.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.1,329.3654,39.72,4.0,1.0,4.0,34.48,88.02,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Recruiting,NCT03646266,RESPIRATORY INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc, Amsterdam, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Completed,NCT01930747,MUSCLE RELAXANTS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Azsintjan, Brugge, Belgium",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Completed,NCT01199237,"AIRWAY REFLEXES, PROTECTIVE|RECOVERY AFTER NEUROMUSCULAR BLOCK|ANESTHETIC RECOVERY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Helen Diller Cancer Center, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Completed,NCT01749501,RESPIRATORY DISTRESS SYNDROME,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00628667,CHRONIC POSTERIOR LARYNGITIS (CPL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00287339,COUGH|GERD,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNC Gastroenterology, UNC Pulmonology, UNC ENT, Chapel Hill, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Unknown status,NCT00773058,ACUTE RESPIRATORY DISTRESS SYNDROME|ADRENAL INSUFFICIENCY,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT01070225,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Unviersity of Dundee, Dundee, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB00742,__MANNITOL,3932678,Completed,NCT01642745,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Saskatchewan, Saskatoon, Saskatchewan, Canada",A23L27/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CC(c1cc2ccccc2s1)N(O)C(N)=O,1,DB00744,__ZILEUTON,4873259,Completed,NCT01805687,ASTHMA,All,18 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States",C07D307/81,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,20.961416045504,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,236.29,66.56,2.0,2.0,2.0,24.14,61.96,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Terminated,NCT02494102,OBSTRUCTIVE SLEEP APNEA|DELAYED EMERGENCE FROM ANESTHESIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Completed,NCT00086281,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|London Health Sciences Centre, Victoria Campus, London, Ontario, Canada",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Completed,NCT00829322,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stoke Mandeville Hospital, Aylesbury, United Kingdom|Macclesfield District Hospital, Cheshire, United Kingdom|University Hospital of North Tees, County Durham, United Kingdom|Basildon and Thurrock University Hospitals, Essex, United Kingdom|Basingstoke and North Hampshire Hospital, Hampshire, United Kingdom|East Kent University Hospitals, Kent, United Kingdom|Queen Elizabeth Hospital, Kings Lynn, United Kingdom|University Hospital, Llandough, United Kingdom|Royal Marsden Hospital Fulham Road, London, United Kingdom|Royal Marsden Hospital Sutton, London, United Kingdom|St George's Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|James Cook University Hospital, Middlesborough, United Kingdom|Harrogate and District NHS Foundation Trust, North Yorkshire, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Papworth Hospital, Papworth Everard, United Kingdom|Withybush General Hospital, Pembrokeshire, United Kingdom|Peterborough District Hospital, Peterborough, United Kingdom|Royal Surrey County Hospital, Surrey, United Kingdom|Great Western Hospital, Swindon, United Kingdom|Hillingdon Hospital, Uxbridge, United Kingdom|Calderdale and Huddersfield NHS Foundation Trust, West Yorkshire, United Kingdom|Mid Yorkshire Hospital NHS Trust, West Yorkshire, United Kingdom",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,,HYPERSENSITIVITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Completed,NCT01993836,ALZHEIMERS DISEASE|POSTOPERATIVE DELIRIUM|POST OPERATIVE COGNITIVE DYSFUNCTION,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Duke University Medical Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Recruiting,NCT04074460,"CANCER, BREAST|CANCER COLORECTAL|CANCER PROSTATE|CANCER, LUNG|CANCER MELANOMA SKIN|CANCER, OTHER",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Peter MacCallum Cancer Centre, Melbourne, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Completed,NCT01212523,"HYPERTENSION, PULMONARY",All,3 Months to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","UH bristol NHS Trust, Bristol, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Completed,,ADVANCED CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,1,DB00757,__DOLASETRON,4906755,Completed,,NAUSEA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,8.18086613688166,2.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.41,324.38,62.4,3.0,1.0,5.0,35.02,89.34,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Unknown status,NCT01044719,CYSTIC FIBROSIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom",C07F7/10,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Recruiting,NCT03891433,"URINARY TRACT INFECTIONS|ENTEROBACTERIACEAE INFECTIONS|INFECTION DUE TO ESBL BACTERIA|CARBAPENEM|ESCHERICHIA COLI INFECTION|KLEBSIELLA PNEUMONIAE INFECTION|CLINICAL TRIAL|DRUG RESISTANCE, BACTERIAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Recruiting,NCT04489459,TREATMENT OF BLOOD STREAM INFECTIONS DUE TO MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Qasr El Ainy, Cairo, Egypt",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,NCT01944319,LOWER RESPIRATORY TRACT INFECTION,All,"60 Years to 95 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University Third Hospita, Haidian District, Beijing, China",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,NCT01429259,CYSTIC FIBROSIS|PNEUMONIA|PSEUDOMONAS AERUGINOSA INFECTION,All,6 Years to 17 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Connecticut Children's Medical Center, Hartford, Connecticut, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Columbia University Medical Center Children's Hospital, New York, New York, United States|University of North Carolina, North Carolina Children's Hospital, Chapel Hill, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Medical Center, Dallas, Texas, United States",C07F7/10,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,NCT02615041,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Prince of Songkla University, Hatyai, Songkla, Thailand",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,NCT02047773,BRONCHIECTASIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, United Kingdom",C07F7/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,,VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,,GRAM NEGATIVE BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
[Cl-].[K+],1,DB00761,__POTASSIUM_CHLORIDE,7084130,Completed,NCT01085071,THORACIC SURGERY|CARDIAC SURGERY|CRITICALLY ILL,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University Medical Center Groningen, University of Groningen, Groningen, Netherlands",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.2,74.551,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[K+],1,DB00761,__POTASSIUM_CHLORIDE,7084130,Completed,,COLONOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.2,74.551,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,1,DB00762,__IRINOTECAN,6403569,Unknown status,NCT02348450,SMALL CELL LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First Affiliated Hospital of AnHui Medical University, Hefei, Anhui, China|FuJian Provincial Tumor Hospital, Fuzhou, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Cancer Hospital Affiliated To GuangXi Medical University, Nanning, Guangxi, China|Fourth hospital of hebei medical university, Shijiazhuang, Hebei, China|The First Affiliated Hospital of HaErBin Medical University, Haerbin, Heilongjiang, China|HeNan Provincial Tumor Hospital, Zhengzhou, Henan, China|WuHan Tongji Hospital, WuHan, Hubei, China|HuNan Provincial Tumor Hospital, Changsha, Hunan, China|JiangSu Provincial Tumor Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China|LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China|ShanDong Provincial Tumor Hospital, Jinan, Shandong, China|Linyi cancer hospital, Linyi, Shandong, China|Changhai Hospital of Shanghai, Shanghai, Shanghai, China|East Hospital Affiliated To Tongji University, Shanghai, Shanghai, China|Shanghai Chest hospital of Shanghai Jiaotong University, Shanghai, Shanghai, China|Hangzhou First People's Hospital, Hangzhou, Zhejiang, China|The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China|ZheJiang Provincial Tumor Hospital, Hangzhou, Zhejiang, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00394355,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT00553891,NASAL OBSTRUCTION|ADENOIDS HYPERTROPHY|ADENOIDECTOMY,All,2 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT01098071,ADENOIDS,All,2 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT01616160,NASAL POLYPS,All,"21 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Massachusetts General Hospital, Boston, Massachusetts, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT01676415,CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,": Northwestern Medical Faculty Foundation (NMFF) Sinus and Allergy Center, Chicago, Illinois, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03011632,SINUSITIS|ASTHMA,All,4 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Lodz, Poland",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Recruiting,NCT03605537,CHOANAL ATRESIA,All,up to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Cincinnati Children's Hospital, Cincinnati, Ohio, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,OTITIS MEDIA WITH EFFUSION,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Recruiting,NCT03809312,CHRONIC SINUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Simon-Pierre Harvey-Bolduc, Québec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,NCT00656747,CHRONIC BRONCHITIS,All,"60 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Escaldes - Engordany, Andorra|Florencio Varela, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Vicente López, Argentina|Concord, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Woodville, South Australia, Australia|Nedlands, Western Australia, Australia|Aalst, Belgium|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Halen, Belgium|Lommel, Belgium|Moerkerke, Belgium|Namur, Belgium|Yvoir, Belgium|Juiz de Fora, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Saint John, New Brunswick, Canada|Saint John, New Brunswick, Canada|Antigonish, Nova Scotia, Canada|Sydney Mines, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Longueuil, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Santiago, Chile|Valparaíso, Chile|Viña del Mar, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Shengyang, Liaoning, China|Shenyang, Liaoning, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Cali, Cauca, Colombia|Bogotá, Colombia|Bucaramanga, Colombia|Cali, Colombia|Medellín, Colombia|Santafe de Bogotá, Colombia|Osijek, Croatia|Petrinja, Croatia|Rijeka, Croatia|Zagreb, Croatia|Kyjov, Czech Republic|Lovosice, Czech Republic|Neratovice, Czech Republic|Pardubice - Trnova, Czech Republic|Praha - Malesice, Czech Republic|Praha - Troja, Czech Republic|Marseille, France|Mont-de-marsan, France|Nice, France|Perpignan, France|Bad Dürrheim, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Cottbus, Brandenburg, Germany|Rüdersdorf, Brandenburg, Germany|Zossen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Neubrandenburg, Mecklenburg-Vorpommern, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Neuwied, Rheinland-Pfalz, Germany|Böhlen, Sachsen, Germany|Delitzsch, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Meißen, Sachsen, Germany|Bad Segeberg, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Athens, Attica, Greece|Mezourlo, Larissa, Greece|Rio, Patras, Greece|Athens, Greece|Ioannina, Greece|HongKong, Hong Kong|Kowloon, Hong Kong|Bandung, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Killarney, Kerry, Ireland|Enniscorthy, Wexford, Ireland|Gorey, Wexford, Ireland|Bray, Wicklow, Ireland|Longford, Ireland|Pregiato di Cava dei Tirreni, Salerno, Italy|Busto Arsizio, Varese, Italy|Bussolengo, Verona, Italy|Ascoli Piceno, Italy|Catania, Italy|Chieti, Italy|Milano, Italy|Milano, Italy|Perugia, Italy|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsu, Latvia|Valmiera, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Guadalajara, Jalisco, Mexico|Huixquilucan, México, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mérida, Yucatán, Mexico|Chihuahua, Mexico|Zacatecas, Mexico|Eindhoven, Noord-Brabant, Netherlands|Heerlen, Netherlands|Hoofddorp, Netherlands|Meppel, Netherlands|Utrecht, Netherlands|Karachi, Sindh, Pakistan|Islamabad, Pakistan|Karachi, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Manila, Philippines|Quezon City, Philippines|Torres Vedras, Lisboa, Portugal|Matosinhos, Porto, Portugal|Vila Nova de Gaia, Porto, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|S. Martinho do Bispo, Portugal|Santarém, Portugal|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Freestate, South Africa|Benoni, Gauteng, South Africa|Centurion, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|Thabazimbi, Limpopo, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Paarl, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Badalona, Barcelona, Spain|Sant Boi de Llobregat, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Requena, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Guadalajara, Spain|Madrid, Spain|Aarau, Aargau, Switzerland|Laufen, Basel-Landschaft, Switzerland|Oberwil, Basel-Landschaft, Switzerland|Binningen, Basel-Stadt, Switzerland|Basel, Switzerland|Bern, Switzerland|Thun, Switzerland|Wettingen, Switzerland|Zürich, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Chiang Mai, Thailand|Nonthaburi, Thailand|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Coventry, Warwickshire, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,NCT00495586,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Clínic, Barcelona, Catalonia, Spain|Primary Healthcare Center La Marina, Barcelona, Catalonia, Spain|Primary Healthcare Center Figueres, Figueres, Catalonia, Spain|Primary Healthcare Center Montilivi, Girona, Catalonia, Spain|Primary Healthcare Center Girona-4, Girona, Catalonia, Spain|Primary Healthcare Centre Breda-Hostalric, Hostalric, Catalonia, Spain|Primary Healthcare Center Lleida, Lleida, Catalonia, Spain|Primary Healthcare Centre Molins de Rei, Molins de Rey, Catalonia, Spain|Primary Healthcare Centre Olot, Olot, Catalonia, Spain|Primary Healthcare Center Reus-3, Reus, Catalonia, Spain|Primary Healthcare Center Les Muralles, Tarragona, Catalonia, Spain|Primary Healthcare Centre Jaume I, Tarragona, Catalonia, Spain|Primary Healthcare Center Valls Urbà, Valls, Catalonia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Active Not Recruiting,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,FEVER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,ACUTE BACTERIAL SINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",C07D313/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00979615,VASOMOTOR RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00818805,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown status,NCT02348450,SMALL CELL LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First Affiliated Hospital of AnHui Medical University, Hefei, Anhui, China|FuJian Provincial Tumor Hospital, Fuzhou, Fujian, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Cancer Hospital Affiliated To GuangXi Medical University, Nanning, Guangxi, China|Fourth hospital of hebei medical university, Shijiazhuang, Hebei, China|The First Affiliated Hospital of HaErBin Medical University, Haerbin, Heilongjiang, China|HeNan Provincial Tumor Hospital, Zhengzhou, Henan, China|WuHan Tongji Hospital, WuHan, Hubei, China|HuNan Provincial Tumor Hospital, Changsha, Hunan, China|JiangSu Provincial Tumor Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China|LiaoNing Provincial Tumor Hospital, Shenyang, Liaoning, China|ShanDong Provincial Tumor Hospital, Jinan, Shandong, China|Linyi cancer hospital, Linyi, Shandong, China|Changhai Hospital of Shanghai, Shanghai, Shanghai, China|East Hospital Affiliated To Tongji University, Shanghai, Shanghai, China|Shanghai Chest hospital of Shanghai Jiaotong University, Shanghai, Shanghai, China|Hangzhou First People's Hospital, Hangzhou, Zhejiang, China|The second affiliated hospital of zhejiang university school of medicine, Hangzhou, Zhejiang, China|ZheJiang Provincial Tumor Hospital, Hangzhou, Zhejiang, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
NC(=O)N1c2ccccc2CC(=O)c2ccccc21,1,DB00776,__OXCARBAZEPINE,8119148,Completed,NCT00142025,BRONCHIAL ASTHMA,All,"17 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,134.080781946241,36.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.76,252.268,63.4,2.0,1.0,3.0,25.72,71.56,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Unknown Status,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Withdrawn,NCT03724955,CYSTIC FIBROSIS RELATED BONE DISEASE,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Emory University Hospital, Atlanta, Georgia, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Unknown status,NCT01761487,CARRIERS OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Soroka University Medical Center, Beer Sheva, Negev, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Unknown status,NCT02582099,RHINOSINUSITIS,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Completed,NCT00749866,BRONCHIECTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, Lothian, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1,1,DB00802,__ALFENTANIL,4167574,Completed,NCT00440960,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment,"Hospital Pompeia, Caxias do Sul, RS, Brazil|Hospital Medianeira, Caxias do Sul, RS, Brazil|General Hospital of Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5464177909197,1036.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,416.5172,81.05,6.0,0.0,3.0,45.56,118.59,9.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1
CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,DB00803,__COLISTIN,,"Active, not recruiting",NCT02918409,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,1155.455,490.66,18.0,18.0,1.0,123.32,297.67,28.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,DB00803,__COLISTIN,,Completed,NCT02683603,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"intensive care unit of the University Hospital Center La Rabta, Tunis, Tunisia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,1155.455,490.66,18.0,18.0,1.0,123.32,297.67,28.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,DB00803,__COLISTIN,,Recruiting,NCT04489459,TREATMENT OF BLOOD STREAM INFECTIONS DUE TO MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Qasr El Ainy, Cairo, Egypt",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,1155.455,490.66,18.0,18.0,1.0,123.32,297.67,28.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00500578,HEMATOLOGICAL MALIGNANCY,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Terminated,NCT02623959,ADVANCED CANCERS|MALIGNANT PLEURAL EFFUSIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT02203019,SEPSIS|RESPIRATORY FAILURE|AGITATION,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center, Lubbock, Texas, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT02717780,"SLEEP APNEA SYNDROMES|SLEEP APNEA, OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Vaud, Switzerland",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT03894800,ACUTE PAIN|TRAUMA|HYPOVOLEMIA,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Harald Lenz, Oslo, Norway",A61N1/303,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01158820,SEDATION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Recruiting,NCT03735563,SURFACTANT DEFICIENCY SYNDROME NEONATAL,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Oulu University Hospital, Oulu, Finland",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00654511,TONSILLITIS,All,2 Years to 12 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Children's National Medical Center, Washington, District of Columbia, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Recruiting,NCT04528173,ANESTHESIA|OPIOID USE|TONSILLITIS|SLEEP DISORDER|SURGERY,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01308320,THYROID NEOPLASMS,Female,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Severance Hospital, Seoul, Korea, Republic of",A61N1/303,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01060137,LUNG CANCER|PAIN,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,"Active, not recruiting",NCT02359175,LUNG NEOPLASMS|PAIN|IMMUNE SUPPRESSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Odense University Hospital, Odense C, Denmark",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,"Active, not recruiting",NCT01050699,CRITICAL ILLNESS|SLEEP|ACUTE LUNG INJURY|ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Southern Arizona VA Health Care System, Tucson, Arizona, United States|University Medical Center, Tucson, Arizona, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Suspended,NCT03405090,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Respiratory Investigation Unit, Kingston, Ontario, Canada",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Recruiting,NCT03834363,COPD,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wilhelmina Ziekenhuis Assen, Assen, Drenthe, Netherlands|Ommelander Ziekenhuis Groningen, Scheemda, Groningen, Netherlands|Elkerliek Ziekenhuis, Helmond, Noord-Brabant, Netherlands|Noordwest Ziekenhuisgroep Alkmaar, Alkmaar, Noord-Holland, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Noord-Holland, Netherlands|Spaarne Gasthuis, Haarlem, Noord-Holland, Netherlands|Medisch Spectrum Twente, Enschede, Overijssel, Netherlands|Isala Klinieken, Zwolle, Overijssel, Netherlands|Ikazia Ziekenhuis, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01368809,AMBULATORY SURGERY|COUGHING,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Cedars Sinai Medical center, Los Angeles, California, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,1,DB00814,__MELOXICAM,6184220,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,22.47274071336161,1458.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,351.401,99.6,5.0,2.0,3.0,34.25,88.62,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Recruiting,NCT04359862,ACUTE RESPIRATORY DISTRESS SYNDROME|COVID19 INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00611195,UPPER RESPIRATORY INFECTIONS,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University children's hospital, Basel, Switzerland",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02203019,SEPSIS|RESPIRATORY FAILURE|AGITATION,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center, Lubbock, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02246023,LUNG CANCER|SARCOIDOSIS|INTERSTITIAL PNEUMONIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University Hospital Zurich, Zurich, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01993836,ALZHEIMERS DISEASE|POSTOPERATIVE DELIRIUM|POST OPERATIVE COGNITIVE DYSFUNCTION,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Duke University Medical Center, Durham, North Carolina, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Not yet recruiting,NCT04452383,SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zagazig University, Zagazig, Egypt",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT03091894,OBSTRUCTIVE SLEEP APNEA OF ADULT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zagazig university, Zagazig, Sharkia, Egypt",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Not yet recruiting,NCT03892122,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"U.O.C. Otorinolaringoiatria Ospedale Di Barletta, Barletta, BAT, Italy",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Terminated,NCT02643979,OBESITY|BARIATRICS|SLEEP APNEA SYNDROMES|GASTRIC BYPASS|ENDOSCOPY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Icahn School of Medicine at Mount Sinai, New York, New York, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01344759,"SLEEP APNEA, OBSTRUCTIVE",All,"12 Months to 25 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Recruiting,NCT04074460,"CANCER, BREAST|CANCER COLORECTAL|CANCER PROSTATE|CANCER, LUNG|CANCER MELANOMA SKIN|CANCER, OTHER",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Peter MacCallum Cancer Centre, Melbourne, Australia",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Not yet recruiting,NCT04475705,SOLID TUMOR|CARCINOMA|MALIGNANCY|CANCER,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01412632,TRANSCERVICAL RESECTION OF ENDOMETRIUM|TRANSCERVICAL RESECTION OF FIBROIDS|TRANSCERVICAL RESECTION OF POLYP,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Regionshospitalet Horsens, Horsens, Region Midt, Denmark",0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT00440960,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment,"Hospital Pompeia, Caxias do Sul, RS, Brazil|Hospital Medianeira, Caxias do Sul, RS, Brazil|General Hospital of Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02168751,PULMONARY RESECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Anesthesiology Department Hospital GU Gregorio Mrañón, Madrid, Spain",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Unknown status,NCT00797160,RESPIRATORY DISTRESS SYNDROME,All,up to 2 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Department of Neonatology of Julia Kubitschek Hospital, Belo Horizonte, Minas Gerais, Brazil",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01212523,"HYPERTENSION, PULMONARY",All,3 Months to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","UH bristol NHS Trust, Bristol, United Kingdom",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01437462,HEALTHY ADULTS|GYNECOLOGICAL DISEASE,Female,"18 Years to 69 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tampere University Hospital, Tampere, Finland",0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT03099616,ANESTHESIA; BARIATRIC SURGERY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Sir Ganga Ram Hospital, New Delhi, Delhi, India",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT03307551,THORACIC DISEASES|SURGERY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Sir Ganga Ram Hospital, New Delhi, Delhi, India",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01557920,AIRWAY COMPLICATION OF ANAESTHESIA|HEALTHY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02578862,ADVANCED CHRONIC RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Ochsner Medical Center, New Orleans, Louisiana, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Recruiting,NCT02457442,"DRUG INTERACTIONS|ANESTHESIA, CONDUCTION",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","Department of Anesthesiology and Pain Therapy, Bern University Hospital, Bern, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Recruiting,NCT02703220,SLEEP APNEA|ELDERLY ADULTS,All,"60 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,"John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Recruiting,NCT04227093,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Antwerp University Hospital, Edegem, Antwerp, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,"Active, not recruiting",NCT03536507,ALTITUDE HYPOXIA,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Unknown status,NCT02371473,"CENTRAL SLEEP APNEA, SECONDARY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT00928655,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital of Zurich, Pulmonary Division and Sleep Disorders Centre, Zurich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT00424970,HIGH ALTITUDE POLYCYTHEMIA,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University Cayetano Heredia, Lima, Peru",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT00517426,CHRONIC HEART FAILURE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Centro Cardiologico Monzino, University of Milan, Milan, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT00222534,RESPIRATORY INSUFFICIENCY|ALKALOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Respiratory Medicine, Haukeland University Hospital, Bergen, Norway|Department of Internal Medicine, Sorlandet Sykehus Kristiansand, Kristiansand, Norway|Department of Internal Medicine, Aker University Hospital, Oslo, Norway|Ullevaal University Hospital, Dept. of Respiratory Medicine, Oslo, Norway|Department of Internal Medicine, St.Olav's Hospital, Trondheim, Norway",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT02760121,"ALTITUDE SICKNESS|HYPERTENSION, PULMONARY",Male,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of British Columbia, Kelowna, British Columbia, Canada",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Terminated,NCT03490916,HIGH ALTITUDE PULMONARY EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UMass Medical School, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT01627639,DECOMPENSATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Unit, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,"Active, not recruiting",NCT03561675,ACUTE MOUNTAIN SICKNESS,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Completed,NCT01993667,PROPHYLAXIS OF ACUTE MOUNTAIN SICKNESS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Utah Health Sciences Center, Salt Lake City, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,"Active, not recruiting",NCT03177811,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT01042158,PULMONARY ARTERIAL HYPERTENSION|SYSTEMIC SCLEROSIS|SCLERODERMA SPECTRUM OF DISEASES|CONNECTIVE TISSUE DISEASE|PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University, Baltimore, Maryland, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Withdrawn,NCT03309592,"PORTOPULMONARY HYPERTENSION|PULMONARY HYPERTENSION|CIRRHOSIS, LIVER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT00617305,PULMONARY ARTERIAL HYPERTENSION,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|West Los Angeles Healthcare Center, Los Angeles, California, United States|Harbor - UCLA, Torrance, California, United States|Cleveland Clinic, Ft. Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Orlando Heart Center, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of Maryland, Baltimore, Maryland, United States|BACH Cardiology, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical Center, New York, New York, United States|Asheville Cardiology Associates, Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT01305252,"HYPERTENSION, PULMONARY",All,"18 Years to 69 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University School of Medicine, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Terminated,NCT01275339,"AORTIC STENOSIS|LV REMODELING, HYPERTROPHY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Terminated,NCT01272388,AORTIC STENOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00838,__CLOCORTOLONE,4376767,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",C07J71/0031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,129.0,26.3496170352573,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.73,410.907,74.6,4.0,2.0,4.0,41.8,105.74,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Completed,NCT03207165,LOW CARDIAC OUTPUT SYNDROME|CARDIOGENIC SHOCK|ACUTE CORONARY SYNDROME|PULMONARY EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Completed,,MAJOR ABDOMINAL SURGERY,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Suspended,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT00480870,"ALZHEIMER DISEASE|SLEEP APNEA, OBSTRUCTIVE",All,"50 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","Instituto do Sono, Sao Paulo, Brazil",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT02264353,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Diego, San Diego, California, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Unknown status,NCT03299257,OSA|SLEEPINESS,All,35 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Instituto do Sono, Sao Paulo, Brazil",C07D405/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,,SLEEP DEPRIVATION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00441246,ACUTE RESPIRATORY INFECTION|BRONCHITIS|RHINOSINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alabama Clinical Therapuetics, LLC, 52 Medical Park East Drive, Suite 214, Birmingham, Alabama, United States|MedCenter, 6651 Madison Ave., Carmichael, California, United States|Torrance Clinical Research, 3640 Lomita Blfd #205, Torrance, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Longmont Clinic, P.C., 1925 W. Mountain View Ave., Longmont, Colorado, United States|Front Range Clinical Research, Wheat Ridge, Colorado, United States|Dawsonville Family Medicine Clinical Trials, 5983 Hwy, 53E. Ste 175, Dawsonville, Georgia, United States|Koch Family Medicine, 81A E. Queenwood Rd., Morton, Illinois, United States|Welborn Clinic Gateway, 4233 Gateway Blvd, Newburgh, Indiana, United States|Sterling Research Group, Ltd., 650 Sprucewood Lane, Erlanger, Kentucky, United States|Columbia Medical Practice, 3450 Knoll Dr. North #200C, Columbia, Maryland, United States|Clinical Associates, 750 Main St. #201, Reisterstown, Maryland, United States|Milford Emergency Associates, Inc., 14 Asylum St., Milford, Massachusetts, United States|Michigan Institute of Medicine, 38525 Eight Mile Rd., Livonia, Michigan, United States|Central Nebraska Medical Clinic, PC, 145 Memorial Drive, Broken Bow, Nebraska, United States|Immedicenter, 557 Broad St., Bloomfield, New Jersey, United States|Central New York Clinical Research, RT 92, The Market Place, Manlius, New York, United States|North Carolina Clinical Research, 4301 Lake Boone Trail, Ste 309-A, Raleigh, North Carolina, United States|DayStar Clinical Research, Inc., 880 Mull Ave., Suite 100, Akron, Ohio, United States|DataPharm, Inc., 6715 Tippecanoe Rd., Bldg E (LL), Canfield, Ohio, United States|Parsons Avenue Medical Clinic, 1493 Parsons Avenue, Columbus, Ohio, United States|Blair Medical Associates, Inc., Station Medical Center, 1414 Ninth Ave., Altoona, Pennsylvania, United States|Lederach Family Medicine, PC, 658 Harleysville Pike, Suite 120, Harleysville,, Pennsylvania, United States|Harleysville Medical Associates, 176 Main Street, Harleysville, Pennsylvania, United States|Greentree Medical Associates, 651 Holiday Drive, Foster Plaza Bldg #5, Pittsburgh, Pennsylvania, United States|MetaClin Research, Inc., 6012 West William Cannon Drive, 6012 West William Cannon Drive, Austin, Texas, United States|Apollo Research Institute, 117 Dilworth Plaza, Poth, Texas, United States|Advanced Clinical Research, Inc., 3590 West 9000 South, Suite 230, West Jordan, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00208065,MIGRAINE|SINUSITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinvest, Inc., Springfield, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00378144,COMMON COLD|HEADACHE|NASAL CONGESTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","JJCPPW Investigational Site, Wilrijk, Antwerp, Belgium",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,ACUTE RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,BRONCHITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,COMMON COLD,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Terminated,NCT00456339,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,18 Months to 12 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT02618057,MYCOPLASMA PNEUMONIAE PNEUMONIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Children's Hospital, Seoul, Korea, Republic of",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00632554,EOSINOPHILIC PNEUMONIA|CHRONIC DISEASE,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT03265405,SARCOIDOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Postgraduate Institute of Medical Education and Research, Chandigarh, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00788749,NASAL POLYPS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Terminated,NCT00600639,ACUTE RESPIRATORY FAILURE,All,76 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Scientifico di Pavia Fondazione Salvatore Maugeri, Pavia, Italy",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00311961,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Isala Klinieken, Zwolle, Overijssel, Netherlands",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT02857842,"LUNG DISEASES, OBSTRUCTIVE|BLOOD EOSINOPHIL COUNT|GLUCOCORTICOIDS|COPD|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bispebjerg University Hospital, Copenhagen, Denmark|Hvidovre University Hospital, Copenhagen, Denmark|North Zealand Hospital, Copenhagen, Denmark|Gentofte University Hospital, Hellerup, Denmark",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT04458636,COPD EXACERBATION,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nuffield Department of Medicine, Oxford, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT02855502,TRACHEAL STENOSIS,All,"10 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Tehran, Iran, Islamic Republic of",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,,COUGH,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,1,DB00862,__VARDENAFIL,6362178,Unknown status,NCT00705588,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pulmonary Institute, Rabin Medical Center, Petach Tikva, Israel",C07F9/6561,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,20.1400439434074,316.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,488.603,109.13,8.0,1.0,4.0,53.22,142.71,7.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,1,DB00863,__RANITIDINE,5098715,Completed,NCT00702871,VENTILATOR ASSOCIATED PNEUMONIA|ETIOLOGICAL ORGANISMS|ANTIMICROBIAL DRUG SUSCEPTIBILITY PATTERN|STRESS ULCER PROPHYLAXIS,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India",A61K9/2806,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,1,DB00863,__RANITIDINE,5098715,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",A61K9/2806,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Terminated,NCT00975663,LUNG AND HEART-LUNG TRANSPLANTATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service de Pneumologie, Bruxelles, Belgium|Pôle Médecine Aiguë et Communautaire, Clinique de Pneumologie,, Grenoble, France|Service de Pneumologie, HCL Lyon, Lyon, France|ApHm -Chirurgie thoracique, Marseille, France|Service de Pneumologie-CHU de Nantes, Nantes, France|Service de Chirurgie Cardiovasculaire - Hôpital Georges Pompidou, Paris, France|Service de Pneumologie - CH de Suresnes, Paris, France|Service de Pneumologie - Phtisiologie - Hôpital Bichat, Paris, France|Service de Pneumologie - CHU de Strasbourg, Strasbourg, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,DB00871,__TERBUTALINE,3937838,Unknown status,NCT00914797,ASTHMA,Male,18 Years to 45 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Bispebjerg Hospital, Respiratory Research Unit, Kobenhavn NV, Denmark",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,DB00871,__TERBUTALINE,3937838,Completed,NCT00124995,STATUS ASTHMATICUS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"CT Children's Medical Center, Hartford, Connecticut, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
COc1ccccc1OCC(O)CO,1,DB00874,__GUAIFENESIN,6372252,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,56.0,23.589806772212896,462.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,198.2158,58.92,4.0,2.0,1.0,20.59,51.24,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
COc1ccccc1OCC(O)CO,1,DB00874,__GUAIFENESIN,6372252,Completed,NCT00441246,ACUTE RESPIRATORY INFECTION|BRONCHITIS|RHINOSINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alabama Clinical Therapuetics, LLC, 52 Medical Park East Drive, Suite 214, Birmingham, Alabama, United States|MedCenter, 6651 Madison Ave., Carmichael, California, United States|Torrance Clinical Research, 3640 Lomita Blfd #205, Torrance, California, United States|Clinicos, LLC, Colorado Springs, Colorado, United States|Longmont Clinic, P.C., 1925 W. Mountain View Ave., Longmont, Colorado, United States|Front Range Clinical Research, Wheat Ridge, Colorado, United States|Dawsonville Family Medicine Clinical Trials, 5983 Hwy, 53E. Ste 175, Dawsonville, Georgia, United States|Koch Family Medicine, 81A E. Queenwood Rd., Morton, Illinois, United States|Welborn Clinic Gateway, 4233 Gateway Blvd, Newburgh, Indiana, United States|Sterling Research Group, Ltd., 650 Sprucewood Lane, Erlanger, Kentucky, United States|Columbia Medical Practice, 3450 Knoll Dr. North #200C, Columbia, Maryland, United States|Clinical Associates, 750 Main St. #201, Reisterstown, Maryland, United States|Milford Emergency Associates, Inc., 14 Asylum St., Milford, Massachusetts, United States|Michigan Institute of Medicine, 38525 Eight Mile Rd., Livonia, Michigan, United States|Central Nebraska Medical Clinic, PC, 145 Memorial Drive, Broken Bow, Nebraska, United States|Immedicenter, 557 Broad St., Bloomfield, New Jersey, United States|Central New York Clinical Research, RT 92, The Market Place, Manlius, New York, United States|North Carolina Clinical Research, 4301 Lake Boone Trail, Ste 309-A, Raleigh, North Carolina, United States|DayStar Clinical Research, Inc., 880 Mull Ave., Suite 100, Akron, Ohio, United States|DataPharm, Inc., 6715 Tippecanoe Rd., Bldg E (LL), Canfield, Ohio, United States|Parsons Avenue Medical Clinic, 1493 Parsons Avenue, Columbus, Ohio, United States|Blair Medical Associates, Inc., Station Medical Center, 1414 Ninth Ave., Altoona, Pennsylvania, United States|Lederach Family Medicine, PC, 658 Harleysville Pike, Suite 120, Harleysville,, Pennsylvania, United States|Harleysville Medical Associates, 176 Main Street, Harleysville, Pennsylvania, United States|Greentree Medical Associates, 651 Holiday Drive, Foster Plaza Bldg #5, Pittsburgh, Pennsylvania, United States|MetaClin Research, Inc., 6012 West William Cannon Drive, 6012 West William Cannon Drive, Austin, Texas, United States|Apollo Research Institute, 117 Dilworth Plaza, Poth, Texas, United States|Advanced Clinical Research, Inc., 3590 West 9000 South, Suite 230, West Jordan, Utah, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,56.0,23.589806772212896,462.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,198.2158,58.92,4.0,2.0,1.0,20.59,51.24,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT00493194,"KIDNEY FAILURE, CHRONIC|TRANSPLANTATION|IMMUNOSUPPRESSION|INTERSTITIAL FIBROSIS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Antwerp, Edegem, Antwerp, Belgium|University Hospital Brussels, Brussels (Jette), Brabant, Belgium|University Hospital Gent, Gent, Oost-Vlaanderen, Belgium",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Not yet recruiting,NCT03901001,INFLUENZA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT00610324,NOSOCOMIAL PNEUMONIA|HEALTHCARE-ASSOCIATED PNEUMONIA|ASPIRATION PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Medical-Neuro Intensive Care Unit, K E M Hospital, Parel, Mumbai, Maharashtra, India",A45D34/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT00248300,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Commonwealth University School of Nursing, Richmond, Virginia, United States",A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Unknown status,NCT01883596,MECHANICAL VENTILATION FOR MORE THAN 48 HOURS.,All,"1 Month to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sinaloa Pediatric Hospital, Culiacan, Sinaloa, Mexico",A45D34/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",A45D34/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT00611195,UPPER RESPIRATORY INFECTIONS,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University children's hospital, Basel, Switzerland",C07D211/58,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01569048,CHRONIC SINUSITIS,All,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01412632,TRANSCERVICAL RESECTION OF ENDOMETRIUM|TRANSCERVICAL RESECTION OF FIBROIDS|TRANSCERVICAL RESECTION OF POLYP,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Regionshospitalet Horsens, Horsens, Region Midt, Denmark",C07D211/58,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Recruiting,NCT02457442,"DRUG INTERACTIONS|ANESTHESIA, CONDUCTION",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","Department of Anesthesiology and Pain Therapy, Bern University Hospital, Bern, Switzerland",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT02717780,"SLEEP APNEA SYNDROMES|SLEEP APNEA, OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Vaud, Switzerland",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT02334046,DRUG USE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Ajou University Hospital, Suwon, Gyeongki-do, Korea, Republic of",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Recruiting,NCT03905837,"LUNG DISEASES|LUNG INFLAMMATION|LUNG INJURY, ACUTE|POSTOPERATIVE COMPLICATIONS",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital Gregorio Maranon, Madrid, Spain",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Unknown status,NCT01381627,LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Recruiting,NCT02164734,"RESPIRATORY DISTRESS SYNDROME, NEWBORN",All,up to 48 Hours   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albany Medical Center, Albany, New York, United States",C07D211/58,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT00391105,RESPIRATORY DISTRESS SYNDROME,All,up to 28 Days   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,,C07D211/58,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT00665119,"RESPIRATORY INSUFFICIENCY|RESPIRATION, ARTIFICIAL|CONSCIOUS SEDATION",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intensive Care Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT03132519,COUGH|HYPERTENSION,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Fundacion Valle del Lili, Cali, Valle, Colombia",C07D211/58,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Not yet recruiting,NCT03783676,COUGH,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01240109,ELECTIVE THYROIDECTOMY,Female,"20 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Severance Hospital, Seoul, Korea, Republic of",C07D211/58,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,1,DB00904,__ONDANSETRON,5344658,Terminated,NCT00588835,TUMOR,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Groningen, Groningen, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,1,DB00904,__ONDANSETRON,5344658,Completed,NCT02760069,NAUSEA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Antonio Military Medical Center, San Antonio, Texas, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C,1,DB00907,__COCAINE,10149843,Completed,NCT01706952,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Other,"Department of Otolaryngology-Head and Neck Surgery. McGill University Health Center, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,22.078482104355306,320.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.97,303.3529,55.84,3.0,0.0,3.0,32.36,81.16,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C401/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Unknown status,NCT00752947,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tieying Sun, Beijing, China|Xiuhong Nie, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,NCT00208065,MIGRAINE|SINUSITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinvest, Inc., Springfield, Missouri, United States",C07D209/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,NCT00446056,ASTHMA,All,6 Years to 14 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Unknown status,NCT02673840,DENGUE FEVER|PLEURAL EFFUSION,All,21 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","National University Hospital (Investigational Medicine Unit), Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",A61K9/0078,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,,HIP ARTHROPLASTY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,"SURGERY, CARDIAC",,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,,PULMONARY ASPIRATION OF GASTRIC CONTENTS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/5047,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00584987,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT01847131,NASAL OBSTRUCTION PRESENT FINDING,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Unknown status,NCT02630121,SLEEP APNEA|CHRONIC NASAL CONGESTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Usf Asthma Allergy and Immunology Cru, Tampa, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,"Active, not recruiting",NCT03228914,ENDOSCOPIC SINUS SURGERY|NASAL POLYPS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Houston, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01853787,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"45 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Scienze Mediche, Università di Ferrara, Ferrara, Italy|: Pneumologia Riabilitativa-Fondazione Maugeri-Istituto Scientifico di Milano- IRCCS, Milano, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00975195,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","352.2046.61006 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia|352.2046.61001 Boehringer Ingelheim Investigational Site, Glebe, New South Wales, Australia|352.2046.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia|352.2046.61004 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia|352.2046.61003 Boehringer Ingelheim Investigational Site, Toorak Gardens, South Australia, Australia|352.2046.61005 Boehringer Ingelheim Investigational Site, Woodville, South Australia, Australia|352.2046.32002 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32016 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32015 Boehringer Ingelheim Investigational Site, Eupen, Belgium|352.2046.32017 Boehringer Ingelheim Investigational Site, Gilly, Belgium|352.2046.32014 Boehringer Ingelheim Investigational Site, Herentals, Belgium|352.2046.32006 Boehringer Ingelheim Investigational Site, Jambes, Belgium|352.2046.32008 Boehringer Ingelheim Investigational Site, Lebbeke, Belgium|352.2046.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|352.2046.32004 Boehringer Ingelheim Investigational Site, Middelheim, Belgium|352.2046.32010 Boehringer Ingelheim Investigational Site, Montigny-le-Tilleul, Belgium|352.2046.32013 Boehringer Ingelheim Investigational Site, Turnhout, Belgium|352.2046.55005 Boehringer Ingelheim Investigational Site, Goiania, Brazil|352.2046.55002 Boehringer Ingelheim Investigational Site, Goiânia, Brazil|352.2046.55001 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55006 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55003 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|352.2046.35905 Boehringer Ingelheim Investigational Site, Bourgas, Bulgaria|352.2046.35902 Boehringer Ingelheim Investigational Site, Rousse, Bulgaria|352.2046.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35906 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35907 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35908 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35903 Boehringer Ingelheim Investigational Site, Stara Zagora, Bulgaria|352.2046.35909 Boehringer Ingelheim Investigational Site, Veliko Tarnovo, Bulgaria|352.2046.86002 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86003 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86006 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86008 Boehringer Ingelheim Investigational Site, Chongqing, China|352.2046.86001 Boehringer Ingelheim Investigational Site, Guangzhou, China|352.2046.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86005 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86007 Boehringer Ingelheim Investigational Site, Wuhan, China|352.2046.45001 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|352.2046.45003 Boehringer Ingelheim Investigational Site, København NV, Denmark|352.2046.45002 Boehringer Ingelheim Investigational Site, Odense C, Denmark|352.2046.3317A Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317B Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317C Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3320A Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320B Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320C Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3335A Boehringer Ingelheim Investigational Site, Clermont Ferrand cedex 1, France|352.2046.3314A Boehringer Ingelheim Investigational Site, Forbach, France|352.2046.3301A Boehringer Ingelheim Investigational Site, Marseille cedex 20, France|352.2046.3333A Boehringer Ingelheim Investigational Site, Marseille, France|352.2046.3326A Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3326C Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3325A Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325C Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325D Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3334A Boehringer Ingelheim Investigational Site, Nantes, France|352.2046.3324A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332B Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332C Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3331A Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331B Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331C Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3329A Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3329B Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3302A Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302B Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302C Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302D Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3336A Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336B Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336C Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3337A Boehringer Ingelheim Investigational Site, Toulouse, France|352.2046.49012 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49020 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49021 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49008 Boehringer Ingelheim Investigational Site, Bochum, Germany|352.2046.49019 Boehringer Ingelheim Investigational Site, Cottbus, Germany|352.2046.49002 Boehringer Ingelheim Investigational Site, Donaustauf, Germany|352.2046.49023 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|352.2046.49013 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49025 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49024 Boehringer Ingelheim Investigational Site, Geesthacht, Germany|352.2046.49022 Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|352.2046.49001 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany|352.2046.49006 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|352.2046.49014 Boehringer Ingelheim Investigational Site, Immenhausen, Germany|352.2046.49016 Boehringer Ingelheim Investigational Site, Kiel, Germany|352.2046.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|352.2046.49004 Boehringer Ingelheim Investigational Site, Mainz, Germany|352.2046.49005 Boehringer Ingelheim Investigational Site, Marburg, Germany|352.2046.49015 Boehringer Ingelheim Investigational Site, München, Germany|352.2046.30003 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30004 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30005 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30007 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30008 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30011 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30012 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30006 Boehringer Ingelheim Investigational Site, Heraklion, Greece|352.2046.30009 Boehringer Ingelheim Investigational Site, Larisa, Greece|352.2046.30001 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.30002 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.36003 Boehringer Ingelheim Investigational Site, Cegled, Hungary|352.2046.36002 Boehringer Ingelheim Investigational Site, Deszk, Hungary|352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary|352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary|352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary|352.2046.36005 Boehringer Ingelheim Investigational Site, Szazhalombatta, Hungary|352.2046.36011 Boehringer Ingelheim Investigational Site, Szigetszentmiklos, Hungary|352.2046.39002 Boehringer Ingelheim Investigational Site, Catania, Italy|352.2046.39007 Boehringer Ingelheim Investigational Site, Cona, Italy|352.2046.39005 Boehringer Ingelheim Investigational Site, Foggia, Italy|352.2046.39003 Boehringer Ingelheim Investigational Site, Modena, Italy|352.2046.39006 Boehringer Ingelheim Investigational Site, Montescano (pv), Italy|352.2046.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|352.2046.39004 Boehringer Ingelheim Investigational Site, Sesto S. Giovanni (mi), Italy|352.2046.39008 Boehringer Ingelheim Investigational Site, Tradate (va), Italy|352.2046.31004 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands|352.2046.31001 Boehringer Ingelheim Investigational Site, Leeuwarden, Netherlands|352.2046.31003 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|352.2046.31002 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands|352.2046.64007 Boehringer Ingelheim Investigational Site, Auckland NZ, New Zealand|352.2046.64003 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand|352.2046.64004 Boehringer Ingelheim Investigational Site, Dunedin, New Zealand|352.2046.64006 Boehringer Ingelheim Investigational Site, Hamilton, New Zealand|352.2046.64001 Boehringer Ingelheim Investigational Site, Newtown Wellington NZ, New Zealand|352.2046.64005 Boehringer Ingelheim Investigational Site, Otahuhu New Zealand, New Zealand|352.2046.64002 Boehringer Ingelheim Investigational Site, Tauranga, New Zealand|352.2046.63001 Boehringer Ingelheim Investigational Site, Caloocan, Philippines|352.2046.63003 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63004 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63009 Boehringer Ingelheim Investigational Site, Muntinlupa, Philippines|352.2046.63006 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63008 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63005 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.63007 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.48006 Boehringer Ingelheim Investigational Site, Bytom, Poland|352.2046.48003 Boehringer Ingelheim Investigational Site, Ostrow Wielkopolska, Poland|352.2046.48001 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48002 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48009 Boehringer Ingelheim Investigational Site, Rzeszow, Poland|352.2046.48011 Boehringer Ingelheim Investigational Site, Tarnowskie Gory, Poland|352.2046.48005 Boehringer Ingelheim Investigational Site, Warsaw, Poland|352.2046.48007 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|352.2046.07011 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|352.2046.07006 Boehringer Ingelheim Investigational Site, Ivanovo, Russian Federation|352.2046.07008 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07009 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07002 Boehringer Ingelheim Investigational Site, Samara, Russian Federation|352.2046.07003 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|352.2046.07001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|352.2046.07004 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.07005 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.27006 Boehringer Ingelheim Investigational Site, Amanzimtoti, South Africa|352.2046.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa|352.2046.27001 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27003 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27007 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|352.2046.27005 Boehringer Ingelheim Investigational Site, Somerset West, South Africa|352.2046.27004 Boehringer Ingelheim Investigational Site, Tygerberg, South Africa|352.2046.34008 Boehringer Ingelheim Investigational Site, Badajoz, Spain|352.2046.34002 Boehringer Ingelheim Investigational Site, Barakaldo (Bilbao), Spain|352.2046.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34004 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34009 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat, Spain|352.2046.34006 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|352.2046.34010 Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón, Spain|352.2046.34013 Boehringer Ingelheim Investigational Site, Salt (Girona), Spain|352.2046.34011 Boehringer Ingelheim Investigational Site, Sevilla, Spain|352.2046.88606 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|352.2046.88604 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|352.2046.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88607 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.88608 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.2161A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2162A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2165A Boehringer Ingelheim Investigational Site, Sfax, Tunisia|352.2046.2164A Boehringer Ingelheim Investigational Site, Sousse, Tunisia|352.2046.2163A Boehringer Ingelheim Investigational Site, Tunis, Tunisia|352.2046.90009 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90019 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90016 Boehringer Ingelheim Investigational Site, Bursa, Turkey|352.2046.90010 Boehringer Ingelheim Investigational Site, Denizli, Turkey|352.2046.90003 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90004 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90006 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90008 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90012 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90017 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90011 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90014 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90018 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90005 Boehringer Ingelheim Investigational Site, Izmit, Turkey|352.2046.90007 Boehringer Ingelheim Investigational Site, Kayseri, Turkey|352.2046.90001 Boehringer Ingelheim Investigational Site, Mersin, Turkey|352.2046.90002 Boehringer Ingelheim Investigational Site, Samsun, Turkey|352.2046.38007 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk, Ukraine|352.2046.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|352.2046.38003 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|352.2046.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38006 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38005 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|352.2046.38001 Boehringer Ingelheim Investigational Site, Vinnytsya, Ukraine|352.2046.44008 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow, United Kingdom|352.2046.44009 Boehringer Ingelheim Investigational Site, Barnsley, United Kingdom|352.2046.44018 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom|352.2046.44010 Boehringer Ingelheim Investigational Site, Birmingham, United Kingdom|352.2046.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom|352.2046.44026 Boehringer Ingelheim Investigational Site, Chertsey, United Kingdom|352.2046.44006 Boehringer Ingelheim Investigational Site, Chesterfield, United Kingdom|352.2046.44012 Boehringer Ingelheim Investigational Site, Cottingham, Hull, United Kingdom|352.2046.44028 Boehringer Ingelheim Investigational Site, Inverness, United Kingdom|352.2046.44016 Boehringer Ingelheim Investigational Site, Isleworth, United Kingdom|352.2046.44002 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|352.2046.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom|352.2046.44017 Boehringer Ingelheim Investigational Site, Norwich, United Kingdom|352.2046.44021 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom|352.2046.44019 Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom|352.2046.44025 Boehringer Ingelheim Investigational Site, Windsor, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Unknown status,NCT01361984,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|COPD|EMPHYSEMA|CHRONIC BRONCHITIS,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01388595,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT02136875,COPD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Chest Institute, Montreal, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00950794,ASTHMA|BRONCHIAL ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT02558088,PHARMACOKINETICS IN HEALTHY YOUNG MEN,Male,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Bispebjerg Hospital, Copenhagen, Select State, Denmark",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Recruiting,NCT02810704,PULMONARY EMBOLISM|VENOUS THROMBOSIS,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA, Los Angeles, California, United States|Stanford University Hospital, Stanford, California, United States|Arthritis Surgery Research Foundation, South Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|New York University, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State Hershey Med Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lifespan Health, East Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Anderson Orthopaedic Institute (VA), Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01033526,COMMON COLD,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Borgo Di Terzo, Bergamo, Italy|Brembate, Bergamo, Italy|Calusco d'Adda, Bergamo, Italy|Capriate San Gervasio, Bergamo, Italy|Caravaggio, Bergamo, Italy|Casazza, Bergamo, Italy|Cologno Al Serio, Bergamo, Italy|Covo, Bergamo, Italy|Dalmine, Bergamo, Italy|Mozzanica, Bergamo, Italy|Ponte San Pietro, Bergamo, Italy|Seriate, Bergamo, Italy|Verdello, Bergamo, Italy|Vertova, Bergamo, Italy|Villa d'Adda, Bergamo, Italy|Angera, Varese, Italy|Carnago, Varese, Italy|Cavaria, Varese, Italy|Comerio, Varese, Italy|Cunardo, Varese, Italy|Fagnano Olona, Varese, Italy|Induno Olona, Varese, Italy|Sesto Calende, Varese, Italy|Solbiate Olona, Varese, Italy|Vedano Olona, Varese, Italy|Vergiate, Varese, Italy|Albano Sant'Alessandro, Italy|Varese, Italy",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Withdrawn,NCT03027167,DVT - DEEP VEIN THROMBOSIS|PE - PULMONARY THROMBOEMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01867281,"ASTHMA, ASPIRIN-INDUCED",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01464944,RESPIRATORY TRACT INFECTIONS|FEVER,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Kiev, Ukraine|Kiev, Ukraine|Lugansk, Ukraine",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01465009,COMMON COLD|PHARYNGITIS|TONSILLITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Reading, Berkshire, United Kingdom|Manchester, Greater Manchester, United Kingdom|Chorley, Lancashire, United Kingdom|Wigan, Lancashire, United Kingdom|Liverpool, Merseyside, United Kingdom|Liverpool, Merseyside, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Birmingham, West Midlands, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00946,__PHENPROCOUMON,4334020,Completed,NCT00586287,PULMONARY EMBOLISM|ATRIAL FIBRILLATION|HIP REPLACEMENT POSTOPERATIVE|KNEE REPLACEMENT POSTOPERATIVE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St. Gallen, St. Gallen, Switzerland",C12R1/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,24.049775149387003,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,280.3178,46.53,2.0,1.0,3.0,29.92,81.64,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",A61K9/0056,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00794768,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02175485,RHINITIS ALLERGIC,All,"20 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 392-001, Shinjuku-ku, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00741897,"RHINITIS, ALLERGIC, PERENNIAL",All,6 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-aventis administrative office, Makati City, Philippines",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00637884,CAT INDUCED ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Terminated,NCT03028129,"TUBERCULOSIS, PULMONARY|ANTIBIOTIC PROPHYLAXIS",Male,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Roberto Oliveira, Dourados, Mato Grosso Do Sul, Brazil",C08G73/08,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT02901288,"TUBERCULOSIS, PULMONARY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT02331823,REINFECTION PULMONARY TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Completed,NCT00298870,PULMONARY TUBERCULOSIS,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Osaka, Japan|Osaka Hospital, Anti-Tuberculosis Association, Osaka Branch, Neyagawa, Osaka, Japan|National Hospital Organization Kinki-chuo Chest Medical Center, Sakai, Osaka, Japan|National Hospital Organization Toneyama, Toyonaka, Osaka, Japan",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT01395654,"HEPATITIS|TUBERCULOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chest Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00956,__HYDROCODONE,6348216,Terminated,NCT02296840,RECURRENT TONSILLITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDERED BREATHING|ADVERSE REACTION TO DRUG,All,4 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,56.346126203823395,1296.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.13,299.3642,38.77,4.0,0.0,5.0,32.05,82.74,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT04263402,2019-NCOV SEVERE PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department and Institute of Infectious Disease, Wuhan, Hubei, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT02552342,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT03978559,PNEUMOCYSTIS PNEUMONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MICU of Peking Union Medical College, Beijing, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01205984,CHRONIC RHINOSINUSITIS|CHILDREN,All,6 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gazi University Faculty of Medicine, Ankara, Turkey",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT04192656,SUDDEN HEARING LOSS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Tsinhgua Changgung Hospital, Beijing, Beijing, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT03393949,LUNG NEOPLASMS,All,65 Years to 85 Years   (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shengjing hospital of China medical university, Shenyang, Liaoning, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT02819453,ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital , Tongji University, Shanghai, Shanghai, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT02115997,WEGENER'S GRANULOMATOSIS OR MICROSCOPIC POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Sir Gangaram Hospital, New Delhi, Delhi, India|Medanta-The Medicity, Gurgaon, Haryana, India|Fortis Memorial Research Instititute, Gurgaon, Haryana, India|Apollo BGS Hospitals, Mysuru, Karnataka, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India|Manipal Hospital, Bangalore, India|St. John's Medical College Hospital; Rheumatology, Bangalore, India|Chanre Rheumatology and Immunology Center and Research, Bangalore, India|MULJIBHAI PATEL UROLOGICAL HOSPITAL; Nephrology, Gujarat, India|Medica Superspeciality Hospital, Kolkata, India|Jasleen Hospital, Nagpur, India|Max Super Speciality Hospital, New Delhi, India|All India Institute of Medical Sciences (AIIMS); Rheumatology, New Delhi, India|Indraprastha Apollo Hospitals; Department of Rheumatology, New Delhi, India|Fortis Hospital, Noida, India|Christian Med Clg & Hspt, Vellore, India",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Terminated,NCT01281748,COPD,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario de Getafe, Getafe, Madrid, Spain",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,1,DB00966,__TELMISARTAN,5591762,Completed,NCT01830530,HYPERTENSION|HIGH ALTITUDE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universidad Peruana Cayetano Heredia, Lima, Peru",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,19.252962073143106,181.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.66,514.6169,72.94,4.0,1.0,6.0,58.61,164.49,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT02507635,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00867191,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00805584,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT00979615,VASOMOTOR RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Terminated,NCT02953106,"ASTHMA, ALLERGIC|RHINITIS,ALLERGIC|ALLERGY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00261105,RESPIRATORY TRACT INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Terminated,NCT00132951,RESPIRATORY TRACT INFECTIONS|CHRONIC BRONCHITIS|PNEUMONIA,All,18 Years to 35 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Québec, Canada",C07H17/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Withdrawn,NCT00245453,"PNEUMONIA, BACTERIAL|BRONCHITIS, CHRONIC",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Western Kentucky Pulmonary Clinic, Louisville, Kentucky, United States|Northshore Research Associates, Slidell, Louisiana, United States",C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00538018,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Terminated,NCT00245440,MAXILLARY SINUSITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Southeastern Researchs Associates,Inc., Taylors, South Carolina, United States",C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00174694,SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00546676,COMMUNITY ACQUIRED PNEUMONIA (CAP)|ACUTE EXACERBATION OF CHRONIC BRONCHITIS (AECB),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00538148,"BRONCHITIS, CHRONIC",All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,1,DB00976,__TELITHROMYCIN,5635485,Completed,NCT00132938,CHRONIC BRONCHITIS,All,"35 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis, Bridgewater, New Jersey, United States|Sanofi-Aventis, Brussels, Belgium|Sanofi-Aventis, Paris, France|Sanofi-Aventis, Budapest, Hungary|Sanofi-Aventis, Casablanca, Morocco|Sanofi-Aventis, Barcelona, Spain|Sanofi-Aventis, Megrine, Tunisia|Sanofi-Aventis, Istanbul, Turkey",C07H17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,25.4296802809092,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,812.018,171.85,11.0,1.0,5.0,90.44,214.68,11.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,1,0,1
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,1,DB00980,__RAMELTEON,6034239,Recruiting,NCT03265951,INSOMNIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Veterans Affairs Medical Center in Buffalo, Buffalo, New York, United States",C07D263/62,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,36.04180783999671,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,38.33,2.0,1.0,3.0,29.99,75.52,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,1,DB00980,__RAMELTEON,6034239,Completed,NCT00316992,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Los Angeles, California, United States|Santa Monica, California, United States|Naples, Florida, United States|St. Petersburg, Florida, United States|Louisville, Kentucky, United States|Lincoln, Nebraska, United States|New York, New York, United States",C07D263/62,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,36.04180783999671,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,38.33,2.0,1.0,3.0,29.99,75.52,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Withdrawn,NCT00633776,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|COPD|CHRONIC BRONCHITIS|EMPHYSEMA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA David Geffen School of Medicine, Los Angeles, California, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT02533505,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Hartford, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT00139932,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT01769898,BRONCHIECTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT00819637,ACUTE ASTHMA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Henry Ford Hospital Emergency Department, Detroit, Michigan, United States",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT02526758,PULMONARY DISEASE，CHRONIC OBSTRUCTIVE;,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT00460577,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",All,5 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator site - five sites in Caracas, Caracas, Venezuela|Novartis Investigator Site, Maracaibo, Venezuela",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT01845025,PERSISTENT ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Avondale, Arizona, United States|Novartis Investigative Site, North Hollywood, California, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Conyers, Georgia, United States|Novartis Investigative Site, Stone Mountain, Georgia, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Gaithersburg, Maryland, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, North Massapequa, New York, United States|Novartis Investigative Site, Elizabeth City, North Carolina, United States|Novartis Investigative Site, Winston Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oaks, Pennsylvania, United States|Novartis Investigative Site, East Greenwich, Rhode Island, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Saint George, Utah, United States|Novartis Investigative Site, Mequon, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT00680056,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|CHRONIC BRONCHITIS|PULMONARY EMPHYSEMA",All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Sao Paulo, Brazil",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT04520230,COPD,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT01466712,COPD|EMPHYSEMA|SMALL AIRWAY DISEASE,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University Hospitals Leuven, Leuven, Flanders, Belgium",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT03563001,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME|SMALL AIRWAY DISEASE|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT03551197,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|EXERCISE|LUNG FUNCTION DECREASED|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT01912872,SEVERE IGE-MEDIATED ASTHMA,All,"6 Years to 55 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Tuxtla Gutierrez, Chiapas, Mexico|Novartis Investigative Site, Mexico City, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Edo. De México, Mexico|Novartis Investigative Site, Nezahualcoyotl, Estado De Mexico, Mexico|Novartis Investigative Site, Pachuca de Soto, Hidalgo, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadaljara, Jalisco, Mexico|Novartis Investigative Site, Tepic, Nayarit, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mérida, Yucatán, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT01787097,CHRONIC OBSTRUCTIVE LUNG DISEASE,All,"35 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Royal Brompton and Harefield NHS trust, London, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT02345993,ASTHMA|ASTHMATIC CRISIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","National Institute of Respiratory Diseases, Mexico, Distrito Federal, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,1,DB00986,__GLYCOPYRRONIUM,6433003,Completed,NCT02236611,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Paraná, Buenos Aires, Argentina|GSK Investigational Site, Concepcion del Uruguay, Entre Ríos, Argentina|GSK Investigational Site, San Rafael, Mendoza, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, San Miguel de Tucuman, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Concepción, Región Del Biobio, Chile|GSK Investigational Site, Talca, Región Del Maule, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Jindrichuv Hradec, Czechia|GSK Investigational Site, Kralupy nad Vltavou, Czechia|GSK Investigational Site, Lovosice, Czechia|GSK Investigational Site, Ostrava - Poruba, Czechia|GSK Investigational Site, Rudna U Prahy, Czechia|GSK Investigational Site, Trebic, Czechia|GSK Investigational Site, Varnsdorf, Czechia|GSK Investigational Site, Bamberg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Brinkum/Stuhr, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Balassagyarmat, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Kapuvár, Hungary|GSK Investigational Site, Nagykanizsa, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Hakadal, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Hønefoss, Norway|GSK Investigational Site, Kolbjørnsvik, Norway|GSK Investigational Site, Kongsvinger, Norway|GSK Investigational Site, Løvenstad, Norway|GSK Investigational Site, Ålesund, Norway|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj Napoca, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Ramnicu Valcea, Romania|GSK Investigational Site, Suceava, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chita, Russian Federation|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, Ryazan,, Russian Federation|GSK Investigational Site, Saint Petesburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Laredo, Cantabria, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Fuenlabrada / Madrid, Spain|GSK Investigational Site, La Roca Del Valles (Barcelona), Spain|GSK Investigational Site, Peralada( Girona), Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.7952319349473,191.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,318.4305,46.53,2.0,1.0,3.0,35.88,101.08,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,1,DB00986,__GLYCOPYRRONIUM,6433003,Completed,NCT02181023,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Fondazione Salvatore Maugeri, Milan, Italy",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,27.7952319349473,191.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,318.4305,46.53,2.0,1.0,3.0,35.88,101.08,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,1,DB00986,__GLYCOPYRRONIUM,6433003,Completed,NCT01985334,COPD,All,"40 Years to 95 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Amstetten, Austria|Novartis Investigative Site, Feldkirch, Austria|Novartis Investigative Site, Hallein, Austria|Novartis Investigative Site, Kirchdorf an der Krems, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Perg, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Gosselies, BEL, Belgium|Novartis Investigative Site, Gozee, BEL, Belgium|Novartis Investigative Site, Zichem, BEL, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Balen, Belgium|Novartis Investigative Site, Braine l'Alleud, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Eghezee, Belgium|Novartis Investigative Site, Erpent, Belgium|Novartis Investigative Site, Geraardsbergen, Belgium|Novartis Investigative Site, Gilly, Belgium|Novartis Investigative Site, Halen, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Heusy, Belgium|Novartis Investigative Site, Ieper, Belgium|Novartis Investigative Site, Knokke-Heist, Belgium|Novartis Investigative Site, Lebbeke, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Maaseik, Belgium|Novartis Investigative Site, Malmedy, Belgium|Novartis Investigative Site, Mechelen, Belgium|Novartis Investigative Site, Melsbroek, Belgium|Novartis Investigative Site, Merksem, Belgium|Novartis Investigative Site, Montegnée, Belgium|Novartis Investigative Site, Natoye, Belgium|Novartis Investigative Site, Paal-Beringen, Belgium|Novartis Investigative Site, Ronse, Belgium|Novartis Investigative Site, Saint-Medard, Belgium|Novartis Investigative Site, Seraing, Belgium|Novartis Investigative Site, Tournai, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Vilvoorde, Belgium|Novartis Investigative Site, Zottegem, Belgium|Novartis Investigative Site, Boskovice, Czech Republic, Czechia|Novartis Investigative Site, Brandys Nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Brno-Kralovo Pole, Czech Republic, Czechia|Novartis Investigative Site, Cvikov, Czech Republic, Czechia|Novartis Investigative Site, Havlickuv Brod, Czech Republic, Czechia|Novartis Investigative Site, Jirkov, Czech Republic, Czechia|Novartis Investigative Site, Kurim, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Lovosice, Czech Republic, Czechia|Novartis Investigative Site, Neratovice, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Pardubice, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Prague 4, Czech Republic, Czechia|Novartis Investigative Site, Prague, Czech Republic, Czechia|Novartis Investigative Site, Praha 10, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Praha 6, Czech Republic, Czechia|Novartis Investigative Site, Praha 9, Czech Republic, Czechia|Novartis Investigative Site, Praha, Czech Republic, Czechia|Novartis Investigative Site, Rokycany, Czech Republic, Czechia|Novartis Investigative Site, Rudna, Czech Republic, Czechia|Novartis Investigative Site, Teplice, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Varnsdorf, Czech Republic, Czechia|Novartis Investigative Site, Zatec, Czech Republic, Czechia|Novartis Investigative Site, Znojmo, Czech Republic, Czechia|Novartis Investigative Site, Praha 8, Czechia|Novartis Investigative Site, Alleroed, Denmark|Novartis Investigative Site, Greve, Denmark|Novartis Investigative Site, Haslev, Denmark|Novartis Investigative Site, Søborg, Denmark|Novartis Investigative Site, Værløse, Denmark|Novartis Investigative Site, Paide, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Tours Cedex 9, Indre Et Loire, France|Novartis Investigative Site, Briis Sous Forges, France|Novartis Investigative Site, Chamalieres, France|Novartis Investigative Site, Chatellerault, France|Novartis Investigative Site, Forbach, France|Novartis Investigative Site, L'Aigle, France|Novartis Investigative Site, La Bouexiere, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Murs Erigne, France|Novartis Investigative Site, Nice, France|Novartis Investigative Site, Saint Jean de Luz, France|Novartis Investigative Site, Saint Laurent Du Var, France|Novartis Investigative Site, Saint Pierre, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulon, France|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Peine, Niedersachsen, Germany|Novartis Investigative Site, Warendorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koblenz, NRW, Germany|Novartis Investigative Site, Essen, Rheinland Pfalz, Germany|Novartis Investigative Site, Cottbus, Sachsen, Germany|Novartis Investigative Site, Geesthacht, Schleswig Holstein, Germany|Novartis Investigative Site, Annaberg-Buchholz, Germany|Novartis Investigative Site, Auerbach, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Neustadt, Germany|Novartis Investigative Site, Bad Salzuflen, Germany|Novartis Investigative Site, Bad Woerishofen, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bensheim, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Bruchsal, Germany|Novartis Investigative Site, Burgwedel, Germany|Novartis Investigative Site, Daaden, Germany|Novartis Investigative Site, Dachau, Germany|Novartis Investigative Site, Deggendorf, Germany|Novartis Investigative Site, Deggingen, Germany|Novartis Investigative Site, Delitzsch, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dueren, Germany|Novartis Investigative Site, Dusseldorf, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Foehren, Germany|Novartis Investigative Site, Frankenberg (Eder), Germany|Novartis Investigative Site, Frankfurt am Main, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Freudenberg, Germany|Novartis Investigative Site, Furstenwalde, Germany|Novartis Investigative Site, Fürstenwalde/Spree, Germany|Novartis Investigative Site, Garmisch-Partenkirchen, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Gießen, Germany|Novartis Investigative Site, Gifhorn, Germany|Novartis Investigative Site, Goch, Germany|Novartis Investigative Site, Goerlitz, Germany|Novartis Investigative Site, Gummersbach, Germany|Novartis Investigative Site, Gütersloh, Germany|Novartis Investigative Site, Hagen, Germany|Novartis Investigative Site, Halberstadt, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hettstedt, Germany|Novartis Investigative Site, Hildesheim, Germany|Novartis Investigative Site, Hoyerswerda, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Jerichow, Germany|Novartis Investigative Site, Kamen, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Köthen, Germany|Novartis Investigative Site, Landau-Pfalz, Germany|Novartis Investigative Site, Landsberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leonberg, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis Investigative Site, Limburgerhof, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Ludwigsburg, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Luedenscheid, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Mayen, Germany|Novartis Investigative Site, Meine, Germany|Novartis Investigative Site, Meissen, Germany|Novartis Investigative Site, Menden, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Mittweida, Germany|Novartis Investigative Site, Mülheim, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Münnerstadt, Germany|Novartis Investigative Site, Neu Isenburg, Germany|Novartis Investigative Site, Neu-Ulm, Germany|Novartis Investigative Site, Neunkirchen, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Northeim, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Obermichelbach, Germany|Novartis Investigative Site, Oschatz, Germany|Novartis Investigative Site, Oschersleben, Germany|Novartis Investigative Site, Osnabrueck, Germany|Novartis Investigative Site, Papenburg, Germany|Novartis Investigative Site, Passau, Germany|Novartis Investigative Site, Plauen, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Prien A. Chiemsee, Germany|Novartis Investigative Site, Radebeul, Germany|Novartis Investigative Site, Ratingen, Germany|Novartis Investigative Site, Raubach, Germany|Novartis Investigative Site, Reinfeld, Germany|Novartis Investigative Site, Rheine, Germany|Novartis Investigative Site, Rodenbach, Germany|Novartis Investigative Site, Roth, Germany|Novartis Investigative Site, Rudersdorf, Germany|Novartis Investigative Site, Rüsselsheim,, Germany|Novartis Investigative Site, Rüsselsheim, Germany|Novartis Investigative Site, Saalfeld, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Schleswig, Germany|Novartis Investigative Site, Schwabach, Germany|Novartis Investigative Site, Schwedt, Germany|Novartis Investigative Site, Schwerin, Germany|Novartis Investigative Site, Schwetzingen, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Sinsheim, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Sonneberg, Germany|Novartis Investigative Site, Strausberg, Germany|Novartis Investigative Site, Teuchern, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wardenburg, Germany|Novartis Investigative Site, Weilheim, Germany|Novartis Investigative Site, Welzheim, Germany|Novartis Investigative Site, Westerkappeln, Germany|Novartis Investigative Site, Wiesloch, Germany|Novartis Investigative Site, Wissen, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Woellstein, Germany|Novartis Investigative Site, Wolfsburg, Germany|Novartis Investigative Site, Zerbst, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Serres, Greece|Novartis Investigative Site, Gyor, HUN, Hungary|Novartis Investigative Site, Szazhalombatta, HUN, Hungary|Novartis Investigative Site, Cegled, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Hatvan, Hungary|Novartis Investigative Site, Komarom, Hungary|Novartis Investigative Site, Mako, Hungary|Novartis Investigative Site, Mateszalka, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Torokbalint, Hungary|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Terlizzi, BA, Italy|Novartis Investigative Site, Triggiano, BA, Italy|Novartis Investigative Site, Romano di Lombardia, BG, Italy|Novartis Investigative Site, Feltre, BL, Italy|Novartis Investigative Site, Telese Terme, BN, Italy|Novartis Investigative Site, San Pietro Vernotico, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Campobasso, CB, Italy|Novartis Investigative Site, Marcianise, CE, Italy|Novartis Investigative Site, Caltanissetta, CL, Italy|Novartis Investigative Site, Saluzzo, CN, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Forlì, FC, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, San Severo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Lodi, LO, Italy|Novartis Investigative Site, Lido di Camaiore, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Cittadella, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pordenone, PN, Italy|Novartis Investigative Site, Voghera, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Riccione, RN, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sondalo, SO, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Montebelluna, TV, Italy|Novartis Investigative Site, Vittorio Veneto, TV, Italy|Novartis Investigative Site, Busto Arsizio, VA, Italy|Novartis Investigative Site, Arzignano, VI, Italy|Novartis Investigative Site, Vicenza, VI, Italy|Novartis Investigative Site, Bussolengo, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Torino, Italy|Novartis Investigative Site, Balvi, LVA, Latvia|Novartis Investigative Site, Jurmala, LVA, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Vilnius, LTU, Lithuania|Novartis Investigative Site, Kaunas, LT, Lithuania|Novartis Investigative Site, Vilnius, LT, Lithuania|Novartis Investigative Site, Alytus, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Utena, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Førde, Norway|Novartis Investigative Site, Kløfta, Norway|Novartis Investigative Site, Lierskogen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Skedsmokorset, Norway|Novartis Investigative Site, Skien, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tananger, Norway|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Nowy Dwor Mazowiecki, Poland|Novartis Investigative Site, Ostrow Wielkopolski, Poland|Novartis Investigative Site, Pila, Poland|Novartis Investigative Site, Sopot, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Aveiro, Portugal|Novartis Investigative Site, Barcelos, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Guimarães, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Vila Franca de Xira, Portugal|Novartis Investigative Site, Vila Nova de Gaia, Portugal|Novartis Investigative Site, Bucharest, District 3, Romania|Novartis Investigative Site, Iasi, Jud. Iasi, Romania|Novartis Investigative Site, Bacau, Romania|Novartis Investigative Site, Bragadiru, Romania|Novartis Investigative Site, Constanta, Romania|Novartis Investigative Site, Ramnicu Valcea, Romania|Novartis Investigative Site, Suceava, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Bardejov, Slovak Republic, Slovakia|Novartis Investigative Site, Bojnice, Slovak Republic, Slovakia|Novartis Investigative Site, Liptovsky Hradok, Slovak Republic, Slovakia|Novartis Investigative Site, Námestovo, Slovensko, Slovakia|Novartis Investigative Site, Kralovsky Chlmec, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Sala, Slovakia|Novartis Investigative Site, Sturovo, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Vrable, Slovakia|Novartis Investigative Site, Golnik, Slovenia|Novartis Investigative Site, Kranj, Slovenia|Novartis Investigative Site, Maribor, Slovenia|Novartis Investigative Site, Murska Sobota, Slovenia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Málaga, Andalucia, Spain|Novartis Investigative Site, Badalona, Barcelona, Spain|Novartis Investigative Site, Centelles, Barcelona, Spain|Novartis Investigative Site, Mataro, Barcelona, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Vic, Barcelona, Spain|Novartis Investigative Site, Ponferrada, Castilla Y Leon, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Canet de Mar, Cataluna, Spain|Novartis Investigative Site, Sant Boi de Llobregat, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Vic, Cataluña, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Benidorm, Comunidad Valenciana, Spain|Novartis Investigative Site, Puerto De Sagunto, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Merida, Extremadura, Spain|Novartis Investigative Site, Motril, Granada, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Palma de Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Madrid, Communidad De, Spain|Novartis Investigative Site, Mostoles, Madrid, Communidad De, Spain|Novartis Investigative Site, Valdemoro, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Linkoping, Ostergotlands Lan, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Gustavsberg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Hollviken, Sweden|Novartis Investigative Site, Kungshamn, Sweden|Novartis Investigative Site, Limhamn, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Råå, Sweden|Novartis Investigative Site, Umea, Sweden|Novartis Investigative Site, Vastra Frolunda, Sweden|Novartis Investigative Site, Aylesbury, Bucks, United Kingdom|Novartis Investigative Site, Fowey, Cornwall, United Kingdom|Novartis Investigative Site, Liskeard, Cornwall, United Kingdom|Novartis Investigative Site, Penzance, Cornwall, United Kingdom|Novartis Investigative Site, Redruth, Cornwall, United Kingdom|Novartis Investigative Site, St Austell, Cornwall, United Kingdom|Novartis Investigative Site, Torpoint, Cornwall, United Kingdom|Novartis Investigative Site, Bath, England, United Kingdom|Novartis Investigative Site, Havant, Hampshire, United Kingdom|Novartis Investigative Site, Burbage, Leicester, United Kingdom|Novartis Investigative Site, Daventry, Northamptonshire, United Kingdom|Novartis Investigative Site, Sneinton, Nottingham, United Kingdom|Novartis Investigative Site, Axbridge, Somerset, United Kingdom|Novartis Investigative Site, Frome, Somerset, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, South Shields, Tyne And Wear, United Kingdom|Novartis Investigative Site, Barry, Vale Of Glamorgan, United Kingdom|Novartis Investigative Site, Leamington Spa, Warwickshire, United Kingdom|Novartis Investigative Site, Crawley, West Sussex, United Kingdom|Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom|Novartis Investigative Site, Trowbridge, Wiltshire, United Kingdom|Novartis Investigative Site, Strensall, Yorkshire, United Kingdom|Novartis Investigative Site, Bexhill-on-Sea, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Chadderton, United Kingdom|Novartis Investigative Site, Cheshire, United Kingdom|Novartis Investigative Site, Chesterfield, United Kingdom|Novartis Investigative Site, Chippenham, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Hamilton, United Kingdom|Novartis Investigative Site, Lancashire, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Motherwell, United Kingdom|Novartis Investigative Site, Oldham, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, South Yorkshire, United Kingdom|Novartis Investigative Site, Stockton on Tees, United Kingdom|Novartis Investigative Site, Vale Of Glanmorgan, United Kingdom|Novartis Investigative Site, Watford, United Kingdom|Novartis Investigative Site, Wiltshire, United Kingdom|Novartis Investigative Site, Wishaw, United Kingdom",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.7952319349473,191.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,318.4305,46.53,2.0,1.0,3.0,35.88,101.08,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,1,DB00986,__GLYCOPYRRONIUM,6433003,Completed,NCT02622243,ASTHMA,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma Research Lab, Saskatoon, Saskatchewan, Canada",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,27.7952319349473,191.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,318.4305,46.53,2.0,1.0,3.0,35.88,101.08,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,"HEART FAILURE, DIASTOLIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Recruiting,NCT03164473,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Terminated,NCT00128895,VASCULITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU University Medical Centre, Amsterdam, Netherlands|University Medical Centre Groningen, Groningen, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|University Hospital Maastricht, Maastricht, Netherlands|UMC St Radboud, Nijmegen, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|University Medical Centre Utrecht, Utrecht, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Active Not Recruiting,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,,IGA NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Recruiting,NCT03625011,TONSILLITIS|TONSILLECTOMY,All,"3 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Children's Healthcare of Atlanta, Atlanta, Georgia, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02926573,HEAD AND NECK CANCER|ACUTE PAIN|POSTOPERATIVE PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00153283,BRONCHIAL ASTHMA,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,1,DB00998,__FROVATRIPTAN,5464864,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,22.47274071336161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,243.3043,70.91,2.0,3.0,3.0,27.55,71.84,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Unknown status,NCT02699125,OBSTRUCTIVE SLEEP APNEA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT02710071,HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Withdrawn,NCT02319564,WHEEZE,All,12 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT02182856,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00911651,COPD,All,"40 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antwerp University Hospital, Antwerp, Belgium",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00667797,ASTHMA|COPD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Birmingham, Alabama, United States|Chula Vista, California, United States|Oakland, California, United States|Wheat Ridge, Colorado, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Brandon, Florida, United States|Des Moines, Iowa, United States|Johnson City, New Jersey, United States|Great Neck, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Winston Salem, North Carolina, United States|Portland, Oregon, United States|Pittsburg, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Morgantown, West Virginia, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Terminated,NCT00600639,ACUTE RESPIRATORY FAILURE,All,76 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Scientifico di Pavia Fondazione Salvatore Maugeri, Pavia, Italy",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT03493503,CHILDHOOD ASTHMA WITH STATUS ASTHMATICUS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT01112241,OBLITERATIVE BRONCHIOLITIS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Unit of Preventive and Occupational Medicine - Laboratory of Respiratory Pathophysiology, University Hospital San Martino, Genoa, Italy",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Terminated,NCT00361452,RSV BRONCHIOLITIS,All,up to 1 Year   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pediatric Ward, Rambam Medical Centre, Haifa, Israel",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT02447250,BRONCHOPULMONARY DYSPLASIA|VERY LOW BIRTH WEIGHT,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Doernbecher Neonatal Care Center at Oregon Health & Science University, Portland, Oregon, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Not yet recruiting,NCT04184609,"ASTHMA IN CHILDREN|DYSPNEA; ASTHMATIC|OBESITY, CHILDHOOD",All,9 Years to 12 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Nevada Las Vegas, Las Vegas, Nevada, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Recruiting,NCT03586544,"ASTHMA IN CHILDREN|OBESITY, CHILDHOOD|EXERCISE INDUCED BRONCHOSPASM",All,8 Years to 12 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Childrens Lung Specialists, Las Vegas, Nevada, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Suspended,NCT02966184,STATUS ASTHMATICUS,All,5 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norton Children's Hospital, Louisville, Kentucky, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Recruiting,NCT02797275,SECONDHAND SMOKE|AIR TRAPPING|TOBACCO|AIRFLOW LIMITATION|HYPERINFLATION|OBSTRUCTIVE LUNG DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VA Medical Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00325767,MUCOCILIARY CLEARANCE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Eudowood Division of Pediatric Respiratory Sciences, Baltimore, Maryland, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT01922271,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Gelsenkirchen, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Gummersbach, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Rüdersdorf, Germany|Novartis Investigative Site, Sonneberg, Germany",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT00900874,BRONCHIAL ASTHMA,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AIIMS, New Delhi, India",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Not yet recruiting,NCT03880903,ACUTE BRONCHIOLITIS,All,up to 24 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT02914652,VENTRICULAR SEPTAL DEFECT,All,21 Years to 26 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dept. of Cardiothoracic and Vascular Surgery, Aarhus, Denmark",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT03044938,ASTHMA|HEART RATE FAST,All,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Jaqueline Ribas de Melo, Sao Paulo, São Paulo, Brazil",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,"Active, not recruiting",NCT03924635,AIRWAY INFLAMMATION|ASTHMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Bradford, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Watford, United Kingdom",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT01721291,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|ASTHMA|HEALTHY SUBJECTS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Brompton Hospital & Imperial College London, London, United Kingdom",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT03333395,MECHANICALLY VENTILATED PATIENTS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Internal Medicine ICU of Ain-Shams University Hospitals, Cairo, Egypt",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT01903785,BRONCHOCONSTRICTION|INHALED SALBUTAMOL|CYCLING PERFORMANCE,All,19 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Environmental Physiology Laboratory, University of British Columbia, Vancouver, British Columbia, Canada",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT01978418,POSTNATAL PULMONARY ADAPTATION|CESAREAN SECTION,All,up to 1 Hour   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Women's Hospital, Helsinki, Finland",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Active Not Recruiting,,AIRWAY INFLAMMATION,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Active Not Recruiting,,AIRWAY OBSTRUCTION,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Active Not Recruiting,,BRADYCARDIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Active Not Recruiting,,GENERAL SURGERY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,ANAESTHESIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,HYPOTENSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,"Active, not recruiting",NCT02152358,VIRAL PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Assistance Publique - Hôpitaux de Marseille, Marseille, France",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,Completed,,INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/5073,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Terminated,NCT00799838,PHARYNGOTONSILLITIS,All,4 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",C07C51/09,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,NCT02178293,PHARYNGITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,GENERAL SURGERY,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/062,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,NCT00000816,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Primary Purpose: Treatment,"USC CRS, Los Angeles, California, United States|Stanford CRS, Palo Alto, California, United States|Ucsf Aids Crs, San Francisco, California, United States|Santa Clara Valley Med. Ctr., San Jose, California, United States|San Mateo County AIDS Program, San Mateo, California, United States|Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami AIDS CRS, Miami, Florida, United States|Queens Med. Ctr., Honolulu, Hawaii, United States|Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States|Northwestern University CRS, Chicago, Illinois, United States|Cook County Hosp. CORE Ctr., Chicago, Illinois, United States|Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Methodist Hosp. of Indiana, Indianapolis, Indiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States|Bmc Actg Crs, Boston, Massachusetts, United States|Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States|Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States|Hennepin County Med. Ctr., Div. of Infectious Diseases, Minneapolis, Minnesota, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States|Washington U CRS, St. Louis, Missouri, United States|Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr., Omaha, Nebraska, United States|SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States|NY Univ. HIV/AIDS CRS, New York, New York, United States|Beth Israel Med. Ctr. (Mt. Sinai), New York, New York, United States|Univ. of Rochester ACTG CRS, Rochester, New York, United States|Unc Aids Crs, Chapel Hill, North Carolina, United States|Carolinas HealthCare System, Carolinas Med. Ctr., Charlotte, North Carolina, United States|Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States|Case CRS, Cleveland, Ohio, United States|The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States|University of Washington AIDS CRS, Seattle, Washington, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Mbeya Med. Research Program, Mbeya Referral Hosp. CRS, Mbeya, Tanzania",A61L15/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,NCT00137657,HIV|MALARIA|DIARRHEA|PNEUMONIA|OPPORTUNISTIC INFECTIONS,All,"15 Years and older   (Child, Adult, Older Adult)",U.S. Fed|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,"CDC KEMRI Research Institute, Kisumu, Kenya",A61L15/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,NCT01167452,OBESITY|PHARMACOKINETICS|MRSA|TUBERCULOSIS|PCP,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61L15/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,,ANTIBIOTIC SIDE EFFECT,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,1,DB01017,__MINOCYCLINE,5908838,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,1,DB01018,__GUANFACINE,5854290,Unknown status,NCT02699125,OBSTRUCTIVE SLEEP APNEA,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,39.2615864802152,71.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.28,246.093,78.97,3.0,3.0,1.0,21.75,69.63,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,1,DB01026,__KETOCONAZOLE,5456851,Completed,NCT01378520,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",A61K8/49,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0
COC(F)(F)C(Cl)Cl,1,DB01028,__METHOXYFLURANE,,Not yet recruiting,NCT04287803,"PAIN, ACUTE|TRAUMA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Dr Michael A Austin, Ottawa, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,164.96599999999995,9.23,1.0,0.0,0.0,11.46,27.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
COC(F)(F)C(Cl)Cl,1,DB01028,__METHOXYFLURANE,,Completed,NCT03894800,ACUTE PAIN|TRAUMA|HYPOVOLEMIA,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Harald Lenz, Oslo, Norway",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,164.96599999999995,9.23,1.0,0.0,0.0,11.46,27.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,1,DB01032,__PROBENECID,3959253,Completed,NCT00304434,INFLUENZA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"VA Palo Alto Health Care System, Palo Alto, California, United States",C07H13/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,34.760467360726,3576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,285.3590000000001,74.68,4.0,1.0,1.0,29.96,73.81,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02778893,NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"XZhang, Zhengzhou, Henan, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT02901288,"TUBERCULOSIS, PULMONARY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT01395654,"HEPATITIS|TUBERCULOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chest Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Completed,NCT00367913,PULMONARY DISEASES,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Llandough Hospital, Penarth, Vale of Glamorgan, United Kingdom",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Suspended,NCT02547116,CYSTIC FIBROSIS|MRSA,All,"12 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Recruiting,NCT03918135,FEVER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pamukkale University, Denizli, Turkey",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Recruiting,NCT04334629,CORONAVIRUS|RESPIRATORY DISTRESS SYNDROME|SARS-COV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01891084,INFLUENZA,All,18 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University Health Service, The Hong Kong Polytechnic University, Hong Kong, Hksar, China",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Unknown status,NCT01681667,PHARYNGITIS,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Albany Medical Center Emergency Department, Albany, New York, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Recruiting,NCT03783702,SINUSITIS|OPIOID USE|OPIOID ABUSE|NARCOTIC USE|OTOLARYNGOLOGIC DISEASE|POSTOPERATIVE PAIN|PAIN,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Health Care, Stanford, California, United States|NorthShore University Health System, Evanston, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|Albert Einstein, Bronx, New York, United States|Vanderbilt, Nashville, Tennessee, United States|University of British Columbia, Vancouver, Canada",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Terminated,NCT02296840,RECURRENT TONSILLITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDERED BREATHING|ADVERSE REACTION TO DRUG,All,4 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Children's Healthcare of Atlanta (CHOA), Atlanta, Georgia, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT02244437,"ACUTE MOUNTAIN SICKNESS, BLOOD OXYGEN SATURATION, HEADACHE",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Buddha Basnyat, MD, Kathmandu, Nepal",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Unknown status,NCT00545961,ACUTE RESPIRATORY INFECTION|SINUSITIS,All,6 Years to 13 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Keski-pohjanmaan keskussairaala, Kokkola, Finland|Oulu University Hospital, Oulu, Finland|Etelä-Pohjanmaan Keskussairaala, Seinäjoki, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03809312,CHRONIC SINUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Simon-Pierre Harvey-Bolduc, Québec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03446534,PNEUMONIA CHILDHOOD|LOWER RESPIRATORY TRACT INFECTION,All,12 Months to 59 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Haukeland University Hospital, Bergen, Norway|Nordlandssykehuset Bodø, Bodø, Norway|Østfold Hospital Trust, Grålum, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University of Oslo, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of Northern Norway, Tromsø, Norway|St. Olav University Hospital, Trondheim, Norway|Ålesund Hospital Trust, Ålesund, Norway",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT00493038,SINUSITIS|BACTERIAL INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Benedetto del Tronto, Ascoli Piceno, Italy|Esine, Brescia, Italy|Lamezia Terme, Catanzaro, Italy|Cesena, Forlì, Italy|Sestri Ponente, Genova, Italy|Monza, Monza-Brianza, Italy|Comiso, Ragusa, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bologna, Italy|Bolzano, Italy|Caserta, Italy|Catania, Italy|Catania, Italy|Firenze, Italy|Foggia, Italy|Lecce, Italy|Lecco, Italy|Matera, Italy|Milano, Italy|Milano, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Pisa, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Siena, Italy|Torino, Italy|Torino, Italy|Treviso, Italy|Udine, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT02891915,PNEUMONIA,All,6 Months to 71 Months   (Child),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama - Children's of Alabama - Infectious Diseases/Virology, Birmingham, Alabama, United States|Arkansas Children's Hospital - Infectious Diseases, Little Rock, Arkansas, United States|University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States|Washington University School of Medicine in St. Louis - Infectious Diseases, Saint Louis, Missouri, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric, Pittsburgh, Pennsylvania, United States|Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT01089218,FEVER|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00656747,CHRONIC BRONCHITIS,All,"60 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Escaldes - Engordany, Andorra|Florencio Varela, Buenos Aires, Argentina|Quilmes, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|San Miguel de Tucumán, Tucuman, Argentina|San Miguel de Tucumán, Tucuman, Argentina|Vicente López, Argentina|Concord, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Woodville, South Australia, Australia|Nedlands, Western Australia, Australia|Aalst, Belgium|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Halen, Belgium|Lommel, Belgium|Moerkerke, Belgium|Namur, Belgium|Yvoir, Belgium|Juiz de Fora, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Winnipeg, Manitoba, Canada|Saint John, New Brunswick, Canada|Saint John, New Brunswick, Canada|Antigonish, Nova Scotia, Canada|Sydney Mines, Nova Scotia, Canada|Burlington, Ontario, Canada|Hamilton, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Toronto, Ontario, Canada|Longueuil, Quebec, Canada|Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Santiago, Chile|Valparaíso, Chile|Viña del Mar, Chile|Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Changsha, Hunan, China|Shengyang, Liaoning, China|Shenyang, Liaoning, China|Chengdu, Sichuan, China|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Cali, Cauca, Colombia|Bogotá, Colombia|Bucaramanga, Colombia|Cali, Colombia|Medellín, Colombia|Santafe de Bogotá, Colombia|Osijek, Croatia|Petrinja, Croatia|Rijeka, Croatia|Zagreb, Croatia|Kyjov, Czech Republic|Lovosice, Czech Republic|Neratovice, Czech Republic|Pardubice - Trnova, Czech Republic|Praha - Malesice, Czech Republic|Praha - Troja, Czech Republic|Marseille, France|Mont-de-marsan, France|Nice, France|Perpignan, France|Bad Dürrheim, Baden-Württemberg, Germany|Augsburg, Bayern, Germany|Cottbus, Brandenburg, Germany|Rüdersdorf, Brandenburg, Germany|Zossen, Brandenburg, Germany|Frankfurt, Hessen, Germany|Frankfurt, Hessen, Germany|Fulda, Hessen, Germany|Neubrandenburg, Mecklenburg-Vorpommern, Germany|Lüdenscheid, Nordrhein-Westfalen, Germany|Neuwied, Rheinland-Pfalz, Germany|Böhlen, Sachsen, Germany|Delitzsch, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Leipzig, Sachsen, Germany|Meißen, Sachsen, Germany|Bad Segeberg, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Hamburg, Germany|Hamburg, Germany|Athens, Attica, Greece|Mezourlo, Larissa, Greece|Rio, Patras, Greece|Athens, Greece|Ioannina, Greece|HongKong, Hong Kong|Kowloon, Hong Kong|Bandung, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Killarney, Kerry, Ireland|Enniscorthy, Wexford, Ireland|Gorey, Wexford, Ireland|Bray, Wicklow, Ireland|Longford, Ireland|Pregiato di Cava dei Tirreni, Salerno, Italy|Busto Arsizio, Varese, Italy|Bussolengo, Verona, Italy|Ascoli Piceno, Italy|Catania, Italy|Chieti, Italy|Milano, Italy|Milano, Italy|Perugia, Italy|Kraslava, Latvia|Riga, Latvia|Riga, Latvia|Riga, Latvia|Talsu, Latvia|Valmiera, Latvia|Ventspils, Latvia|Kaunas, Lithuania|Kaunas, Lithuania|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Guadalajara, Jalisco, Mexico|Huixquilucan, México, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Mérida, Yucatán, Mexico|Chihuahua, Mexico|Zacatecas, Mexico|Eindhoven, Noord-Brabant, Netherlands|Heerlen, Netherlands|Hoofddorp, Netherlands|Meppel, Netherlands|Utrecht, Netherlands|Karachi, Sindh, Pakistan|Islamabad, Pakistan|Karachi, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Manila, Philippines|Quezon City, Philippines|Torres Vedras, Lisboa, Portugal|Matosinhos, Porto, Portugal|Vila Nova de Gaia, Porto, Portugal|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|S. Martinho do Bispo, Portugal|Santarém, Portugal|Port Elizabeth, Eastern Cape, South Africa|Bloemfontein, Freestate, South Africa|Benoni, Gauteng, South Africa|Centurion, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Durban, KwaZulu Natal, South Africa|Durban, KwaZulu Natal, South Africa|Thabazimbi, Limpopo, South Africa|Witbank, Mpumalanga, South Africa|Cape Town, Western Cape, South Africa|Paarl, Western Cape, South Africa|Somerset West, Western Cape, South Africa|Badalona, Barcelona, Spain|Sant Boi de Llobregat, Barcelona, Spain|Palma de Mallorca, Illes Baleares, Spain|Requena, Valencia, Spain|Barcelona, Spain|Barcelona, Spain|Guadalajara, Spain|Madrid, Spain|Aarau, Aargau, Switzerland|Laufen, Basel-Landschaft, Switzerland|Oberwil, Basel-Landschaft, Switzerland|Binningen, Basel-Stadt, Switzerland|Basel, Switzerland|Bern, Switzerland|Thun, Switzerland|Wettingen, Switzerland|Zürich, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Chiang Mai, Thailand|Nonthaburi, Thailand|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Glasgow, Stratchclyde, United Kingdom|Coventry, Warwickshire, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Unknown status,NCT03264911,GROUP A STREPTOCOCCAL PHARYNGITIS,All,3 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Geneva (HUG), Geneva, GE, Switzerland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT03431337,"SINUSITIS, ACUTE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center Internal Medicine and Pediatrics, Cohoes, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT02340000,SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center Internal Medicine and Pediatrics, Latham, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00147914,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT00456339,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,18 Months to 12 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT00799838,PHARYNGOTONSILLITIS,All,4 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00603317,ORAL ANTICOAGULATION|DEEP VENOUS THROMBOSIS|ATRIAL FIBRILLATION|PULMONARY EMBOLISM,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hopital Lariboisière - Service de médecine interne, Paris, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00495586,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Clínic, Barcelona, Catalonia, Spain|Primary Healthcare Center La Marina, Barcelona, Catalonia, Spain|Primary Healthcare Center Figueres, Figueres, Catalonia, Spain|Primary Healthcare Center Montilivi, Girona, Catalonia, Spain|Primary Healthcare Center Girona-4, Girona, Catalonia, Spain|Primary Healthcare Centre Breda-Hostalric, Hostalric, Catalonia, Spain|Primary Healthcare Center Lleida, Lleida, Catalonia, Spain|Primary Healthcare Centre Molins de Rei, Molins de Rey, Catalonia, Spain|Primary Healthcare Centre Olot, Olot, Catalonia, Spain|Primary Healthcare Center Reus-3, Reus, Catalonia, Spain|Primary Healthcare Center Les Muralles, Tarragona, Catalonia, Spain|Primary Healthcare Centre Jaume I, Tarragona, Catalonia, Spain|Primary Healthcare Center Valls Urbà, Valls, Catalonia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00190437,CHRONIC OBSTRUCTIVE LUNG DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Assistance Publique-Hopitaux de Paris, Paris, Ile de France, France|Hopital Henri Mondor, Creteil, Val de Marne, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Terminated,NCT01533818,FAST BREATHING IN YOUNG INFANTS,All,up to 59 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Primary Health Centers, Karachi, Sind, Pakistan",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,1,DB01066,__CEFDITOREN,5958915,Unknown status,NCT01553006,RHINOSINUSITIS,All,1 Year to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Thammasat University, Prathumthani, Thailand",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,17.675927637117802,208.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.7,506.57800000000003,160.1,9.0,3.0,4.0,49.19,124.18,7.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT02062710,COUGH REFLEX SENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Einstein Division/Montefiore Medical Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01299194,BRONCHIECTASIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01748279,COPD,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(O)(P(=O)(O)O)P(=O)(O)O,1,DB01077,__ETIDRONIC_ACID,,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,206.0282,135.29,7.0,5.0,0.0,13.97,34.51,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](NC(=N)N)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,1,DB01082,__STREPTOMYCIN,3962429,Unknown status,NCT02331823,REINFECTION PULMONARY TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,22.538450481529303,7028.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.6,581.5741,331.43,19.0,14.0,3.0,55.87,149.47,9.0,1.0,0.0,0.0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0
CCOC(=O)c1ccc(N)cc1,1,DB01086,__BENZOCAINE,4041174,Completed,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,35.7789687673258,1497.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.2,165.1891,52.32,2.0,1.0,1.0,17.46,47.53,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0
CCOC(=O)c1ccc(N)cc1,1,DB01086,__BENZOCAINE,4041174,Completed,,PHARYNGITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,35.7789687673258,1497.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.2,165.1891,52.32,2.0,1.0,1.0,17.46,47.53,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,NCT00403650,SARCOIDOSIS|PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati, Cincinnati, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Terminated,NCT00409526,PULMONARY HYPERTENSION,All,up to 7 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comer Children's Hospital, The University of Chicago Hospitals, Chicago, Illinois, United States|Shaare Zedek Medical Center, Jerusalem, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Recruiting,NCT03620526,HEART FAILURE WITH NORMAL EJECTION FRACTION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","National Taiwan University Hospital, Taipei, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Terminated,NCT00120380,HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hannover Medical School, Hannover, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Unknown status,NCT01116063,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"25 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pulmoanry Division, Carmel Medical Center, Haifa, Israel",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC(C)n1c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1,DB01095,__FLUVASTATIN,5354772,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,10.5464177909197,1359.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.69,411.4659,82.69,4.0,3.0,3.0,44.31,114.86,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1,1,DB01105,__SIBUTRAMINE,5436272,Completed,NCT00729963,OBSTRUCTIVE SLEEP APNEA|OBESITY|HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,33.2819975769523,330.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.05,279.848,3.24,1.0,0.0,2.0,32.9,83.92,5.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)[O-])NC1=O)C(C)O,1,DB01111,__COLISTIMETHATE,,Completed,NCT01844778,CYSTIC FIBROSIS,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Southampton, Hampshire, United Kingdom|Novartis Investigative Site, Penarth, Vale of Glamorgan, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,1634.87,706.71,33.0,18.0,1.0,161.9,370.19,44.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,1,DB01112,__CEFUROXIME,,Completed,NCT00818610,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Centre Hospitalier du Centre du Valais, Sion, Valais, Switzerland|HFR-Fribourg, Hôpital Cantonal, Fribourg, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland|Hôpital Neuchâtelois - La Chaux-de-Fonds, La Chaux-de-Fonds, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Stadtspital Triemli, Zürich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.24,424.385,173.76,7.0,3.0,3.0,38.75,97.17,8.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],1,DB01115,__NIFEDIPINE,5264446,Completed,NCT01830530,HYPERTENSION|HIGH ALTITUDE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universidad Peruana Cayetano Heredia, Lima, Peru",A61K9/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],1,DB01115,__NIFEDIPINE,5264446,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",A61K9/14,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,1,DB01118,__AMIODARONE,5134127,Not yet recruiting,NCT04092621,NEW ONSET ATRIAL FIBRILLATION|SEPSIS|RESPIRATORY FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,645.3116,42.68,3.0,0.0,3.0,56.78,145.05,11.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,1,DB01118,__AMIODARONE,5134127,Unknown status,NCT00724581,ATRIAL FIBRILLATION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aarhus University Hospital, Skejby, Aarhus, Denmark",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,645.3116,42.68,3.0,0.0,3.0,56.78,145.05,11.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",C07D213/30,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Recruiting,NCT04473274,CORONAVIRUS INFECTION|DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT01656005,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Withdrawn,NCT00384566,HEART FAILURE|CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alfred Hospital, Melbourne, Victoria, Australia",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Recruiting,NCT02618057,MYCOPLASMA PNEUMONIAE PNEUMONIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Children's Hospital, Seoul, Korea, Republic of",C07D413/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Unknown status,NCT02600806,COMMUNITY ACQUIRED PNEUMONIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General Universitario de Elche, Elche, Alicante, Spain",C07D413/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Unknown status,NCT02901288,"TUBERCULOSIS, PULMONARY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui Chest Hospital, Hefei, Anhui, China|Beijing Research Institute for Tuberculosis Control, Beijing, Beijing, China|Beijing Chest Hospital,Capital Meical University, Beijing, Beijing, China|Chongqing Infectious Disease Medical Center, Chongqing, Chongqing, China|Pulmonary Hospital of Lanzhou, Lanzhou, Gansu, China|Centre for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China|Guangxi Center for Disease Prevention and Control, Nanning, Guangxi, China|HeBei Province Center for Disease Prevention and Control, Shijiazhuang, Hebei, China|Infectious Disease Prevention Hospital in Heilongjiang Province, Ha'erbin, Heilongjiang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, Heilongjiang, China|Harbin Chest Hospital, Harbin, Heilongjiang, China|The Infectious Hospital of Hebi, Hebi, Henan, China|Kaifeng Pulmonary Disease Hospital, Kaifeng, Henan, China|Sixth People's Hospital of Nanyang City, Nanyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xianxiang, Henan, China|Wuhan medical treatment center, Wuhan, Hubei, China|Wuhan Institute For Tuberculosis Control, Wuhan, Hubei, China|Hunan Institute For Tuberculosis Control, Changsha, Hunan, China|The Sixth People's Hospital of Nantong, Nantong, Jiangsu, China|The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China|The Third People's Hospital of Zenjiang, Zhenjiang, Jiangsu, China|Changchun Infectious Disease Hospital, Changchun, Jilin, China|Tuberculosis Hospital in Jilin Province, Jilin, Jilin, China|China Shenyang Chest Hospital, Shenyang, Jilin, China|The Fourth People's Hospital of Ningxia Autonomous Region, Yinchuan, Ningxia, China|The 4th People's Hospital of Qinghai Province, Xining Shi, Qinghai, China|The Infectious Disease Hospital of Wangkai Zaozhuang, Tengzhou, Shandong, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|Taiyuan Fourth People's Hospital, Taiyuan, Shanxi, China|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province, Xi'an, Shanxi, China|Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China|Tianjin Haihe Hospital, Tianjin, Tianjin, China|Tianjin centers for Disease Control and Prevention, Tianjin, Tianjin, China|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC, Wulumuqi, Xinjiang, China|The Third People's Hospital of Kunming City, Kunming, Yunnan, China",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT01524302,"PNEUMONIA, BACTERIAL|COMMUNITY-ACQUIRED",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sparrow Hospital, Lansing, Michigan, United States",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT02018081,INTENSIVE CARE UNIT SYNDROME|COMMUNITY-ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Toulouse, Toulouse, France",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT00665327,PNEUMONIA,All,65 Years and older   (Older Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mobile, Alabama, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Brea, California, United States|Fullerton, California, United States|La Jolla, California, United States|Madera, California, United States|Bridgeport, Connecticut, United States|Farmington, Connecticut, United States|Stamford, Connecticut, United States|Brandon, Florida, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Austell, Georgia, United States|Blue Ridge, Georgia, United States|Columbus, Georgia, United States|Fort Gordon, Georgia, United States|Marietta, Georgia, United States|Honolulu, Hawaii, United States|Coeur d'Alene, Idaho, United States|Elk Grove Village, Illinois, United States|Springfield, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Cumberland, Maryland, United States|Kalamazoo, Michigan, United States|Royal Oak, Michigan, United States|Duluth, Minnesota, United States|Columbia, Missouri, United States|St. Louis, Missouri, United States|Anaconda, Montana, United States|Omaha, Nebraska, United States|Holmdel, New Jersey, United States|Neptune, New Jersey, United States|Newark, New Jersey, United States|Albany, New York, United States|Johnson City, New York, United States|Kingston, New York, United States|Manhasset, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Elizabeth City, North Carolina, United States|Winston-Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Akron, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Lima, Ohio, United States|Tulsa, Oklahoma, United States|Allentown, Pennsylvania, United States|Beaver, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Summerville, South Carolina, United States|Jackson, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|El Paso, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Lynchburg, Virginia, United States|Norfolk, Virginia, United States|San Juan, Puerto Rico",C07D413/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Terminated,NCT00429975,"PNEUMONIA, PNEUMOCOCCAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT00645073,ACUTE BACTERIAL SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Columbiana, Alabama, United States|Eclectic, Alabama, United States|Tuscaloosa, Alabama, United States|Mesa, Arizona, United States|Fresno, California, United States|Fresno, California, United States|Murray, Kentucky, United States|Portage, Michigan, United States|Eugene, Oregon, United States|Lake Oswego, Oregon, United States|Orangeburg, South Carolina, United States|Kingsport, Tennessee, United States|Milan, Tennessee, United States|Corsicana, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|West Jordan, Utah, United States|Winchester, Virginia, United States|Spokane, Washington, United States|Gorzow Wielkopolski, Poland|Krakow, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Przybyslawice, Poland|Skierniewice, Poland|Szczecin, Poland|Szczecin, Poland|Szczecin, Poland",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT01467297,COPD EXACERBATION,All,"40 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IRCCS Ospedale Maggiore Policlinico via F. Sforza 35, Milan, Italy",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
NCCCNCCSP(=O)(O)O,1,DB01143,__AMIFOSTINE,5424471,Completed,NCT00158041,HEAD AND NECK CANCER|LUNG CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Mt. Sinai Medical Center, Miami Beach, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,NCT00628225,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"35 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Active Not Recruiting,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(=O)O,1,DB01163,__AMDINOCILLIN,4127649,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.41,325.426,73.21,5.0,1.0,3.0,34.18,84.31,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,,FEVER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,NCT01823289,PULMONARY FUNGAL INFECTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,NCT00528190,CYSTIC FIBROSIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Shawn Aaron, The Ottawa Hospital-General Campus, Ottawa, Ontario, Canada|Felix Ratjen, The Hospital for Sick Children, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Terminated,NCT00787917,CYSTIC FIBROSIS|ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator Site, Leuven, Belgium|Novartis Investigator Site, Berlin, Germany|Novartis Investigator Site, Bonn, Germany|Novartis Investigator Site, Munich, Germany|Novartis Investigator Site, Milan, Italy|Novartis Investigator Site, Rome, Italy|Novartis Investigator Site, Nijmegen, Netherlands|Novartis Investigator Site, Utrecht, Netherlands|Novartis Investigator Site, Cambridge, United Kingdom|Novartis Investigator Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,NCT01259336,CHRONIC CAVITARY PULMONARY ASPERGILLOSIS,All,"14 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PGIMER, Chandigarh, Punjab, India",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Terminated,NCT00754793,CHRONIC SINUSITIS|FACIAL PAIN DISORDER|DEPRESSION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Washington Medical Center, Seattle, Washington, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT00872027,DEPRESSION,All,"25 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of Minnesota Medical Center, Minneapolis, Minnesota, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT00621946,SEVERE ASTHMA|MODERATE OR SEVERE MAJOR DEPRESSIVE DISORDER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT01324700,DEPRESSION|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Parkland Health and Hospital System (Asthma, Allergy, & Arthritis Clinics), Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,1,DB01183,__NALOXONE,6159498,Completed,NCT02885948,RESPIRATORY DEPRESSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Prof. Alistair Nichol, Dublin, Ireland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,27.3681184418571,1213.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,327.3743,70.0,5.0,2.0,5.0,33.83,88.72,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Withdrawn,NCT03504033,LIVER FUNCTION AFTER PARTIAL LIVER RESECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital RWTH Aachen University, Department of Anesthesiology, Aachen, Germany",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Recruiting,NCT04074460,"CANCER, BREAST|CANCER COLORECTAL|CANCER PROSTATE|CANCER, LUNG|CANCER MELANOMA SKIN|CANCER, OTHER",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Peter MacCallum Cancer Centre, Melbourne, Australia",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT03099616,ANESTHESIA; BARIATRIC SURGERY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Sir Ganga Ram Hospital, New Delhi, Delhi, India",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT02717780,"SLEEP APNEA SYNDROMES|SLEEP APNEA, OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Vaud, Switzerland",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Recruiting,NCT03006250,ANESTHESIA; ADVERSE EFFECT|LARYNGEAL MASKS|RESPIRATORY SYSTEM ABNORMALITIES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Chiang Mai University, Chiang Mai, Thailand|Chiang Mai University, Chiang Mai, Thailand",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT01886664,LIVER TRANSPLANTATION|POSTREPERFUSION SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Seoul National University Hospital, Seoul, Korea, Republic of",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT01199237,"AIRWAY REFLEXES, PROTECTIVE|RECOVERY AFTER NEUROMUSCULAR BLOCK|ANESTHETIC RECOVERY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Helen Diller Cancer Center, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB01198,__ZOPICLONE,5206025,Unknown status,NCT02820441,"SLEEP APNEA, CENTRAL|VENTRICULAR DYSFUNCTION",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Clinique de Physiologie Sommeil et Exercice, Pole Thorax et Vaisseaux , University Hospital Grenoble Alpes, Grenoble, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.7435470954229,218.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT01326611,CHRONIC LUNG DISEASE,All,up to 2 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","Zekai Tahir Burak Maternity Teaching Hospital Neonatology department, Ankara, Turkey",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00368342,ASTHMA,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00367913,PULMONARY DISEASES,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Llandough Hospital, Penarth, Vale of Glamorgan, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00598897,MYCOBACTERIUM AVIUM COMPLEX LUNG DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas Health Science Center at Tyler, Tyler, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Not yet recruiting,NCT03824847,"INFLUENZA, HUMAN",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00297674,SEPSIS|VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"1st Department of Critical Care, Evangelismos General Hospital, Athens, Greece|2nd Department of Critical Care, ATTIKON University Hospital, Athens, Greece|4th Department of Internal Medicine, ATTIKON University Hospital, Athens, Greece",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT04066621,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS IN CHILDREN,All,6 Years to 14 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT01559753,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT00358202,PNEUMONIA,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CPL Associates,LLC, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT00035347,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Sylmar, California, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Ft Gordon, Georgia, United States|Pfizer Investigational Site, Shawnee Mission, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Royal Oak, Michigan, United States|Pfizer Investigational Site, Kirkwood, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Mineola, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Winston-salem, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Sellersville, Pennsylvania, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Ste-foy, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Rotenburg (wuemme), Niedersachsen, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Luedenscheid, Germany|Pfizer Investigational Site, Maroussi. Attikis, Athens, Greece|Pfizer Investigational Site, Barcelona, Cataluna, Spain|Pfizer Investigational Site, Tarrasa, Cataluna, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Terminated,NCT00429975,"PNEUMONIA, PNEUMOCOCCAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT01645735,INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Phoenix, Arizona, United States|Investigational Site, Sylmar, California, United States|Investigational Site, DeLand, Florida, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Kansas City, Kansas, United States|Investigational Site, Royal Oak, Michigan, United States|Investigational Site, Minneapolis, Minnesota, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Omaha, Nebraska, United States|Investigational Site, Laconia, New Hampshire, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Lima, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tbilisi, Georgia|Investigational Site, Matrahaza, Hungary|Investigational Site, Lodz, Poland|Investigational Site, Lublin, Poland|Investigational Site, Wilkowice-Bystra, Poland|Investigational Site, Craiova, Dolj, Romania|Investigational Site, Bucharest, Romania|Investigational Site, Iasi, Romania|Investigational Site, Moscow, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, Yaroslavl, Russian Federation|Investigational Site, Alicante, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Dnipropetrovsk, Ukraine|Investigational Site, Ivano-Frankivsik, Ukraine|Investigational Site, Kharkiv, Ukraine|Investigational Site, Kyiv, Ukraine|Investigational Site, Zaporizhzhya, Ukraine",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT01669980,INFECTIONS|PNEUMONIA,All,"2 Months to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Investigational Site, Long Beach, California, United States|Oakland, California, United States|Investigational Site, Orange County, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Boston, Massachusetts, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Pittsburgh, Pennsylvania, United States|Investigational Site, Memphis, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Investigational Site, Norfolk, Virginia, United States|Investigational Site, Morgantown, West Virginia, United States|Investigative Site, Buenos Aires, Argentina|Investigational Site 1, Tbilisi, Georgia|Investigational Site 2, Tbilisi, Georgia|Investigational Site 3, Tbilisi, Georgia|Investigational Site, Donetsk, Ukraine|Investigational Site, Ivano-Frankivsk, Ukraine|Investigational Site, Kryvyi Rih, Ukraine|Investigational Site, Kyiv, Ukraine",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Completed,NCT01723150,"LIVER ABSCESS, PYOGENIC",All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,1,DB01216,__FINASTERIDE,6046183,Recruiting,NCT02703220,SLEEP APNEA|ELDERLY ADULTS,All,"60 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other,"John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,25.4296802809092,1662.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,372.5441,58.2,2.0,2.0,4.0,43.93,108.2,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Not yet recruiting,NCT04452383,SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Zagazig University, Zagazig, Egypt",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Unknown status,NCT02924090,DEPRESSION,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Health Sciences Centre, Winnipeg, Manitoba, Canada",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,"Active, not recruiting",NCT02643381,CARDIOPULMONARY ARREST|RESPIRATORY ARREST,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Parkland Hospital, Dallas, Texas, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Unknown status,NCT03067103,"SLEEP DISORDER; BREATHING-RELATED|PAIN, POSTOPERATIVE|CHILD, ONLY",All,3 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Juliana Alves de Sousa Caixeta, Anápolis, GO, Brazil",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01158820,SEDATION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT02425202,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Health Sciences Center, Winnipeg, Manitoba, Canada",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT02962999,CHRONIC OBSTRUCTIVE PULMONARY DISEASE MILD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE MODERATE|CHRONIC OBSTRUCTIVE PULMONARY DISEASE SEVERE|LUNGCANCER|ANESTHESIA,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Cukurova University, Adana, Turkey|Cukurova University Faculty of Medicine Research Hospital, Adana, Turkey",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01827020,"NOSE DEFORMITIES, ACQUIRED",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turgut Ozal Medical Center, Malatya, Turkey",C07D307/52,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Recruiting,NCT03735563,SURFACTANT DEFICIENCY SYNDROME NEONATAL,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Oulu University Hospital, Oulu, Finland",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Withdrawn,NCT02397356,"PAIN, POSTOPERATIVE",Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Tampere University Hospital, Tampere, Finland",C07D307/52,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT00834730,MODERATE SEDATION|LACERATION,All,36 Months to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,CARDIO RESPIRATORY ARREST,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,"PAIN, ACUTE",,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02533505,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Hartford, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT03369847,ASTHMA|PEDIATRIC ALL,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kings County Hospital Center, Brooklyn, New York, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT02526758,PULMONARY DISEASE，CHRONIC OBSTRUCTIVE;,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT03478683,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Gold River, California, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, Clearwater, Florida, United States|GSK Investigational Site, DeBary, Florida, United States|GSK Investigational Site, Edgewater, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Port Charlotte, Florida, United States|GSK Investigational Site, Port Orange, Florida, United States|GSK Investigational Site, Peachtree Corners, Georgia, United States|GSK Investigational Site, Flint, Michigan, United States|GSK Investigational Site, Fridley, Minnesota, United States|GSK Investigational Site, Woodbury, Minnesota, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Shelby, North Carolina, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Anderson, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Easley, South Carolina, United States|GSK Investigational Site, Fort Mill, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Lancaster, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Rock Hill, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Baytown, Texas, United States|GSK Investigational Site, Cypress, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Tomball, Texas, United States|GSK Investigational Site, Jindrichuv Hradec, Czechia|GSK Investigational Site, Kralupy nad Vltavou, Czechia|GSK Investigational Site, Lovosice, Czechia|GSK Investigational Site, Rokycany, Czechia|GSK Investigational Site, Teplice, Czechia|GSK Investigational Site, Ruedersdorf, Brandenburg, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Zutphen, Netherlands",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT04355637,CORONAVIRUS INFECTION,All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT04132570,RHINITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Beijing Tongren Hospital, Cmu, Beijing, Beijing, China|The No.2 Hospital of Baoding, Baoding, Hebei, China|Cangzhou Center Hospital, Cangzhou, Hebei, China|The Second Hospital to Hebei Medical University, Shijiazhuang, Hebei, China|Shandong provincial hospital, Jinan, Shandong, China|The No.2 People'S Hospital Og Weifang, Weifang, Shandong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02409563,ALLERGIC RHINITIS,All,6 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02696850,RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS|ALLERGIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT01270256,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02002715,EOSINOPHILIC BRONCHITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00560586,OBSTRUCTIVE SLEEP APNEA,All,6 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kosair Children's Hospital Sleep Center, Louisville, Kentucky, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00912171,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,2 Years to 10 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department if Pediatrics, Hospital S. Orsola-Malpighi , University of Bologna, Bologna, Italy",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT03563001,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME|SMALL AIRWAY DISEASE|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT03551197,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|EXERCISE|LUNG FUNCTION DECREASED|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT02504801,"POST OPERATIVE COMPLICATION, PULMONARY|LUNG CANCER|COPD",All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT03394222,LUNG CANCER,All,"45 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT03521063,"BRONCHOPULMONARY DYSPLASIA|INFANT,PREMATURE|RESPIRATORY DISTRESS SYNDROME",All,up to 12 Hours   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT03275415,RESPIRATORY DISTRESS SYNDROME|BRONCHOPULMONARY DYSPLASIA,All,up to 4 Hours   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",,A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT00883532,RESPIRATORY DISTRESS SYNDROME|CHRONIC LUNG DISEASE OF PREMATURITY,All,up to 4 Hours   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","China Medical University, Taichung, Taiwan, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT03615742,EXPOSURE TO POLLUTION|GLUCOCORTICOID RESISTANCE,All,19 Years to 49 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of British Columbia, Vancouver, British Columbia, Canada",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Terminated,NCT00146497,PREMATURE INFANTS|RESPIRATORY DISTRESS SYNDROME|CHRONIC LUNG DISEASE|BRONCHOALVEOLAR LAVAGE FLUID|CYTOKINES,All,up to 1 Day   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"China Medical University Hospital, Taichung, Taiwan",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Not yet recruiting,NCT04342039,EPIGENETIC EFFECTS OF INTRANASAL STEROIDS|ENVIRONMENTAL EXPOSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT04171180,COUGH VARIANT ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the Second Affiliated Hospital of Zhejiang University School of Medicin, Hangzhou, Zhejiang, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT02934945,BRONCHIAL ASTHMA,All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Terminated,NCT01912872,SEVERE IGE-MEDIATED ASTHMA,All,"6 Years to 55 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Tuxtla Gutierrez, Chiapas, Mexico|Novartis Investigative Site, Mexico City, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Edo. De México, Mexico|Novartis Investigative Site, Nezahualcoyotl, Estado De Mexico, Mexico|Novartis Investigative Site, Pachuca de Soto, Hidalgo, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadaljara, Jalisco, Mexico|Novartis Investigative Site, Tepic, Nayarit, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mérida, Yucatán, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Terminated,NCT01070888,EXERCISE INDUCED ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00733473,ASTHMA|ACUTE ASTHMA,All,6 Months to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Kecioren, Turkey",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Withdrawn,NCT02357277,OSTEOPOROSIS,Female,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",,A61K9/008,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT01787097,CHRONIC OBSTRUCTIVE LUNG DISEASE,All,"35 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Royal Brompton and Harefield NHS trust, London, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Active Not Recruiting,,AIRWAY INFLAMMATION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,1,DB01223,__AMINOPHYLLINE,3965256,Recruiting,NCT04101500,ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",A61K9/2013,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.5754532947288,845.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.77,420.4264,69.3,3.0,1.0,4.0,16.86,44.93,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D281/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Not yet recruiting,NCT04513314,"COVID19|HYPERACTIVE DELIRIUM|PNEUMONIA, VIRAL",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Jackson Memorial Hospital, Miami, Florida, United States",C07D281/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,"Active, not recruiting",NCT02996214,SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K47/6925,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Completed,NCT03092986,"CARCINOMA, NON-SMALL-CELL LUNG",All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Oncology,Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh",A61K47/6925,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Completed,NCT01317615,"CARCINOMA, LARGE CELL|NEUROENDOCRINE TUMORS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hemer, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ulm, Germany",A61K47/6925,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,NAUSEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03323047,TONSILLITIS,All,3 Years to 13 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Children's Hospital, London, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04545242,ACUTE HYPOXEMIC RESPIRATORY FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Mutua Terrassa (ICU), Terrassa, Barcelona, Spain|Hospital General La Mancha Centro (ICU), Alcazar de San Juan, Ciudad Real, Spain|Complejo Hospitalario Universitario de Santiago (Anesthesia), Santiago De Compostela, La Coruña, Spain|Hospital General El Bierzo (ICU), Ponferrada, León, Spain|Hospital Universitario del Henares (ICU), Coslada, Madrid, Spain|Hospital Universitario de Getafe (ICU), Getafe, Madrid, Spain|Hospital Universitario Puerta de Hierro (ICU), Majadahonda, Madrid, Spain|Hospital Nuestra Señora del Prado (ICU), Talavera De La Reina, Toledo, Spain|Hospital Universitario de Cruces (Anesthesia), Barakaldo, Vizcaya, Spain|Hospital Universitario de Cruces (ICU), Barakaldo, Vizcaya, Spain|Complejo Hospitalario Universitario de Albacete (ICU), Albacete, Spain|Hospital Clinic de Barcelona (AVI), Barcelona, Spain|Hospital Clinic de Barcelona (Cardiac ICU), Barcelona, Spain|Hospital Clínic (Hepatic ICU), Barcelona, Spain|Hospital Clínic de Barcelona (Anesthesia), Barcelona, Spain|Hospital General de Ciudad Real (ICU), Ciudad Real, Spain|Hospital Virgen de la Luz (ICU), Cuenca, Spain|Hospital Universitario de A Coruña (ICU), La Coruña, Spain|Complejo Asistencial Universitario de León (ICU), León, Spain|Hospital Universitario La Princesa (ICU), Madrid, Spain|Hospital Universitario Ramón y Cajal (Anesthesia), Madrid, Spain|Hospital Clínico Universitario San Carlos (ICU), Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz (ICU), Madrid, Spain|Hospital Universitario Doce de Octubre (ICU), Madrid, Spain|Hospital Universitario La Paz (Anesthesia), Madrid, Spain|Hospital Universitario La Paz (ICU), Madrid, Spain|Hospital Universitario Virgen de Arrixaca (Anesthesia), Murcia, Spain|Hospital Universitario Virgen de Arrixaca (ICU), Murcia, Spain|Hospital Universitario Regional de Malaga Carlos Haya (ICU), Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Montecelo (Anesthesia), Pontevedra, Spain|Hospital Universitario Nuestra Señora de Candelaria (ICU), Santa Cruz De Tenerife, Spain|Hospital General de Segovia (ICU), Segovia, Spain|Hospital Clinico Universitario de Valencia (Anesthesia), Valencia, Spain|Hospital Clinico Universitario de Valencia (ICU), Valencia, Spain|Hospital Clínico Universitario de Valladolid (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (Anesthesia), Valladolid, Spain|Hospital Universitario Río Hortega (ICU), Valladolid, Spain|Hospital Virgen de la Concha (ICU), Zamora, Spain|Hospital Universitario Severo Ochoa (ICU), Leganés, ´Madrid, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT01743755,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Canisius Wilhelmina Hospital, Nijmegen, Gelderland, Netherlands|Catharina hospital Eindhoven, Eindhoven, Noord-Brabant, Netherlands|OLVG, Amsterdam, Noord-Holland, Netherlands|St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02682134,SORE THROAT,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01052038,SORE THROAT|PAIN,Female,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Northwesten University, Chicago, Illinois, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT01024075,CHRONIC RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Calgary, Calgary, Alberta, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01834820,BRONCHIOLITIS,All,2 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Health Services Research","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Distrito Federal, Mexico",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Suspended,NCT04221087,"BRONCHIOLITIS, VIRAL",All,up to 2 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01990781,"POSTOPERATIVE SORE THROAT, COUGH, HOARSENESS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Koshi, Nepal",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT01660867,ACUTE BRONCHIOLITIS,All,3 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT03200600,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY--COMPLICATIONS|DEXAMETHASONE|FLUBIPROFEN AXETIL|DELIRIUM",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04155008,ONCOLOGIC COMPLICATIONS|QUALITY OF LIFE|NUTRITION POOR|HEAD AND NECK CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT03172988,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY|DEXAMETHASONE|FLUBIPROFEN AXETIL|LONG-TERM EFFECTS SECONDARY TO CANCER THERAPY IN ADULTS",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT00588835,TUMOR,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Center Groningen, Groningen, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT02275702,LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Institut Universitaire de Cardiologie et de Pneumologie de Québec, IUCPQ, Québec, Canada|IUCPQ, Québec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT03366584,HYALINE MEMBRANE DISEASE|NECROTIZING ENTEROCOLITIS OF NEWBORN,Female,"17 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Suspended,NCT04325061,ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Suspended,NCT03630367,PREMATURE BIRTH,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Ahmed Abbas, Assiut, Cairo, Egypt",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01731795,ACUTE RESPIRATORY DISTRESS SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain|Hospital Clinico de Valencia, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01042145,CROUP,All,1 Year to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, St. Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03705273,ASTHMA|CROUP,All,1 Year to 7 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04412694,HYPOCALCEMIA|VITAMIN D DEFICIENCY|POSTOPERATIVE COMPLICATIONS|POSTOPERATIVE NAUSEA|POSTOPERATIVE PAIN|VOICE HOARSENESS|HYPOPARATHYROIDISM POSTPROCEDURAL,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Department of General and Oncological Surgery, Medical University of Lodz, Łódź, Łódzkie, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT02237820,HEART FAILURE|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Enrolling by invitation,NCT03900624,ASTHMA CHILDHOOD,All,5 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03889743,ASTHMA|INFLAMMATION,All,3 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Turku University Hospital, Turku, Finland|Haukeland University Hospital, Bergen, Norway|Akershus University Hospital, Oslo, Norway|Ullevål University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Karolinska Universitetssjukhuset, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT02780479,ASTHMA|STATUS ASTHMATICUS|WHEEZES,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wolfson Children Hospital, Jacksonville, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01241006,ASTHMA|REACTIVE AIRWAY DISEASE,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alameda County Medical Center, Oakland, California, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02450968,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Recruiting,NCT04359862,ACUTE RESPIRATORY DISTRESS SYNDROME|COVID19 INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Recruiting,NCT04074460,"CANCER, BREAST|CANCER COLORECTAL|CANCER PROSTATE|CANCER, LUNG|CANCER MELANOMA SKIN|CANCER, OTHER",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Peter MacCallum Cancer Centre, Melbourne, Australia",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Not yet recruiting,NCT04475705,SOLID TUMOR|CARCINOMA|MALIGNANCY|CANCER,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02168751,PULMONARY RESECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Anesthesiology Department Hospital GU Gregorio Mrañón, Madrid, Spain",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01437462,HEALTHY ADULTS|GYNECOLOGICAL DISEASE,Female,"18 Years to 69 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Tampere University Hospital, Tampere, Finland",0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01557920,AIRWAY COMPLICATION OF ANAESTHESIA|HEALTHY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02578862,ADVANCED CHRONIC RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Ochsner Medical Center, New Orleans, Louisiana, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Recruiting,NCT02457442,"DRUG INTERACTIONS|ANESTHESIA, CONDUCTION",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","Department of Anesthesiology and Pain Therapy, Bern University Hospital, Bern, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Recruiting,NCT02945072,CHILD BEHAVIOR|PROBLEM BEHAVIOR,All,2 Years to 10 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening","Dr. Philipp Buehler, Zurich, Switzerland",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02717780,"SLEEP APNEA SYNDROMES|SLEEP APNEA, OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Vaud, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01930747,MUSCLE RELAXANTS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Azsintjan, Brugge, Belgium",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Recruiting,NCT03006250,ANESTHESIA; ADVERSE EFFECT|LARYNGEAL MASKS|RESPIRATORY SYSTEM ABNORMALITIES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Chiang Mai University, Chiang Mai, Thailand|Chiang Mai University, Chiang Mai, Thailand",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02166853,ACUTE RESPIRATORY DISTRESS SYNDROME,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Clermont-Ferrand, Clermont-Ferrand, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Terminated,NCT00665418,LARYNGOSPASM,All,25 Months to 84 Months   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Unknown status,NCT01715584,HYPERTENSION,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"London Health Sciences Centre - Victoria Campus, London, Ontario, Canada",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01792063,COUGHING ON INDUCTION|VAPORS; INHALATION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Cerrahpasa Medical Faculty Anesthesiology and Reanimation Department, Istanbul, Fatih, Turkey",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02334046,DRUG USE,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Ajou University Hospital, Suwon, Gyeongki-do, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01886664,LIVER TRANSPLANTATION|POSTREPERFUSION SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Seoul National University Hospital, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT01199237,"AIRWAY REFLEXES, PROTECTIVE|RECOVERY AFTER NEUROMUSCULAR BLOCK|ANESTHETIC RECOVERY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Helen Diller Cancer Center, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,,GENERAL SURGERY,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,,ADENOTONSILLECTOMY,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Active Not Recruiting,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,NCT01014156,ACUTE PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Free University Medical Center, Amsterdam, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,NCT01105091,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California - San Diego, La Jolla, California, United States|University of Colorado - Denver, Aurora, Colorado, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,NCT01462565,"HYPERTENSION, PULMONARY",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Miami Beach, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Amsterdam, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,1,DB01241,__GEMFIBROZIL,4126637,Withdrawn,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/235,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,1026.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,250.3334,46.53,3.0,1.0,1.0,28.9,71.82,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,1,DB01242,__CLOMIPRAMINE,5008262,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,35.8775334195774,561.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,314.8520000000001,6.48,2.0,0.0,3.0,35.73,95.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Terminated,NCT00536107,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Taipei, Taiwan",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Completed,NCT02088515,SQUAMOUS CELL CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hunan Xiangya Hospital, Changsha, Hunan, China|Nanjing Military General Hospital, Nanjing, Jiangsu, China|Shanghai Chest hospital, Shanghai, Shanghai, China|Xijing Hospital, Xian, Shanxi, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Not yet recruiting,NCT03799601,NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Unknown status,NCT00813332,ADVANCED NSCLC|RECURRENT NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Hospital of Tianjin Medical University, Tianjin, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,1,DB01248,__DOCETAXEL,4814470,Unknown status,NCT02283424,"NEOPLASMS, THERAPY-ASSOCIATED",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"PLA General Hospital, BeiJing, China",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,1,DB01268,__SUNITINIB,6573293,Completed,NCT01402089,NON SMALL-CELL LUNG CANCER|RENAL-CELL CANCER|GASTROINTESTINAL STROMA TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St.Gallen, St.Gallen, Switzerland",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Completed,NCT02922387,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|COMMUNITY ACQUIRED PNEUMONIA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Completed,NCT02233231,ASTHMA,All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Completed,NCT00424528,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BRONCHITIS|EMPHYSEMA,All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jasper, Alabama, United States|Tucson, Arizona, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|DeFuniak Springs, Florida, United States|DeLand, Florida, United States|Topeka, Kansas, United States|Hazard, Kentucky, United States|Madisonville, Kentucky, United States|Marrero, Louisiana, United States|Sunset, Louisiana, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|St. Charles, Missouri, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|E. Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Tacoma, Washington, United States|Morgantown, West Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Terminated,NCT02275481,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"55 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, Alabama, United States|Clinical Trial Connection, Flagstaff, Arizona, United States|Waterbury Pulmonary Associates LLC, Waterbury, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|Southeastern Intergrted Medical, PL d/b/a Florida Medical Research, Gainesville, Florida, United States|Miami VA Medical Center, Miami, Florida, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|VA Western New York Healthcare System, Buffalo, New York, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Gastonia Phannaceutical Research, Gastonia, North Carolina, United States|Clinical Research of Lake Norman, Huntersville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Consolidated Clinical Trials, Inc., Monroeville, Pennsylvania, United States|Temple University Hospital, Temple Lung Center, Philadelphia, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Clinical Research of Rock Hill, Rock Hill, South Carolina, United States|S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|Mid State Pulmonary, Nashville, Tennessee, United States|Family Medicine Rural Health Clinic, PA, DBA FMC Science, Lampasas, Texas, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Unknown status,NCT01361984,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|COPD|EMPHYSEMA|CHRONIC BRONCHITIS,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Terminated,NCT00819637,ACUTE ASTHMA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Henry Ford Hospital Emergency Department, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Completed,NCT00773786,COPD,All,"40 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St Francis Hospital and Medical center, Hartford, Connecticut, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,1,DB01288,__FENOTEROL,4275219,Completed,NCT00460577,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",All,5 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator site - five sites in Caracas, Caracas, Venezuela|Novartis Investigator Site, Maracaibo, Venezuela",C07C309/63,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,20.961416045504,784.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.36,303.3529,92.95,5.0,5.0,2.0,31.75,85.0,6.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Completed,NCT02446782,PLEURAL EFFUSION|PLEURISY|EMPYEMA,All,"12 Years to 80 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PGIMER, Chandigarh, India",C12Q1/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CN[C@@H](C)[C@H](O)c1ccccc1,1,DB01364,__EPHEDRINE,3946046,Completed,,BRADYCARDIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,39.2287315961313,1627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.8,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@H](O)c1ccccc1,1,DB01364,__EPHEDRINE,3946046,Completed,,HYPOTENSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,39.2287315961313,1627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.8,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@H](O)c1ccccc1,1,DB01364,__EPHEDRINE,3946046,Completed,,"CARDIAC OUTPUT, LOW",,,,,"FISABIO, Elche, Alicante, Spain",C07D317/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,39.2287315961313,1627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.8,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,NCT01091337,ASTHMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Philippine General Hospital, Manila, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Terminated,NCT00394485,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Philippine General Hospital, Manila, National Capital Region, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C([O-])O.[Na+],1,DB01390,__SODIUM_BICARBONATE,5840737,Not yet recruiting,NCT04530448,COVID|CORONAVIRUS|CORONAVIRUS INFECTION|AKI|ACUTE KIDNEY INJURY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])O.[Na+],1,DB01390,__SODIUM_BICARBONATE,5840737,Completed,NCT02476526,CHRONIC KIDNEY DISEASE|PULMONARY EMBOLISM|RENAL ARTERY STENOSIS|PULMONARY CANCER,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Recruiting,NCT03679611,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto Western Hospital, Toronto, Ontario, Canada",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Completed,NCT02845375,RESPIRATORY INSUFFICIENCY,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, ZH, Netherlands",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Completed,NCT02243943,POSTOPERATIVE RESPIRATORY CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden Medical University, Leiden, Zuid Holland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Completed,NCT01199237,"AIRWAY REFLEXES, PROTECTIVE|RECOVERY AFTER NEUROMUSCULAR BLOCK|ANESTHETIC RECOVERY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Helen Diller Cancer Center, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,1,DB01408,__BAMBUTEROL,5709884,Unknown status,NCT02002754,EOSINOPHILIC BRONCHITIS|COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,35.680404115074204,498.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.69,367.44,91.34,4.0,2.0,1.0,40.74,98.28,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,1,DB01408,__BAMBUTEROL,5709884,Completed,NCT01796730,COPD,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China|Guangzhou Institution of Respiratory Disease (GIRD), The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,35.680404115074204,498.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.69,367.44,91.34,4.0,2.0,1.0,40.74,98.28,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",A61K9/0075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT02039050,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Recruiting,NCT03275116,CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ciro, center of expertise in chronic organ failure, Horn, Netherlands",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT00424528,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BRONCHITIS|EMPHYSEMA,All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jasper, Alabama, United States|Tucson, Arizona, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|DeFuniak Springs, Florida, United States|DeLand, Florida, United States|Topeka, Kansas, United States|Hazard, Kentucky, United States|Madisonville, Kentucky, United States|Marrero, Louisiana, United States|Sunset, Louisiana, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|St. Charles, Missouri, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|E. Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Tacoma, Washington, United States|Morgantown, West Virginia, United States",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",A61K9/0075,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT01112241,OBLITERATIVE BRONCHIOLITIS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Unit of Preventive and Occupational Medicine - Laboratory of Respiratory Pathophysiology, University Hospital San Martino, Genoa, Italy",A61K9/0075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT00680056,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|CHRONIC BRONCHITIS|PULMONARY EMPHYSEMA",All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Sao Paulo, Brazil",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT00152984,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"CHU Sart Tilman, Angleur, Belgium|A.Z. VUB, Brussel, Belgium|Boehringer Ingelheim Investigational Site, Genk, Belgium|Boehringer Ingelheim Investigational Site, Hasselt, Belgium|St. Elisabethziekenhuis, Herentals, Belgium|Clinique Reine Astrid, Malmedy, Belgium|Sint-Elisabethziekenhuis, Turnhout, Belgium|VGH Research Pavillion, Vancouver, British Columbia, Canada|BG 034, Room C2027, Winnipeg, Manitoba, Canada|Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Respiratory Research Lab, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Department of Respiratory Medicine, Toronto, Ontario, Canada|Centre de Recherche Clinique -CUSE, Sherbrooke, Quebec, Canada|Hopital Laval, Ste-Foy, Quebec, Canada|Lungemedicinsk Forskning 2B, Aarhus, Denmark|Lungemedicinsk afdeling Y, Hellerup, Denmark|Medicinsk afdeling B0642, Hiller?d, Denmark|Lungemedicinsk Klinik, Hvidovre, Denmark|H:S Bispebjerg Hospital, K?benhavn NV, Denmark|Lungemedicinsk Forskning, Odense C, Denmark|Hopital d'Annecy, Annecy, France|Hopital Prive Antony, Antony cedex, France|Boehringer Ingelheim Investigational Site, Chamalieres, France|Hopital Gabriel Montpied, Clermont Ferrand cedex 1, France|Hopital Ambroise Pare, Marseille, France|Hopital Notre Dame de Bon Secours, Metz cedex 1, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Hopital Arnaud de Villeneuve, Montpellier, France|Boehringer Ingelheim Investigational Site, Nantes, France|Centre Medical Erdre St Augustin, Nantes, France|Boehringer Ingelheim Investigational Site, Nice, France|Hopital Maison blanche, Reims cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Berlin, Germany|MEDARS GmbH, Berlin, Germany|Boehringer Ingelheim Investigational Site, Bonn, Germany|Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|Boehringer Ingelheim Investigational Site, Furth, Germany|Inamed Research GmbH & Co. KG, Gauting, Germany|Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|ClinPharm Internat. GmbH & Co. KG, Gorlitz, Germany|Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg, Germany|Med. Einrichtung der Universitat zu Koln, Koln, Germany|Boehringer Ingelheim Investigational Site, Minden, Germany|Boehringer Ingelheim Investigational Site, Munchen, Germany|Boehringer Ingelheim Investigational Site, Rudersdorf, Germany|A. O. Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, Italy|A.O. S. Martino e Cliniche Universitarie di Genova, Genova, Italy|Universita di Genova, Genova, Italy|A.O. Pisana, Pisa, Italy|Ziekenhuisgroep Twent, Almelo, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Atrium medisch centrum, Heerlen, Netherlands|Ziekenhuigroep Twente, Hengelo, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Maxima Medisch Centrum, Velthoven, Netherlands|Boehringer Ingelheim Investigational Site, Bellville, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Durban, South Africa|Boehringer Ingelheim Investigational Site, George, South Africa|Boehringer Ingelheim Investigational Site, Paarl, South Africa|Boehringer Ingelheim Investigational Site, Pretoria, South Africa|Boehringer Ingelheim Investigational Site, Somerset West, South Africa",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT00525512,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|EXERCISE",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"205.368.01023 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States|205.368.01022 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|205.368.01003 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|205.368.01008 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States|205.368.01017 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States|205.368.01028 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States|205.368.01004 Boehringer Ingelheim Investigational Site, Bay Pines, Florida, United States|205.368.01013 Boehringer Ingelheim Investigational Site, North Miami Beach, Florida, United States|205.368.01025 Boehringer Ingelheim Investigational Site, Hazard, Kentucky, United States|205.368.01029 Boehringer Ingelheim Investigational Site, Biddeford, Maine, United States|205.368.01016 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|205.368.01002 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|205.368.01021 Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|205.368.01014 Boehringer Ingelheim Investigational Site, Albany, New York, United States|205.368.01030 Boehringer Ingelheim Investigational Site, Tulsa, Oklahoma, United States|205.368.01018 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States|205.368.01027 Boehringer Ingelheim Investigational Site, Gaffney, South Carolina, United States|205.368.01019 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States|205.368.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States|205.368.01024 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States|205.368.01015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|205.368.54001 Boehringer Ingelheim Investigational Site, Rosario, Argentina|205.368.54002 Boehringer Ingelheim Investigational Site, Vicente López, Argentina|205.368.55003 Boehringer Ingelheim Investigational Site, Goiânia, Brazil|205.368.55004 Boehringer Ingelheim Investigational Site, Porto Alegre - RS, Brazil|205.368.55002 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|205.368.07006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|205.368.07001 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|205.368.07003 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|205.368.07004 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|205.368.07005 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|205.368.07008 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|205.368.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|205.368.49004 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany|205.368.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|205.368.49006 Boehringer Ingelheim Investigational Site, Münster, Germany|205.368.49002 Boehringer Ingelheim Investigational Site, Schmallenberg, Germany|205.368.49001 Boehringer Ingelheim Investigational Site, Tübingen, Germany|205.368.39006 Boehringer Ingelheim Investigational Site, Ferrara, Italy|205.368.39004 Boehringer Ingelheim Investigational Site, Milano, Italy|205.368.39002 Boehringer Ingelheim Investigational Site, Parma, Italy|205.368.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|205.368.35103 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|205.368.35102 Boehringer Ingelheim Investigational Site, Matosinhos, Portugal|205.368.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70004 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70005 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70006 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70007 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|205.368.34005 Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain|205.368.34002 Hospital de Cruces, Barakaldo (Bilbao), Spain|205.368.34001 Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|205.368.34003 Hospital Gregorio Maranon, Madrid, Spain|205.368.34004 Hospital Universitario Vírgen del Rocío, Sevilla, Spain|205.368.34006 Boehringer Ingelheim Investigational Site, Sevilla, Spain|205.368.88604 Boehringer Ingelheim Investigational Site, Keelung, Taiwan|205.368.88602 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|205.368.88603 Boehringer Ingelheim Investigational Site, Taipei City, Taiwan|205.368.88601 Chang Gung Memorial Hosp-Linkou, Taoyuan, Taiwan|205.368.38003 Boehringer Ingelheim Investigational Site, Dnyepropyetrovsk, Ukraine|205.368.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|205.368.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Unknown status,NCT01466712,COPD|EMPHYSEMA|SMALL AIRWAY DISEASE,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University Hospitals Leuven, Leuven, Flanders, Belgium",A61K9/0075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01333800,ASTHMA,All,6 Years to 15 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hospital San Rafael, Bogotá, Colombia",A61K9/124,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01430260,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"handok pharmaceuticals co. LTD, Seoul, Korea, Republic of",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01654536,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC PSF AMC - Division of Allergy, Asthma and Immunology, Orange, California, United States|Allergy Associates Medical Group Inc., San Diego, California, United States|Bensch Research Associates, Stockton, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|DataQuest Medical Research LLC, Lawerenceville, Georgia, United States|Asthma & Allergy Consultants, PC, Lilburn, Georgia, United States|Gordon D Raphael, MD, Bethesda, Maryland, United States|Medical Education and Research Management Services of New England, Gardner, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti, Michigan, United States|Clinical Research Institute Inc., Minneappolis, Minnesota, United States|The Clinical Research Center, LLC, St. Louis, Missouri, United States|Clinical Research Group of Montanta, Bozeman, Montana, United States|Ocean Allergy & Respiratory Research Center, Brick, New Jersey, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy and Asthma Center of NC, PA, High Point, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Allergy Assocaites Research Center, Portland, Oregon, United States|Valley Clinical Research Center, Bethlehem, Pennsylvania, United States|Asthma and Allergy Research Associates, Upland, Pennsylvania, United States|National Allergy, Asthma & Uticaria Centers of Charleston, P.A., Charleston, South Carolina, United States|Isis Clinical Research, LLC, Austin, Texas, United States|Sirius Clinical Research LLC, Austin, Texas, United States|Pharmaceutical Research and Consulting Inc., Dallas, Texas, United States|Kerrville Research Associates, PA, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|ASTHMA Inc. Clinical Research Center, Seattle, Washington, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT03839433,BRONCHIAL ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,1,DB01413,__CEFEPIME,5409898,Unknown status,NCT01667094,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Alfred Hospital, Melbourne, Victoria, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,11.9591778065258,178.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.37,480.561,150.04,8.0,2.0,4.0,47.53,141.98,7.0,0.0,1.0,0.0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1,1,DB01413,__CEFEPIME,5409898,Completed,NCT00358202,PNEUMONIA,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CPL Associates,LLC, Buffalo, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,11.9591778065258,178.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.37,480.561,150.04,8.0,2.0,4.0,47.53,141.98,7.0,0.0,1.0,0.0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1
CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O,1,DB01418,__ACENOCOUMAROL,4334020,Completed,NCT00711308,ACUTE PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pneumology Service. Hospital Clínico, Santiago de Compostela, A Coruña, Spain|Pneumology Service. Hospital Xeral Cies, Vigo, Pontevedra, Spain|Pneumology Service. Hospital do Meixoeiro, Vigo, Pontevedra, Spain|Pneumology Service, Lugo, Spain",C12R1/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,24.049775149387003,46.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,353.3255,109.42,5.0,1.0,3.0,34.35,94.18,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown status,NCT03292744,FRAIL ELDERLY SYNDROME|ELDERLY INFECTION,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cipto Mangunkusumo National Hospital, Jakarta, Indonesia",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT04085770,CARDIAC VALVE REPLACEMENT COMPLICATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"El-Demerdash Cardiac Academy Hospital, Ain Shams University, Cairo, Egypt",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT02747381,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown Status,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
Nc1ccc(/N=N/c2ccccc2)c(N)n1,1,DB01438,__PHENAZOPYRIDINE,5567716,Completed,,URINARY RETENTION,,,,,"FISABIO, Elche, Alicante, Spain",C07C57/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,35.0890162015647,371.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,213.2385,89.65,5.0,2.0,2.0,22.66,68.25,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0
O=C(O)CCCO,1,DB01440,__GAMMA-HYDROXYBUTYRIC_ACID,6780889,Terminated,NCT00498485,CHRONIC FATIGUE SYNDROME,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UMDNJ - Pain & Fatigue Study Center, ADMC 1618, Newark, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,25.4625351649931,3.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.63,104.1045,57.53,3.0,2.0,0.0,10.17,23.8,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
COc1cc(CC(C)N)c(OC)cc1C,1,DB01528,"__4-METHYL-2,5-DIMETHOXYAMPHETAMINE",WO-1998042331-A1,Completed,NCT01654809,INFLUENZA,All,"6 Months and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Sanhe Centre for Disease Control and Prevention, Langfang, Hebei, China|Jiuyuan Center for Disease Control and Prevention, Baotou, Inner Mongolia, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Completed,NCT02096107,GRAFT DYSFUNCTION|INTERSTITIAL FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of South Carolina, Charleston, South Carolina, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,1,DB01597,__CILASTATIN,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,358.45300000000015,129.72,6.0,4.0,1.0,38.28,92.85,11.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,NCT00445094,INFECTIONS|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Unknown status,NCT01356472,"METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS|PNEUMONIA, VENTILATOR-ASSOCIATED",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,NCT01489124,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Prince of Songkla University, Hat Yai, Songkla, Thailand",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,NCT02683603,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"intensive care unit of the University Hospital Center La Rabta, Tunis, Tunisia",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Recruiting,NCT04255017,2019-NCOV,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department and Institute of Infectious Disease, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Not yet recruiting,NCT04286503,NOVEL CORONAVIRUS INFECTIOUS DISEASE (COVID-19),All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT04252885,CORONAVIRUS INFECTIONS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](N=CN3CCCCCC3)[C@H]2SC1(C)C,1,DB01605,__PIVMECILLINAM,4203972,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,25.9225035421671,142.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.23,439.569,88.51,5.0,0.0,3.0,47.7,113.03,7.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Unknown status,NCT01667094,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Alfred Hospital, Melbourne, Victoria, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Recruiting,NCT03891433,"URINARY TRACT INFECTIONS|ENTEROBACTERIACEAE INFECTIONS|INFECTION DUE TO ESBL BACTERIA|CARBAPENEM|ESCHERICHIA COLI INFECTION|KLEBSIELLA PNEUMONIAE INFECTION|CLINICAL TRIAL|DRUG RESISTANCE, BACTERIAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Recruiting,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,1,DB01607,__TICARCILLIN,4127649,Unknown status,NCT01667094,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Alfred Hospital, Melbourne, Victoria, Australia",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,934.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.99,384.42699999999996,124.01,6.0,3.0,3.0,36.14,87.93,5.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Completed,,INFECTION IN SOLID ORGAN TRANSPLANT RECIPIENTS,,,,,"FISABIO, Elche, Alicante, Spain",C07D473/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT04341493,CORONAVIRUS INFECTION,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT04355026,COVID-19,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SB Celje, Celje, Slovenia",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT04346667,SARS-COV-2|CORONAVIRUS INFECTION|ASYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT04351191,SARS-COV2|SYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,"Active, not recruiting",NCT04316377,CORONA VIRUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Akershus University Hospital, Lørenskog, Norway",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Suspended,NCT04334967,COVID-19|CORONA VIRUS INFECTION|SARS-COV-2|2019-NCOV|2019 NOVEL CORONAVIRUS,All,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Portland Providence Medical Center, Portland, Oregon, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Not yet recruiting,NCT04382625,SARS-COV-2 PNEUMONIA|COVID-19,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kootenai Health, Coeur d'Alene, Idaho, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Not yet recruiting,NCT04316494,ANCA ASSOCIATED VASCULITIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|WEGENER GRANULOMATOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT04161339,CARDIOVASCULAR DISEASES|ENDOTHELIAL DYSFUNCTION|SLEEP APNEA|ATHEROSCLEROSIS|CORONARY ARTERY DISEASE,All,"60 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Completed,NCT03073798,COPD|CHRONIC BRONCHITIS|EMPHYSEMA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Completed,NCT01480661,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"30 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","Antwerp University Hospital, Edegem, Antwerp, Belgium|ZNA Middelheim, Antwerp, Belgium",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Unknown status,NCT01830959,SARCOIDOSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Unknown status,NCT01595750,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"55 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Spanish Research Center for Respiratory Diseases, Bunyola, Balearic Island, Spain",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Completed,NCT01630200,CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ALLIED CONDITIONS,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Deparment for Respiratory and Critical Care Medicine, Otto Wangner Hospital, Vienna, Austria",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Completed,NCT01443845,COPD|COPD EXACERBATION|LUNG DISEASES|RESPIRATORY DISORDERS|PULMONARY DISEASE|CHRONIC OBSTRUCTIVE LUNG DISEASES|CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Forest Investigative Site 081, Anniston, Alabama, United States|Forest Investigative Site 065, Athens, Alabama, United States|Forest Investigative Site 131, Florence, Alabama, United States|Forest Investigative Site 073, Mobile, Alabama, United States|Forest Investigative Site 272, Mesa, Arizona, United States|Forest Investigative Site 091, Peoria, Arizona, United States|Forest Investigative Site 034, Phoenix, Arizona, United States|Forest Investigative Site 188, Phoenix, Arizona, United States|Forest Investigative Site 211, Phoenix, Arizona, United States|Forest Investigative Site 247, Phoenix, Arizona, United States|Forest Investigative Site 208, Fort Smith, Arkansas, United States|Forest Investigative Site 101, Little Rock, Arkansas, United States|Forest Investigative Site 074, Bellflower, California, United States|Forest Investigative Site 060, Fresno, California, United States|Forest Investigative Site 329, Fresno, California, United States|Forest Investigative Site 245, Fullerton, California, United States|Forest Investigative Site 310, Garden Grove, California, United States|Forest Investigative Site 297, Lakewood, California, United States|Forest Investigative Site 116, Long Beach, California, United States|Forest Investigative Site 085, Los Angeles, California, United States|Forest Investigative Site 241, Los Angeles, California, United States|Forest Investigative Site 299, Northridge, California, United States|Forest Investigative Site 213, Palo Alto, California, United States|Forest Investigative Site 268, Pismo Beach, California, United States|Forest Investigative Site 025, Riverside, California, United States|Forest Investigative Site 143, Roseville, California, United States|Forest Investigative Site 104, Sacramento, California, United States|Forest Investigative Site 352, San Diego, California, United States|Forest Investigative Site 038, San Diego, California, United States|Forest Investigative Site 326, San Jose, California, United States|Forest Investigative Site 209, Torrance, California, United States|Forest Investigative Site 331, Stamford, Connecticut, United States|Forest Investigative Site 017, Waterbury, Connecticut, United States|Forest Investigative Site 124, Newark, Delaware, United States|Forest Investigative Site 196, Brandon, Florida, United States|Forest Investigative Site 224, Brandon, Florida, United States|Forest Investigative Site 358, Brandon, Florida, United States|Forest Investigative Site 166, Chiefland, Florida, United States|Forest Investigative Site 111, Clearwater, Florida, United States|Forest Investigative Site 123, Clearwater, Florida, United States|Forest Investigative Site 291, Coral Gables, Florida, United States|Forest Investigative Site 239, DeFuniak Springs, Florida, United States|Forest Investigative Site 001, Fort Lauderdale, Florida, United States|Forest Investigative Site 165, Fort Walton Beach, Florida, United States|Forest Investigative Site 102, Gainesville, Florida, United States|Forest Investigative Site 003, Hollywood, Florida, United States|Forest Investigative Site 023, Jacksonville, Florida, United States|Forest Investigative Site 077, Kissimmee, Florida, United States|Forest Investigative Site 330, Kissimmee, Florida, United States|Forest Investigative Site 027, Miami, Florida, United States|Forest Investigative Site 229, Miami, Florida, United States|Forest Investigative Site 115, Miami, Florida, United States|Forest Investigative Site 339, Miami, Florida, United States|Forest Investigative Site 092, Naples, Florida, United States|Forest Investigative Site 004, Orlando, Florida, United States|Forest Investigative Site 187, Ormond Beach, Florida, United States|Forest Investigative Site 069, Pensacola, Florida, United States|Forest Investigative Site 161, Ponte Vedra, Florida, United States|Forest Investigative Site 087, Port Orange, Florida, United States|Forest Investigative Site 357, Saint Petersburg, Florida, United States|Forest Investigative Site 109, St. Cloud, Florida, United States|Forest Investigative Site 121, St. Petersburg, Florida, United States|Forest Investigative Site 002, Tamarac, Florida, United States|Forest Investigative Site 287, Tampa, Florida, United States|Forest Investigative Site 052, Tampa, Florida, United States|Forest Investigative Site 011, Winter Park, Florida, United States|Forest Investigative Site 348, Winter Park, Florida, United States|Forest Investigative Site 103, Canton, Georgia, United States|Forest Investigative Site 292, Dawsonville, Georgia, United States|Forest Investigative Site 042, Duluth, Georgia, United States|Forest Investigative Site 140, Gainesville, Georgia, United States|Forest Investigative Site 030, Lawrenceville, Georgia, United States|Forest Investigative Site 321, Woodstock, Georgia, United States|Forest Investigative Site 008, Coeur d' Alene, Idaho, United States|Forest Investigative Site 119, Eagle, Idaho, United States|Forest Investigative Site 201, Bolingbrook, Illinois, United States|Forest Investigative Site 206, Downers Grove, Illinois, United States|Forest Investigative Site 136, Elk Grove Village, Illinois, United States|Forest Investigative Site 139, Oak Lawn, Illinois, United States|Forest Investigative Site 227, Peoria, Illinois, United States|Forest Investigative Site 334, Springfield, Illinois, United States|Forest Investigative Site 263, Elwood, Indiana, United States|Forest Investigative Site 342, Lafayette, Indiana, United States|Forest Investigative Site 293, Michigan City, Indiana, United States|Forest Investigative Site 264, Muncie, Indiana, United States|Forest Investigative Site 135, Council Bluffs, Iowa, United States|Forest Investigative Site 256, Iowa City, Iowa, United States|Forest Investigative Site 214, Olathe, Kansas, United States|Forest Investigative Site 316, Topeka, Kansas, United States|Forest Investigative Site 301, Wichita, Kansas, United States|Forest Investigative Site 051, Bowling Green, Kentucky, United States|Forest Investigative Site 075, Crescent Springs, Kentucky, United States|Forest Investigative Site 351, Hazard, Kentucky, United States|Forest Investigative Site 068, Lexington, Kentucky, United States|Forest Investigative Site 088, Louisville, Kentucky, United States|Forest Investigative Site 053, Owensboro, Kentucky, United States|Forest Investigative Site 273, Lafayette, Louisiana, United States|Forest Investigative Site 070, Opelousas, Louisiana, United States|Forest Investigative Site 097, Sunset, Louisiana, United States|Forest Investigative Site 128, Lewiston, Maine, United States|Forest Investigative Site 248, Baltimore, Maryland, United States|Forest Investigative Site 020, Columbia, Maryland, United States|Forest Investigative Site 072, Towson, Maryland, United States|Forest Investigative Site 106, Fall River, Massachusetts, United States|Forest Investigative Site 044, North Dartmouth, Massachusetts, United States|Forest Investigative Site 350, Pittsfield, Massachusetts, United States|Forest Investigative Site 157, Ann Arbor, Michigan, United States|Forest Investigative Site 341, Detroit, Michigan, United States|Forest Investigative Site 328, Kalamazoo, Michigan, United States|Forest Investigative Site 063, Livonia, Michigan, United States|Forest Investigative Site 322, Saint Joseph, Michigan, United States|Forest Investigative Site 303, Edina, Minnesota, United States|Forest Investigative Site 056, Fridley, Minnesota, United States|Forest Investigative Site 082, Rochester, Minnesota, United States|Forest Investigative Site 033, Chesterfield, Missouri, United States|Forest Investigative Site 117, Springfield, Missouri, United States|Forest Investigative Site 098, St. Charles, Missouri, United States|Forest Investigative Site 186, St. Louis, Missouri, United States|Forest Investigative Site 288, St. Louis, Missouri, United States|Forest Investigative Site 333, Butte, Montana, United States|Forest Investigative Site 029, Missoula, Montana, United States|Forest Investigative Site 197, Bellevue, Nebraska, United States|Forest Investigative Site 267, Fremont, Nebraska, United States|Forest Investigative Site 337, Fremont, Nebraska, United States|Forest Investigative Site 315, Lincoln, Nebraska, United States|Forest Investigative Site 108, Lincoln, Nebraska, United States|Forest Investigative Site 345, Omaha, Nebraska, United States|Forest Investigative Site 079, Henderson, Nevada, United States|Forest Investigative Site 270, Henderson, Nevada, United States|Forest Investigative Site 067, Cherry Hill, New Jersey, United States|Forest Investigative Site 327, Clifton, New Jersey, United States|Forest Investigative Site 144, Hackensack, New Jersey, United States|Forest Investigative Site 317, Summit, New Jersey, United States|Forest Investigative Site 226, Brooklyn, New York, United States|Forest Investigative Site 199, Great Neck, New York, United States|Forest Investigative Site 071, New York, New York, United States|Forest Investigative Site 013, Rochester, New York, United States|Forest Investigative Site 066, Syracuse, New York, United States|Forest Investigative Site 158, West Seneca, New York, United States|Forest Investigative Site 313, Asheville, North Carolina, United States|Forest Investigative Site 193, Burlington, North Carolina, United States|Forest Investigative Site 142, Charlotte, North Carolina, United States|Forest Investigative Site 259, Charlotte, North Carolina, United States|Forest Investigative Site 019, Elizabeth City, North Carolina, United States|Forest Investigative Site 318, Shelby, North Carolina, United States|Forest Investigative Site 078, Shelby, North Carolina, United States|Forest Investigative Site 176, Wilmington, North Carolina, United States|Forest Investigative Site 314, Winston Salem, North Carolina, United States|Forest Investigative Site 282, Winston-Salem, North Carolina, United States|Forest Investigative Site 164, Canton, Ohio, United States|Forest Investigative Site 061, Cincinatti, Ohio, United States|Forest Investigative Site 149, Cincinnati, Ohio, United States|Forest Investigative Site 040, Cincinnati, Ohio, United States|Forest Investigative Site 280, Cincinnati, Ohio, United States|Forest Investigative Site 009, Columbus, Ohio, United States|Forest Investigative Site 353, Dayton, Ohio, United States|Forest Investigative Site 059, Marion, Ohio, United States|Forest Investigative Site 154, Marion, Ohio, United States|Forest Investigative Site 346, Toledo, Ohio, United States|Forest Investigative Site 105, Zanesville, Ohio, United States|Forest Investigative Site 167, Oklahoma City, Oklahoma, United States|Forest Investigative Site 281, Oklahoma City, Oklahoma, United States|Forest Investigative Site 236, Tulsa, Oklahoma, United States|Forest Investigative Site 285, Medford, Oregon, United States|Forest Investigative Site 289, Portland, Oregon, United States|Forest Investigative Site 218, Portland, Oregon, United States|Forest Investigative Site 086, Altoona, Pennsylvania, United States|Forest Investigative Site 340, Beaver, Pennsylvania, United States|Forest Investigative Site 120, Downingtown, Pennsylvania, United States|Forest Investigative Site 062, Erie, Pennsylvania, United States|Forest Investigative Site 277, Norristown, Pennsylvania, United States|Forest Investigative Site 230, Philadelphia, Pennsylvania, United States|Forest Investigative Site 205, Philadelphia, Pennsylvania, United States|Forest Investigative Site 336, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 364, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 344, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 010, Tipton, Pennsylvania, United States|Forest Investigative Site 064, Uniontown, Pennsylvania, United States|Forest Investigative Site 228, Johnston, Rhode Island, United States|Forest Investigative Site 283, Lincoln, Rhode Island, United States|Forest Investigative Site 365, Providence, Rhode Island, United States|Forest Investigative Site 305, Charleston, South Carolina, United States|Forest Investigative Site 093, Easley, South Carolina, United States|Forest Investigative Site 257, Fort Mill, South Carolina, United States|Forest Investigative Site 233, Gaffney, South Carolina, United States|Forest Investigative Site 110, Greenville, South Carolina, United States|Forest Investigative Site 300, Pelzer, South Carolina, United States|Forest Investigative Site 204, Rock Hill, South Carolina, United States|Forest Investigative Site 021, Spartanburg, South Carolina, United States|Forest Investigative Site 012, Union, South Carolina, United States|Forest Investigative Site 058, Rapid City, South Dakota, United States|Forest Investigative Site 223, Bristol, Tennessee, United States|Forest Investigative Site 050, Fayetteville, Tennessee, United States|Forest Investigative Site 253, Shelbyville, Tennessee, United States|Forest Investigative Site 024, Arlington, Texas, United States|Forest Investigative Site 177, Boerne, Texas, United States|Forest Investigative Site 090, Corsicana, Texas, United States|Forest Investigative Site 172, Dallas, Texas, United States|Forest Investigative Site 237, Houston, Texas, United States|Forest Investigative Site 271, Houston, Texas, United States|Forest Investigative Site 370, Houston, Texas, United States|Forest Investigative Site 195, Houston, Texas, United States|Forest Investigative Site 312, Houston, Texas, United States|Forest Investigative Site 332, Huntsville, Texas, United States|Forest Investigative Site 232, Longview, Texas, United States|Forest Investigative Site 049, Tyler, Texas, United States|Forest Investigative Site 181, Colchester, Vermont, United States|Forest Investigative Site 125, Abingdon, Virginia, United States|Forest Investigative Site 202, Richmond, Virginia, United States|Forest Investigative Site 231, Richmond, Virginia, United States|Forest Investigative Site 045, Richmond, Virginia, United States|Forest Investigative Site 184, Spokane, Washington, United States|Forest Investigative Site 174, Spokane, Washington, United States|Forest Investigative Site 217, Tacoma, Washington, United States|Forest Investigative Site 335, Charleston, West Virginia, United States|Forest Investigative Site 319, Morgantown, West Virginia, United States|Forest Investigative Site 146, West Allis, Wisconsin, United States|Forest Investigative Site 418, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Forest Investigative Site 402, Florida, Buenos Aires, Argentina|Forest Investigative Site 405, La Plata, Buenos Aires, Argentina|Forest Investigative Site 413, Mar del Plata, Buenos Aires, Argentina|Forest Investigative Site 407, Parana, Entre Rios, Argentina|Forest Investigative Site 406, Lanús Este, Provincia de Buenos Aires, Argentina|Forest Investigative Site 412, Rosario, Santa Fe, Argentina|Forest Investigative Site 409, Rosario, Santa Fe, Argentina|Forest Investigative Site 403, Buenos Aires, Argentina|Forest Investigative Site 411, Ciudad Autonoma de Buenos Aires, Argentina|Forest Investigative Site 414, Ciudad Autonoma de Buenos Aires, Argentina|Forest Investigative Site 419, Ciudad Autonoma de Buenos Aires, Argentina|Forest Investigative Site 416, Ciudad Autonoma de Buenos Aires, Argentina|Forest Investigative Site 415, Derqui Pilar - Buenos Aires, Argentina|Forest Investigative Site 410, Florencio Varela, Argentina|Forest Investigative Site 417, La Plata, Argentina|Forest Investigative Site 420, Mendoza, Argentina|Forest Investigative Site 404, Mendoza, Argentina|Forest Investigative Site 401, San Miguel de Tucuman, Argentina|Forest Investigative Site 408, Santa Fe, Argentina|Forest Investigative Site 235, Calgary, Alberta, Canada|Forest Investigative Site 162, North Vancouver, British Columbia, Canada|Forest Investigative Site 302, Burlington, Ontario, Canada|Forest Investigative Site 185, Montreal, Quebec, Canada|Forest Investigative Site 127, Saskatoon, Saskatchewan, Canada|Forest Investigative Site 421, Talcahuano, Chile|Forest Investigative Site 442, Bogota, Colombia|Forest Investigative Site 443, Bogota, Colombia|Forest Investigative Site 461, Chieti, Italy|Forest Investigative Site 464, Roma, Italy|Forest Investigative Site 505, Batu Caves, Malaysia|Forest Investigative Site 501, Kuala Lumpur, Malaysia|Forest Investigative Site 504, Kuala Lumpur, Malaysia|Forest Investigative Site 502, Kuantan, Malaysia|Forest Investigative Site 522, Monterrey, Nuevo León, Mexico|Forest Investigative Site 526, Merida, Yucatan, Mexico|Forest Investigative Site 524, Guadalajara, Mexico|Forest Investigative Site 521, Monterrey, Mexico|Forest Investigative Site 543, Bellavista, Peru|Forest Investigative Site 550, Lima, Peru|Forest Investigative Site 551, Lima, Peru|Forest Investigative Site 545, Lima, Peru|Forest Investigative Site 546, Lima, Peru|Forest Investigative Site 549, Lima, Peru|Forest Investigative Site 544, Lima, Peru|Forest Investigative Site 541, Pueblo Libre, Peru|Forest Investigative Site 569, Cavite, Philippines|Forest Investigative Site 567, Iloilo City, Philippines|Forest Investigative Site 568, Iloilo City, Philippines|Forest Investigative Site 565, Manila, Philippines|Forest Investigative Site 563, Pasig City, Philippines|Forest Investigative Site 562, Quezon City, Philippines|Forest Investigative Site 564, Quezon City, Philippines|Forest Investigative Site 566, Quezon City, Philippines|Forest Investigative Site 561, Quezon City, Philippines|Forest Investigative Site 585, Brasov, Romania|Forest Investigative Site 586, Bucharest, Romania|Forest Investigative Site 587, Bucharest, Romania|Forest Investigative Site 588, Bucharest, Romania|Forest Investigative Site 584, Bucharest, Romania|Forest Investigative Site 582, Bucharest, Romania|Forest Investigative Site 581, Iasi, Romania|Forest Investigative Site 583, Iasi, Romania|Forest Investigative Site 608, Barnaul, Russian Federation|Forest Investigative Site 602, Kazan, Russian Federation|Forest Investigative Site 618, Kemerovo, Russian Federation|Forest Investigative Site 609, Krasnodar, Russian Federation|Forest Investigative Site 614, Krasnoyarsk, Russian Federation|Forest Investigative Site 617, Moscow, Russian Federation|Forest Investigative Site 605, Novosibirsk, Russian Federation|Forest Investigative Site 600, St Petersburg, Russian Federation|Forest Investigative Site 612, St. Petersburg, Russian Federation|Forest Investigative Site 619, St. Petersburg, Russian Federation|Forest Investigative Site 604, St. Petersburg, Russian Federation|Forest Investigative Site 611, St. Petersburg, Russian Federation|Forest Investigative Site 610, St. Petersburg, Russian Federation|Forest Investigative Site 601, St. Petersburg, Russian Federation|Forest Investigative Site 606, St.Petersburg, Russian Federation|Forest Investigative Site 607, Tomsk, Russian Federation|Forest Investigative Site 620, Yaroslavl, Russian Federation|Forest Investigative Site 629, Knez Selo, Nišava District, Serbia|Forest Investigative Site 622, Belgrade, Serbia|Forest Investigative Site 623, Belgrade, Serbia|Forest Investigative Site 624, Belgrade, Serbia|Forest Investigative Site 625, Beograd, Serbia|Forest Investigative Site 628, Kragujevac, Serbia|Forest Investigative Site 627, Sremska Kamenica, Serbia|Forest Investigative Site 641, Cadiz, Spain|Forest Investigative Site 647, Loja, Spain|Forest Investigative Site 644, Salt, Spain|Forest Investigative Site 723, Kaohsiung Hsien, Taiwan|Forest Investigative Site 724, Puzih City, Taiwan|Forest Investigative Site 725, Taipei, Taiwan|Forest Investigative Site 722, Taipei, Taiwan|Forest Investigative Site 662, Hat Yai, Songkhla, Thailand|Forest Investigative Site 664, Bangkok, Thailand|Forest Investigative Site 663, Bangkok, Thailand|Forest Investigative Site 661, Muang, Thailand|Forest Investigative Site 699, Cherkasy, Ukraine|Forest Investigative Site 691, Dnipropetrovsk, Ukraine|Forest Investigative Site 692, Donetsk, Ukraine|Forest Investigative Site 689, Donetsk, Ukraine|Forest Investigative Site 690, Ivano-Frankivsk, Ukraine|Forest Investigative Site 697, Kharkiv, Ukraine|Forest Investigative Site 693, Kharkiv, Ukraine|Forest Investigative Site 682, Kharkiv, Ukraine|Forest Investigative Site 709, Kremenchuk, Ukraine|Forest Investigative Site 698, Kyiv, Ukraine|Forest Investigative Site 683, Kyiv, Ukraine|Forest Investigative Site 684, Kyiv, Ukraine|Forest Investigative Site 687, Kyiv, Ukraine|Forest Investigative Site 685, Kyiv, Ukraine|Forest Investigative Site 681, Lviv, Ukraine|Forest Investigative Site 708, Mykolayiv, Ukraine|Forest Investigative Site 706, Poltava, Ukraine|Forest Investigative Site 695, Sumy, Ukraine|Forest Investigative Site 707, Vinnitsa, Ukraine|Forest Investigative Site 688, Zaporizhzhia, Ukraine|Forest Investigative Site 696, Zaporizhzhya, Ukraine|Forest Investigative Site 694, Zaporizhzhya, Ukraine|Forest Investigative Site 705, Zaporizhzhya, Ukraine",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Not Yet Recruiting,,LATERAL EPICONDYLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Not yet recruiting,NCT03900988,INFLUENZA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",,C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Completed,NCT00878878,PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"ICON Development Solutions, Elliott City, Maryland, United States",C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Completed,NCT01326611,CHRONIC LUNG DISEASE,All,up to 2 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","Zekai Tahir Burak Maternity Teaching Hospital Neonatology department, Ankara, Turkey",C12Q1/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,1,DB02709,__RESVERATROL,5747536,Completed,NCT03349619,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo, Palermo, Italy",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)C[C@H](NC(=O)CP(=O)(O)O)C(=O)O,1,DB03459,__SPARFOSIC_ACID,4154759,Terminated,NCT00730041,OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Arkansas Center for Sleep Medicine, Little Rock, Arkansas, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Sleep Center at National Jewish Medical Center, Denver, Colorado, United States|Louisiana Sleep Foundation, Baton Rouge, Louisiana, United States|Regions Hospital; Health Partners Sleep Health Center, St. Paul, Minnesota, United States|NYU Sleep Disorders Center, New York, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States",C07F9/3808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,9.13365777531366,84.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,255.1193,161.23,8.0,5.0,0.0,19.82,46.97,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,,URINARY TRACT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(N)=O,1,DB03904,__UREA,,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,1,DB04216,__QUERCETIN,4211772,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",C07H17/07,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.232550976406003,3241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,302.2357,127.45,7.0,5.0,3.0,28.54,76.86,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
Cc1cn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]c1=O,1,DB04243,__TMP,WO-2012095303-A1,Recruiting,NCT03978559,PNEUMOCYSTIS PNEUMONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MICU of Peking Union Medical College, Beijing, China",C12N15/115,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,97.0,32.7488,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,338.2079,169.35,9.0,5.0,2.0,28.47,68.12,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N[C@@H](CSCC(=O)O)C(=O)O,1,DB04339,__CARBOCISTEINE,,Completed,NCT01968434,COUGH|UPPER RESPIRATORY TRACT INFECTION,All,2 Years to 5 Years   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Pediatric Ambulatory Clinic Bat-Yam, Bat Yam, Israel|Pediatric Ambulatory Clinic Kfar-Saba, Kfar Saba, Israel|Pediatric Community Ambulatory Clinic - Petach-Tikva, Petaẖ Tiqwa, Israel|Pediatric Ambulatory Clinic Ramat Aviv Gimel, Tel Aviv, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.2,179.19400000000005,100.62,5.0,3.0,0.0,16.69,39.11,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C13K5/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT01151306,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"45 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nottingham Respiratory Biomedical Research Unit, Nottingham, United Kingdom",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Terminated,NCT02172508,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT01748279,COPD,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT02286960,DYSPHONIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,BRONCHIOLITIS OBLITERANS SYNDROME (BOS),,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,GENERAL SURGERY,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,1,DB04703,__HESPERIDIN,4078137,Completed,,VENOUS INSUFFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",C07H17/07,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.012772336187602,842.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,610.5606,234.29,15.0,8.0,5.0,58.76,140.77,7.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,1
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,1,DB04743,__NIMESULIDE,5283261,Withdrawn,NCT01257126,UPPER RESPIRATORY INFECTIONS,All,3 Years to 7 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.2303127374278,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.56,308.31,101.22,4.0,1.0,2.0,28.87,76.31,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0
CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1,1,DB04743,__NIMESULIDE,5283261,Completed,NCT02229747,PHARYNGITIS,All,2 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.2303127374278,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.56,308.31,101.22,4.0,1.0,2.0,28.87,76.31,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0
Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,1,DB04817,__METAMIZOLE,4699776,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",A61K9/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,27.4995379781925,194.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.4,311.36,81.16,6.0,1.0,2.0,31.41,80.04,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0
CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,1,DB04846,__CELIPROLOL,4767784,Completed,NCT02380053,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom",C07D215/227,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,21.059980697755602,352.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.29,379.501,90.9,5.0,3.0,1.0,43.18,108.25,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1,1,DB04855,__DRONEDARONE,5223510,Unknown Status,,PAROXYSMAL ATRIAL FIBRILLATION,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,23.1298383950389,80.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.46,556.756,88.85,5.0,1.0,3.0,66.05,158.13,17.0,1.0,0.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Unknown status,NCT01771406,HYPERTENSION|ENDOTHELIAL DYSFUNCTION|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Leuven, Leuven, Belgium",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,"Active, not recruiting",NCT02053246,PULMONARY HYPERTENSION|DIASTOLIC HEART FAILURE|HEART FAILURE WITH PRESERVED EJECTION FRACTION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Florida, Gainesville, Florida, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,NCT02710071,HYPERTENSION,All,"30 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Active Not Recruiting,,DIASTOLIC HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C/C=C1\[C@H]2C=C(C)C[C@]1(N)c1ccc(=O)[nH]c1C2,1,DB04864,__HUPERZINE_A,5106979,Not Yet Recruiting,,BIOMARKERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/48,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,24.969711903735103,196.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,242.3162,55.12,2.0,2.0,3.0,26.87,75.8,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,1,DB04920,__CLEVIDIPINE,5856346,Completed,NCT01121458,"HYPERTENSION, PULMONARY",All,"21 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"VA North Texas Health Care System, Dallas, Texas, United States",C07D211/90,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,48.723793096367395,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.98,456.316,90.93,4.0,1.0,2.0,45.12,113.93,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Completed,NCT02606877,IDIOPATHIC PULMONARY FIBROSIS,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southmead Hospital, Bristol, United Kingdom|Papworth Hospital, Cambridge, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|University College London Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Recruiting,NCT03939520,PROGRESSIVE IDIOPATHIC PULMONARY FIBROSIS,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Unknown status,NCT03260556,"SARCOIDOSIS, PULMONARY",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Unknown status,NCT02821689,DERMATOPOLYMYOSITIS|INTERSTITIAL LUNG DISEASE,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1,1,DB05016,__ATALUREN,US-20040204461-A1,Completed,NCT03256968,CYSTIC FIBROSIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,21.7499332635167,46.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.96,284.242,76.22,4.0,1.0,3.0,27.66,94.66,3.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,NCT02055352,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Florida, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Vicente Lopez, Buenos Aires, Argentina|Novartis Investigative Site, Zarate, Buenos Aires, Argentina|Novartis Investigative Site, Santa Rosa, La Pampa, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Argentina|Novartis Investigative Site, Salta, Argentina|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Bernardo do Campo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Santiago, Region Metropolitana, Chile|Novartis Investigative Site, Rancagua, Chile|Novartis Investigative Site, Santo Domingo, Republica Dominicana, Dominican Republic|Novartis Investigative Site, Santo Domingo, Republica Dominicana, Dominican Republic|Novartis Investigative Site, Guayaquil, Guayas, Ecuador|Novartis Investigative Site, San Pedro Sula, Honduras|Novartis Investigative Site, Tegucigalpa, Honduras|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, León, Guanajuato, Mexico|Novartis Investigative Site, Panama City, Panamá, Panama",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,NCT01377051,COPD|LUNG DISEASES|DYSPNEA|HYPOXEMIA|TACHYCARDIA,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pneumologia Riabilitativa - Fondazione Maugeri - Istituto Scientifico di Milano - IRCCS, Milano, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,NCT02039011,ASTHMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
O=C(O)CSCC(=O)NC1CCSC1=O,1,DB05057,__ERDOSTEINE,4411909,Withdrawn,NCT01176318,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom",C07D333/36,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,19.3515267253947,55.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,249.30700000000002,83.47,4.0,2.0,1.0,23.92,57.92,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)[O-])c3O[C@H]2C[C@H]1O.[Na+],1,DB05229,__BERAPROST,6197328,Completed,NCT03431649,PEDIATRIC PULMONARY HYPERTENSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",A61K38/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,18.5301546232982,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,420.4738,89.82,5.0,2.0,3.0,44.85,123.56,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+],1,DB05245,__SILVER_SULFADIAZINE,3983209,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,765.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,357.13699999999994,95.17,6.0,1.0,2.0,24.1,63.4,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,1,DB05316,__PIMAVANSERIN,7115634,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,69.6523542577876,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.19,427.564,44.81,3.0,1.0,3.0,47.76,122.93,8.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,1
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Unknown status,NCT01328652,LARYNGOPHARYNGEAL REFLUX|HYPERTROPHY OF LINGUAL TONSIL,All,18 Years to 59 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advanced Center for Specialty Care, Chicago, Illinois, United States",H01L28/84,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,1,DB05767,__ANDROGRAPHOLIDE,,Unknown status,NCT03134443,ACUTE TONSILLITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.57,350.455,86.99,4.0,3.0,3.0,38.27,94.93,3.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,1,DB05767,__ANDROGRAPHOLIDE,,Unknown status,NCT03132623,ACUTE BRONCHITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.57,350.455,86.99,4.0,3.0,3.0,38.27,94.93,3.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H]2[C@@](C)(CC[C@@H](O)[C@@]2(C)CO)[C@@H]1C/C=C1/C(=O)OC[C@H]1O,1,DB05767,__ANDROGRAPHOLIDE,,Unknown status,NCT03132610,ACUTE EXACERBATION OF CHRONIC BRONCHITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.57,350.455,86.99,4.0,3.0,3.0,38.27,94.93,3.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Completed,NCT02476526,CHRONIC KIDNEY DISEASE|PULMONARY EMBOLISM|RENAL ARTERY STENOSIS|PULMONARY CANCER,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Terminated,NCT00996424,CYSTIC FIBROSIS,All,"6 Years to 64 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Ghent, Ghent, Belgium",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Completed,NCT03388853,COPD,All,"40 Years to 100 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cukurova University Faculty of Medicine, Chest Diseases Department, Adana, Turkey|Health Sciences University, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)N[C@@H](CS)C(=O)O,1,DB06151,__ACETYLCYSTEINE,8148356,Completed,NCT02168387,ATELECTASIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,79.3116901784431,8.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.03,163.195,66.4,3.0,3.0,0.0,15.34,37.67,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Recruiting,NCT03679611,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto Western Hospital, Toronto, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Not yet recruiting,NCT04263363,RESPIRATORY COMPLICATION|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,NCT02845375,RESPIRATORY INSUFFICIENCY,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, ZH, Netherlands",1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Recruiting,NCT02822001,NEUROMUSCULAR BLOCKADE|RESPIRATORY INSUFFICIENCY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Memorial Hermann Hospital, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,NCT01579851,ANESTHESIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Foch, Suresnes, Ile de France, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,NCT02243943,POSTOPERATIVE RESPIRATORY CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden Medical University, Leiden, Zuid Holland, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,,LAPAROSCOPIC CHOLECYSTECTOMY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F,1,DB06207,__SILODOSIN,5403847,Completed,,BENIGN PROSTATIC HYPERTROPHY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,28.6494589211277,67.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,495.5345,97.05,6.0,3.0,3.0,49.89,128.92,14.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,1,DB06209,__PRASUGREL,5288726,Completed,NCT01305369,CHRONIC ASTHMA,All,"18 Years to 74 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medicina 3 Ospedale San Paolo Dipartimento di Medicina Chirurgia e Odontoiatria, Università di Milano, Milan, Italy",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,56.0,17.478798332614602,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,373.441,46.61,3.0,0.0,4.0,37.7,96.81,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,,APLASTIC ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,NCT00965848,"INFECTION|CROSS INFECTION|BACTERIAL INFECTIONS|PNEUMONIA, VENTILATOR-ASSOCIATED|INTRA-ABDOMINAL INFECTIONS|URINARY TRACT INFECTIONS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangkok, Thailand|Chiang Mai, Thailand|Chiang Rai, Thailand|Chonburi, Thailand|Khon Kaen, Thailand|Khon Khen, Thailand|Nakhonratsima, Thailand|Nakornnayok, Thailand|Pathumthani, Thailand",C07C307/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,NCT00986102,"PNEUMONIA|PNEUMONIA, VENTILATOR-ASSOCIATED|URINARY TRACT INFECTIONS",All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hk, Hong Kong|Bandung, Indonesia|Jakarta, Indonesia|Surabaya, Indonesia|Ipoh, Malaysia|Johor Bahru, Malaysia|Kota Bharu, Malaysia|Kuala Lumpur K Lumpur, Malaysia|Kuala Lumpur N/A, Malaysia|Pulau Pinang, Malaysia|Selangor, Malaysia|Seremban, Malaysia|Terengganu, Malaysia|Singapore, Singapore|Hanoi, Vietnam|Ho Chi Minh City, Vietnam",C07C307/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,NCT01467648,VENTILATOR ASSOCIATED PNEUMONIA,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Prince of Songkla University, Hat Yai, Songkla, Thailand",C07C307/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,NCT00862641,"ASTHMA|CORONARY ARTERY DISEASE|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Montgomery, Alabama, United States|Anaheim, California, United States|Encinitas, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Long Beach, California, United States|Mission Viejo, California, United States|Roseville, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Deland, Florida, United States|Miami, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Stockbridge, Georgia, United States|Aurora, Illinois, United States|Topeka, Kansas, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|No. Dartmouth, Massachusetts, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Papillion, Nebraska, United States|Brick, New Jersey, United States|Raleigh, North Carolina, United States|Chardon, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma, Oklahoma, United States|Medford, Oregon, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,DIASTOLIC HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,AGITATION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,1,DB06217,__VERNAKALANT,WO-2005113011-A2,Recruiting,,PAROXYSMAL ATRIAL FIBRILLATION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/54 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.74,349.471,51.16,5.0,1.0,3.0,39.63,98.27,7.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Recruiting,NCT04394377,CORONAVIRUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp, Botucatu, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Completed,NCT02161965,PERMANENT ATRIAL FIBRILLATION|VENOUS THROMBOSIS|PULMONARY EMBOLISM|ANTICOAGULATION TREATMENT AT LEAST > OR = TO 12-MONTH,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University Hospital Angers, Angers, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,"Active, not recruiting",NCT02066662,"ATRIAL FIBRILLATION OR PULMONARY EMBOLISM|NEED OF LONG TERM ORAL ANTICOAGULATION THERAPY (OAT)|EXISTENT CORONARY OR VALVULAR CALCIFICATION, OR BOTH AND AGATSTON SCORE > 50 IN AT LEAST ONE LOCATION",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science,"Hospital Coburg, Med. Clinic II for Internal Medicine and Cardiology, Coburg, Bavaria, Germany|University Hospital Aachen, Department of Cardiology, Aachen, North Rhine Westphalia, Germany|St.-Antonius-Hospital Eschweiler, Internal Medicine, Eschweiler, North Rhine Westphalia, Germany",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Completed,NCT02584660,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montgomery, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|Sylmar, California, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Davenport, Iowa, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Jackson, Michigan, United States|Lansing, Michigan, United States|Royal Oak, Michigan, United States|Saint Louis, Missouri, United States|Atlantic City, New Jersey, United States|Camden, New Jersey, United States|Brooklyn, New York, United States|Buffalo, New York, United States|New York, New York, United States|Stony Brook, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Toledo, Ohio, United States|Zanesville, Ohio, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Bellingham, Washington, United States|Everett, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Recruiting,NCT02810704,PULMONARY EMBOLISM|VENOUS THROMBOSIS,All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Mayo Clinic, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA, Los Angeles, California, United States|Stanford University Hospital, Stanford, California, United States|Arthritis Surgery Research Foundation, South Miami, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|New York University, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State Hershey Med Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Lifespan Health, East Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Anderson Orthopaedic Institute (VA), Alexandria, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Recruiting,NCT04263038,PULMONARY EMBOLISM|EMBOLISM|EMBOLISM AND THROMBOSIS|LUNG DISEASES|CARDIOVASCULAR DISEASES|RESPIRATORY TRACT DISEASES|VENOUS THROMBOEMBOLISM|ANTICOAGULANT-INDUCED BLEEDING|BLEEDING,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Ottawa Hospital, Ottawa, Canada|Haga Ziekenhuis, Den Haag, Netherlands|HMC Westeinde, Den Haag, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Tergooi ziekenhuis, Hilversum, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Alrijne ziekenhuis, Leiderdorp, Netherlands|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|Cantonal Hospital of Aarau, Aarau, Aargau, Switzerland|Cantonal Hospital of Liestal, Liestal, Basel, Switzerland|Hospital of Bienne, Bienne, Bern, Switzerland|Cantonal Hospital of St. Gallen, St. Gallen, Saint Gallen, Switzerland|Cantonal Hospital of Olten, Olten, Solothurn, Switzerland|Cantonal Hospital of Frauenfeld, Frauenfeld, Thurgau, Switzerland|Cantonal Hospital of Uri, Altdorf, Uri, Switzerland|Hospital of Sion, Sion, Valais, Switzerland|University Hospital of Lausanne, Lausanne, Vaud, Switzerland|Hospital of Nyon, Nyon, Vaud, Switzerland|Cantonal Hospital of Winterthur, Winterthur, Zurich, Switzerland|Cantonal Hospital of Baden, Baden, Switzerland|University Hospital of Basel, Basel, Switzerland|University Hospital Inselspital, Bern, Switzerland|Tiefenau Hospital, Bern, Switzerland|Regional Hospital of Emmental, Burgdorf, Switzerland|Hospital of Delémont, Delémont, Switzerland|Cantonal Hospital of Fribourg, Fribourg, Switzerland|Geneva University Hospital, Geneva, Switzerland|Cantonal Hospital of Lucerne, Lucerne, Switzerland|Hospital of Neuchâtel, Neuchâtel, Switzerland|Triemli Hospital, Zürich, Switzerland|University Hospital Zürich, Zürich, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00826943,ALLERGIC RHINITIS,All,"18 Years to 77 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vanderbilt University Asthma, Sinus, and Allergy Clinic, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00894231,PERENNIAL ALLERGIC RHINITIS,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAADRS, Coral Gables, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00160680,"RHINITIS, ALLERGIC, PERENNIAL",,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Genova, Italy",4,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02253121,HYPERGLYCEMIA STEROID-INDUCED,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Slotervaart Hospital, Amsterdam, Netherlands|OLVG West, Amsterdam, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Isala, Zwolle, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Suspended,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
CCCCCCCCCCNCCN[C@@]1(C)C[C@H](O[C@H]2[C@H](Oc3c4cc5cc3Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]5C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c5cc(O)c(CNCP(=O)(O)O)c(O)c5-c5cc3ccc5O)[C@H](O)c3ccc(c(Cl)c3)O4)O[C@H](CO)[C@@H](O)[C@@H]2O)O[C@@H](C)[C@H]1O,1,DB06402,__TELAVANCIN,6635618,Completed,NCT03172793,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Hartford Hospital, Hartford, Connecticut, United States|IU Health University Hospital, Indianapolis, Indiana, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|St. Christophers Hospital for Children, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Shadyside, Pittsburgh, Pennsylvania, United States",A61K47/6951,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,29.6679603277274,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,1755.65,598.09,29.0,23.0,10.0,175.85,429.41,30.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Completed,NCT01042158,PULMONARY ARTERIAL HYPERTENSION|SYSTEMIC SCLEROSIS|SCLERODERMA SPECTRUM OF DISEASES|CONNECTIVE TISSUE DISEASE|PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University, Baltimore, Maryland, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Terminated,NCT02253394,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Brigham & Women's Hospital, Boston, Massachusetts, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Withdrawn,NCT03309592,"PORTOPULMONARY HYPERTENSION|PULMONARY HYPERTENSION|CIRRHOSIS, LIVER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Terminated,NCT00840463,PULMONARY HYPERTENSION|HEART FAILURE WITH PRESERVED EJECTION FRACTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","UT Southwestern Medical Center, Dallas, Texas, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Completed,NCT01338636,EXERCISE-INDUCED PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Hospital, Boston, Massachusetts, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O,1,DB06403,__AMBRISENTAN,RE42462,Completed,NCT01051960,SYSTEMIC SCLEROSIS|SHORTNESS OF BREATH|PULMONARY HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,188.225630916445,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,378.42800000000005,81.54,6.0,1.0,3.0,38.86,104.17,7.0,0.0,1.0,0.0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,1,DB06413,__ARMODAFINIL,4927855,Completed,NCT00711516,EXCESSIVE SLEEPINESS,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peninsula Sleep Center, Burlingame, California, United States|Pacific Research, San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Stanford University, Stanford, California, United States|Beth Israel Deaconess Medical, Boston, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,1,DB06413,__ARMODAFINIL,4927855,Completed,NCT00518986,SLEEP DISORDERS|OBSTRUCTIVE SLEEP APNEA|MAJOR DEPRESSIVE DISORDER|DYSTHYMIC DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Jasper Summit Research, LLC, Jasper, Alabama, United States|Pulmonary Associates, P.A., Phoenix, Arizona, United States|Psypharma Clinical Research, Phoenix, Arizona, United States|PsyPharm Clinical Research, Inc., Tucson, Arizona, United States|Behavioral Research Specialists, Glendale, California, United States|California Clinical Trials Medical Group, Inc., Glendale, California, United States|Pacific Sleep Medicine Services, Inc., Redlands, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Pacific Sleep Medicine Services, Inc., San Diego, California, United States|California Clinical Trials Medical Group, Inc., San Diego, California, United States|SDS Clinical Research, Santa Ana, California, United States|St. Johns Medical Plaza Sleep Disorders Center, Santa Monica, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Rocky Mountain Center for Clinical Research, Wheat Ridge, Colorado, United States|PAB Clinical Research, Brandon, Florida, United States|Florida Sleep Institute, Spring Hill, Florida, United States|Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|SomnoMedics, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Florida Pulmonary Research Center, LLC, Winter Park, Florida, United States|The Sleep Disorders Center, Atlanta, Georgia, United States|Neurotrials Research, Inc, Atlanta, Georgia, United States|Sleep Disorders Center of Georgia, Atlanta, Georgia, United States|SleepMed, Inc, Macon, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Peoria Pulmonary Associates, Peoria, Illinois, United States|Sleep and Behavior Medicine, Vernon Hills, Illinois, United States|The Center for Sleep and Wake Disorders, Danville, Indiana, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Community Research, Crestview, Kentucky, United States|Clinical Trials of America, Shreveport, Louisiana, United States|The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States|Sleep Health Centers, Brighton, Massachusetts, United States|AccelRx Research, Fall River, Massachusetts, United States|The Center for Sleep Medicine, Hattiesburg, Mississippi, United States|Washington University, St. Louis, Missouri, United States|Somnos Sleep Center, Lincoln, Nebraska, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Clinilabs, Inc, New York City, New York, United States|Sleep Medicine Centers, West Seneca, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Hickory, North Carolina, United States|Tri-State Sleep Disorders Center, Cincinnati, Ohio, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Sleep Lab of Northeastern PA, Clarks Summit, Pennsylvania, United States|University of Pennsylvania Center for Sleep, Philadelphia, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|University Services, West Chester, Pennsylvania, United States|AccelRx Research, Lincoln, Rhode Island, United States|Lowcountry Lung and Critical Care, Charleston, South Carolina, United States|SleepMed of South Carolina, Columbia, South Carolina, United States|Sleep Medicine of Middle Tennessee, Nashville, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Sleep Medicine Associates of Texas, P.A., Dallas, Texas, United States|Baylor College of Medicine VAMC Sleep Research, Houston, Texas, United States|Houston Sleep Center, Houston, Texas, United States|Northwest Clinical Research, Bellevue, Washington, United States|Pacific Sleep Medicine Services, Inc., Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,NCT01645735,INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Phoenix, Arizona, United States|Investigational Site, Sylmar, California, United States|Investigational Site, DeLand, Florida, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Kansas City, Kansas, United States|Investigational Site, Royal Oak, Michigan, United States|Investigational Site, Minneapolis, Minnesota, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Omaha, Nebraska, United States|Investigational Site, Laconia, New Hampshire, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Lima, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tbilisi, Georgia|Investigational Site, Matrahaza, Hungary|Investigational Site, Lodz, Poland|Investigational Site, Lublin, Poland|Investigational Site, Wilkowice-Bystra, Poland|Investigational Site, Craiova, Dolj, Romania|Investigational Site, Bucharest, Romania|Investigational Site, Iasi, Romania|Investigational Site, Moscow, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, Yaroslavl, Russian Federation|Investigational Site, Alicante, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Dnipropetrovsk, Ukraine|Investigational Site, Ivano-Frankivsik, Ukraine|Investigational Site, Kharkiv, Ukraine|Investigational Site, Kyiv, Ukraine|Investigational Site, Zaporizhzhya, Ukraine",C07F9/65613,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,NCT01669980,INFECTIONS|PNEUMONIA,All,"2 Months to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Investigational Site, Long Beach, California, United States|Oakland, California, United States|Investigational Site, Orange County, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Boston, Massachusetts, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Pittsburgh, Pennsylvania, United States|Investigational Site, Memphis, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Investigational Site, Norfolk, Virginia, United States|Investigational Site, Morgantown, West Virginia, United States|Investigative Site, Buenos Aires, Argentina|Investigational Site 1, Tbilisi, Georgia|Investigational Site 2, Tbilisi, Georgia|Investigational Site 3, Tbilisi, Georgia|Investigational Site, Donetsk, Ukraine|Investigational Site, Ivano-Frankivsk, Ukraine|Investigational Site, Kryvyi Rih, Ukraine|Investigational Site, Kyiv, Ukraine",C07F9/65613,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Withdrawn,NCT01666743,COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP),All,65 Years and older   (Older Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65613,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,,BACTEREMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Recruiting,,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Recruiting,,CYSTIC FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Not yet recruiting,NCT04168203,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM|VENOUS THROMBOEMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Suspended,NCT03988842,PULMONARY EMBOLISM WITH ACUTE COR PULMONALE|PULMONARY EMBOLISM|PULMONARY EMBOLISM WITH PULMONARY INFARCTION|PULMONARY EMBOLISM SUBACUTE MASSIVE|RIGHT VENTRICULAR DYSFUNCTION|RIGHT VENTRICULAR FAILURE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cedars-Sinai Medical Center, Los Angeles, California, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N,1,DB06614,__PERAMIVIR,6562861,Completed,NCT02609399,INFLUENZA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maricopa Integrated Health System, Phoenix, Arizona, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",C07D339/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,35.5818394628226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,328.4072,148.53,7.0,6.0,1.0,34.85,94.46,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Withdrawn,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Unknown status,NCT03228628,PAIN|ANXIETY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Unknown status,NCT02243826,LUMBAR PUNCTURE,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU de Clermont-Ferrand, Clermont-Ferrand, France",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Completed,NCT00630474,OBSTRUCTIVE SLEEP APNEA SYNDROME|RHINITIS,All,"20 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Division, University Hospital Zurich, Switzerland, Zurich, Switzerland|Pulmonary Division, University Hospital Zurich, Zurich, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Completed,,OBSTRUCTIVE SLEEP APNEA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",C07D277/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Unknown status,NCT02979561,ANGIOGRAPHICALLY CONFIRMED ACUTE MASSIVE PULMONARY EMBOLISM TREATED WITH ENDOVASCULAR MECHANICAL FRAGMENTATION AND THROMBOLYTIC THERAPY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Completed,,VENOUS THROMBOEMBOLISM,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Suspended,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,1,DB06703,__GADOBUTROL,5980864,Completed,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D257/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,103.722869052752,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,604.72,181.08,9.0,3.0,4.0,45.39,143.47,10.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,CARDIOMYOPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(=O)OC(C)C[N+](C)(C)C,1,DB06709,__METHACHOLINE,4059686,Not yet recruiting,NCT03105843,ASTHMA|COUGH|COUGH VARIANT ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Kingston Health Sciences Centre, Kingston, Ontario, Canada",A61K9/2027,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,26.021068194418696,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.7,160.234,26.3,1.0,0.0,0.0,18.43,55.76,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)C[N+](C)(C)C,1,DB06709,__METHACHOLINE,4059686,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",A61K9/2027,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,26.021068194418696,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.7,160.234,26.3,1.0,0.0,0.0,18.43,55.76,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1,1,DB06755,__BETA_CAROTENE,,Unknown status,NCT03366584,HYALINE MEMBRANE DISEASE|NECROTIZING ENTEROCOLITIS OF NEWBORN,Female,"17 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,9.72,536.888,0.0,0.0,0.0,2.0,71.84,191.61,10.0,1.0,0.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)CCCC2(C)C)C(C)(C)CCC1,1,DB06755,__BETA_CAROTENE,,Completed,NCT00712647,LUNG CANCER,All,"45 Years to 69 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,9.72,536.888,0.0,0.0,0.0,2.0,71.84,191.61,10.0,1.0,0.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT01862523,RHINITIS,All,18 Years to 60 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UZ Leuven, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT01223820,IDIOPATHIC RHINITIS PATIENTS|HEALTHY CONTROLS,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UZ Leuven, NKO-GH Kapucijnenvoer 33, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT02288156,NON-ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ORL, Leuven, Vlaams-Brabant, Belgium",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Recruiting,,NEUROENDOCRINE TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
NCc1ccc(S(N)(=O)=O)cc1,1,DB06795,__MAFENIDE,3983209,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.37,186.232,86.18,3.0,2.0,1.0,18.24,46.69,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C1N2CN3CN1CN(C2)C3,1,DB06799,__METHENAMINE,3931386,Active Not Recruiting,,URINARY TRACT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C08L61/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,38.2102301895316,2756.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,140.1863,12.96,4.0,0.0,3.0,14.25,37.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,1,DB07615,__TRANILAST,4070484,Completed,NCT00818805,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,13.1090987494609,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.89,327.3313,84.86,5.0,2.0,2.0,34.2,91.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1c(Sc2ccccc2)n(COCCO)c(=O)[nH]c1=O,1,DB07892,__1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL_THIOTHYMINE,5112835,Completed,NCT00161122,RECURRENT UPPER AND LOWER RESPIRATORY TRACT INFECTIONS (RTIS),All,18 Months to 72 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands",C07D239/60,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,29.6679603277274,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,308.353,78.87,4.0,2.0,2.0,30.59,89.35,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0
CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1,1,DB08167,__METHYLTHIONINIUM,WO-2008006979-A2,Active Not Recruiting,,URINARY TRACT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.8,284.399,19.37,3.0,0.0,3.0,33.11,86.98,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0
c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,1,DB08799,__ANTAZOLINE,4000302,Completed,,PAROXYSMAL ATRIAL FIBRILLATION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,20.4357379001622,248.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.22,265.3529,27.63,3.0,1.0,3.0,30.11,82.89,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,1,DB08820,__IVACAFTOR,7495103,Unknown status,NCT01937325,CYSTIC FIBROSIS,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The Alfred, Melbourne, Victoria, Australia",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,64.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,392.4907,78.43,4.0,3.0,3.0,43.04,118.68,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O,1,DB08820,__IVACAFTOR,7495103,Recruiting,NCT03251911,CHRONIC BRONCHITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,64.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,392.4907,78.43,4.0,3.0,3.0,43.04,118.68,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Recruiting,NCT03672643,ALK OR ROS1-POSITIVE NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fujian Province Oncology Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Nanjing Bayi Hospital of PLA, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Internal Department, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Not yet recruiting,NCT04341935,CORONAVIRUS INFECTION|TYPE 2 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,TRANSIENT SEVERE ARTERIAL PHASE MOTION,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,NCT04505098,COVID19|ATHEROSCLEROSIS|CARDIOVASCULAR DISEASES|UPPER RESPIRATORY TRACT INFECTIONS,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Kaiser Permanente Northern California, Oakland, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Skåne University Hospital, Department of Rheumatology, Lund, Skåne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, Göteborg, Västra Götaland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,1,DB08897,__ACLIDINIUM,5840279,Completed,NCT02972476,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, Tayside, United Kingdom|Blackpool Teaching Hospital NHS Foundation Trust, Blackpool, United Kingdom|NHS Lothian, Edinburgh, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|NHS Fife, Kirkcaldy, United Kingdom|NHS Lanarkshire, Wishaw, United Kingdom",A61M15/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,45.0,29.109427298301807,60.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,484.651,55.76,3.0,1.0,5.0,52.09,141.33,10.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,1,DB08897,__ACLIDINIUM,5840279,Completed,NCT02424344,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Sainte Foy, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt, Germany|Research Site, Großhansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Jena, Germany|Research Site, Lübeck, Germany|Research Site, München, Germany|Research Site, Wiesbaden, Germany|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Törökbálint, Hungary|Research Site, Alicante, Spain|Research Site, Cáceres, Spain|Research Site, Madrid, Spain",A61M15/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,45.0,29.109427298301807,60.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,484.651,55.76,3.0,1.0,5.0,52.09,141.33,10.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,1,DB08897,__ACLIDINIUM,5840279,Completed,NCT01966107,COPD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|MODERATE TO VERY SEVERE COPD,All,"40 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Florence, Alabama, United States|Research Site, Foley, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Jasper, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Encinitas, California, United States|Research Site, Escondido, California, United States|Research Site, Fresno, California, United States|Research Site, Gold River, California, United States|Research Site, Huntington Beach, California, United States|Research Site, La Mirada, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Lincoln, California, United States|Research Site, Loma Linda, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, North Hollywood, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palm Springs, California, United States|Research Site, Paramount, California, United States|Research Site, Pismo Beach, California, United States|Research Site, Port Hueneme, California, United States|Research Site, Poway, California, United States|Research Site, Rialto, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Jose, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Vista, California, United States|Research Site, Westminster, California, United States|Research Site, Wildomar, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Centennial, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Bristol, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeBary, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Eustis, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Palmetto Bay, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Santa Rosa Beach, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Blue Ridge, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Duluth, Georgia, United States|Research Site, Johns Creek, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Norcross, Georgia, United States|Research Site, Oakwood, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Snellville, Georgia, United States|Research Site, Snellville, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Hayden Lake, Idaho, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Gillespie, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Morton, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, O'Fallon, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Elwood, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Lenexa, Kansas, United States|Research Site, Pratt, Kansas, United States|Research Site, Topeka, Kansas, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Madisonville, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Eunice, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Marshall, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Zachary, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Bingham Farms, Michigan, United States|Research Site, Buckley, Michigan, United States|Research Site, Caro, Michigan, United States|Research Site, Chesterfield, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Rochester, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Stevensville, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Charles, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Fremont, Nebraska, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Sparks, Nevada, United States|Research Site, Belvidere, New Jersey, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hopewell Jct, New York, United States|Research Site, Jamaica, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Wappingers Falls, New York, United States|Research Site, Westfield, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Whiteville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Belle Vernon, Pennsylvania, United States|Research Site, Bensalem, Pennsylvania, United States|Research Site, Carnegie, Pennsylvania, United States|Research Site, Clairton, Pennsylvania, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Feasterville-Trevose, Pennsylvania, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Scottdale, Pennsylvania, United States|Research Site, Smithfield, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Hodges, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Pelzer, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Union, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Athens, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Fayetteville, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Hendersonville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Smyrna, Tennessee, United States|Research Site, Spring Hill, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Corsicana, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dickinson, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Murray, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Riverton, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Bellingham, Washington, United States|Research Site, Everett, Washington, United States|Research Site, Port Orchard, Washington, United States|Research Site, Spokane Valley, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Lewisburg, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kamloops, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Langley, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, West Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Dorchester, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thorold, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada",A61M15/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,45.0,29.109427298301807,60.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,484.651,55.76,3.0,1.0,5.0,52.09,141.33,10.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,1,DB08897,__ACLIDINIUM,5840279,Recruiting,NCT03275116,CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ciro, center of expertise in chronic organ failure, Horn, Netherlands",A61M15/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,45.0,29.109427298301807,60.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,484.651,55.76,3.0,1.0,5.0,52.09,141.33,10.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT01957150,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Jasper, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Indian Land, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Spokane Valley, Washington, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Neu isenburg, Hessen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Beek, Netherlands|GSK Investigational Site, EDE, Netherlands|GSK Investigational Site, Eindhoven, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Losser, Netherlands|GSK Investigational Site, Voerendaal, Netherlands|GSK Investigational Site, Barcelona, Catalonia, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Mérida (Badajoz), Spain|GSK Investigational Site, Ponferrada (León), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00603044,CHILDHOOD OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS),All,2 Years to 12 Years   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Chicago, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Terminated,NCT01013701,PATIENTS WITH NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,1,DB08911,__TRAMETINIB,7378423,Recruiting,NCT03975829,"DIFFUSE ASTROCYTOMA|ANAPLASTIC ASTROCYTOMA|ASTROCYTOMA|OLIGODENDROGLIOMA, CHILDHOOD|ANAPLASTIC OLIGODENDROGLIOMA|GLIOBLASTOMA|PILOCYTIC ASTROCYTOMA|GIANT CELL ASTROCYTOMA|PLEOMORPHIC XANTHOASTROCYTOMA|ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA|ANGIOCENTRIC GLIOMA|CHORDOID GLIOMA OF THIRD VENTRICLE|GANGLIOCYTOMA|GANGLIOGLIOMA|ANAPLASTIC GANGLIOGLIOMA|DYSPLASTIC GANGLIOCYTOMA OF CEREBRELLUM|DESMOPLASTIC INFANTILE ASTROCYTOMA AND GANGLIOGLIOMA|PAPILLARY GLIONEURONAL TUMOR|ROSETTE-FORMING GLIONEURONA TUMOR|CENTRAL NEUROCYTOMA|EXTRAVENTRICULAR NEUROCYTOMA|CEREBELLAR LIPONEUROCYTOMA|NEUROFIBROMATOSIS TYPE 1",All,"1 Year and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Childrens Hospital, Phoenix, Arizona, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Novartis Investigative Site, Rennes, Bretagne, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom",C07C275/50,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,1,DB08911,__TRAMETINIB,7378423,Recruiting,NCT03340506,MELANOMA|NON SMALL CELL LUNG CANCER|SOLID TUMOR|RARE CANCERS|HIGH GRADE GLIOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Honor Health Research Institute, Scottsdale, Arizona, United States|James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Songkla, Thailand",C07C275/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,1,DB08912,__DABRAFENIB,7994185,Recruiting,NCT03975829,"DIFFUSE ASTROCYTOMA|ANAPLASTIC ASTROCYTOMA|ASTROCYTOMA|OLIGODENDROGLIOMA, CHILDHOOD|ANAPLASTIC OLIGODENDROGLIOMA|GLIOBLASTOMA|PILOCYTIC ASTROCYTOMA|GIANT CELL ASTROCYTOMA|PLEOMORPHIC XANTHOASTROCYTOMA|ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA|ANGIOCENTRIC GLIOMA|CHORDOID GLIOMA OF THIRD VENTRICLE|GANGLIOCYTOMA|GANGLIOGLIOMA|ANAPLASTIC GANGLIOGLIOMA|DYSPLASTIC GANGLIOCYTOMA OF CEREBRELLUM|DESMOPLASTIC INFANTILE ASTROCYTOMA AND GANGLIOGLIOMA|PAPILLARY GLIONEURONAL TUMOR|ROSETTE-FORMING GLIONEURONA TUMOR|CENTRAL NEUROCYTOMA|EXTRAVENTRICULAR NEUROCYTOMA|CEREBELLAR LIPONEUROCYTOMA|NEUROFIBROMATOSIS TYPE 1",All,"1 Year and older   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Childrens Hospital, Phoenix, Arizona, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Novartis Investigative Site, Rennes, Bretagne, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0
CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,1,DB08912,__DABRAFENIB,7994185,Recruiting,NCT03340506,MELANOMA|NON SMALL CELL LUNG CANCER|SOLID TUMOR|RARE CANCERS|HIGH GRADE GLIOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Honor Health Research Institute, Scottsdale, Arizona, United States|James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Songkla, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,27.170989137353892,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.44,519.562,110.86,6.0,2.0,4.0,49.71,127.51,5.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,DB08916,__AFATINIB,6251912,Completed,NCT02208843,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center, Alexandria University Hospital, Alexandria, Egypt|National Cancer Institute, Cairo University, Cairo, Egypt|Kasr Al Ainy Hospital, Cairo, Egypt|Nilai Medical Centre, Nilai, Malaysia|Baguio General Hospital and Medical Center, Baguio City, Philippines|St. Luke's Medical Center, Taguig, Philippines|University Clinical Center, Gdansk, Gdansk, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin-Zdunowo, Poland|Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer, Warsaw, Poland|Braila County Emergency Hospital, Medical Oncology, Braila, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Craiova, Romania|Regional Oncology Institute of Iasi, Medical Oncology, Iasi, Romania|Institute for Oncol & Radiol of Serbia, Clinic f. Med. Onco., Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Inst. for Pulm. Diseases of Vojvodine, Clinic f. Pulm. Oncol, Sremska Kamenica, Serbia|Wattanosoth Hospital, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Rajavithi Hospital, Bangkok, Thailand|Songklanagarind Hospital, Songkhla, Thailand",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,DB08916,__AFATINIB,6251912,Terminated,NCT02695290,"CARCINOMA, NON-SMALL-CELL LUNG|ERBB RECEPTORS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1200.208.10032 Boehringer Ingelheim Investigational Site, Fountain Valley, California, United States",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,DB08916,__AFATINIB,6251912,Not yet recruiting,NCT04413201,NON-SQUAMOUS NSCLC,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Evangelisches Krankenhaus Hamm, Hamm, Germany",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,DB08916,__AFATINIB,6251912,Completed,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/94,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Unknown status,NCT02625558,SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Recruiting,NCT03809156,PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peter Lougheed Center, Calgary, Alberta, Canada|Vancouver General Hospital, The Lung Centre, Vancouver, British Columbia, Canada",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Completed,NCT02191137,"HYPERTENSION, PULMONARY",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tucson, Arizona, United States|La Jolla, California, United States|Moreno Valley, California, United States|Pomona, California, United States|Sacramento, California, United States|San Juan Capistrano, California, United States|Santa Barbara, California, United States|Aurora, Colorado, United States|Hartford, Connecticut, United States|Celebration, Florida, United States|Jacksonville, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Weston, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Detroit, Michigan, United States|Troy, Michigan, United States|Pascagoula, Mississippi, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Newark, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Liverpool, New York, United States|Mineola, New York, United States|New Hyde Park, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Sioux Falls, South Dakota, United States|El Paso, Texas, United States|Houston, Texas, United States|Temple, Texas, United States|Milwaukee, Wisconsin, United States|Milwaukee, Wisconsin, United States|Guaynabo, Puerto Rico",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Completed,NCT02024386,"HYPERTENSION, PULMONARY|ALTITUDE SICKNESS",All,18 Years to 40 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Duke Center for Hyperbaric Medicine and Environmental Physiology, Trent Drive, Building CR2, Room 0584, Box 3823,, Durham, North Carolina, United States",C07D471/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Completed,,ALTITUDE SICKNESS,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,1,DB08932,__MACITENTAN,7094781,Completed,NCT02310672,PULMONARY ARTERIAL HYPERTENSION,All,18 Years to 64 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachussetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rudgers New Jersey Medical School, New Brunswick, New Jersey, United States|Cornell University, New York, New York, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical, Dallas, Texas, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|The Prince Charles Hospital, Chermside, Queensland, Australia|Hopital Gabriel Montpied, Clermont-Ferrand, France|Hôpital Michallon, La Tronche, France|""CHRU de Lille - Hôpital Albert Calmette "", Lille Cedex, France|Hopital de Brabois, Nancy, France|Hôpital Laennec, Nantes Cedex 01, France|Hôpital Pasteur, Nice, France|Hôpital Européen Georges-Pompidou, Paris, France|Medizinische Klinik und Poliklinik II Universitätsklinik Bonn, Bonn, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz Centrum für Thrombose und Hämostase, Mainz, Germany|Grantham Hospital, Cardiac Medical Unit, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Pulmonology institute, Soroka Medical Center, Beer-Sheva, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Policlinico San Matteo Ambulatorio Scompenso Cardiaco e Trapianti, Pavia, Italy|Hospital Pulau Pinang, George Town, Malaysia|Institut Jantung Negara (National Heart Institute), Kuala Lumpur, Malaysia|VU University Medical Center (VUMC), Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|St. Antonius Ziekenhuis, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|Erasmus University medical Center, Rotterdam, Netherlands|Russian Cardiology Scientific and Production Complex, Moscow, Russian Federation|Almazov Federal North-West Medical Research Centre of Department of Health, Saint Petersburg, Russian Federation|National University Hospital - The Heart Institute - Cardiac Department, Singapore, Singapore|National Heart Centre (NHC) Singapore, Singapore, Singapore|Golden Jubilee National Hospital, Glasgow, United Kingdom|The Royal Free Hospital, London, United Kingdom|""Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital"", Sheffield, United Kingdom",C07D405/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,56.5761103924105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.05,588.273,128.22,9.0,2.0,3.0,50.55,126.98,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1
CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,1,DB08932,__MACITENTAN,7094781,Unknown status,NCT02893176,LUNG TRANSPLANT REJECTION,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Califonia, Los Angeles, Los Angeles, California, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,56.5761103924105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.05,588.273,128.22,9.0,2.0,3.0,50.55,126.98,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1
CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,1,DB08932,__MACITENTAN,7094781,Completed,,PORTOPULMONARY HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,56.5761103924105,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.05,588.273,128.22,9.0,2.0,3.0,50.55,126.98,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT02858180,"HEPATITIS C, CHRONIC|HEART FAILURE|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|LUNG DISEASES, INTERSTITIAL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Henry Ford Health System, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center - Dept of Gastroenterology, Durham, North Carolina, United States|Harborview Medical Center, Seattle, Washington, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1,1,DB09019,__BROMHEXINE,4229477,Recruiting,NCT04355026,COVID-19,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SB Celje, Celje, Slovenia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,16.920265303188902,272.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.08,376.13,29.26,2.0,1.0,2.0,32.98,85.56,3.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1
CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,1,DB09020,__BISACODYL,7291324,Completed,,COLONOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,60.4858415983901,209.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.71,361.3906,65.49,3.0,0.0,3.0,38.48,100.15,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1
CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,1,DB09020,__BISACODYL,7291324,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,60.4858415983901,209.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.71,361.3906,65.49,3.0,0.0,3.0,38.48,100.15,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c3nsc(N)n3)[C@H]2SC1,1,DB09050,__CEFTOLOZANE,7129232,Completed,NCT02421120,CYSTIC FIBROSIS|CYSTIC FIBROSIS PULMONARY EXACERBATION|PSEUDOMONAS AERUGINOSA INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Hartford Hospital, Hartford, Connecticut, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States",C07D501/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,36.04180783999671,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,666.69,302.21,14.0,7.0,4.0,62.04,194.51,12.0,1.0,0.0,0.0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,1,0,1
O=C([O-])CCCO.[Na+],1,DB09072,__SODIUM_OXYBATE,6780889,Terminated,NCT00498485,CHRONIC FATIGUE SYNDROME,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UMDNJ - Pain & Fatigue Study Center, ADMC 1618, Newark, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,25.4625351649931,19.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.34,126.087,60.36,3.0,1.0,0.0,9.74,34.64,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,1,DB09075,__EDOXABAN,7365205,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,73.33210127518021,31.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.61,548.06,136.63,7.0,3.0,4.0,56.31,140.14,6.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1
OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2,1,DB09076,__UMECLIDINIUM,5873360,Completed,NCT02236611,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Paraná, Buenos Aires, Argentina|GSK Investigational Site, Concepcion del Uruguay, Entre Ríos, Argentina|GSK Investigational Site, San Rafael, Mendoza, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, San Miguel de Tucuman, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Concepción, Región Del Biobio, Chile|GSK Investigational Site, Talca, Región Del Maule, Chile|GSK Investigational Site, Puente Alto - Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Jindrichuv Hradec, Czechia|GSK Investigational Site, Kralupy nad Vltavou, Czechia|GSK Investigational Site, Lovosice, Czechia|GSK Investigational Site, Ostrava - Poruba, Czechia|GSK Investigational Site, Rudna U Prahy, Czechia|GSK Investigational Site, Trebic, Czechia|GSK Investigational Site, Varnsdorf, Czechia|GSK Investigational Site, Bamberg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Brinkum/Stuhr, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Dueren, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Gelsenkirchen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Balassagyarmat, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Kapuvár, Hungary|GSK Investigational Site, Nagykanizsa, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Hakadal, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Hønefoss, Norway|GSK Investigational Site, Kolbjørnsvik, Norway|GSK Investigational Site, Kongsvinger, Norway|GSK Investigational Site, Løvenstad, Norway|GSK Investigational Site, Ålesund, Norway|GSK Investigational Site, Brasov, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj Napoca, Romania|GSK Investigational Site, Cluj-Napoca, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Ramnicu Valcea, Romania|GSK Investigational Site, Suceava, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chita, Russian Federation|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, Ryazan,, Russian Federation|GSK Investigational Site, Saint Petesburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Laredo, Cantabria, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Fuenlabrada / Madrid, Spain|GSK Investigational Site, La Roca Del Valles (Barcelona), Spain|GSK Investigational Site, Peralada( Girona), Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Stockholm, Sweden",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,428.595,29.46,2.0,1.0,5.0,50.42,141.75,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0
COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,1,DB09079,__NINTEDANIB,6762180,Completed,NCT02606877,IDIOPATHIC PULMONARY FIBROSIS,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southmead Hospital, Bristol, United Kingdom|Papworth Hospital, Cambridge, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|University College London Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Brompton Hospital, London, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,45.30688515164579,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,539.6248,94.22,6.0,2.0,5.0,58.79,159.1,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1
COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1,1,DB09079,__NINTEDANIB,6762180,Recruiting,NCT03939520,PROGRESSIVE IDIOPATHIC PULMONARY FIBROSIS,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,45.30688515164579,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,539.6248,94.22,6.0,2.0,5.0,58.79,159.1,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,1,DB09080,__OLODATEROL,5964416,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.2389371444998,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.02,386.44800000000004,100.05,6.0,4.0,3.0,41.34,106.9,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,1,DB09080,__OLODATEROL,5964416,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.02,386.44800000000004,100.05,6.0,4.0,3.0,41.34,106.9,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,1,DB09080,__OLODATEROL,5964416,Completed,NCT03055988,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CIMS Studienzentrum Bamberg GmbH, Bamberg, Germany|Klinische Forschung Berlin GbR, Berlin, Germany|Universitätsklinikum Bonn AöR, Bonn, Germany|Praxis Dr. med. Claus Keller, Frankfurt, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany|Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg, Heidelberg, Germany|KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|RoMed Kliniken, Rosenheim, Germany",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.2389371444998,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.02,386.44800000000004,100.05,6.0,4.0,3.0,41.34,106.9,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,1,DB09082,__VILANTEROL,5873360,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,486.43,91.18,6.0,4.0,2.0,53.67,129.09,16.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,1,DB09082,__VILANTEROL,5873360,Completed,NCT01957150,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Jasper, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Indian Land, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Spokane Valley, Washington, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Neu isenburg, Hessen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Beek, Netherlands|GSK Investigational Site, EDE, Netherlands|GSK Investigational Site, Eindhoven, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Losser, Netherlands|GSK Investigational Site, Voerendaal, Netherlands|GSK Investigational Site, Barcelona, Catalonia, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Mérida (Badajoz), Spain|GSK Investigational Site, Ponferrada (León), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,486.43,91.18,6.0,4.0,2.0,53.67,129.09,16.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,1,DB09082,__VILANTEROL,5873360,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,486.43,91.18,6.0,4.0,2.0,53.67,129.09,16.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,1,DB09083,__IVABRADINE,7361650,Completed,NCT01365286,"ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical University of Lodz, Department of Pneumonology and Allergy, Lodz, Poland",H04L51/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,25.95535842625101,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,468.594,60.47,6.0,0.0,4.0,54.56,133.51,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,DB09084,__BENZYDAMINE,4211782,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.8877389679459,285.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,309.413,30.29,3.0,0.0,3.0,35.62,105.56,7.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12,1,DB09084,__BENZYDAMINE,4211782,Completed,NCT03074968,INTUBATION COMPLICATION,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","SNUH, Seoul, Jongro Gu, Korea, Republic of",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.8877389679459,285.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,309.413,30.29,3.0,0.0,3.0,35.62,105.56,7.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB09095,__DIFLUOCORTOLONE,5310545,Unknown Status,,ACUTE RESPIRATORY DISTRESS SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,15.770344360253803,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,394.459,74.6,4.0,2.0,4.0,40.2,100.99,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Not Yet Recruiting,,END STAGE LIVER DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
O=S(=O)(O)CCS,1,DB09110,__COENZYME_M,,Unknown status,NCT03172052,PLEURAL EFFUSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Not yet recruiting,NCT04213508,OTORHINOLARYNGOLOGIC DISEASES|RHINOSINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Imam abdulrahman bin faisal university, Dammam, Eastern Province, Saudi Arabia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT02233985,BRONCHIOLITIS|WHEEZING,All,2 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Unidad Medica de Alta Especialidad Bajío No. 48 Hospital de Gineco - Pediatría. Instituto Mexicano del Seguro Social, Leon, Guanajuato, Mexico",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT03493503,CHILDHOOD ASTHMA WITH STATUS ASTHMATICUS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,NCT03768882,SORE THROAT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pamukkale University, Denizli, Turkey",C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Active Not Recruiting,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,,"PAIN, ACUTE",,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O,1,DB09270,__UBIDECARENONE,4325942,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,21.158545350007106,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.94,863.3435,52.6,4.0,0.0,1.0,112.38,286.61,31.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[N+]1(CC2CC2)[C@H]2C[C@H](OC(=O)[C@H](CO)c3ccccc3)C[C@@H]1[C@H]1O[C@@H]21,1,DB09271,__CIMETROPIUM,,Unknown Status,,COLONOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.45,358.457,59.06,3.0,1.0,5.0,38.5,107.58,7.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O,1,DB09273,__DOXOFYLLINE,5788987,Not yet recruiting,NCT04238221,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","L. Sacco Hospital, Milan, Italy",A61K9/4808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,18.135896014291802,94.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.94,266.257,76.9,5.0,0.0,3.0,25.92,64.69,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1,1,DB09280,__LUMACAFTOR,7495103,Completed,,CYSTIC FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.37,452.414,97.75,6.0,2.0,5.0,44.12,111.97,5.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1,1,DB09282,__MOLSIDOMINE,4731241,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,12.222016879196598,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,242.235,77.91,5.0,0.0,2.0,23.94,76.99,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0
Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,1,DB09290,__RAMOSETRON,6235745,Completed,,NAUSEA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,19.220107189059306,160.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,279.343,50.68,2.0,1.0,4.0,31.2,82.14,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
O=S(=O)([O-])[O-].[Zn+2],1,DB09322,__ZINC_SULFATE,,Completed,NCT01791608,DIARRHEA|ACUTE RESPIRATORY INFECTION,All,2 Years to 5 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CES University, Medellín, Antioquia, Colombia",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,161.472,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Zn+2],1,DB09322,__ZINC_SULFATE,,Not yet recruiting,NCT04050488,"EARLY-ONSET SEPSES, NEONATAL|PERIVENTRICULAR HAEMORRHAGE NEONATAL|BRONCHOPULMONARY DYSPLASIA|RETINOPATHY OF PREMATURITY|ENTEROCOLITIS, NECROTIZING|SMALL FOR GESTATIONAL AGE INFANT",All,up to 3 Days   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,161.472,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB09324,__SULBACTAM,4331599,Completed,NCT01760109,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chongqing Red Cross hospital, Chongqing, China",C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.6717797080022,493.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.92,233.24200000000002,91.75,5.0,1.0,2.0,20.63,48.21,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB09324,__SULBACTAM,4331599,Completed,NCT04066621,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS IN CHILDREN,All,6 Years to 14 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,15.6717797080022,493.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.92,233.24200000000002,91.75,5.0,1.0,2.0,20.63,48.21,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,1,DB09330,__OSIMERTINIB,8946235,Not yet recruiting,NCT04413201,NON-SQUAMOUS NSCLC,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Evangelisches Krankenhaus Hamm, Hamm, Germany",C07D401/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,1,DB09330,__OSIMERTINIB,8946235,Completed,NCT03853551,NON SMALL CELL LUNG CANCER,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Hyderabad, Telangana, India|Research Site, Hyderabad, Telangana, India|Research Site, Kolkata, West Bengal, India",C07D401/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,30.325058009404696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,499.619,87.55,7.0,2.0,4.0,56.84,150.32,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC,1,DB09389,__NORGESTREL,4145416,Recruiting,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.25,312.453,37.3,2.0,1.0,4.0,36.83,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CC(=O)[O-].[Na+],1,DB09395,__SODIUM_ACETATE,,Terminated,,CANCER-RELATED MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.2,82.0338,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-].[Na+],1,DB09395,__SODIUM_ACETATE,,Withdrawn,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.2,82.0338,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=P([O-])(O)O.[K+],1,DB09413,__MONOPOTASSIUM_PHOSPHATE,10632150,Recruiting,,POSTOPERATIVE COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,136.0855,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])(O)O.[Na+],1,DB09449,"__SODIUM_PHOSPHATE,_MONOBASIC",7084130,Completed,,OBSTRUCTIVE SLEEP APNEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,119.977,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Completed,NCT00424528,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BRONCHITIS|EMPHYSEMA,All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jasper, Alabama, United States|Tucson, Arizona, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|DeFuniak Springs, Florida, United States|DeLand, Florida, United States|Topeka, Kansas, United States|Hazard, Kentucky, United States|Madisonville, Kentucky, United States|Marrero, Louisiana, United States|Sunset, Louisiana, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|St. Charles, Missouri, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|E. Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Tacoma, Washington, United States|Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Terminated,NCT02275481,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"55 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, Alabama, United States|Clinical Trial Connection, Flagstaff, Arizona, United States|Waterbury Pulmonary Associates LLC, Waterbury, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|Southeastern Intergrted Medical, PL d/b/a Florida Medical Research, Gainesville, Florida, United States|Miami VA Medical Center, Miami, Florida, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|VA Western New York Healthcare System, Buffalo, New York, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Gastonia Phannaceutical Research, Gastonia, North Carolina, United States|Clinical Research of Lake Norman, Huntersville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Consolidated Clinical Trials, Inc., Monroeville, Pennsylvania, United States|Temple University Hospital, Temple Lung Center, Philadelphia, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Clinical Research of Rock Hill, Rock Hill, South Carolina, United States|S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|Mid State Pulmonary, Nashville, Tennessee, United States|Family Medicine Rural Health Clinic, PA, DBA FMC Science, Lampasas, Texas, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,1,DB11089,__DOCUSATE,4156715,Terminated,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/466,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.9716215938725,95.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,422.577,106.97,5.0,1.0,0.0,46.82,107.35,18.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Active Not Recruiting,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Completed,,COLONOSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB11256,__LEVOMEFOLIC_ACID,5798338,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,459.4558,198.48,12.0,7.0,3.0,46.56,126.68,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Not Yet Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,1,DB11362,__SELEXIPAG,7205302,Completed,NCT03078907,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","LA Biomedical Research Institute, Torrance, California, United States|Northside Hospital, Atlanta, Georgia, United States|Kentuckiana Pulmonary Research Center, Louisville, Kentucky, United States|Tufts Medical Center, Pulmonary/Critical Care & Sleep, Boston, Massachusetts, United States|University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division, Omaha, Nebraska, United States|NYU Winthrop Hospital, Mineola, New York, United States|UNC Pulmonary Speciality Clinic, Chapel Hill, North Carolina, United States|Duke University School of Medicine, Duke Pulmonary Vascular Disease center, Durham, North Carolina, United States|University of Cincinnati, Heart, Lung and Vascular Institute, Cincinnati, Ohio, United States|CCF- Akron General Medical Hospital, Cleveland, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Pulmonary Vascular Disease Program, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Care Medicine, Nashville, Tennessee, United States|Methodist Clinical Trials, San Antonio, Texas, United States|University of Texas Health Science Center (San Antonio), San Antonio, Texas, United States|Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2, Innsbruck, Austria|Krankenhaus der Elisabethinen, Servicestelle Klinische Studien, Linz, Austria|Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire, Le Kremlin-Bicêtre, France|CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie, Lille, France|Hospital Larrey CHU de Toulouse, Toulouse, France|Universitätsklinikum Giessen, Giessen, Germany|Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin, Köln, Germany|Universitätsklinikum Leipzig AöR, Abteilung Pneumologie, Leipzig, Germany|Katholisches Klinikum Lünen/Werne GmbH, Haus E, Lünen, Germany|Mater Misericordiae University Hospital, Dublin, Ireland|Oslo University Hospital, dept of cardiology, Oslo, Norway|Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia, Coimbra, Portugal|Hospital Geral de Santo António-DEFI, Porto, Portugal|Sahlgrenska University Hospital, Gothenburg, Gothenburg, Sweden|Skåne University Hospital, VO Hjärt och Lungmedicin, Lund, Sweden|Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin, St. Gallen, Switzerland|Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11, Zurich, Switzerland|Papworth Hospital, Pulmonary Vascular Disease Unit, Cambridge, United Kingdom|Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit, Clydebank, United Kingdom|The Royal Free Hospital, Cardiology Department, London, United Kingdom|Royal Brompton Hospital, Hypertension, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Cardiothoracic Department, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Pulmonary Vascular Medicine, Sheffield, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,59.7301792644612,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.4,496.63,101.49,7.0,1.0,3.0,54.98,136.81,11.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1
O=C1CC[C@@H](C(=O)N2CSC[C@H]2C(=O)O)N1,1,DB11364,__PIDOTIMOD,4839387,Recruiting,NCT04322669,RECURRENT RESPIRATORY TRACT INFECTIONS,All,3 Years to 14 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigator Site 01 Children's Hospital Captial Institute of Pediatrics, Beijing, China|Investigator Site 16, Changchun, China|Investigator Site 09, Changde, China|Investigator Site 12, Changsha, China|Investigator Site 07, Guangzhou, China|Investigator Site 10, Guilin, China|Investigator Site 14, Kunming, China|Investigator Site 03, Nanjing, China|Investigator Site 11, Sanya, China|Investigator Site 02, Shanghai, China|Investigator Site 06, Shantou, China|Investigator Site 13, Shaoyang, China|Investigator Site 05, Tianjin, China|Investigator Site 04, Xiamen, China|Investigator Site 08, Yanji, China|Investigator Site 15, Zhengzhou, China",C07K5/06173,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,16.920265303188902,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,244.27,86.71,4.0,2.0,2.0,22.47,55.83,2.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,1,DB11376,__AZAPERONE,4508715,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,35.64754923099029,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.73,327.403,36.44,4.0,0.0,3.0,36.19,94.27,6.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02576041,ALLERGIC RHINITIS|URTICARIA,All,21 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
O=C(CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1)OCCCCO[N+](=O)[O-],1,DB11660,__LATANOPROSTENE_BUNOD,6211233,Not Yet Recruiting,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,16.8217006509373,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.94,507.624,139.36,7.0,3.0,2.0,56.95,136.66,19.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,NAUSEA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Unknown Status,,VOMITING,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO,1,DB11712,__TEZACAFTOR,7495103,Recruiting,NCT03624101,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,44.058399556459,9.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.97,520.505,113.18,6.0,4.0,5.0,51.79,125.53,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,1,DB11737,__ICOTINIB,US-20040048883-A1,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,1,DB11737,__ICOTINIB,US-20040048883-A1,Unknown status,NCT02283424,"NEOPLASMS, THERAPY-ASSOCIATED",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"PLA General Hospital, BeiJing, China",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,1,DB11737,__ICOTINIB,US-20040048883-A1,Unknown status,NCT02404675,NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Chest Hospital, Capital Medical University, Beijing, China",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,1,DB11737,__ICOTINIB,US-20040048883-A1,Unknown status,NCT02194556,EGFR POSITIVE NON-SMALL CELL LUNG CANCER|ADENOCARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital of Guangxi Medical University, NanNing, Guangxi, China",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1,1,DB11737,__ICOTINIB,US-20040048883-A1,Completed,NCT02744664,LUNG NEOPLASMS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,39.754409741473104,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.88,391.42699999999996,74.73,7.0,1.0,4.0,42.08,105.82,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,1,DB11793,__NIRAPARIB,8859562,Recruiting,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,1,DB11817,__BARICITINIB,8158616,Active Not Recruiting,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(=O)NCC(=O)O)[C@@H](O)CCCC(=O)O,1,DB11858,__LEUKOTRIENE_D4,,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,496.66,149.95,7.0,5.0,0.0,56.08,140.42,20.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,1,DB11885,__ANLOTINIB,8148532,Recruiting,NCT03768037,ADVANCED NON-SQUAMOUS NSCLC,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Chest Hospital, Beijing, Beijing, China",C07D239/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,1,DB11885,__ANLOTINIB,8148532,Not yet recruiting,NCT03799601,NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China",C07D239/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,1,DB11885,__ANLOTINIB,8148532,Recruiting,NCT03755869,NON-SQUAMOUS NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shaanxi Provincial Cancer Hospital, Xian, Shanxi, China",C07D239/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,1,DB11885,__ANLOTINIB,8148532,Not yet recruiting,NCT03890055,SMALL CELL LUNG CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,1,DB11885,__ANLOTINIB,8148532,Not Yet Recruiting,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1
Cc1oc(=O)oc1CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)c2n3C(C)S2)CC1,1,DB11892,__PRULIFLOXACIN,EP-0580860-B1,Completed,NCT01710488,COPD EXACERBATION,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Hospita ""San Francesco Caracciolo"", Agnone, Italy|Hospital of Alghero, Alghero, Italy|Hospital ""Cardinal Massaia"", Asti, Italy|Hospital ""Fatebenefratelli"", Benevento, Italy|Hospital of Bordighera, Bordighera, Italy|Hospital ""San Giovanni di Dio"", Cagliari, Italy|Hospital ""Pugliese-Ciaccio"", Catanzaro, Italy|Hospital ""L.Parodi Delfino"", Colleferro, Italy|Hospita ""San Giovanni di Dio"", Crotone, Italy|Hospital ""E.Profili"" of Fabriano, Fabriano, Italy|Hospital ""F. Veneziale"", Isernia, Italy|Hospital Civile Legnano, Legnano, Italy|Hospital of Ortona, Ortona, Italy|Hospital Fatebenefratelli ""Buccheri La Ferla"", Palermo, Italy|Hospital ""Sant'Anna"", Reggio Emilia, Italy|Hospital "" Santa Maria Nuova"", Reggio Emilia, Italy|Hospital ""Policlinico Universitario Campus Biomedico"", Rome, Italy|Hospital ""Casa Sollievo della Sofferenza"", San Giovanni Rotondo, Italy|Hospital of Scandiano, Scandiano, Italy|Hospital ""Paolo Dettori"", Tempio Pausania, Italy|Hospital ""Santa Maria"" of Terni, Terni, Italy|Hospital ""San Giovanni Bosco"", Torino, Italy|Hospital ""Jazzolino"", Vibo Valentia, Italy|Hospital ""San Bortolo"", Vicenza, Italy|Hospital ""Santa Maria Maddalena"", Volterra, Italy",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,66.2683011971498,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.77,461.46,99.62,8.0,1.0,5.0,44.94,127.37,4.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1
O=C(O)CCCC(=O)NCCc1c[nH]cn1,1,DB11944,__INGAVIRIN,,Completed,NCT03154515,"COMMON COLD|INFLUENZA, HUMAN|ACUTE RESPIRATORY INFECTION",All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","State educational institution of higher professional education ""Chelyabinsk State Medical Academy of Federal Agency of Health Care and Social Development"", Chelyabinsk, Russian Federation|N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology, Moscow, Russian Federation|State budgetary health care institution novosibirsk region ""city clinical infectious diseases hospital no. 1"", Novosibirsk, Russian Federation|North-western State Medical University named after I.I.Mechnikov, Saint Petersburg, Russian Federation|Saratov State Medical University named after V. I. Razumovsky, Saratov, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Pacific State Medical University"" of the Ministry of Healthcare of the Russian Federation, Vladivostok, Russian Federation|Volgograd State Medical University, Volgograd, Russian Federation|Yaroslavl State Medical University, Yaroslavl, Russian Federation|Federal State Budgetary Institution of Higher Professional Education ""Urals State Medical University"" of the Ministry of Healthcare of the Russian Federation, Yekaterinburg, Russian Federation",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.11,225.248,95.08,4.0,3.0,1.0,23.14,56.6,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1,1,DB11963,__DACOMITINIB,7772243,Not yet recruiting,NCT04511533,METASTATIC NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Artemis Hospital, Gurgaon, Haryana, India|Apex Wellness Hospital, Nashik, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India|Medica Superspeciality Hospital, Kolkata, West Bengal, India",C07D403/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,63.1799420932667,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.88,469.939,79.38,6.0,2.0,4.0,49.06,129.91,7.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
O=c1c(-c2ccccc2)coc2ccccc12,1,DB12007,__ISOFLAVONE,4234577,Completed,NCT01052116,ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore - Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,20.041479291155802,192.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.51,222.243,26.3,2.0,0.0,3.0,23.64,65.74,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C,1,DB12127,__SULTAMICILLIN,4432987,Withdrawn,NCT01118403,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital Pablo Tobón Uribe, Medellín, Antioquia, Colombia",C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.979917452103706,73.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.55,594.65,182.48,8.0,2.0,5.0,58.76,138.12,9.0,0.0,1.0,0.0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C,1,DB12127,__SULTAMICILLIN,4432987,Completed,NCT01892488,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitätsklinikum Aachen, Aachen, Germany|Krankenhaus Bad Arolsen, Bad Arolsen, Germany|Lungenklinik Ballenstedt, Ballenstedt, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|HELIOS Klinikum Emil von Behring Berlin, Berlin, Germany|Pneumologische Praxis am Schloss Charlottenburg Berlin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Klinikum der Ruhr-Universität Bochum, Bochum, Germany|Pneumologische Gemeinschaftspraxis Bonn, Bonn, Germany|Forschungszentrum Borstel, Borstel, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitätsklinikum Dresden, Dresden, Germany|Pneumologische Klinik Waldhof Elgershausen, Elgershausen, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Praxis Dr. med. Ina Itzigehl Euskirchen, Euskirchen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|HELIOS Klinik Hagen-Ambrock, Hagen, Germany|Elbpneumologie Hamburg, Hamburg, Germany|Schwerpunktpraxis Colonnaden Hamburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Lungenfachklinik Immenhausen, Immenhausen, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein Kiel, Kiel, Germany|Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Diakoniekrankenhaus Rotenburg, Rotenburg, Germany|Krankenhaus Bethanien Solingen, Solingen, Germany|HELIOS Klinikum Wuppertal-Barmen, Wuppertal, Germany",C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.979917452103706,73.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.55,594.65,182.48,8.0,2.0,5.0,58.76,138.12,9.0,0.0,1.0,0.0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,1
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,1,DB12130,__LORLATINIB,8680111,Not yet recruiting,NCT04362072,CARCINOMA|NON-SMALL-CELL LUNG,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Cancer & Blood Center, Llc, Athens, Georgia, United States|Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna, Lublin, Poland|Elkardia Lubelskie Centrum Kardiologii, Lublin, Poland|Centrum Medyczne Luxmed Sp. z o.o., Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Centrum Medyczne EVOMED, Szczecin, Poland|Dom Lekarski Centrum Medyczne Outlet Park, Szczecin, Poland|Dom Lekarski S.A., Szczecin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Tadeusza Sokolowskiego Pomorskiego UM, Szczecin, Poland|Hospital Teresa Herrera (C.H.U.A.C), A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain",C07D498/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,1,DB12130,__LORLATINIB,8680111,Recruiting,NCT04541706,ADVANCED NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Artemis Hospital, Gurugram, Haryana, India|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India",C07D498/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,1,DB12160,__BUCILLAMINE,4241086,Unknown Status,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,14.6204234173186,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.52,223.31,66.4,3.0,4.0,0.0,22.09,54.7,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Completed,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Unknown status,NCT01465906,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",C07C49/86,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Completed,,GRAM NEGATIVE BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Completed,,URINARY TRACT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Unknown Status,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB12407,__IOBITRIDOL,6437010,Completed,,DIAGNOSTIC IMAGING,,,,,"FISABIO, Elche, Alicante, Spain",B01J49/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,21.8813527998521,81.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,835.169,191.1,9.0,7.0,1.0,61.59,156.01,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0
CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB12407,__IOBITRIDOL,6437010,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",B01J49/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,21.8813527998521,81.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,835.169,191.1,9.0,7.0,1.0,61.59,156.01,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
CN(C)c1cc(CNCC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,1,DB12455,__OMADACYCLINE,7326696,Not yet recruiting,NCT04460586,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Southern California, Los Angeles, California, United States",C07D317/66,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,128.0,49.709439618883295,10.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.94,556.66,176.66,10.0,6.0,4.0,60.02,153.93,7.0,1.0,0.0,0.0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1
O=[O+][O-],1,DB12510,__OZONE,,Unknown Status,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
O=N[O-],1,DB12529,__NITRITE,,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,46.0055,52.49,3.0,0.0,0.0,2.44,7.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(CS(=O)Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1,1,DB12770,__LAFUTIDINE,WO-2002098352-A2,Completed,,PULMONARY ASPIRATION OF GASTRIC CONTENTS,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,50.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,431.55,84.67,5.0,1.0,3.0,46.25,120.24,11.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1,1,DB12863,__SIVELESTAT,5403850,Completed,NCT00219375,ACUTE LUNG INJURY|SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region Facility, Chubu, Japan|Chugoku Region Facility, Chugoku, Japan|Hokkaido Region Facility, Hokkaido, Japan|Hokuriku Regional Facility, Hokuriku, Japan|Kanto Regional Facility, Kanto, Japan|Kinki Region Facility, Kinki, Japan|Kyushu Region Facility, Kyushu, Japan|Shikoku Region Facility, Shikoku, Japan|Tohoku Region Facility, Tohoku, Japan",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,11.1706605885131,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,434.46,138.87,6.0,3.0,2.0,42.97,107.78,8.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
CCOC(=O)c1c(N)sc2c1CCN(Cc1ccccc1)C2,1,DB13001,__TINORIDINE,5518738,Completed,NCT01224756,PAIN|INFLAMMATION,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Semarang, Central Java, Indonesia|Jakarta, DKI Jakarta, Indonesia|Surabaya, East Java, Indonesia|Bandung, West Java, Indonesia",A61K9/1617,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,15.3432308671635,157.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.2,316.42,55.56,3.0,1.0,3.0,34.64,90.05,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1
O=C1c2ccccc2C(=O)C1c1ccc(F)cc1,1,DB13136,__FLUINDIONE,WO-2002062322-A2,Completed,NCT02161965,PERMANENT ATRIAL FIBRILLATION|VENOUS THROMBOSIS|PULMONARY EMBOLISM|ANTICOAGULATION TREATMENT AT LEAST > OR = TO 12-MONTH,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University Hospital Angers, Angers, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,32.7488,9.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.09,240.233,34.14,2.0,0.0,3.0,23.35,65.45,1.0,0.0,1.0,0.0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,NCT00831376,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Dundee, Angus, United Kingdom",C09K3/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,MUCOCILIARY CLEARANCE,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Terminated,,ASTHMA ACUTE,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Fe+3].[OH-].[OH-].[OH-],1,DB13423,__FERRIC_HYDROXIDE,,Recruiting,NCT03748043,IRON-DEFICIENCY,All,3 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Valley University, Qinā, Egypt",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,106.866,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,1,DB13609,__UMIFENOVIR,5198552,Completed,,"INFECTIONS, CORONAVIRUS",,,,,"FISABIO, Elche, Alicante, Spain",C07D209/42,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,16.558861578266402,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.97,477.42,54.7,3.0,1.0,3.0,48.17,124.41,8.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0
CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12,1,DB13609,__UMIFENOVIR,5198552,Recruiting,,COPD PATIENTS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/42,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,16.558861578266402,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.97,477.42,54.7,3.0,1.0,3.0,48.17,124.41,8.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,1,DB13679,__DEXCHLORPHENIRAMINE,4619934,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.6717797080022,310.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.74,274.79,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+],1,DB13706,__EOSIN,3932356,Not yet recruiting,NCT04527016,ASTHMA IN CHILDREN,All,1 Year to 5 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",C08F2/46,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,37.4217129715189,1701.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.12,691.8589999999997,89.49,5.0,0.0,4.0,46.14,155.26,1.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
O=[Mn](=O)(=O)[O-].[K+],1,DB13831,__POTASSIUM_PERMANGANATE,,Completed,NCT00610324,NOSOCOMIAL PNEUMONIA|HEALTHCARE-ASSOCIATED PNEUMONIA|ASPIRATION PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Medical-Neuro Intensive Care Unit, K E M Hospital, Parel, Mumbai, Maharashtra, India",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,158.032,74.27,4.0,0.0,0.0,6.08,5.77,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[Mn](=O)(=O)[O-].[K+],1,DB13831,__POTASSIUM_PERMANGANATE,,Completed,,HEALTHCARE ASSOCIATED PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,158.032,74.27,4.0,0.0,0.0,6.08,5.77,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01957150,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Jasper, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Wilmington, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Indian Land, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Spokane Valley, Washington, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Neu isenburg, Hessen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Beek, Netherlands|GSK Investigational Site, EDE, Netherlands|GSK Investigational Site, Eindhoven, Netherlands|GSK Investigational Site, Hengelo, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Losser, Netherlands|GSK Investigational Site, Voerendaal, Netherlands|GSK Investigational Site, Barcelona, Catalonia, Spain|GSK Investigational Site, Alicante, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, L'Hospitalet de Llobregat, Spain|GSK Investigational Site, Mérida (Badajoz), Spain|GSK Investigational Site, Ponferrada (León), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00788749,NASAL POLYPS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00175565,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|EMPHYSEMA|CHRONIC BRONCHITIS,All,"40 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00184977,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|LUNG DISEASES, OBSTRUCTIVE|BRONCHITIS, CHRONIC",All,"30 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Department of Family Medicine, University of Maastricht, Maastricht, Netherlands|Department of Family Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT00235053,"ASTHMA|CANDIDIASIS, ORAL|VOICE DISORDERS",All,18 Years to 55 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Medical Group & Research Center, San Diego, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Terminated,NCT01554488,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00603044,CHILDHOOD OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS),All,2 Years to 12 Years   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Chicago, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Terminated,NCT01013701,PATIENTS WITH NASAL POLYPS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT02338362,"OCULAR HYPERTENSION|GLAUCOMA, OPEN-ANGLE",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Withdrawn,NCT04271839,PERSISTENT ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00292838,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00692978,HEALTHY|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Asthma Lab, Royal Brompton Hospital, London, United Kingdom|Department of Nuclear Medicine, Royal Brompton Hospital, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00995475,COPD,,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT02136875,COPD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montreal Chest Institute, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,ALLERGIC ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,CHRONIC BRONCHITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,1,DB13931,__NETARSUDIL,8450344,Completed,,OCULAR HYPERTENSION,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,58.0874350602681,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.77,453.542,94.31,4.0,2.0,4.0,51.09,134.66,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Not Yet Recruiting,,BARIATRIC SURGERY CANDIDATE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
COC(=O)OCOc1c2n(ccc1=O)N([C@@H]1c3ccccc3SCc3c1ccc(F)c3F)[C@@H]1COCCN1C2=O,1,DB13997,__BALOXAVIR_MARBOXIL,8927710,Completed,NCT04141930,INFLUENZA|RESPIRATORY VIRAL INFECTION,All,"3 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,54.7690917677981,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,571.55,97.85,8.0,0.0,6.0,53.87,140.76,6.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,1,DB14104,__LINOLEIC_ACID,3932476,Completed,,MALNUTRITION,,,,,"FISABIO, Elche, Alicante, Spain",C07C231/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00394355,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT00553891,NASAL OBSTRUCTION|ADENOIDS HYPERTROPHY|ADENOIDECTOMY,All,2 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT01098071,ADENOIDS,All,2 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT01616160,NASAL POLYPS,All,"21 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Massachusetts General Hospital, Boston, Massachusetts, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,"RHINITIS, ALLERGIC, SEASONAL",,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=P([O-])([O-])[O-].[Al+3],1,DB14517,__ALUMINIUM_PHOSPHATE,,Completed,NCT01711645,DIPHTHERIA|PERTUSSIS|TETANUS,Female,18 Years to 45 Years   (Adult),NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Prevention,"Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville, Tennessee, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,121.9529,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=P([O-])([O-])[O-].[Al+3],1,DB14517,__ALUMINIUM_PHOSPHATE,,Completed,,DIPHTHERIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,121.9529,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,1,DB14541,__HYDROCORTISONE_CYPIONATE,4304765,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.53,486.649,100.9,5.0,2.0,5.0,54.76,132.33,7.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1,1,DB14569,__TEDIZOLID,WO-2005058886-A1,Completed,NCT02444234,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Southern California, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.95,370.344,106.26,7.0,1.0,4.0,36.84,115.06,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Recruiting,NCT04192656,SUDDEN HEARING LOSS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Tsinhgua Changgung Hospital, Beijing, Beijing, China",A61K9/0007,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,VIRAL BRONCHIOLITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,1,DB14726,__DABIGATRAN,6087380,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",C07D277/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,1,DB14726,__DABIGATRAN,6087380,Unknown status,NCT02979561,ANGIOGRAPHICALLY CONFIRMED ACUTE MASSIVE PULMONARY EMBOLISM TREATED WITH ENDOVASCULAR MECHANICAL FRAGMENTATION AND THROMBOLYTIC THERAPY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,1,DB14726,__DABIGATRAN,6087380,Terminated,NCT02596555,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany",C07D277/64,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,471.52099999999996,150.22,8.0,4.0,4.0,50.96,143.26,9.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Recruiting,NCT03475589,STAGE IV CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Completed,NCT03384511,MALIGNANCIES|STOMACH CANCER|NON-SMALL CELL LUNG CANCER|ESOPHAGEAL CANCER|BREAST CANCER|OVARY CANCER|CERVICAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Not yet recruiting,NCT03792503,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xinqiao Hospital of Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB14936,__MENAQUINONE_6,6190695,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,24.37832399022561,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.01,580.8821,34.14,2.0,0.0,2.0,74.54,193.11,17.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Terminated,NCT03200600,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY--COMPLICATIONS|DEXAMETHASONE|FLUBIPROFEN AXETIL|DELIRIUM",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Terminated,NCT03172988,"CARCINOMA, NON-SMALL-CELL LUNG|SURGERY|DEXAMETHASONE|FLUBIPROFEN AXETIL|LONG-TERM EFFECTS SECONDARY TO CANCER THERAPY IN ADULTS",All,"18 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Peking University First Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C1c2c(O)c(=O)ccn2N([C@@H]2c3ccccc3SCc3c2ccc(F)c3F)[C@@H]2COCCN12,1,DB15675,__BALOXAVIR,,Completed,NCT04141930,INFLUENZA|RESPIRATORY VIRAL INFECTION,All,"3 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,483.49,73.32,6.0,1.0,6.0,45.53,124.13,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0
O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O,1,,_SUCRALFATE,,Completed,NCT00702871,VENTILATOR ASSOCIATED PNEUMONIA|ETIOLOGICAL ORGANISMS|ANTIMICROBIAL DRUG SUSCEPTIBILITY PATTERN|STRESS ULCER PROPHYLAXIS,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O,1,,_REGADENOSON,,Completed,NCT00862641,"ASTHMA|CORONARY ARTERY DISEASE|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Montgomery, Alabama, United States|Anaheim, California, United States|Encinitas, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Long Beach, California, United States|Mission Viejo, California, United States|Roseville, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Deland, Florida, United States|Miami, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Stockbridge, Georgia, United States|Aurora, Illinois, United States|Topeka, Kansas, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|No. Dartmouth, Massachusetts, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Papillion, Nebraska, United States|Brick, New Jersey, United States|Raleigh, North Carolina, United States|Chardon, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma, Oklahoma, United States|Medford, Oregon, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=S(=O)([O-])CCS.[Na+],1,,_MESNA,,Unknown status,NCT03172052,PLEURAL EFFUSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT03152149,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT02039050,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Recruiting,NCT03275116,CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ciro, center of expertise in chronic organ failure, Horn, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT00424528,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BRONCHITIS|EMPHYSEMA,All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jasper, Alabama, United States|Tucson, Arizona, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|DeFuniak Springs, Florida, United States|DeLand, Florida, United States|Topeka, Kansas, United States|Hazard, Kentucky, United States|Madisonville, Kentucky, United States|Marrero, Louisiana, United States|Sunset, Louisiana, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|St. Charles, Missouri, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|E. Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Tacoma, Washington, United States|Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT01112241,OBLITERATIVE BRONCHIOLITIS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Unit of Preventive and Occupational Medicine - Laboratory of Respiratory Pathophysiology, University Hospital San Martino, Genoa, Italy",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT00680056,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|CHRONIC BRONCHITIS|PULMONARY EMPHYSEMA",All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Sao Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT00152984,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"CHU Sart Tilman, Angleur, Belgium|A.Z. VUB, Brussel, Belgium|Boehringer Ingelheim Investigational Site, Genk, Belgium|Boehringer Ingelheim Investigational Site, Hasselt, Belgium|St. Elisabethziekenhuis, Herentals, Belgium|Clinique Reine Astrid, Malmedy, Belgium|Sint-Elisabethziekenhuis, Turnhout, Belgium|VGH Research Pavillion, Vancouver, British Columbia, Canada|BG 034, Room C2027, Winnipeg, Manitoba, Canada|Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Respiratory Research Lab, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Department of Respiratory Medicine, Toronto, Ontario, Canada|Centre de Recherche Clinique -CUSE, Sherbrooke, Quebec, Canada|Hopital Laval, Ste-Foy, Quebec, Canada|Lungemedicinsk Forskning 2B, Aarhus, Denmark|Lungemedicinsk afdeling Y, Hellerup, Denmark|Medicinsk afdeling B0642, Hiller?d, Denmark|Lungemedicinsk Klinik, Hvidovre, Denmark|H:S Bispebjerg Hospital, K?benhavn NV, Denmark|Lungemedicinsk Forskning, Odense C, Denmark|Hopital d'Annecy, Annecy, France|Hopital Prive Antony, Antony cedex, France|Boehringer Ingelheim Investigational Site, Chamalieres, France|Hopital Gabriel Montpied, Clermont Ferrand cedex 1, France|Hopital Ambroise Pare, Marseille, France|Hopital Notre Dame de Bon Secours, Metz cedex 1, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Hopital Arnaud de Villeneuve, Montpellier, France|Boehringer Ingelheim Investigational Site, Nantes, France|Centre Medical Erdre St Augustin, Nantes, France|Boehringer Ingelheim Investigational Site, Nice, France|Hopital Maison blanche, Reims cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Berlin, Germany|MEDARS GmbH, Berlin, Germany|Boehringer Ingelheim Investigational Site, Bonn, Germany|Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|Boehringer Ingelheim Investigational Site, Furth, Germany|Inamed Research GmbH & Co. KG, Gauting, Germany|Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|ClinPharm Internat. GmbH & Co. KG, Gorlitz, Germany|Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg, Germany|Med. Einrichtung der Universitat zu Koln, Koln, Germany|Boehringer Ingelheim Investigational Site, Minden, Germany|Boehringer Ingelheim Investigational Site, Munchen, Germany|Boehringer Ingelheim Investigational Site, Rudersdorf, Germany|A. O. Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, Italy|A.O. S. Martino e Cliniche Universitarie di Genova, Genova, Italy|Universita di Genova, Genova, Italy|A.O. Pisana, Pisa, Italy|Ziekenhuisgroep Twent, Almelo, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Atrium medisch centrum, Heerlen, Netherlands|Ziekenhuigroep Twente, Hengelo, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Maxima Medisch Centrum, Velthoven, Netherlands|Boehringer Ingelheim Investigational Site, Bellville, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Durban, South Africa|Boehringer Ingelheim Investigational Site, George, South Africa|Boehringer Ingelheim Investigational Site, Paarl, South Africa|Boehringer Ingelheim Investigational Site, Pretoria, South Africa|Boehringer Ingelheim Investigational Site, Somerset West, South Africa",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT00525512,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|EXERCISE",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"205.368.01023 Boehringer Ingelheim Investigational Site, Jasper, Alabama, United States|205.368.01022 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|205.368.01003 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|205.368.01008 Boehringer Ingelheim Investigational Site, Fort Collins, Colorado, United States|205.368.01017 Boehringer Ingelheim Investigational Site, Hartford, Connecticut, United States|205.368.01028 Boehringer Ingelheim Investigational Site, Waterbury, Connecticut, United States|205.368.01004 Boehringer Ingelheim Investigational Site, Bay Pines, Florida, United States|205.368.01013 Boehringer Ingelheim Investigational Site, North Miami Beach, Florida, United States|205.368.01025 Boehringer Ingelheim Investigational Site, Hazard, Kentucky, United States|205.368.01029 Boehringer Ingelheim Investigational Site, Biddeford, Maine, United States|205.368.01016 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|205.368.01002 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|205.368.01021 Boehringer Ingelheim Investigational Site, Kansas City, Missouri, United States|205.368.01014 Boehringer Ingelheim Investigational Site, Albany, New York, United States|205.368.01030 Boehringer Ingelheim Investigational Site, Tulsa, Oklahoma, United States|205.368.01018 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States|205.368.01027 Boehringer Ingelheim Investigational Site, Gaffney, South Carolina, United States|205.368.01019 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States|205.368.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States|205.368.01024 Boehringer Ingelheim Investigational Site, Union, South Carolina, United States|205.368.01015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|205.368.54001 Boehringer Ingelheim Investigational Site, Rosario, Argentina|205.368.54002 Boehringer Ingelheim Investigational Site, Vicente López, Argentina|205.368.55003 Boehringer Ingelheim Investigational Site, Goiânia, Brazil|205.368.55004 Boehringer Ingelheim Investigational Site, Porto Alegre - RS, Brazil|205.368.55002 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|205.368.07006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|205.368.07001 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|205.368.07003 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|205.368.07004 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|205.368.07005 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|205.368.07008 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|205.368.49005 Boehringer Ingelheim Investigational Site, Berlin, Germany|205.368.49004 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau, Germany|205.368.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|205.368.49006 Boehringer Ingelheim Investigational Site, Münster, Germany|205.368.49002 Boehringer Ingelheim Investigational Site, Schmallenberg, Germany|205.368.49001 Boehringer Ingelheim Investigational Site, Tübingen, Germany|205.368.39006 Boehringer Ingelheim Investigational Site, Ferrara, Italy|205.368.39004 Boehringer Ingelheim Investigational Site, Milano, Italy|205.368.39002 Boehringer Ingelheim Investigational Site, Parma, Italy|205.368.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|205.368.35103 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|205.368.35102 Boehringer Ingelheim Investigational Site, Matosinhos, Portugal|205.368.70001 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70004 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70005 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70006 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|205.368.70007 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|205.368.34005 Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain|205.368.34002 Hospital de Cruces, Barakaldo (Bilbao), Spain|205.368.34001 Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|205.368.34003 Hospital Gregorio Maranon, Madrid, Spain|205.368.34004 Hospital Universitario Vírgen del Rocío, Sevilla, Spain|205.368.34006 Boehringer Ingelheim Investigational Site, Sevilla, Spain|205.368.88604 Boehringer Ingelheim Investigational Site, Keelung, Taiwan|205.368.88602 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|205.368.88603 Boehringer Ingelheim Investigational Site, Taipei City, Taiwan|205.368.88601 Chang Gung Memorial Hosp-Linkou, Taoyuan, Taiwan|205.368.38003 Boehringer Ingelheim Investigational Site, Dnyepropyetrovsk, Ukraine|205.368.38001 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|205.368.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Unknown status,NCT01466712,COPD|EMPHYSEMA|SMALL AIRWAY DISEASE,All,"Child, Adult, Older Adult",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University Hospitals Leuven, Leuven, Flanders, Belgium",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
CC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+],1,,_SULBACTAM_SODIUM,4942229,Completed,NCT01760109,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chongqing Red Cross hospital, Chongqing, China",C07D499/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,17.051684839524402,28.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)[C@H](C(=O)[O-])N2C(=O)C[C@H]2S1(=O)=O.[Na+],1,,_SULBACTAM_SODIUM,4942229,Completed,NCT04066621,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS IN CHILDREN,All,6 Years to 14 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,17.051684839524402,28.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)[O-])C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O.[Na+],1,,_PIPERACILLIN_SODIUM,4477452,Completed,NCT01760109,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chongqing Red Cross hospital, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,29.0108626460502,108.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1.[Na+],1,,_CEFTRIAXONE_SODIUM,,Completed,NCT04066621,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS IN CHILDREN,All,6 Years to 14 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT04066621,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS IN CHILDREN,All,6 Years to 14 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT01559753,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Recruiting,NCT02735707,"COMMUNITY-ACQUIRED PNEUMONIA, INFLUENZA, COVID-19",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT00358202,PNEUMONIA,All,"60 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CPL Associates,LLC, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT00035347,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Sylmar, California, United States|Pfizer Investigational Site, Sarasota, Florida, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Columbus, Georgia, United States|Pfizer Investigational Site, Ft Gordon, Georgia, United States|Pfizer Investigational Site, Shawnee Mission, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Royal Oak, Michigan, United States|Pfizer Investigational Site, Kirkwood, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Mineola, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Winston-salem, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Sellersville, Pennsylvania, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Ste-foy, Quebec, Canada|Pfizer Investigational Site, Regina, Saskatchewan, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Rotenburg (wuemme), Niedersachsen, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Luedenscheid, Germany|Pfizer Investigational Site, Maroussi. Attikis, Athens, Greece|Pfizer Investigational Site, Barcelona, Cataluna, Spain|Pfizer Investigational Site, Tarrasa, Cataluna, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Terminated,NCT00429975,"PNEUMONIA, PNEUMOCOCCAL",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT01645735,INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Investigational Site, Phoenix, Arizona, United States|Investigational Site, Sylmar, California, United States|Investigational Site, DeLand, Florida, United States|Investigational Site, Chicago, Illinois, United States|Investigational Site, Kansas City, Kansas, United States|Investigational Site, Royal Oak, Michigan, United States|Investigational Site, Minneapolis, Minnesota, United States|Investigational Site, St. Louis, Missouri, United States|Investigational Site, Omaha, Nebraska, United States|Investigational Site, Laconia, New Hampshire, United States|Investigational Site, Columbus, Ohio, United States|Investigational Site, Lima, Ohio, United States|Investigational Site, Oklahoma City, Oklahoma, United States|Investigational Site, Tbilisi, Georgia|Investigational Site, Matrahaza, Hungary|Investigational Site, Lodz, Poland|Investigational Site, Lublin, Poland|Investigational Site, Wilkowice-Bystra, Poland|Investigational Site, Craiova, Dolj, Romania|Investigational Site, Bucharest, Romania|Investigational Site, Iasi, Romania|Investigational Site, Moscow, Russian Federation|Investigational Site, St. Petersburg, Russian Federation|Investigational Site, Yaroslavl, Russian Federation|Investigational Site, Alicante, Spain|Investigational Site, Barcelona, Spain|Investigational Site, Dnipropetrovsk, Ukraine|Investigational Site, Ivano-Frankivsik, Ukraine|Investigational Site, Kharkiv, Ukraine|Investigational Site, Kyiv, Ukraine|Investigational Site, Zaporizhzhya, Ukraine",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT01669980,INFECTIONS|PNEUMONIA,All,"2 Months to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Investigational Site, Long Beach, California, United States|Oakland, California, United States|Investigational Site, Orange County, California, United States|Investigational Site, San Diego, California, United States|Investigational Site, Boston, Massachusetts, United States|Investigational Site, Cleveland, Ohio, United States|Investigational Site, Toledo, Ohio, United States|Investigational Site, Pittsburgh, Pennsylvania, United States|Investigational Site, Memphis, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Investigational Site, Norfolk, Virginia, United States|Investigational Site, Morgantown, West Virginia, United States|Investigative Site, Buenos Aires, Argentina|Investigational Site 1, Tbilisi, Georgia|Investigational Site 2, Tbilisi, Georgia|Investigational Site 3, Tbilisi, Georgia|Investigational Site, Donetsk, Ukraine|Investigational Site, Ivano-Frankivsk, Ukraine|Investigational Site, Kryvyi Rih, Ukraine|Investigational Site, Kyiv, Ukraine",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Completed,NCT01723150,"LIVER ABSCESS, PYOGENIC",All,"21 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Singapore|National University Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O.NCCCC[C@H](N)C(=O)O,1,,_AZTREONAM_LYSINE,WO-2005005424-A1,Completed,NCT01469364,COMPLICATION OF TRANSPLANTED LUNG,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Duke University Medical Center, Durham, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,1,,_AZTREONAM,,Completed,NCT01469364,COMPLICATION OF TRANSPLANTED LUNG,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Duke University Medical Center, Durham, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,1,,_AZTREONAM,,Unknown status,NCT03158116,TRACHEOSTOMY INFECTION,All,"7 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Benioff Children's Hospital Oakland, Oakland, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O,1,,_AZTREONAM,,Completed,NCT02894684,CYSTIC FIBROSIS|INFECTION|PSEUDOMONAS,Male,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Liverpool Heart & Chest Hospital NHS Trust, Liverpool, United Kingdom",,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N.O.O.O,1,,_PERAMIVIR,,Completed,NCT02609399,INFLUENZA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Maricopa Integrated Health System, Phoenix, Arizona, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Completed,NCT00610324,NOSOCOMIAL PNEUMONIA|HEALTHCARE-ASSOCIATED PNEUMONIA|ASPIRATION PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA,All,"13 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Medical-Neuro Intensive Care Unit, K E M Hospital, Parel, Mumbai, Maharashtra, India",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,1,,_DEXMEDETOMIDINE_HYDROCHLORIDE,US-20050101621-A1,Unknown status,NCT03312413,ANESTHESIA COMPLICATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","China,Chongqing The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,6.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C([O-])CCC(=O)O.[Na+],1,,_SODIUM_SUCCINATE,,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)[O-])[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12.[Na+],1,,_METHYLPREDNISOLONE_SODIUM_SUCCINATE,4292300,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,50.333682416476705,144.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Terminated,NCT00975663,LUNG AND HEART-LUNG TRANSPLANTATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Service de Pneumologie, Bruxelles, Belgium|Pôle Médecine Aiguë et Communautaire, Clinique de Pneumologie,, Grenoble, France|Service de Pneumologie, HCL Lyon, Lyon, France|ApHm -Chirurgie thoracique, Marseille, France|Service de Pneumologie-CHU de Nantes, Nantes, France|Service de Chirurgie Cardiovasculaire - Hôpital Georges Pompidou, Paris, France|Service de Pneumologie - CH de Suresnes, Paris, France|Service de Pneumologie - Phtisiologie - Hôpital Bichat, Paris, France|Service de Pneumologie - CHU de Strasbourg, Strasbourg, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
O=C([O-])CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]4[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]5[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]6[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]7[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]8[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]9[C@@H](CSCCC(=O)[O-])O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],1,,_SUGAMMADEX_SODIUM,,Recruiting,NCT03679611,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto Western Hospital, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Recruiting,NCT03679611,OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto Western Hospital, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Not yet recruiting,NCT04263363,RESPIRATORY COMPLICATION|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Completed,NCT02845375,RESPIRATORY INSUFFICIENCY,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Leiden University Medical Center, Leiden, ZH, Netherlands",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Recruiting,NCT02822001,NEUROMUSCULAR BLOCKADE|RESPIRATORY INSUFFICIENCY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Memorial Hermann Hospital, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Completed,NCT01579851,ANESTHESIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Foch, Suresnes, Ile de France, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Completed,NCT02243943,POSTOPERATIVE RESPIRATORY CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Leiden Medical University, Leiden, Zuid Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=[Mg].O=[Mg].O=[Mg].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O,1,,_TALC,,Completed,NCT00789087,RECURRENT MALIGNANT PLEURAL EFFUSION.,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of São Paulo Medical School, São Paulo, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Recruiting,NCT04497766,ASTHMA IN CHILDREN,All,2 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"King edward medical university/mayo hospital lahore, Lahore, Punjab, Pakistan",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Withdrawn,NCT02498496,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"35 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Recruiting,NCT03738917,ACUTE BRONCHITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nova Lloreda Health Center, Badalona, Catalonia, Spain|Martí i Julià Health Center, Badalona, Catalonia, Spain|Balaguer Health Center, Balaguer, Catalonia, Spain|Via Roma Health Centre, Barcelona, Catalonia, Spain|La Marina Health Center, Barcelona, Catalonia, Spain|CAP Passeig Maragall (EAP Camp de l'Arpa), Barcelona, Catalonia, Spain|Cornellà - La Gavarra Health Center, Cornellà De Llobregat, Catalonia, Spain|Pineda de Mar Health Center, Pineda De Mar, Catalonia, Spain|Ca n'OriacHealth Center, Sabadell, Catalonia, Spain|Molí Nou Health Center, Sant Boi De Llobregat, Catalonia, Spain|Singuerlin Health Center, Santa Coloma De Gramenet, Catalonia, Spain|CAP Jaume I, Tarragona, Catalonia, Spain",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Recruiting,NCT04101500,ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT01943552,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"50 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"244.2514.86008 Boehringer Ingelheim Investigational Site, Chengdu, China|244.2514.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86007 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86010 Boehringer Ingelheim Investigational Site, Guangzhou, China|244.2514.86009 Boehringer Ingelheim Investigational Site, Hangzhou, China|244.2514.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|244.2514.86002 Boehringer Ingelheim Investigational Site, Tianjin, China|244.2514.86011 Boehringer Ingelheim Investigational Site, Wuhan, China|244.2514.86012 Boehringer Ingelheim Investigational Site, Wuhan, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT00202176,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Respiratory Investigation Unit, Kingston, Ontario, Canada",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT00911651,COPD,All,"40 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antwerp University Hospital, Antwerp, Belgium",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],1,,_FONDAPARINUX,,"Active, not recruiting",NCT01727401,MEDICAL PATIENT|THROMBOCYTOPENIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Marcello Di Nisio, Chieti, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](COC[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](COC[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],1,,_FONDAPARINUX,,Withdrawn,NCT00377091,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Mary's Medical Center, Duluth, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1.CN[C@@H](C)[C@@H](O)c1ccccc1.O=S(=O)(O)O,1,,_PSEUDOEPHEDRINE_SULFATE,4601894,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,15.770344360253803,99.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,1,,_OLODATEROL_HYDROCHLORIDE,7491719,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,28.4851845007084,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,Completed,NCT01124422,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Easley, South Carolina, United States|GSK Investigational Site, Gaffney, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Union, South Carolina, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Webster, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, Canada|GSK Investigational Site, Quebec, Canada",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,Unknown status,NCT01465906,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,Completed,NCT00412204,COPD,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Unknown status,NCT01661985,URETHRITIS|CERVICITIS|GENITAL MYCOPLASMA INFECTION|CHLAMYDIA TRACHOMATIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Withdrawn,NCT00952861,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"50 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Odense University Hospital, Odense, Denmark",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01825408,SINUSITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Otolaryngology-Head and Neck Surgery clinics at UNC Hospitals, Chapel Hill, North Carolina, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00883818,OVERACTIVE BLADDER SYNDROME,Female,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inha University College of Medicine, Inchon, Korea, Republic of|Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of|Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,"Active, not recruiting",NCT04167085,EPISTAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","100 UCLA Medical Plaza, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Terminated,NCT02623959,ADVANCED CANCERS|MALIGNANT PLEURAL EFFUSIONS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01323101,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00170222,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"45 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Medisch centrum Alkmaar, Alkmaar, Noord-holland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Unknown status,NCT00857038,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|INFLAMMATION|PULMONARY EMPHYSEMA,All,"41 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical Center Alkmaar, Alkmaar, Noord-Holland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C=C1CS[C@H]([C@H](NC(=O)CCCC[C@@H](N)C(=O)O)C(=O)O)N=C1C(=O)O,1,,_CEPHALOSPORIN,,Unknown status,NCT02913118,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","China-Japan Friendship Hospital, Beijing, Beijing, China|Beijing Chaoyang Hospital, Beijing, Beijing, China|Beijing Hospital of TCM, Beijing, Beijing, China|Beijing LuHe Hospital, Capital Medical University, Beijing, Beijing, China|Fu Xing Hospital, Capital Medical Unviersity, Beijing, Beijing, China|The First Affiliated Hospital of Wenzhou University, Wenzhou, Fujian, China|First Hospital of QinHuangDao, QinHuangDao, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Nanjing General Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of NanChang University, NanChang, Jiangxi, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Qingdao Municipal Hospital, Qingdao, Shandong, China|The Central Hospital of ZiBo City, ZiBo, Shandong, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|The General Hospital of Tianjin Medical University, Tianjin, Tianjin, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,1
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,1,,_FORMOTEROL_FUMARATE,,Withdrawn,NCT00633776,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|COPD|CHRONIC BRONCHITIS|EMPHYSEMA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA David Geffen School of Medicine, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,1,,_FORMOTEROL_FUMARATE,,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,1,,_FORMOTEROL_FUMARATE,,Completed,NCT02533505,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Hartford, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,1,,_FORMOTEROL_FUMARATE,,Completed,NCT00139932,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-],1,,_ACLIDINIUM_BROMIDE,US-20050209272-A1,Completed,NCT02972476,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"NHS Tayside, Dundee, Tayside, United Kingdom|Blackpool Teaching Hospital NHS Foundation Trust, Blackpool, United Kingdom|NHS Lothian, Edinburgh, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|NHS Fife, Kirkcaldy, United Kingdom|NHS Lanarkshire, Wishaw, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,14.6532783014024,62.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-],1,,_ACLIDINIUM_BROMIDE,US-20050209272-A1,Completed,NCT02375724,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 110 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hannover, Germany|Research Site, Luebeck, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Debrecen, Hungary|Research Site, Komárom, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szazhalombatta, Hungary|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Laredo, Spain|Research Site, Madrid, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Sidcup, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,14.6532783014024,62.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-],1,,_ACLIDINIUM_BROMIDE,US-20050209272-A1,Completed,NCT01966107,COPD|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|MODERATE TO VERY SEVERE COPD,All,"40 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Florence, Alabama, United States|Research Site, Foley, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Jasper, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Encinitas, California, United States|Research Site, Escondido, California, United States|Research Site, Fresno, California, United States|Research Site, Gold River, California, United States|Research Site, Huntington Beach, California, United States|Research Site, La Mirada, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Lincoln, California, United States|Research Site, Loma Linda, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, North Hollywood, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palm Springs, California, United States|Research Site, Paramount, California, United States|Research Site, Pismo Beach, California, United States|Research Site, Port Hueneme, California, United States|Research Site, Poway, California, United States|Research Site, Rialto, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, San Jose, California, United States|Research Site, Santa Ana, California, United States|Research Site, Santa Monica, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Vista, California, United States|Research Site, Westminster, California, United States|Research Site, Wildomar, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Centennial, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Bristol, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Wilmington, Delaware, United States|Research Site, Bay Pines, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeBary, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Eustis, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Palmetto Bay, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Santa Rosa Beach, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Blue Ridge, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Duluth, Georgia, United States|Research Site, Johns Creek, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Norcross, Georgia, United States|Research Site, Oakwood, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Snellville, Georgia, United States|Research Site, Snellville, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Hayden Lake, Idaho, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Meridian, Idaho, United States|Research Site, Champaign, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Gillespie, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Morton, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, O'Fallon, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Elwood, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Lenexa, Kansas, United States|Research Site, Pratt, Kansas, United States|Research Site, Topeka, Kansas, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Madisonville, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Eunice, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Marshall, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Zachary, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Bingham Farms, Michigan, United States|Research Site, Buckley, Michigan, United States|Research Site, Caro, Michigan, United States|Research Site, Chesterfield, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Rochester, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Stevensville, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Charles, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Fremont, Nebraska, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Sparks, Nevada, United States|Research Site, Belvidere, New Jersey, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hopewell Jct, New York, United States|Research Site, Jamaica, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Wappingers Falls, New York, United States|Research Site, Westfield, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Whiteville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Belle Vernon, Pennsylvania, United States|Research Site, Bensalem, Pennsylvania, United States|Research Site, Carnegie, Pennsylvania, United States|Research Site, Clairton, Pennsylvania, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Feasterville-Trevose, Pennsylvania, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Scottdale, Pennsylvania, United States|Research Site, Smithfield, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Hodges, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Pelzer, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Union, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Athens, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Fayetteville, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Hendersonville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Smyrna, Tennessee, United States|Research Site, Spring Hill, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Corsicana, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dickinson, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Murray, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Riverton, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Bellingham, Washington, United States|Research Site, Everett, Washington, United States|Research Site, Port Orchard, Washington, United States|Research Site, Spokane Valley, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Lewisburg, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kamloops, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Langley, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, West Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Dorchester, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thorold, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,14.6532783014024,62.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-],1,,_ACLIDINIUM_BROMIDE,US-20050209272-A1,Recruiting,NCT03275116,CHRONIC OBSTRUCTIVE AIRWAY DISEASE,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ciro, center of expertise in chronic organ failure, Horn, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,14.6532783014024,62.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61K9/0051,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT03460678,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"King Hussein Cancer Center (KHCC), Amman, Jordan|American University of Beirut Medical Center, Beirut, Lebanon",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Unknown status,NCT02399566,LUNG ADENOCARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Not yet recruiting,NCT03792503,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xinqiao Hospital of Chongqing, Chongqing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Recruiting,NCT03768037,ADVANCED NON-SQUAMOUS NSCLC,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Chest Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Recruiting,NCT03655834,NON SMALL CELL LUNG CANCER|MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Antoni van Leeuwenhoek, Amsterdam, Netherlands|Maastricht University Medical centre, Maastricht, Netherlands|Radboud university medical centre, Nijmegen, Netherlands|Erasmus University Medical Centre, Rotterdam, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,1,,_PEMETREXED,WO-2001056575-A1,Unknown status,NCT02804646,ADENOCARCINOMA OF LUNG,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anhui provincial hospital, Hefei, Anhui, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Unknown status,NCT02031601,NON SMALL CELL LUNG CANCER,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yu Li, Jinan, Shandong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Terminated,NCT00536107,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Completed,NCT02088515,SQUAMOUS CELL CARCINOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hunan Xiangya Hospital, Changsha, Hunan, China|Nanjing Military General Hospital, Nanjing, Jiangsu, China|Shanghai Chest hospital, Shanghai, Shanghai, China|Xijing Hospital, Xian, Shanxi, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Not yet recruiting,NCT03799601,NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology,, Wuhan, Hubei, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Unknown status,NCT00813332,ADVANCED NSCLC|RECURRENT NSCLC,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Cancer Hospital of Tianjin Medical University, Tianjin, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,1,,_DOCETAXEL,,Unknown status,NCT02283424,"NEOPLASMS, THERAPY-ASSOCIATED",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"PLA General Hospital, BeiJing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)N[C@@H]1[C@@H](NC(=N)N)C=C(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO,1,,_ZANAMIVIR,,Completed,NCT00980109,INFLUENZA,All,"20 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Faculty of Medicine Siriraj Hospital, Bangkok, Bangkoknoi, Thailand|Hospital for Tropical Diseases, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,1,1,0,1
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT02261727,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The George Institute for Global Health, Sydney, New South Wales, Australia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT01794780,COPD,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Zhengzhou, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT01769898,BRONCHIECTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00395408,ASTHMA,All,6 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00534976,EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB),All,4 Years to 14 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Unknown status,NCT01761487,CARRIERS OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Soroka University Medical Center, Beer Sheva, Negev, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Unknown status,NCT02582099,RHINOSINUSITIS,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Completed,NCT00749866,BRONCHIECTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Infirmary of Edinburgh, Edinburgh, Lothian, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CN[C@@H]1C(O)[C@@H](OC2[C@@H](O)[C@H](O[C@H]3OC(CO)[C@@H](O)[C@H](O)C3NO)C(N)C[C@H]2N)OC[C@H]1O,1,,_GENTAMICIN_A,,Unknown status,NCT01761487,CARRIERS OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Soroka University Medical Center, Beer Sheva, Negev, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCC(C)CCCCC(=O)N(C)[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,,_POLYMYXIN_E,,Unknown status,NCT01761487,CARRIERS OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Soroka University Medical Center, Beer Sheva, Negev, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O.O,1,,_CALCIFEDIOL,,Completed,NCT02805907,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Servicio Murciano de Salud, Murcia, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
CCCCCCOC(=O)/N=C(\N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,,_DABIGATRAN_ETEXILATE,,Unknown status,NCT03129555,DEEP VEIN THROMBOSIS|PULMONARY EMBOLISM,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Bispebjerg Hospital, Copenhagen NV, Denmark|Amager Hospital, Copenhagen S, Denmark|Rigshospitalet, Copenhagen Ø, Denmark|Frederiksberg Hospital, Frederiksberg, Denmark|Nordsjællands Hospital - Frederiksund, Frederikssund, Denmark|Gentofte Hospital, Gentofte, Denmark|Glostrup Hospital, Glostrup, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjællands Hospital - Hillerød, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Bornhoms Hospital, Rønne, Denmark",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CCCCCCOC(=O)/N=C(\N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,,_DABIGATRAN_ETEXILATE,,Unknown status,NCT02979561,ANGIOGRAPHICALLY CONFIRMED ACUTE MASSIVE PULMONARY EMBOLISM TREATED WITH ENDOVASCULAR MECHANICAL FRAGMENTATION AND THROMBOLYTIC THERAPY,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)C(O)C(O)C(=O)O,1,,_ARFORMOTEROL_TARTRATE,6161536,Completed,NCT00424528,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BRONCHITIS|EMPHYSEMA,All,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jasper, Alabama, United States|Tucson, Arizona, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|DeFuniak Springs, Florida, United States|DeLand, Florida, United States|Topeka, Kansas, United States|Hazard, Kentucky, United States|Madisonville, Kentucky, United States|Marrero, Louisiana, United States|Sunset, Louisiana, United States|Ann Arbor, Michigan, United States|Kalamazoo, Michigan, United States|St. Charles, Missouri, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Medford, Oregon, United States|Portland, Oregon, United States|E. Providence, Rhode Island, United States|Lincoln, Rhode Island, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Tacoma, Washington, United States|Morgantown, West Virginia, United States",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,26.415326803425106,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)C(O)C(O)C(=O)O,1,,_ARFORMOTEROL_TARTRATE,6161536,Terminated,NCT02275481,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"55 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, Alabama, United States|Clinical Trial Connection, Flagstaff, Arizona, United States|Waterbury Pulmonary Associates LLC, Waterbury, Connecticut, United States|George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|Southeastern Intergrted Medical, PL d/b/a Florida Medical Research, Gainesville, Florida, United States|Miami VA Medical Center, Miami, Florida, United States|Gwinnett Biomedical Research, Lawrenceville, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|VA Western New York Healthcare System, Buffalo, New York, United States|Clinical Research of Gastonia, Gastonia, North Carolina, United States|Gastonia Phannaceutical Research, Gastonia, North Carolina, United States|Clinical Research of Lake Norman, Huntersville, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|Southeastern Research Center, Winston-Salem, North Carolina, United States|Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, United States|Remington-Davis, Inc., Columbus, Ohio, United States|Consolidated Clinical Trials, Inc., Monroeville, Pennsylvania, United States|Temple University Hospital, Temple Lung Center, Philadelphia, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|Clinical Research of Rock Hill, Rock Hill, South Carolina, United States|S. Carolina Pharmaceutical Research, Spartanburg, South Carolina, United States|Mid State Pulmonary, Nashville, Tennessee, United States|Family Medicine Rural Health Clinic, PA, DBA FMC Science, Lampasas, Texas, United States|Metroplex Pulmonary and Sleep Center, McKinney, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,26.415326803425106,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,1,,_CALCITONIN,,Completed,NCT00239889,FOREARM FRACTURE,Female,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis, Nuernberg, Germany|Novartis, Basel, Switzerland",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0
O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,,_SALMETEROL_XINAFOATE,4572192,Not yet recruiting,NCT04503460,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom",A61N1/3622,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,29.175137066469496,619.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0
O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,,_SALMETEROL_XINAFOATE,4572192,Completed,NCT00975195,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","352.2046.61006 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia|352.2046.61001 Boehringer Ingelheim Investigational Site, Glebe, New South Wales, Australia|352.2046.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia|352.2046.61004 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia|352.2046.61003 Boehringer Ingelheim Investigational Site, Toorak Gardens, South Australia, Australia|352.2046.61005 Boehringer Ingelheim Investigational Site, Woodville, South Australia, Australia|352.2046.32002 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32016 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|352.2046.32015 Boehringer Ingelheim Investigational Site, Eupen, Belgium|352.2046.32017 Boehringer Ingelheim Investigational Site, Gilly, Belgium|352.2046.32014 Boehringer Ingelheim Investigational Site, Herentals, Belgium|352.2046.32006 Boehringer Ingelheim Investigational Site, Jambes, Belgium|352.2046.32008 Boehringer Ingelheim Investigational Site, Lebbeke, Belgium|352.2046.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium|352.2046.32004 Boehringer Ingelheim Investigational Site, Middelheim, Belgium|352.2046.32010 Boehringer Ingelheim Investigational Site, Montigny-le-Tilleul, Belgium|352.2046.32013 Boehringer Ingelheim Investigational Site, Turnhout, Belgium|352.2046.55005 Boehringer Ingelheim Investigational Site, Goiania, Brazil|352.2046.55002 Boehringer Ingelheim Investigational Site, Goiânia, Brazil|352.2046.55001 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55006 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|352.2046.55003 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|352.2046.35905 Boehringer Ingelheim Investigational Site, Bourgas, Bulgaria|352.2046.35902 Boehringer Ingelheim Investigational Site, Rousse, Bulgaria|352.2046.35904 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35906 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35907 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35908 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria|352.2046.35903 Boehringer Ingelheim Investigational Site, Stara Zagora, Bulgaria|352.2046.35909 Boehringer Ingelheim Investigational Site, Veliko Tarnovo, Bulgaria|352.2046.86002 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86003 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86006 Boehringer Ingelheim Investigational Site, Beijing, China|352.2046.86008 Boehringer Ingelheim Investigational Site, Chongqing, China|352.2046.86001 Boehringer Ingelheim Investigational Site, Guangzhou, China|352.2046.86004 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86005 Boehringer Ingelheim Investigational Site, Shanghai, China|352.2046.86007 Boehringer Ingelheim Investigational Site, Wuhan, China|352.2046.45001 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|352.2046.45003 Boehringer Ingelheim Investigational Site, København NV, Denmark|352.2046.45002 Boehringer Ingelheim Investigational Site, Odense C, Denmark|352.2046.3317A Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317B Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3317C Boehringer Ingelheim Investigational Site, Brest, France|352.2046.3320A Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320B Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3320C Boehringer Ingelheim Investigational Site, Castelnau le Lez, France|352.2046.3335A Boehringer Ingelheim Investigational Site, Clermont Ferrand cedex 1, France|352.2046.3314A Boehringer Ingelheim Investigational Site, Forbach, France|352.2046.3301A Boehringer Ingelheim Investigational Site, Marseille cedex 20, France|352.2046.3333A Boehringer Ingelheim Investigational Site, Marseille, France|352.2046.3326A Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3326C Boehringer Ingelheim Investigational Site, Montpellier, France|352.2046.3325A Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325C Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3325D Boehringer Ingelheim Investigational Site, Nantes Cedex 1, France|352.2046.3334A Boehringer Ingelheim Investigational Site, Nantes, France|352.2046.3324A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332A Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332B Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3332C Boehringer Ingelheim Investigational Site, Nîmes, France|352.2046.3331A Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331B Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3331C Boehringer Ingelheim Investigational Site, Perpignan, France|352.2046.3329A Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3329B Boehringer Ingelheim Investigational Site, Saint Laurent du Var, France|352.2046.3302A Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302B Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302C Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3302D Boehringer Ingelheim Investigational Site, Saint-Pierre cedex, France|352.2046.3336A Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336B Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3336C Boehringer Ingelheim Investigational Site, Toulouse cedex 9, France|352.2046.3337A Boehringer Ingelheim Investigational Site, Toulouse, France|352.2046.49012 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49020 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49021 Boehringer Ingelheim Investigational Site, Berlin, Germany|352.2046.49008 Boehringer Ingelheim Investigational Site, Bochum, Germany|352.2046.49019 Boehringer Ingelheim Investigational Site, Cottbus, Germany|352.2046.49002 Boehringer Ingelheim Investigational Site, Donaustauf, Germany|352.2046.49023 Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|352.2046.49013 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49025 Boehringer Ingelheim Investigational Site, Frankfurt, Germany|352.2046.49024 Boehringer Ingelheim Investigational Site, Geesthacht, Germany|352.2046.49022 Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|352.2046.49001 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany|352.2046.49006 Boehringer Ingelheim Investigational Site, Heidelberg, Germany|352.2046.49014 Boehringer Ingelheim Investigational Site, Immenhausen, Germany|352.2046.49016 Boehringer Ingelheim Investigational Site, Kiel, Germany|352.2046.49003 Boehringer Ingelheim Investigational Site, Köln, Germany|352.2046.49004 Boehringer Ingelheim Investigational Site, Mainz, Germany|352.2046.49005 Boehringer Ingelheim Investigational Site, Marburg, Germany|352.2046.49015 Boehringer Ingelheim Investigational Site, München, Germany|352.2046.30003 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30004 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30005 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30007 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30008 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30011 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30012 Boehringer Ingelheim Investigational Site, Athens, Greece|352.2046.30006 Boehringer Ingelheim Investigational Site, Heraklion, Greece|352.2046.30009 Boehringer Ingelheim Investigational Site, Larisa, Greece|352.2046.30001 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.30002 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|352.2046.36003 Boehringer Ingelheim Investigational Site, Cegled, Hungary|352.2046.36002 Boehringer Ingelheim Investigational Site, Deszk, Hungary|352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary|352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary|352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary|352.2046.36005 Boehringer Ingelheim Investigational Site, Szazhalombatta, Hungary|352.2046.36011 Boehringer Ingelheim Investigational Site, Szigetszentmiklos, Hungary|352.2046.39002 Boehringer Ingelheim Investigational Site, Catania, Italy|352.2046.39007 Boehringer Ingelheim Investigational Site, Cona, Italy|352.2046.39005 Boehringer Ingelheim Investigational Site, Foggia, Italy|352.2046.39003 Boehringer Ingelheim Investigational Site, Modena, Italy|352.2046.39006 Boehringer Ingelheim Investigational Site, Montescano (pv), Italy|352.2046.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy|352.2046.39004 Boehringer Ingelheim Investigational Site, Sesto S. Giovanni (mi), Italy|352.2046.39008 Boehringer Ingelheim Investigational Site, Tradate (va), Italy|352.2046.31004 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands|352.2046.31001 Boehringer Ingelheim Investigational Site, Leeuwarden, Netherlands|352.2046.31003 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|352.2046.31002 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands|352.2046.64007 Boehringer Ingelheim Investigational Site, Auckland NZ, New Zealand|352.2046.64003 Boehringer Ingelheim Investigational Site, Christchurch, New Zealand|352.2046.64004 Boehringer Ingelheim Investigational Site, Dunedin, New Zealand|352.2046.64006 Boehringer Ingelheim Investigational Site, Hamilton, New Zealand|352.2046.64001 Boehringer Ingelheim Investigational Site, Newtown Wellington NZ, New Zealand|352.2046.64005 Boehringer Ingelheim Investigational Site, Otahuhu New Zealand, New Zealand|352.2046.64002 Boehringer Ingelheim Investigational Site, Tauranga, New Zealand|352.2046.63001 Boehringer Ingelheim Investigational Site, Caloocan, Philippines|352.2046.63003 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63004 Boehringer Ingelheim Investigational Site, Manila, Philippines|352.2046.63009 Boehringer Ingelheim Investigational Site, Muntinlupa, Philippines|352.2046.63006 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63008 Boehringer Ingelheim Investigational Site, Quezon City, Philippines|352.2046.63005 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.63007 Boehringer Ingelheim Investigational Site, Quezon, Philippines|352.2046.48006 Boehringer Ingelheim Investigational Site, Bytom, Poland|352.2046.48003 Boehringer Ingelheim Investigational Site, Ostrow Wielkopolska, Poland|352.2046.48001 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48002 Boehringer Ingelheim Investigational Site, Poznan, Poland|352.2046.48009 Boehringer Ingelheim Investigational Site, Rzeszow, Poland|352.2046.48011 Boehringer Ingelheim Investigational Site, Tarnowskie Gory, Poland|352.2046.48005 Boehringer Ingelheim Investigational Site, Warsaw, Poland|352.2046.48007 Boehringer Ingelheim Investigational Site, Wroclaw, Poland|352.2046.07011 Boehringer Ingelheim Investigational Site, Ekaterinburg, Russian Federation|352.2046.07006 Boehringer Ingelheim Investigational Site, Ivanovo, Russian Federation|352.2046.07008 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07009 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|352.2046.07002 Boehringer Ingelheim Investigational Site, Samara, Russian Federation|352.2046.07003 Boehringer Ingelheim Investigational Site, Saratov, Russian Federation|352.2046.07001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|352.2046.07004 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.07005 Boehringer Ingelheim Investigational Site, Yaroslavl, Russian Federation|352.2046.27006 Boehringer Ingelheim Investigational Site, Amanzimtoti, South Africa|352.2046.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa|352.2046.27001 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27003 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|352.2046.27007 Boehringer Ingelheim Investigational Site, Pretoria, South Africa|352.2046.27005 Boehringer Ingelheim Investigational Site, Somerset West, South Africa|352.2046.27004 Boehringer Ingelheim Investigational Site, Tygerberg, South Africa|352.2046.34008 Boehringer Ingelheim Investigational Site, Badajoz, Spain|352.2046.34002 Boehringer Ingelheim Investigational Site, Barakaldo (Bilbao), Spain|352.2046.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34004 Boehringer Ingelheim Investigational Site, Barcelona, Spain|352.2046.34009 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat, Spain|352.2046.34006 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|352.2046.34010 Boehringer Ingelheim Investigational Site, Pozuelo de Alarcón, Spain|352.2046.34013 Boehringer Ingelheim Investigational Site, Salt (Girona), Spain|352.2046.34011 Boehringer Ingelheim Investigational Site, Sevilla, Spain|352.2046.88606 Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|352.2046.88604 Boehringer Ingelheim Investigational Site, Taichung, Taiwan|352.2046.88601 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88603 Boehringer Ingelheim Investigational Site, Taipei, Taiwan|352.2046.88607 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.88608 Boehringer Ingelheim Investigational Site, Taiwan, Taiwan|352.2046.2161A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2162A Boehringer Ingelheim Investigational Site, Ariana, Tunisia|352.2046.2165A Boehringer Ingelheim Investigational Site, Sfax, Tunisia|352.2046.2164A Boehringer Ingelheim Investigational Site, Sousse, Tunisia|352.2046.2163A Boehringer Ingelheim Investigational Site, Tunis, Tunisia|352.2046.90009 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90019 Boehringer Ingelheim Investigational Site, Ankara, Turkey|352.2046.90016 Boehringer Ingelheim Investigational Site, Bursa, Turkey|352.2046.90010 Boehringer Ingelheim Investigational Site, Denizli, Turkey|352.2046.90003 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90004 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90006 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90008 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90012 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90017 Boehringer Ingelheim Investigational Site, Istanbul, Turkey|352.2046.90011 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90014 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90018 Boehringer Ingelheim Investigational Site, Izmir, Turkey|352.2046.90005 Boehringer Ingelheim Investigational Site, Izmit, Turkey|352.2046.90007 Boehringer Ingelheim Investigational Site, Kayseri, Turkey|352.2046.90001 Boehringer Ingelheim Investigational Site, Mersin, Turkey|352.2046.90002 Boehringer Ingelheim Investigational Site, Samsun, Turkey|352.2046.38007 Boehringer Ingelheim Investigational Site, Ivano-Frankivsk, Ukraine|352.2046.38002 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|352.2046.38003 Boehringer Ingelheim Investigational Site, Kharkov, Ukraine|352.2046.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38006 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|352.2046.38005 Boehringer Ingelheim Investigational Site, Vinnitsa, Ukraine|352.2046.38001 Boehringer Ingelheim Investigational Site, Vinnytsya, Ukraine|352.2046.44008 Boehringer Ingelheim Investigational Site, Baillieston, Glasgow, United Kingdom|352.2046.44009 Boehringer Ingelheim Investigational Site, Barnsley, United Kingdom|352.2046.44018 Boehringer Ingelheim Investigational Site, Belfast, United Kingdom|352.2046.44010 Boehringer Ingelheim Investigational Site, Birmingham, United Kingdom|352.2046.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom|352.2046.44026 Boehringer Ingelheim Investigational Site, Chertsey, United Kingdom|352.2046.44006 Boehringer Ingelheim Investigational Site, Chesterfield, United Kingdom|352.2046.44012 Boehringer Ingelheim Investigational Site, Cottingham, Hull, United Kingdom|352.2046.44028 Boehringer Ingelheim Investigational Site, Inverness, United Kingdom|352.2046.44016 Boehringer Ingelheim Investigational Site, Isleworth, United Kingdom|352.2046.44002 Boehringer Ingelheim Investigational Site, Liverpool, United Kingdom|352.2046.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom|352.2046.44017 Boehringer Ingelheim Investigational Site, Norwich, United Kingdom|352.2046.44021 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom|352.2046.44019 Boehringer Ingelheim Investigational Site, Sunderland, United Kingdom|352.2046.44025 Boehringer Ingelheim Investigational Site, Windsor, United Kingdom",A61N1/3622,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,60.0,29.175137066469496,619.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT03086070,LARYNGOPHARYNGEAL REFLUX|CHRONIC RHINOSINUSITIS (DIAGNOSIS),All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Terminated,NCT01777854,LARYNGOPHARYNGEAL REFLUX|THROAT PAIN,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Genesys Regional Medical Center, Grand Blanc, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Withdrawn,NCT02123498,EUSTACHIAN TUBE DYSFUNCTION|LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"11234 Anderson Street, Loma Linda, California, United States|1895 Orange Tree Lane, Suite 102, Redlands, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Completed,NCT02467621,GASTROINTESTINAL BLEEDING|STRESS ULCERS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark|Dept. of Intensive Care, Århus University Hospital Nørrebrogade, Aarhus, Denmark|Dept. of Intensive Care, Århus University Hospital Skejby, Arhus, Denmark|Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Neurointensive Care, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Dept. of Intensive Care, Bispebjerg Hospital, Copenhagen, Denmark|Dept. of Intensive Care, Copenhagen University Hospital Herlev, Herlev, Denmark|Dept. of Intensive Care, Herning Hospital, Herning, Denmark|Dept. of Intensive Care, Hillerød Hospital, Hillerød, Denmark|Dept. of Intensive Care, Hjørring Hospital, Hjørring, Denmark|Dept. of Intensive Care, Holbæk Hospital, Holbæk, Denmark|Dept. of Intensive Care, Holstebro Hospital, Holstebro, Denmark|Dept. of Intensive Care, Køge University Hospital, Køge, Denmark|Dept. of Intensive Care, Nykøbing Falster Sygehus, Nykøbing Falster, Denmark|Dept. of Intensive Care, Randers Hospital, Randers, Denmark|Dept. of Intensive Care, Roskilde Hospital, Roskilde, Denmark|Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark|Dept. of Intensive Care, Vejle Hospital, Vejle, Denmark|Dept. of Intensive Care, Viborg Hospital, Viborg, Denmark|Dept. of Intensive Care, Helsinki University Hospital, Helsinki, Finland|Dept. of Intensive Care, Kuopio University Hospital, Kuopio, Finland|Dept. of Intensive Care, Oulu University Hospital, Oulu, Finland|Dept. of Intensive Care, Tampere University Hospital, Tampere, Finland|Dept. of Intensive Care, Turku University Hospital, Turku, Finland|Dept. of Intensive Care, University Medical Center Groningen, Groningen, Netherlands|Dept. of Intensive Care, Heerlen Hospital, Heerlen, Netherlands|Dept. of Intensive Care, Bergen University Hospital, Bergen, Norway|Dept. of Intensive Care, Akershus University Hospital, Lørenskog, Norway|Dept. of Intensive Care, Oslo University Hospital, Oslo, Norway|Dept. of Intensive Care, Stavanger University Hospital, Stavanger, Norway|Dept. of Intensive Care, Basel University Hospital, Basel, Switzerland|Dept. of Intensive Care, Bern University Hospital, Bern, Switzerland|Dept. of Intensive Care, University Hospital of Wales, Cardiff, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,1,,_PANTOPRAZOLE,,Completed,NCT00307944,ACID REFLUX DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"University Ear, Nose and Throat Specialists, Cincinnati, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O,1,,_OSELTAMIVIR_PHOSPHATE,6419934,Not yet recruiting,NCT04183725,INFLUENZA IN CHILDREN,All,2 Years to 14 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K38/1793,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,84.0,22.3084662929423,177.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O,1,,_OSELTAMIVIR_PHOSPHATE,6419934,Unknown status,NCT02232945,INFLUENZA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China",A61K38/1793,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,84.0,22.3084662929423,177.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1.O=P(O)(O)O,1,,_OSELTAMIVIR_PHOSPHATE,6419934,Terminated,NCT01690637,INFLUENZA|HUMAN INFLUENZA,All,up to 9 Years   (Child),U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Nacional San Juan de Dios de San Miguel, San Miguel, El Salvador|Hospital Nacional San Juan de Dios de Santa Ana, Santa Ana, El Salvador|Hospital Jose Domingo de Obaldia, David, Panama|Hospital de Especialidades Pediátricas Omar Torrijos Herrera, Panama City, Panama|Hospital Del Nino, Panama City, Panama",A61K38/1793,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,84.0,22.3084662929423,177.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CC(=O)OC(C)C[N+](C)(C)C.[Cl-],1,,_METHACHOLINE_CHLORIDE,4059686,Completed,NCT01907334,ASTHMA,All,4 Years to 11 Years   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor),"University of Florida Asthma Research Lab, Gainesville, Florida, United States",A61K9/2027,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,26.021068194418696,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
CCC(c1ccccc1)c1c(O)oc2ccccc2c1=O,1,,_PHENPROCOUMON,,Completed,NCT00586287,PULMONARY EMBOLISM|ATRIAL FIBRILLATION|HIP REPLACEMENT POSTOPERATIVE|KNEE REPLACEMENT POSTOPERATIVE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cantonal Hospital St. Gallen, St. Gallen, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2/C(O)=N/CC(=O)O)cc1,1,,_SIVELESTAT,5403850,Completed,NCT00219375,ACUTE LUNG INJURY|SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region Facility, Chubu, Japan|Chugoku Region Facility, Chugoku, Japan|Hokkaido Region Facility, Hokkaido, Japan|Hokuriku Regional Facility, Hokuriku, Japan|Kanto Regional Facility, Kanto, Japan|Kinki Region Facility, Kinki, Japan|Kyushu Region Facility, Kyushu, Japan|Shikoku Region Facility, Shikoku, Japan|Tohoku Region Facility, Tohoku, Japan",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,11.1706605885131,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)[O-])cc1.[Na+],1,,_SIVELESTAT_SODIUM,EP-1166773-A1,Completed,NCT00219375,ACUTE LUNG INJURY|SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region Facility, Chubu, Japan|Chugoku Region Facility, Chugoku, Japan|Hokkaido Region Facility, Hokkaido, Japan|Hokuriku Regional Facility, Hokuriku, Japan|Kanto Regional Facility, Kanto, Japan|Kinki Region Facility, Kinki, Japan|Kyushu Region Facility, Kyushu, Japan|Shikoku Region Facility, Shikoku, Japan|Tohoku Region Facility, Tohoku, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,31.507833836423696,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,1,,_DEXTROMETHORPHAN_HYDROBROMIDE,4316888,Completed,NCT00377403,ACUTE RESPIRATORY INFECTIONS|ACUTE RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington University in St. Louis, St. Louis, Missouri, United States",8,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,22.3084662929423,267.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O,1,,_DEXTROMETHORPHAN_HYDROBROMIDE,4316888,Terminated,NCT02651116,COUGH,All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Avail Clinical Research, LLC, DeLand, Florida, United States|Clinical Associates of Orlando LLC, Orlando, Florida, United States|Elite Clinical Trials LLLP, Blackfoot, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|Kentucky Pediatric/Adult Research, Bardstown, Kentucky, United States|All Children Pediatrics, Louisville, Kentucky, United States|Bluegrass Clinical Research, Inc, Louisville, Kentucky, United States|MedPharmics, LLC, Metairie, Louisiana, United States|Midwest Children's Health Research Institute, Lincoln, Nebraska, United States|Meridian Clinical Research LLC, Omaha, Nebraska, United States|Rapid Medical Research, Inc, Cleveland, Ohio, United States|Coastal Pediatric Associates, Charleston, South Carolina, United States|Coastal Pediatric Associates, Mount Pleasant, South Carolina, United States|Carolina Ear, Nose & Throat Clinic/CENTRI Inc., Orangeburg, South Carolina, United States|Meridian Clinical Research, LLC, Dakota Dunes, South Dakota, United States|Texas Health Care, PLLC, Fort Worth, Texas, United States|Ventavia Research Group, LLC, Fort Worth, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States",8,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,22.3084662929423,267.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,1,,_PRAZOSIN_HYDROCHLORIDE,4092315,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,26.9410049487669,287.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",A61K9/14,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.Cl,1,,_MORPHINE_HYDROCHLORIDE,4389404,Completed,NCT02622022,INTERSTITIAL LUNG DISEASE|DYSPNEA|MORPHINE,All,"18 Years to 110 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aarhus University Hospital, Aarhus C, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,22.965563974619602,135.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CNC(=S)S,1,,_METAM,,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, Hajdú-Bihar, Hungary",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Recruiting,NCT03454217,SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lausanne University Hospital, Lausanne, Vaud, Switzerland",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT01267136,TONSILLITIS|PAIN,All,4 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States",C07C213/10,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02484859,NASAL POLYPS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Recep Tayyip Erdogan University, Rize, Eastern Blacksea, Turkey",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Unknown status,NCT03067103,"SLEEP DISORDER; BREATHING-RELATED|PAIN, POSTOPERATIVE|CHILD, ONLY",All,3 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Juliana Alves de Sousa Caixeta, Anápolis, GO, Brazil",C07C213/10,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02964416,BRAIN NEOPLASM,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aga Khan University, Karachi, Sindh, Pakistan",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=C1OC2(c3ccccc31)c1cc(Br)c(O)c(Br)c1Oc1c2cc(Br)c(O)c1Br,1,,_EOSIN,4400249,Not yet recruiting,NCT04527016,ASTHMA IN CHILDREN,All,1 Year to 5 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",C07D461/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,26.415326803425106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT01265342,BRONCHIAL SPASM|RESPIRATORY SOUNDS|RESPIRATORY TRACT INFECTIONS,All,12 Months to 71 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ASL NA/3 Sud, Castellammare di Stabia, Italy|AUSL Chieti, Chieti, Italy|ASL Monza Brianza, Monza, Italy|ASL Torino 3, Pinerolo, Italy|ASP di Reggio Calabria, Reggio Calabria, Italy|Ausl Roma E, Roma, Italy|AUSL Taranto, Taranto, Italy|Azienda ULSS 20 Verona, Verona, Italy|ASL 12, Viareggio, Italy",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Unknown status,NCT02687100,"ANESTHESIA, ENDOTRACHEAL",All,"18 Months to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT03369847,ASTHMA|PEDIATRIC ALL,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kings County Hospital Center, Brooklyn, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT02577497,ASTHMA,All,6 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Virginia - Fontaine Research Park, Charlottesville, Virginia, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Withdrawn,NCT02319564,WHEEZE,All,12 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Unknown status,NCT02526758,PULMONARY DISEASE，CHRONIC OBSTRUCTIVE;,All,"40 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital, Guangzhou, Guangdong, China",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Terminated,NCT00826748,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Weill Cornell Medical College, New York, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Terminated,NCT00962299,WHEEZING|DYSPNEA,All,1 Year to 4 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Princess Amalia Children's Clinic, Zwolle, Overijssel, Netherlands",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CCC(C)CCCCC(=O)N(CS(=O)(=O)O)[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@@H](CN[C@@H](CCNCS(=O)(=O)O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CCNCS(=O)(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(=O)(=O)O)NC1=O)[C@@H](C)O,1,,_COLISTIMETHATE,,Completed,NCT01844778,CYSTIC FIBROSIS,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, St. Gallen, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Southampton, Hampshire, United Kingdom|Novartis Investigative Site, Penarth, Vale of Glamorgan, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, East Yorkshire, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,0
CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,,_COLISTIN,,"Active, not recruiting",NCT02918409,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Jewish Health, Denver, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,,_COLISTIN,,Completed,NCT02683603,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"intensive care unit of the University Hospital Center La Rabta, Tunis, Tunisia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H](CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O,1,,_COLISTIN,,Recruiting,NCT04489459,TREATMENT OF BLOOD STREAM INFECTIONS DUE TO MULTIDRUG-RESISTANT KLEBSIELLA PNEUMONIAE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Qasr El Ainy, Cairo, Egypt",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
NC(CS)C(=O)O,1,,_CYSTEINE,,Not yet recruiting,NCT03900988,INFLUENZA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(CS)C(=O)O,1,,_CYSTEINE,,Recruiting,NCT03364218,BRONCHIOLITIS ACUTE,All,up to 2 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carilion Clinic, Roanoke, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O,1,,_METOPROLOL_SUCCINATE,4780318,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,45.471159572065105,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Suspended,NCT04330300,HYPERTENSION|COVID-19,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University Hospital Galway, Galway, Ireland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Terminated,NCT02358642,PNEUMONIA|NEUROLOGICAL DYSPHAGIA,All,"60 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Prince of Wales Hospital, Hong Kong, Hong Kong",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Recruiting,NCT04394117,SARS-COV-2|COVID-19,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Royal prince Alfred Virtual Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|John Hunter Hospital, New Lambton Heights, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1.[Br-],1,,_ROCURONIUM_BROMIDE,5767112,Recruiting,NCT03646266,RESPIRATORY INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc, Amsterdam, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,28.9780077619663,55.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O,1,,_INDACATEROL_MALEATE,6878721,Completed,NCT01985334,COPD,All,"40 Years to 95 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Amstetten, Austria|Novartis Investigative Site, Feldkirch, Austria|Novartis Investigative Site, Hallein, Austria|Novartis Investigative Site, Kirchdorf an der Krems, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Perg, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Gosselies, BEL, Belgium|Novartis Investigative Site, Gozee, BEL, Belgium|Novartis Investigative Site, Zichem, BEL, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Balen, Belgium|Novartis Investigative Site, Braine l'Alleud, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Eghezee, Belgium|Novartis Investigative Site, Erpent, Belgium|Novartis Investigative Site, Geraardsbergen, Belgium|Novartis Investigative Site, Gilly, Belgium|Novartis Investigative Site, Halen, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Heusy, Belgium|Novartis Investigative Site, Ieper, Belgium|Novartis Investigative Site, Knokke-Heist, Belgium|Novartis Investigative Site, Lebbeke, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Maaseik, Belgium|Novartis Investigative Site, Malmedy, Belgium|Novartis Investigative Site, Mechelen, Belgium|Novartis Investigative Site, Melsbroek, Belgium|Novartis Investigative Site, Merksem, Belgium|Novartis Investigative Site, Montegnée, Belgium|Novartis Investigative Site, Natoye, Belgium|Novartis Investigative Site, Paal-Beringen, Belgium|Novartis Investigative Site, Ronse, Belgium|Novartis Investigative Site, Saint-Medard, Belgium|Novartis Investigative Site, Seraing, Belgium|Novartis Investigative Site, Tournai, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Vilvoorde, Belgium|Novartis Investigative Site, Zottegem, Belgium|Novartis Investigative Site, Boskovice, Czech Republic, Czechia|Novartis Investigative Site, Brandys Nad Labem, Czech Republic, Czechia|Novartis Investigative Site, Brno-Kralovo Pole, Czech Republic, Czechia|Novartis Investigative Site, Cvikov, Czech Republic, Czechia|Novartis Investigative Site, Havlickuv Brod, Czech Republic, Czechia|Novartis Investigative Site, Jirkov, Czech Republic, Czechia|Novartis Investigative Site, Kurim, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Lovosice, Czech Republic, Czechia|Novartis Investigative Site, Neratovice, Czech Republic, Czechia|Novartis Investigative Site, Ostrava, Czech Republic, Czechia|Novartis Investigative Site, Pardubice, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Plzen, Czech Republic, Czechia|Novartis Investigative Site, Prague 4, Czech Republic, Czechia|Novartis Investigative Site, Prague, Czech Republic, Czechia|Novartis Investigative Site, Praha 10, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Praha 6, Czech Republic, Czechia|Novartis Investigative Site, Praha 9, Czech Republic, Czechia|Novartis Investigative Site, Praha, Czech Republic, Czechia|Novartis Investigative Site, Rokycany, Czech Republic, Czechia|Novartis Investigative Site, Rudna, Czech Republic, Czechia|Novartis Investigative Site, Teplice, Czech Republic, Czechia|Novartis Investigative Site, Trebic, Czech Republic, Czechia|Novartis Investigative Site, Varnsdorf, Czech Republic, Czechia|Novartis Investigative Site, Zatec, Czech Republic, Czechia|Novartis Investigative Site, Znojmo, Czech Republic, Czechia|Novartis Investigative Site, Praha 8, Czechia|Novartis Investigative Site, Alleroed, Denmark|Novartis Investigative Site, Greve, Denmark|Novartis Investigative Site, Haslev, Denmark|Novartis Investigative Site, Søborg, Denmark|Novartis Investigative Site, Værløse, Denmark|Novartis Investigative Site, Paide, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Tours Cedex 9, Indre Et Loire, France|Novartis Investigative Site, Briis Sous Forges, France|Novartis Investigative Site, Chamalieres, France|Novartis Investigative Site, Chatellerault, France|Novartis Investigative Site, Forbach, France|Novartis Investigative Site, L'Aigle, France|Novartis Investigative Site, La Bouexiere, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Murs Erigne, France|Novartis Investigative Site, Nice, France|Novartis Investigative Site, Saint Jean de Luz, France|Novartis Investigative Site, Saint Laurent Du Var, France|Novartis Investigative Site, Saint Pierre, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulon, France|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Peine, Niedersachsen, Germany|Novartis Investigative Site, Warendorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koblenz, NRW, Germany|Novartis Investigative Site, Essen, Rheinland Pfalz, Germany|Novartis Investigative Site, Cottbus, Sachsen, Germany|Novartis Investigative Site, Geesthacht, Schleswig Holstein, Germany|Novartis Investigative Site, Annaberg-Buchholz, Germany|Novartis Investigative Site, Auerbach, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Neustadt, Germany|Novartis Investigative Site, Bad Salzuflen, Germany|Novartis Investigative Site, Bad Woerishofen, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bensheim, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Bruchsal, Germany|Novartis Investigative Site, Burgwedel, Germany|Novartis Investigative Site, Daaden, Germany|Novartis Investigative Site, Dachau, Germany|Novartis Investigative Site, Deggendorf, Germany|Novartis Investigative Site, Deggingen, Germany|Novartis Investigative Site, Delitzsch, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dueren, Germany|Novartis Investigative Site, Dusseldorf, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Elsterwerda, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Foehren, Germany|Novartis Investigative Site, Frankenberg (Eder), Germany|Novartis Investigative Site, Frankfurt am Main, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Freudenberg, Germany|Novartis Investigative Site, Furstenwalde, Germany|Novartis Investigative Site, Fürstenwalde/Spree, Germany|Novartis Investigative Site, Garmisch-Partenkirchen, Germany|Novartis Investigative Site, Gauting, Germany|Novartis Investigative Site, Gießen, Germany|Novartis Investigative Site, Gifhorn, Germany|Novartis Investigative Site, Goch, Germany|Novartis Investigative Site, Goerlitz, Germany|Novartis Investigative Site, Gummersbach, Germany|Novartis Investigative Site, Gütersloh, Germany|Novartis Investigative Site, Hagen, Germany|Novartis Investigative Site, Halberstadt, Germany|Novartis Investigative Site, Halle, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Hettstedt, Germany|Novartis Investigative Site, Hildesheim, Germany|Novartis Investigative Site, Hoyerswerda, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Jerichow, Germany|Novartis Investigative Site, Kamen, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Kleve, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Köthen, Germany|Novartis Investigative Site, Landau-Pfalz, Germany|Novartis Investigative Site, Landsberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leonberg, Germany|Novartis Investigative Site, Leverkusen, Germany|Novartis Investigative Site, Limburgerhof, Germany|Novartis Investigative Site, Loehne, Germany|Novartis Investigative Site, Ludwigsburg, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Luedenscheid, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Mayen, Germany|Novartis Investigative Site, Meine, Germany|Novartis Investigative Site, Meissen, Germany|Novartis Investigative Site, Menden, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Mittweida, Germany|Novartis Investigative Site, Mülheim, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, München, Germany|Novartis Investigative Site, Münnerstadt, Germany|Novartis Investigative Site, Neu Isenburg, Germany|Novartis Investigative Site, Neu-Ulm, Germany|Novartis Investigative Site, Neunkirchen, Germany|Novartis Investigative Site, Neuss, Germany|Novartis Investigative Site, Neuwied, Germany|Novartis Investigative Site, Northeim, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Nürnberg, Germany|Novartis Investigative Site, Obermichelbach, Germany|Novartis Investigative Site, Oschatz, Germany|Novartis Investigative Site, Oschersleben, Germany|Novartis Investigative Site, Osnabrueck, Germany|Novartis Investigative Site, Papenburg, Germany|Novartis Investigative Site, Passau, Germany|Novartis Investigative Site, Plauen, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Prien A. Chiemsee, Germany|Novartis Investigative Site, Radebeul, Germany|Novartis Investigative Site, Ratingen, Germany|Novartis Investigative Site, Raubach, Germany|Novartis Investigative Site, Reinfeld, Germany|Novartis Investigative Site, Rheine, Germany|Novartis Investigative Site, Rodenbach, Germany|Novartis Investigative Site, Roth, Germany|Novartis Investigative Site, Rudersdorf, Germany|Novartis Investigative Site, Rüsselsheim,, Germany|Novartis Investigative Site, Rüsselsheim, Germany|Novartis Investigative Site, Saalfeld, Germany|Novartis Investigative Site, Saarbruecken, Germany|Novartis Investigative Site, Schleswig, Germany|Novartis Investigative Site, Schwabach, Germany|Novartis Investigative Site, Schwedt, Germany|Novartis Investigative Site, Schwerin, Germany|Novartis Investigative Site, Schwetzingen, Germany|Novartis Investigative Site, Siegen, Germany|Novartis Investigative Site, Sinsheim, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Sonneberg, Germany|Novartis Investigative Site, Strausberg, Germany|Novartis Investigative Site, Teuchern, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wardenburg, Germany|Novartis Investigative Site, Weilheim, Germany|Novartis Investigative Site, Welzheim, Germany|Novartis Investigative Site, Westerkappeln, Germany|Novartis Investigative Site, Wiesloch, Germany|Novartis Investigative Site, Wissen, Germany|Novartis Investigative Site, Witten, Germany|Novartis Investigative Site, Woellstein, Germany|Novartis Investigative Site, Wolfsburg, Germany|Novartis Investigative Site, Zerbst, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Serres, Greece|Novartis Investigative Site, Gyor, HUN, Hungary|Novartis Investigative Site, Szazhalombatta, HUN, Hungary|Novartis Investigative Site, Cegled, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Hatvan, Hungary|Novartis Investigative Site, Komarom, Hungary|Novartis Investigative Site, Mako, Hungary|Novartis Investigative Site, Mateszalka, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Torokbalint, Hungary|Novartis Investigative Site, County Limerick, Ireland|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Terlizzi, BA, Italy|Novartis Investigative Site, Triggiano, BA, Italy|Novartis Investigative Site, Romano di Lombardia, BG, Italy|Novartis Investigative Site, Feltre, BL, Italy|Novartis Investigative Site, Telese Terme, BN, Italy|Novartis Investigative Site, San Pietro Vernotico, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Campobasso, CB, Italy|Novartis Investigative Site, Marcianise, CE, Italy|Novartis Investigative Site, Caltanissetta, CL, Italy|Novartis Investigative Site, Saluzzo, CN, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Forlì, FC, Italy|Novartis Investigative Site, Foggia, FG, Italy|Novartis Investigative Site, San Severo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Lodi, LO, Italy|Novartis Investigative Site, Lido di Camaiore, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Cittadella, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pordenone, PN, Italy|Novartis Investigative Site, Voghera, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Riccione, RN, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sondalo, SO, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Montebelluna, TV, Italy|Novartis Investigative Site, Vittorio Veneto, TV, Italy|Novartis Investigative Site, Busto Arsizio, VA, Italy|Novartis Investigative Site, Arzignano, VI, Italy|Novartis Investigative Site, Vicenza, VI, Italy|Novartis Investigative Site, Bussolengo, VR, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Torino, Italy|Novartis Investigative Site, Balvi, LVA, Latvia|Novartis Investigative Site, Jurmala, LVA, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Riga, LV, Latvia|Novartis Investigative Site, Daugavpils, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Riga, Latvia|Novartis Investigative Site, Vilnius, LTU, Lithuania|Novartis Investigative Site, Kaunas, LT, Lithuania|Novartis Investigative Site, Vilnius, LT, Lithuania|Novartis Investigative Site, Alytus, Lithuania|Novartis Investigative Site, Kaunas, Lithuania|Novartis Investigative Site, Klaipeda, Lithuania|Novartis Investigative Site, Utena, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Førde, Norway|Novartis Investigative Site, Kløfta, Norway|Novartis Investigative Site, Lierskogen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Skedsmokorset, Norway|Novartis Investigative Site, Skien, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tananger, Norway|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Nowy Dwor Mazowiecki, Poland|Novartis Investigative Site, Ostrow Wielkopolski, Poland|Novartis Investigative Site, Pila, Poland|Novartis Investigative Site, Sopot, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Aveiro, Portugal|Novartis Investigative Site, Barcelos, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Guimarães, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Vila Franca de Xira, Portugal|Novartis Investigative Site, Vila Nova de Gaia, Portugal|Novartis Investigative Site, Bucharest, District 3, Romania|Novartis Investigative Site, Iasi, Jud. Iasi, Romania|Novartis Investigative Site, Bacau, Romania|Novartis Investigative Site, Bragadiru, Romania|Novartis Investigative Site, Constanta, Romania|Novartis Investigative Site, Ramnicu Valcea, Romania|Novartis Investigative Site, Suceava, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Bardejov, Slovak Republic, Slovakia|Novartis Investigative Site, Bojnice, Slovak Republic, Slovakia|Novartis Investigative Site, Liptovsky Hradok, Slovak Republic, Slovakia|Novartis Investigative Site, Námestovo, Slovensko, Slovakia|Novartis Investigative Site, Kralovsky Chlmec, Slovakia|Novartis Investigative Site, Levice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Presov, Slovakia|Novartis Investigative Site, Sala, Slovakia|Novartis Investigative Site, Sturovo, Slovakia|Novartis Investigative Site, Trnava, Slovakia|Novartis Investigative Site, Vrable, Slovakia|Novartis Investigative Site, Golnik, Slovenia|Novartis Investigative Site, Kranj, Slovenia|Novartis Investigative Site, Maribor, Slovenia|Novartis Investigative Site, Murska Sobota, Slovenia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Marbella, Andalucia, Spain|Novartis Investigative Site, Málaga, Andalucia, Spain|Novartis Investigative Site, Badalona, Barcelona, Spain|Novartis Investigative Site, Centelles, Barcelona, Spain|Novartis Investigative Site, Mataro, Barcelona, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Vic, Barcelona, Spain|Novartis Investigative Site, Ponferrada, Castilla Y Leon, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Canet de Mar, Cataluna, Spain|Novartis Investigative Site, Sant Boi de Llobregat, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Vic, Cataluña, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Benidorm, Comunidad Valenciana, Spain|Novartis Investigative Site, Puerto De Sagunto, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Merida, Extremadura, Spain|Novartis Investigative Site, Motril, Granada, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Palma de Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Madrid, Madrid, Communidad De, Spain|Novartis Investigative Site, Mostoles, Madrid, Communidad De, Spain|Novartis Investigative Site, Valdemoro, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Linkoping, Ostergotlands Lan, Sweden|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Gustavsberg, Sweden|Novartis Investigative Site, Helsingborg, Sweden|Novartis Investigative Site, Hollviken, Sweden|Novartis Investigative Site, Kungshamn, Sweden|Novartis Investigative Site, Limhamn, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Råå, Sweden|Novartis Investigative Site, Umea, Sweden|Novartis Investigative Site, Vastra Frolunda, Sweden|Novartis Investigative Site, Aylesbury, Bucks, United Kingdom|Novartis Investigative Site, Fowey, Cornwall, United Kingdom|Novartis Investigative Site, Liskeard, Cornwall, United Kingdom|Novartis Investigative Site, Penzance, Cornwall, United Kingdom|Novartis Investigative Site, Redruth, Cornwall, United Kingdom|Novartis Investigative Site, St Austell, Cornwall, United Kingdom|Novartis Investigative Site, Torpoint, Cornwall, United Kingdom|Novartis Investigative Site, Bath, England, United Kingdom|Novartis Investigative Site, Havant, Hampshire, United Kingdom|Novartis Investigative Site, Burbage, Leicester, United Kingdom|Novartis Investigative Site, Daventry, Northamptonshire, United Kingdom|Novartis Investigative Site, Sneinton, Nottingham, United Kingdom|Novartis Investigative Site, Axbridge, Somerset, United Kingdom|Novartis Investigative Site, Frome, Somerset, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, South Shields, Tyne And Wear, United Kingdom|Novartis Investigative Site, Barry, Vale Of Glamorgan, United Kingdom|Novartis Investigative Site, Leamington Spa, Warwickshire, United Kingdom|Novartis Investigative Site, Crawley, West Sussex, United Kingdom|Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom|Novartis Investigative Site, Trowbridge, Wiltshire, United Kingdom|Novartis Investigative Site, Strensall, Yorkshire, United Kingdom|Novartis Investigative Site, Bexhill-on-Sea, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Chadderton, United Kingdom|Novartis Investigative Site, Cheshire, United Kingdom|Novartis Investigative Site, Chesterfield, United Kingdom|Novartis Investigative Site, Chippenham, United Kingdom|Novartis Investigative Site, Coventry, United Kingdom|Novartis Investigative Site, Hamilton, United Kingdom|Novartis Investigative Site, Lancashire, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Motherwell, United Kingdom|Novartis Investigative Site, Oldham, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, South Yorkshire, United Kingdom|Novartis Investigative Site, Stockton on Tees, United Kingdom|Novartis Investigative Site, Vale Of Glanmorgan, United Kingdom|Novartis Investigative Site, Watford, United Kingdom|Novartis Investigative Site, Wiltshire, United Kingdom|Novartis Investigative Site, Wishaw, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,58.3174192488552,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O,1,,_INDACATEROL_MALEATE,6878721,Completed,NCT01377051,COPD|LUNG DISEASES|DYSPNEA|HYPOXEMIA|TACHYCARDIA,All,"50 Years to 85 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pneumologia Riabilitativa - Fondazione Maugeri - Istituto Scientifico di Milano - IRCCS, Milano, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,1,,_ALBUTEROL_SULFATE,4409237,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,1,,_ALBUTEROL_SULFATE,4409237,Completed,NCT00667797,ASTHMA|COPD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Birmingham, Alabama, United States|Chula Vista, California, United States|Oakland, California, United States|Wheat Ridge, Colorado, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Brandon, Florida, United States|Des Moines, Iowa, United States|Johnson City, New Jersey, United States|Great Neck, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Winston Salem, North Carolina, United States|Portland, Oregon, United States|Pittsburg, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Morgantown, West Virginia, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],1,,_DICLOFENAC_POTASSIUM,5674854,Terminated,NCT01019980,FEVER,All,2 Years to 6 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de niños ""J. M. de los Rios"", Distrito Metropolitano, Caracas, Venezuela|Ciudad Hospitalaria Enrique Tejera, Valencia, Estado Carabobo, Venezuela",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.0089529559128,236.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],1,,_DICLOFENAC_POTASSIUM,5674854,Withdrawn,NCT01257126,UPPER RESPIRATORY INFECTIONS,All,3 Years to 7 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.0089529559128,236.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Unknown status,NCT02278081,RHINITIS|NASAL OBSTRUCTION|GERD,All,"7 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT00369265,LARYNGOPHARYNGEAL REFLUX,All,"18 Years to 89 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Henry Ford Hospital, Department of Otolaryngology, Detroit, Michigan, United States|American Institute for Voice and Ear Research, Philadelphia, Pennsylvania, United States|Cornell University, Van Lawrence Voice Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT00637416,DYSPHONIA,All,"3 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Kansas Medical Center, Kansas City, Kansas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT00708149,RESPIRATORY FAILURE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Far Eastern Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Withdrawn,NCT02530879,LARYNGOPHARYNGEAL REFLUX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Temple Otolaryngology, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00628667,CHRONIC POSTERIOR LARYNGITIS (CPL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00287339,COUGH|GERD,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNC Gastroenterology, UNC Pulmonology, UNC ENT, Chapel Hill, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],1,,_GLYCOPYRROLATE,4824676,Completed,NCT01199237,"AIRWAY REFLEXES, PROTECTIVE|RECOVERY AFTER NEUROMUSCULAR BLOCK|ANESTHETIC RECOVERY",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF Helen Diller Cancer Center, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States",A61K9/7023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,26.3496170352573,464.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],1,,_GLYCOPYRROLATE,4824676,Completed,NCT03081156,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States",A61K9/7023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,26.3496170352573,464.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,1,,_PROCATEROL,4616022,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,329.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,1,,_PROCATEROL,4616022,Completed,NCT01091337,ASTHMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Philippine General Hospital, Manila, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,329.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,1,,_PROCATEROL,4616022,Terminated,NCT00394485,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Philippine General Hospital, Manila, National Capital Region, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,329.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2nc(O)ccc12.Cl,1,,_PROCATEROL_HYDROCHLORIDE,4322425,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,24.509743526561106,47.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C,1,,_METHAZOLAMIDE,,Completed,NCT02760121,"ALTITUDE SICKNESS|HYPERTENSION, PULMONARY",Male,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of British Columbia, Kelowna, British Columbia, Canada",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0
CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C,1,,_METHAZOLAMIDE,,"Active, not recruiting",NCT02463357,MOUNTAIN SICKNESS,Male,18 Years to 30 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alma College, Alma, Michigan, United States",,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,1,,_BENZYDAMINE_HYDROCHLORIDE,4749794,Completed,NCT03574246,"SORE THROAT|NAUSEA AND VOMITING, POSTOPERATIVE",All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Ankara University Faculty of Dentistry, Ankara, Yenimahalle, Turkey",C07D231/56,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,22.3084662929423,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl,1,,_BENZYDAMINE_HYDROCHLORIDE,4749794,Completed,NCT03074968,INTUBATION COMPLICATION,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","SNUH, Seoul, Jongro Gu, Korea, Republic of",C07D231/56,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,22.3084662929423,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1,1,,_CEFDITOREN_PIVOXIL,5994340,Unknown status,NCT01553006,RHINOSINUSITIS,All,1 Year to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Thammasat University, Prathumthani, Thailand",C07D409/12,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,27.0395696010185,136.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Terminated,NCT02494102,OBSTRUCTIVE SLEEP APNEA|DELAYED EMERGENCE FROM ANESTHESIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Penn State Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Completed,NCT00086281,OBSTRUCTIVE SLEEP APNEA SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|London Health Sciences Centre, Victoria Campus, London, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Completed,NCT00829322,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stoke Mandeville Hospital, Aylesbury, United Kingdom|Macclesfield District Hospital, Cheshire, United Kingdom|University Hospital of North Tees, County Durham, United Kingdom|Basildon and Thurrock University Hospitals, Essex, United Kingdom|Basingstoke and North Hampshire Hospital, Hampshire, United Kingdom|East Kent University Hospitals, Kent, United Kingdom|Queen Elizabeth Hospital, Kings Lynn, United Kingdom|University Hospital, Llandough, United Kingdom|Royal Marsden Hospital Fulham Road, London, United Kingdom|Royal Marsden Hospital Sutton, London, United Kingdom|St George's Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|James Cook University Hospital, Middlesborough, United Kingdom|Harrogate and District NHS Foundation Trust, North Yorkshire, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Papworth Hospital, Papworth Everard, United Kingdom|Withybush General Hospital, Pembrokeshire, United Kingdom|Peterborough District Hospital, Peterborough, United Kingdom|Royal Surrey County Hospital, Surrey, United Kingdom|Great Western Hospital, Swindon, United Kingdom|Hillingdon Hospital, Uxbridge, United Kingdom|Calderdale and Huddersfield NHS Foundation Trust, West Yorkshire, United Kingdom|Mid Yorkshire Hospital NHS Trust, West Yorkshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Recruiting,NCT03475589,STAGE IV CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Completed,NCT03384511,MALIGNANCIES|STOMACH CANCER|NON-SMALL CELL LUNG CANCER|ESOPHAGEAL CANCER|BREAST CANCER|OVARY CANCER|CERVICAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jinan, Shandong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Not yet recruiting,NCT03792503,ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xinqiao Hospital of Chongqing, Chongqing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Completed,NCT00445094,INFECTIONS|PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Unknown status,NCT01356472,"METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS|PNEUMONIA, VENTILATOR-ASSOCIATED",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Completed,NCT01489124,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Prince of Songkla University, Hat Yai, Songkla, Thailand",C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12.O,1,,_IMIPENEM,4727062,Completed,NCT02683603,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"intensive care unit of the University Hospital Center La Rabta, Tunis, Tunisia",C07K5/06191,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-],1,,_BENZALKONIUM_CHLORIDE,3992432,Completed,NCT03323528,PHARYNGITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","doc-HNO for the DoriPha investigators, Röthenbach an der Pegnitz, Germany",C07C17/208,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,20.928561161420106,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1.[Cl-],1,,_BENZALKONIUM_CHLORIDE,3992432,Unknown status,NCT02269800,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07C17/208,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,20.928561161420106,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,,_BENZALKONIUM,EP-0842248-B1,Completed,NCT03323528,PHARYNGITIS,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","doc-HNO for the DoriPha investigators, Röthenbach an der Pegnitz, Germany",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,81.61153206431341,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1,1,,_BENZALKONIUM,EP-0842248-B1,Unknown status,NCT02269800,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,81.61153206431341,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_CETIRIZINE_HYDROCHLORIDE,5993833,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl,1,,_BUPROPION_HYDROCHLORIDE,RE33994,Completed,NCT00666978,BLADDER CANCER|CERVICAL CANCER|ESOPHAGEAL CANCER|GASTRIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|LEUKEMIA|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER|TOBACCO USE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Swope Health Central, Kansas City, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,35.3190003901517,98.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O,1,,_STREPTOMYCIN,3962429,Unknown status,NCT02331823,REINFECTION PULMONARY TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Pulmonary Hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,22.538450481529303,7028.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Recruiting,NCT04340557,SARS-COV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Terminated,NCT02416102,COPD|CHRONIC BRONCHITIS,All,"35 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Miami, Miami, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00720226,COPD|EMPHYSEMA|CHRONIC BRONCHITIS|SMOKING,All,"40 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT03335904,SLEEP DISORDERED BREATHING|HYPOXIA|RESPIRATION; SLEEP DISORDER|CHEMORECEPTOR APNEA,All,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of British Columbia, Kelowna, British Columbia, Canada",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00701428,HYPERTENSION|SLEEP APNEA,All,"50 Years to 69 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skaraborg Hospital, Skoevde, West Gotaland, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,"Active, not recruiting",NCT02696564,EMPHYSEMA,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|University of California at San Diego, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Western Connecticut Health Network, Danbury, Connecticut, United States|University of Florida College of Medicine, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Hospitals, Chicago, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|St. Louis University School of Medicine, Saint Louis, Missouri, United States|St. Louis Asthma Clinical Research Center - Washington University School of Medicine, Saint Louis, Missouri, United States|New York University School of Medicine, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at The University of Vermont, Colchester, Vermont, United States|Pacific Northwest Airways - VA Puget Sound Healthcare System, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
Nc1nc(O)c2ncn(COC(CO)CO)c2n1,1,,_GANCICLOVIR,,"Active, not recruiting",NCT02152358,VIRAL PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Assistance Publique - Hôpitaux de Marseille, Marseille, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(O)O,1,,_BICARBONATE,,Not yet recruiting,NCT04530448,COVID|CORONAVIRUS|CORONAVIRUS INFECTION|AKI|ACUTE KIDNEY INJURY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"WVU Medicine Heart & Vascular Institute, Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)O,1,,_BICARBONATE,,Completed,NCT02476526,CHRONIC KIDNEY DISEASE|PULMONARY EMBOLISM|RENAL ARTERY STENOSIS|PULMONARY CANCER,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"VA Greater Los Angeles Healthcare System, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O,1,,_COLIMYCIN,,Completed,NCT02683603,PNEUMONIA VENTILATOR ASSOCIATED,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"intensive care unit of the University Hospital Center La Rabta, Tunis, Tunisia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,1,,_CHLOROQUINE_PHOSPHATE,5021426,Not yet recruiting,NCT04286503,NOVEL CORONAVIRUS INFECTIOUS DISEASE (COVID-19),All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,90.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,1,,_CHLOROQUINE_PHOSPHATE,5021426,Recruiting,NCT04331600,COVID-19,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,90.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl,1,,_OXYMETAZOLINE_HYDROCHLORIDE,4603131,Unknown status,NCT02630121,SLEEP APNEA|CHRONIC NASAL CONGESTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Usf Asthma Allergy and Immunology Cru, Tampa, Florida, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,51.0893447504055,258.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)[O-])C[C@@H]21.[Na+],1,,_EPOPROSTENOL_SODIUM,4335139,Completed,NCT01462565,"HYPERTENSION, PULMONARY",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Miami Beach, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Amsterdam, Netherlands",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,21.5528039590135,63.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Recruiting,NCT04335786,ACUTE RESPIRATORY DISTRESS SYNDROME|SARS-COV-2|COVID|COVID-19|SEVERE ACUTE RESPIRATORY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Terminated,NCT02058823,HYPOXIA|SLEEP APNEA|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","Laboratoire EFCR - Functional Cardio-respiratory Exploration Laboratory, La Tronche, Isère, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00409487,"HYPERTENSION,|OBSTRUCTIVE SLEEP APNEA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Grenoble, Grenoble, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Completed,NCT00862043,PULMONARY HYPERTENSION|VALVULAR HEART DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Universitario Alava, Vitoria, Alava, Spain|Hospital German Trias y Pujol, Badalona, Barcelona, Spain|Hospital de la Santa Creu y San Pau, Barcelona, Barcelon, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital de Galdakao, Galdakao, Vizcaya, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Virgen de las Nieves, Granada, Spain|Hospital Juan Canalejo, La Coruna, Spain|Hospital de Leon, Leon, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico de Valladolid, Valladolid, Spain",A61K9/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Completed,NCT03431649,PEDIATRIC PULMONARY HYPERTENSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",A61K9/19,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Terminated,NCT00430716,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Charlotte, North Carolina, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Richmond, Virginia, United States|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Haidari, Athens, Greece|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Ahmedabad, Gujarat, India|Pfizer Investigational Site, Vadodara, Gujarat, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Noida, Uttar Pradesh, India|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Manila City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Zabrze, Poland|Pfizer Investigational Site, Timisoara, Timis, Romania|Pfizer Investigational Site, Iasi, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Amphoe Mueang, Khon Kaen, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Norwich, Norfolk, United Kingdom|Pfizer Investigational Site, Newcastle Upon Tyne, Tyne and Wear, United Kingdom",A61K9/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_SILDENAFIL_CITRATE,WO-1999030688-A1,Completed,NCT00627965,HIGH ALTITUDE PULMONARY EDEMA|ACUTE MOUNTAIN SICKNESS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,A61K9/19,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O,1,,_BERAPROST,5403867,Completed,NCT03431649,PEDIATRIC PULMONARY HYPERTENSION,All,1 Year to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Dr. Soetomo General Hospital, Surabaya, East Java, Indonesia",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,16.0988932010924,256.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC(OP(C)(=O)F)C(C)(C)C,1,,_SOMAN,4292308,Completed,NCT02454582,RESPIRATORY INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Medical University of Vienna, Anesthesia, Vienna, Austria",A61K39/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.298260744573803,282.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,1,,_VINBLASTINE_SULFATE,4303584,Completed,NCT03092986,"CARCINOMA, NON-SMALL-CELL LUNG",All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Oncology,Bangabandhu Sheikh Mujib Medical university, Dhaka, Bangladesh",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,19.975769522988106,398.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT02877485,NASAL OBSTRUCTION,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford Hospital and Clinics, Stanford, California, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,,_ESTROGEN,,Terminated,NCT00203996,POLYCYSTIC OVARY SYNDROME|OBSTRUCTIVE SLEEP APNEA,All,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0
CCCCCCCCCCCCCCC(=O)O,1,,_PENTADECANOIC_ACID,3932476,Completed,NCT00572975,CYSTIC FIBROSIS|PANCREATIC INSUFFICIENCY,All,"8 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",C07C231/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,30.3907677775724,382.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
N#[N+][O-],1,,_NITROUS_OXIDE,,Unknown status,NCT03228628,PAIN|ANXIETY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CHU de Clermont-Ferrand, Clermont-Ferrand, Auvergne, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
N#[N+][O-],1,,_NITROUS_OXIDE,,Unknown status,NCT02243826,LUMBAR PUNCTURE,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU de Clermont-Ferrand, Clermont-Ferrand, France",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1.O,1,,_DACOMITINIB,,Not yet recruiting,NCT04511533,METASTATIC NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Artemis Hospital, Gurgaon, Haryana, India|Apex Wellness Hospital, Nashik, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India|Medica Superspeciality Hospital, Kolkata, West Bengal, India",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_FENTANYL_CITRATE,4486423,Completed,NCT01308320,THYROID NEOPLASMS,Female,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Severance Hospital, Seoul, Korea, Republic of",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_FENTANYL_CITRATE,4486423,Suspended,NCT03405090,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Respiratory Investigation Unit, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT00137657,HIV|MALARIA|DIARRHEA|PNEUMONIA|OPPORTUNISTIC INFECTIONS,All,"15 Years and older   (Child, Adult, Older Adult)",U.S. Fed|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,"CDC KEMRI Research Institute, Kisumu, Kenya",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT03087890,HIV-1-INFECTION|PNEUMOCYSTIS PNEUMONIA|OPPORTUNISTIC INFECTIONS|PREVENTIVE THERAPY|ANTIBIOTIC SIDE EFFECT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Amana Regional Referral Hospital, Dar es Salaam, Tanzania|Mbagala District Hospital, Dar es Salaam, Tanzania|Mnazimmoja Health Centre, Dar Es Salaam, Tanzania|Mwananyamala Regional Referral Hospital, Dar es Salaam, Tanzania|Pasada Upendano, Dar es Salaam, Tanzania|Temeke Regional Referral Hospital, Dar es Salaam, Tanzania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
O=C1N=C(O)NC1(c1ccccc1)c1ccccc1,1,,_PHENYTOIN,3962430,Completed,NCT00366067,BRONCHIAL ASTHMA,All,4 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"""Rea"" Rehabilitation Centre, Tbilisi, Georgia",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,1,,_HYDROXYCHLOROQUINE_SULFATE,5318960,Recruiting,NCT04346667,SARS-COV-2|CORONAVIRUS INFECTION|ASYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan",A61K47/44,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,1,,_HYDROXYCHLOROQUINE_SULFATE,5318960,Recruiting,NCT04351191,SARS-COV2|SYMPTOMATIC CONDITION|COVID-19,All,20 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan",A61K47/44,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,1,,_HYDROXYCHLOROQUINE_SULFATE,5318960,"Active, not recruiting",NCT04316377,CORONA VIRUS INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Akershus University Hospital, Lørenskog, Norway",A61K47/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1,1,,_CEFTOLOZANE,,Completed,NCT02421120,CYSTIC FIBROSIS|CYSTIC FIBROSIS PULMONARY EXACERBATION|PSEUDOMONAS AERUGINOSA INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Hartford Hospital, Hartford, Connecticut, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,,_DAPTOMYCIN,4874843,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,,_BACITRACIN,,Withdrawn,NCT00671541,CHRONIC SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Lahey Clinic, Inc, Burlington, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,1,,_DEXLANSOPRAZOLE,,Unknown status,NCT01328652,LARYNGOPHARYNGEAL REFLUX|HYPERTROPHY OF LINGUAL TONSIL,All,18 Years to 59 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advanced Center for Specialty Care, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,1,,_ARMODAFINIL,,Completed,NCT00711516,EXCESSIVE SLEEPINESS,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peninsula Sleep Center, Burlingame, California, United States|Pacific Research, San Diego, California, United States|VA San Diego Healthcare System, San Diego, California, United States|Stanford University, Stanford, California, United States|Beth Israel Deaconess Medical, Boston, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,1,,_ARMODAFINIL,,Completed,NCT00518986,SLEEP DISORDERS|OBSTRUCTIVE SLEEP APNEA|MAJOR DEPRESSIVE DISORDER|DYSTHYMIC DISORDER,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Jasper Summit Research, LLC, Jasper, Alabama, United States|Pulmonary Associates, P.A., Phoenix, Arizona, United States|Psypharma Clinical Research, Phoenix, Arizona, United States|PsyPharm Clinical Research, Inc., Tucson, Arizona, United States|Behavioral Research Specialists, Glendale, California, United States|California Clinical Trials Medical Group, Inc., Glendale, California, United States|Pacific Sleep Medicine Services, Inc., Redlands, California, United States|Pacific Research Network, Inc., San Diego, California, United States|Pacific Sleep Medicine Services, Inc., San Diego, California, United States|California Clinical Trials Medical Group, Inc., San Diego, California, United States|SDS Clinical Research, Santa Ana, California, United States|St. Johns Medical Plaza Sleep Disorders Center, Santa Monica, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Rocky Mountain Center for Clinical Research, Wheat Ridge, Colorado, United States|PAB Clinical Research, Brandon, Florida, United States|Florida Sleep Institute, Spring Hill, Florida, United States|Clinical Research Group of St. Petersburg, St. Petersburg, Florida, United States|SomnoMedics, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Florida Pulmonary Research Center, LLC, Winter Park, Florida, United States|The Sleep Disorders Center, Atlanta, Georgia, United States|Neurotrials Research, Inc, Atlanta, Georgia, United States|Sleep Disorders Center of Georgia, Atlanta, Georgia, United States|SleepMed, Inc, Macon, Georgia, United States|Chicago Research Center, Chicago, Illinois, United States|Peoria Pulmonary Associates, Peoria, Illinois, United States|Sleep and Behavior Medicine, Vernon Hills, Illinois, United States|The Center for Sleep and Wake Disorders, Danville, Indiana, United States|Vince & Associates Clinical Research, Overland Park, Kansas, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Community Research, Crestview, Kentucky, United States|Clinical Trials of America, Shreveport, Louisiana, United States|The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States|Sleep Health Centers, Brighton, Massachusetts, United States|AccelRx Research, Fall River, Massachusetts, United States|The Center for Sleep Medicine, Hattiesburg, Mississippi, United States|Washington University, St. Louis, Missouri, United States|Somnos Sleep Center, Lincoln, Nebraska, United States|Brooklyn Medical Institute, Brooklyn, New York, United States|Clinilabs, Inc, New York City, New York, United States|Sleep Medicine Centers, West Seneca, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials of America, Hickory, North Carolina, United States|Tri-State Sleep Disorders Center, Cincinnati, Ohio, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, United States|North Star Medical Research, LLC, Middleburg Heights, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Sleep Lab of Northeastern PA, Clarks Summit, Pennsylvania, United States|University of Pennsylvania Center for Sleep, Philadelphia, Pennsylvania, United States|CRI Worldwide, Philadelphia, Pennsylvania, United States|University Services, West Chester, Pennsylvania, United States|AccelRx Research, Lincoln, Rhode Island, United States|Lowcountry Lung and Critical Care, Charleston, South Carolina, United States|SleepMed of South Carolina, Columbia, South Carolina, United States|Sleep Medicine of Middle Tennessee, Nashville, Tennessee, United States|FutureSearch Trials of Neurology, Austin, Texas, United States|Sleep Medicine Associates of Texas, P.A., Dallas, Texas, United States|Baylor College of Medicine VAMC Sleep Research, Houston, Texas, United States|Houston Sleep Center, Houston, Texas, United States|Northwest Clinical Research, Bellevue, Washington, United States|Pacific Sleep Medicine Services, Inc., Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,DB00035,__DESMOPRESSIN,5500413,Terminated,NCT01530451,NOCTURIA|OBSTRUCTIVE SLEEP APNOEA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Prince of Wales Hospital, Shatin, Hong Kong",C07K7/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,DB00067,__VASOPRESSIN,9375478,Suspended,NCT02975999,PLEURAL EFFUSION|SINGLE-VENTRICLE,All,18 Months to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advocate Children's Hospital, Oak Lawn, Illinois, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,DB00067,__VASOPRESSIN,9375478,Terminated,NCT01370096,PULMONARY HYPERTENSION,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stollery Children's Hospital, Edmonton, Alberta, Canada",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,13.3062280539641,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,2140.46,463.93,16.0,14.0,8.0,108.29,272.59,38.0,1.0,0.0,0.0,1,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CC(=O)C(=O)O,0,DB00119,__PYRUVIC_ACID,,Terminated,NCT00332215,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of Minnesota General Clinical Research Center, Minneapolis, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CC(=O)C(=O)O,0,DB00119,__PYRUVIC_ACID,,Terminated,NCT00262652,MODERATE ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","David Geffen School of Medicine, UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT00318331,CRITICAL ILLNESS|SEPSIS|RESPIRATORY INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Christiana Hospital, Newark, Delaware, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT02026609,REFRACTORY ASCITES|HEPATIC HYDROTHORAX|HEPATIC ENCEPHALOPATHY|CIRRHOSIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Montreal, Montreal, Quebec, Canada|University Hospitals of Geneva, Geneva, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Terminated,NCT02949843,EGFR ACTIVATING MUTATION|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IV NON-SMALL CELL LUNG CANCER,All,"Child, Adult, Older Adult",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Withdrawn,NCT00268255,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(=O)O)C(=O)O,0,DB00143,__GLUTATHIONE,3934038,Withdrawn,NCT02316925,IMPROVEMENT IN IMMUNE CELL FUNCTION IN ELDERLY HUMANS,All,"50 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",,A01K61/80,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,38.44021437811861,8725.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,307.323,158.82,7.0,6.0,0.0,29.11,69.11,9.0,0.0,1.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
NCC(=O)O,0,DB00145,__GLYCINE,,Terminated,NCT01417481,CYSTIC FIBROSIS,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Infantil de México, Mexico DF, Mexico|Unidad de Investigación Médica en Enfermedades Respiratorias, Hospital de Pediatría, CMN SXXI, IMSS, Mexico DF, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,75.0666,63.32,3.0,2.0,0.0,6.65,16.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)C[C@H](N)C(=O)O,0,DB00149,__LEUCINE,3931141,Terminated,NCT00014768,CYSTIC FIBROSIS,Female,"Child, Adult, Older Adult",NIH|Other,Observational Model: Natural History,"University of Utah School of Medicine, Salt Lake City, Utah, United States",C07K14/595,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,25.692519353580106,22082.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,131.1729,63.32,3.0,2.0,0.0,14.16,34.17,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
NC(=O)NCCC[C@H](N)C(=O)O,0,DB00155,__CITRULLINE,3950513,Withdrawn,NCT00742534,BRONCHOPULMONARY DYSPLASIA,All,up to 14 Days   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,78.7860120331013,1323.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,175.1857,118.44,4.0,4.0,0.0,17.35,41.33,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,0,DB00158,__FOLIC_ACID,3960757,Terminated,NCT00923273,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,0,DB00158,__FOLIC_ACID,3960757,Terminated,NCT00402883,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gainsville Hematology Oncology Associates, Gainesville, Florida, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Associates in Hematology Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,0,DB00163,__VITAMIN_E,3932634,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,0,DB00163,__VITAMIN_E,3932634,Terminated,NCT01897792,COAGULOPATHY|NOSOCOMIAL PNEUMONIA,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","The University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,0,DB00163,__VITAMIN_E,3932634,Withdrawn,NCT00003599,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,0,DB00171,__ATP,3933594,Withdrawn,NCT00159315,ASTHMA|COPD|SMOKING,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom",G01N33/525,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,2074.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,507.181,279.13,14.0,7.0,3.0,38.92,95.81,8.0,1.0,0.0,0.0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,0,DB00175,__PRAVASTATIN,5622985,Terminated,NCT00467831,HERMANSKY-PUDLAK SYNDROME (HPS)|PULMONARY FIBROSIS|OCULOCUTANEOUS ALBINISM|PLATELET STORAGE POOL DEFICIENCY|METABOLIC DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,0,DB00179,__MASOPROCOL,3995632,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",B01J4/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,26.2510523830058,271.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,302.3649,80.92,4.0,4.0,2.0,33.63,86.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00283634,NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Tennesee, Knoxville, Tennessee, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT01163786,BRONCHIOLITIS OBLITERANS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00714246,NON SMALL CELL LUNG CANCER,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00040768,RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT00424840,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC,0,DB00206,__RESERPINE,3952072,Withdrawn,NCT02684786,PULMONARY ARTERY HYPERTENSION,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Florida, Jacksonville, Florida, United States",B07B4/025,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,62.0,17.183104375859802,31990.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.05,608.6787,117.78,8.0,1.0,6.0,66.06,161.42,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Suspended,NCT03050060,METASTATIC KIDNEY CARCINOMA|RECURRENT LUNG NON-SMALL CELL CARCINOMA|STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7|STAGE IV RENAL CELL CANCER AJCC V7|STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT00791336,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Iowa Department of Radiation Oncology, Iowa City, Iowa, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Terminated,NCT01108666,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,DB00220,__NELFINAVIR,5484926,Withdrawn,NCT01447589,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oxford Radcliffe NHS Trust, Oxford, Oxfordshire, United Kingdom",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,0,DB00222,__GLIMEPIRIDE,6150383,Terminated,NCT00343980,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, St Leonards, New South Wales, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, Australia|Novo Nordisk Investigational Site, Garran, Australia|Novo Nordisk Investigational Site, Kingswood, Australia|Novo Nordisk Investigational Site, Osijek, Croatia|Novo Nordisk Investigational Site, Zagreb, Croatia|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, India|Novo Nordisk Investigational Site, Bangalore, India|Novo Nordisk Investigational Site, Chennai, India|Novo Nordisk Investigational Site, Coimbatore, India|Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Cebu City, Philippines|Novo Nordisk Investigational Site, Makati City, Philippines|Novo Nordisk Investigational Site, Manila, Philippines|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Bornova-IZMIR, Turkey|Novo Nordisk Investigational Site, Bursa, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey|Novo Nordisk Investigational Site, Istanbul, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,19.7786402184849,200.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,490.62,124.68,5.0,3.0,3.0,53.49,129.8,6.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00227,__LOVASTATIN,6080428,Withdrawn,NCT00689806,SEVERE PERSISTENT ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1,0,DB00269,__CHLOROTRIANISENE,4310523,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,15.0803917944927,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.95,380.86400000000003,27.69,3.0,0.0,3.0,41.6,119.17,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Withdrawn,NCT00198328,HEAD NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inovio Biomedical Corporation, San Diego, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,0,DB00305,__MITOMYCIN,7806265,Terminated,NCT01523275,LARYNGEAL STENOSIS|SUBGLOTTIC STENOSIS|TRACHEAL STENOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCSF - Voice and Swallowing Clinic, San Francisco, California, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,50.79365079365071,3420.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.55,334.3272,146.89,7.0,3.0,4.0,32.77,83.27,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,0,DB00307,__BEXAROTENE,5780676,Terminated,NCT00153842,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norris Cotton Cancer Center, Lebanon, New Hampshire, United States",C07C65/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,37.22458366701571,808.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.86,348.4779,37.3,2.0,1.0,3.0,40.89,117.12,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
CN(C)CCC=C1c2ccccc2CCc2ccccc21,0,DB00321,__AMITRIPTYLINE,3965255,Terminated,NCT02434523,LARYNGEAL DISEASES|CHRONIC LARYNGEAL NEUROPATHY,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Boston Medical Center, Boston, Massachusetts, United States",A61K9/282,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB00324,__FLUOROMETHOLONE,3962414,Withdrawn,NCT00824811,EPIPHORA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,1087.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.34,376.4617,74.6,4.0,2.0,4.0,40.05,100.87,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,0,DB00351,__MEGESTROL_ACETATE,5145684,Terminated,NCT00637728,ANOREXIA|CACHEXIA|WEIGHT LOSS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Innovative Medical Research of South Florida, Inc, Miami, Florida, United States|Western Maryland Health System, Cumberland, Maryland, United States|Lowcountry Hematology & Oncology, PA, Mt. Pleasant, South Carolina, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,19.450091377646306,2187.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.71,384.51599999999996,60.44,3.0,0.0,4.0,43.51,108.66,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,DB00377,__PALONOSETRON,5202333,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,0,DB00390,__DIGOXIN,3933997,Terminated,NCT00281021,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G01N31/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00473486,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Muenster, Dept. of Medicine, Hematology / Oncology, Muenster, Germany",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00543335,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD . Anderson Cancer Center, Houston, Texas, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00417248,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States|Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Horizon Oncology Center, Lafayette, Indiana, United States|Medical Consultants, P.C., Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Oncology Partners Network, Cincinnati, Ohio, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT01159327,SMALL CELL LUNG CANCER,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of",C07D209/46,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT00801801,NON SQUAMOUS CELL LUNG CANCER|NON SMALL CELL LUNG CANCER,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT02021929,HEPATOPULMONARY SYNDROME,All,"21 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic Arizona, Phoenix, Arizona, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Columbia University-NewYork-Presbyterian Hospital, New York, New York, United States|University of Pennsylvania - Perelman Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Health Science Center at Houston Medical School, Houston, Texas, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,0,DB00419,__MIGLUSTAT,5472969,Terminated,NCT00537602,CYSTIC FIBROSIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Corporacio Parc Tauli / Parc Tauli Hospital, Barcelona, Spain",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,13.766196431138198,165.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.1,219.278,84.16,5.0,4.0,1.0,23.99,55.74,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0
Oc1ncnc2[nH]ncc12,0,DB00437,__ALLOPURINOL,8084483,Withdrawn,NCT00214084,OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"University of Wisconsin, Madison, Wisconsin, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,0,DB00460,__VERTEPORFIN,5214036,Terminated,NCT02702700,"PLEURAL EFFUSION, MALIGNANT",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud (VD), Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT01924169,HEMATOLOGIC DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT02018523,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,0,DB00480,__LENALIDOMIDE,5635517,Terminated,NCT02963610,RELAPSED OR REFRACTORY SOLID TUMORS|NONSMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C,0,DB00524,__METOLAZONE,4472380,Withdrawn,NCT01617798,RESPIRATORY FAILURE|VOLUME OVERLOAD|HYPERNATREMIA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oregon Health Sciences University, Portland, Oregon, United States",C07K5/022,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,23.7212263085484,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,365.835,92.5,4.0,2.0,3.0,36.38,94.59,2.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Terminated,NCT00646659,HEAD AND NECK CANCER,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitair Ziekenhuis Antwerpen, Edegem, Belgium",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,0,DB00544,__FLUOROURACIL,6670335,Withdrawn,NCT00006106,LIP AND ORAL CAVITY CANCER|HEAD AND NECK CANCER|OROPHARYNGEAL CANCER,All,"18 Years to 79 Years   (Adult, Older Adult)",NIH|Other,Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,0,DB00607,__NAFCILLIN,4217274,Terminated,,BACTEREMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,19.450091377646306,817.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,414.475,95.94,5.0,2.0,4.0,42.22,108.14,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1
C[C@H](N)[C@H](O)c1cccc(O)c1,0,DB00610,__METARAMINOL,4275219,Withdrawn,,PREECLAMPSIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/63,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,20.961416045504,260.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.59,167.205,66.48,3.0,3.0,1.0,17.84,46.89,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT01796405,LANGERHANS CELL HISTIOCYTOSIS,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Terminated,NCT00227617,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL TUMOR|LUNG CANCER|NEOPLASTIC SYNDROME|NEUROENDOCRINE TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Univeristy of California, San Francisco, San Francisco, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,0,DB00650,__LEUCOVORIN,4148999,Withdrawn,NCT03169738,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,0,DB00661,__VERAPAMIL,5785994,Terminated,NCT02454608,SINUSITIS|NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,0,DB00693,__FLUORESCEIN,10293047,Withdrawn,NCT02628496,LARYNGEAL DYSPLASIA|LARYNGEAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,18.135896014291802,9013.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.64,332.3063,75.99,3.0,2.0,5.0,33.14,91.22,0.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,0,DB00709,__LAMIVUDINE,5905082,Withdrawn,NCT00001080,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,,C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
CC(C)Cn1cnc2c(N)nc3ccccc3c21,0,DB00724,__IMIQUIMOD,4689338,Terminated,NCT00596336,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Royal Bournemouth hospital, Bournemouth, Dorset, United Kingdom",C07D471/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],0,DB00727,__NITROGLYCERIN,5186938,Terminated,NCT01210378,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MAASTRO clinic, Maastricht, Netherlands",A61K9/7061,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,18.3658802028789,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.25,227.0865,157.11,9.0,0.0,0.0,15.68,37.59,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,0,DB00738,__PENTAMIDINE,4399151,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,27.170989137353892,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.32,340.4195,118.2,6.0,4.0,2.0,38.85,120.53,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,0,DB00756,__HEXACHLOROPHENE,3932684,Terminated,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",C11D3/43,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.421384422678003,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.77,406.904,40.46,2.0,2.0,2.0,34.07,88.59,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,0,DB00788,__NAPROXEN,5637320,Terminated,NCT01612975,PLEURAL EFFUSION|PLEURAL EFFUSION MALIGNANT,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB00806,__PENTOXIFYLLINE,4189469,Terminated,NCT00593658,HEPATOPULMONARY SYNDROME,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
C[C@@H]1O[C@@H]1P(=O)(O)O,0,DB00828,__FOSFOMYCIN,,Withdrawn,NCT02218359,"PNEUMONIA, BACTERIAL",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.86,138.059,70.06,4.0,2.0,1.0,10.8,25.87,1.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00096265,METASTATIC MALIGNANT NEOPLASM IN THE BRAIN|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7,All,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Scottsdale Health Care-Osborn, Scottsdale, Arizona, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Integrated Community Oncology Network-Florida Cancer Center Beaches, Jacksonville Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Integrated Community Oncology Network-Southside Cancer Center, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|21st Century Oncology-Orange Park, Orange Park, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|21st Century Oncology-Palatka, Palatka, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States|Tallahassee Memorial HealthCare, Tallahassee, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Saint John's Hospital, Springfield, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Franciscan Saint Margaret Health-Hammond Campus, Hammond, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Finley Hospital, Dubuque, Iowa, United States|Norton Suburban Hospital and Medical Campus, Louisville, Kentucky, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Sparta Cancer Treatment Center, Sparta, New Jersey, United States|University of Rochester, Rochester, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Wheaton Franciscan Cancer Care - All Saints, Racine, Wisconsin, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00629187,CENTRAL NERVOUS SYSTEM NEOPLASMS|NEOPLASM METASTASIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00266812,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00632203,"CARCINOMA, NON-SMALL-CELL LUNG|ADENOCARCINOMA|CARCINOMA, LARGE CELL|CARCINOMA, SQUAMOUS CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00034697,"METASTASES, NEOPLASM|CARCINOMA, NON-SMALL-CELL LUNG|BRAIN NEOPLASMS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00423150,"COLORECTAL NEOPLASM|HEAD AND NECK NEOPLASM|CARCINOMA, NON-SMALL-CELL LUNG|ESOPHAGEAL NEOPLASM",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT02477813,SMALL CELL LUNG CANCER RECURRENT,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ircc Irst, Meldola, FC, Italy|Oncologia Medica, Azienda ospedaliera universitaria di Ferrara, Ferrara, FE, Italy|Oncologia Medica AOU Policlinico di Modena, Modena, MO, Italy|U.O. Oncologia Medica, Faenza, RA, Italy|U.O Oncologia medica, Lugo, RA, Italy|UO Oncologia Medica, Ospedale S.Maria delle Croci, Ravenna, RA, Italy|U.O Oncologia medica, Rimini, RN, Italy|Oncologia Medica Ospedale Guglielmo da Saliceto, Piacenza, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT00385398,LUNG CANCER|METASTATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2,0,DB00872,__CONIVAPTAN,5723606,Withdrawn,NCT00811486,RIGHT HEART FAILURE|PULMONARY HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado at Denver and Health Sciences Center General Clinical Research Center, Denver, Colorado, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,25.4296802809092,57.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,498.5744,78.09,3.0,2.0,6.0,55.51,150.83,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0
Cc1cccn2c(=O)c(-c3nn[nH]n3)cnc12,0,DB00885,__PEMIROLAST,5034230,Terminated,NCT03119714,ALLERGIC ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Lung and Allergy Research Unit C2-88 Karolinska University Hospital Huddinge, Stockholm, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,23.8197909608,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.13,228.2101,87.13,5.0,1.0,3.0,21.96,63.35,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
NC12CC3CC(CC(C3)C1)C2,0,DB00915,__AMANTADINE,RE39069,Terminated,NCT00830323,INFLUENZA A INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices civils de Lyon, Lyon, France",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,52.4692498819277,1321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.53,151.2487,26.02,1.0,1.0,3.0,17.92,45.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01935947,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01886573,STAGE IA NON-SMALL CELL LUNG CARCINOMA|STAGE IB NON-SMALL CELL LUNG CARCINOMA|STAGE IIA NON-SMALL CELL LUNG CARCINOMA|STAGE IIB NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01207726,STAGE IA NON-SMALL CELL LUNG CARCINOMA|STAGE IB NON-SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT02712905,SOLID TUMORS AND HEMATOLOGIC MALIGNANCY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|Moores UCSD Cancer Center, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Center for Research, Inc., Kansas City, Kansas, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University, New York, New York, United States|Oregon Health Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Institut Jules Bordet, Brussel, Belgium|Netherland Cancer Institute, Amsterdam, Netherlands|VU Medical Center, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT00901537,NON-SMALL CELL LUNG CANCER|SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Loma Linda University Cancer Center, Loma Linda, California, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,DB00947,__FULVESTRANT,6774122,Terminated,NCT00592007,NON SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moores UCSD Cancer Center, La Jolla, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,DB00947,__FULVESTRANT,6774122,Terminated,NCT00932152,NON-SMALL CELL LUNG CANCER|POSTMENOPAUSAL WOMEN,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,DB00947,__FULVESTRANT,6774122,Withdrawn,NCT03169738,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,43.007043265775394,1402.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.54,606.78,57.53,3.0,2.0,4.0,65.88,155.34,15.0,1.0,0.0,0.0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,0,DB00977,__ETHINYLESTRADIOL,5876746,Terminated,NCT02144246,CYSTIC FIBROSIS EXACERBATIONS WHILE ON AND OFF HORMONAL CONTRACEPTION,Female,18 Years to 40 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1,0,DB00982,__ISOTRETINOIN,7435427,Withdrawn,NCT00003599,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,84.76560093636421,968.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.66,300.4351,37.3,2.0,1.0,1.0,36.15,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,0,DB00995,__AURANOFIN,4330530,Withdrawn,NCT02126527,"RECURRENT NON-SMALL CELL LUNG CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Florida, Jacksonville, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,16.8217006509373,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.99,678.4839999999998,114.43,5.0,0.0,1.0,50.82,114.88,15.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
NC(=O)NO,0,DB01005,__HYDROXYUREA,,Terminated,NCT00532883,HEMOGLOBIN SC DISEASE,All,"5 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hospital and Research Center, Oakland, California, United States|University of California Davis, Sacramento, California, United States|University of Colorado, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Saint Christopher's Hospital, Philadelphia, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,0,DB01005,__HYDROXYUREA,,Terminated,NCT00350844,SICKLE CELL DISEASE|PULMONARY HYPERTENSION,All,"10 Years to 25 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,0,DB01005,__HYDROXYUREA,,Withdrawn,NCT01950585,PULMONARY HYPERTENSION,All,"18 Years to 110 Years   (Adult, Older Adult)",NIH|Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00006054,IMMUNOLOGIC DEFICIENCY SYNDROMES|CHEDIAK-HIGASHI SYNDROME|COMMON VARIABLE IMMUNODEFICIENCY|GRAFT VERSUS HOST DISEASE|X-LINKED LYMPHOPROLIFERATIVE SYNDROME|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|X-LINKED AGAMMAGLOBULINEMIA|WISKOTT-ALDRICH SYNDROME|CHRONIC GRANULOMATOUS DISEASE|X-LINKED HYPER IGM SYNDROME|SEVERE COMBINED IMMUNODEFICIENCY|LEUKOCYTE ADHESION DEFICIENCY SYNDROME|VIRUS-ASSOCIATED HEMOPHAGOCYTIC SYNDROME,All,"up to 35 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Fairview University Medical Center, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00253461,"LUNG CANCER|METASTATIC CANCER|OVARIAN CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01904253,SMALL CELL LUNG CANCER (SCLC),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Baden-Württemberg, Germany|Lungenklinik Heckeshorn- HELIOS Kliniken GmbH, Berlin, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Germany|Klinikum Koeln-Merheim, Koplin, Germany|St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz, Mainz, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Turin, Italy|IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A, Aviano, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico, Catania, Italy|Azienda Ospedaliera Instituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera San Gerardo U.O Oncologia Medica, Monza, Italy|Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|A.O.V.V. Ospedale Eugenio Morelli-Sondalo, Sondalo, Italy|National Cancer Center Hospital East, Chiba, Japan|National Kyushi Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Hyogo, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Nippon Medical School Hospital, Tokyo, Japan|Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00697476,SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Clinico Humanitas, Rozzano, Milan, Italy",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01803269,EXTENSIVE STAGE SMALL CELL LUNG CANCER|RECURRENT SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Ingalls Park, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00087048,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00315211,MEDIASTINAL NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aultman Hospital, Canton, Ohio, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00812266,EXTENSIVE DISEASE|FIRST-LINE|SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. Oncology, Rigshospitalet, Copenhagen, Denmark",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT02100007,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of WA Seattle Cancer Care Alliance, Seattle, Washington, United States|The Bays St Mary's Hospital, London, England, United Kingdom|Sarah Cannon Research Instititute UK, London, England, United Kingdom",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,0,DB01039,__FENOFIBRATE,5145684,Terminated,NCT00816829,DYSLIPIDEMIA|SLEEP APNEA SYNDROME|OVERWEIGHT|OBESITY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Site 1, Paris, France",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00800150,CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,DB01042,__MELPHALAN,8410077,Terminated,NCT00618540,"HISTIOCYTOSIS, LANGERHANS-CELL",All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Terminated,NCT03492736,OBSTRUCTIVE SLEEP APNEA,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","University of California, San Diego, San Diego, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00800150,CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00618540,"HISTIOCYTOSIS, LANGERHANS-CELL",All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT01583686,CERVICAL CANCER|PANCREATIC CANCER|OVARIAN CANCER|MESOTHELIOMA|LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00416884,LEUKEMIA,All,"4 Years to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00345059,ADVANCED NON-SMALL CELL LUNG CANCER,All,"up to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Azienda Ospedaliera Giovanni Paolo II, Sciacca, AG, Italy|Azienda Ospedaliera S. Giuseppe Moscati, U.O. di Oncologia Medica, Monteforte Irpino, AV, Italy|Ospedale Fatebenefratelli, U.O. di Oncologia, Benevento, BN, Italy|Azienda Ospedaliera G. Rummo, Benevento, BN, Italy|Università di Chieti, Chieti, CH, Italy|Ospedali Riuniti, Foggia, FG, Italy|Ospedale Umberto di Frosinone, Frosinone, FR, Italy|Ospedale di Gaeta, Gaeta, LT, Italy|Div. di Medicina Generale Osp. dei SS. Benedetto e Geltrude -Presidio Osp. Di Cuggiono - Az. Osp. Di Legnano, Cuggiono, MI, Italy|Ospedale Civile di Legnano, Legnano, MI, Italy|Ospedale S. Paolo, Milano, MI, Italy|Ospedale S. Gerado, Monza, MI, Italy|Azienda Ospedaliera Carlo Poma, Divisione di Oncologia ed Ematologia, Mantova, MN, Italy|Casa di Cura La Maddalena S.p.A., Dipartimento Oncologico, Palermo, PA, Italy|Azienda Ospedaliera V. Cervello, Palermo, PA, Italy|Ospedale Buccheri La Ferla - Fatebenefratelli, Palermo, PA, Italy|U.L.S.S. 15 Regione Veneto, Cittadella, PD, Italy|Istituto Oncologico Veneto, Padova, PD, Italy|Azienda Ospedaliera Universitaria Senese, Siena, SI, Italy|Ospedale E. Morelli, Sondalo, SO, Italy|Presidio Ospedaliaro Alto Gardo e Ledro, Arco, TN, Italy|Azienda Ospedaliera Di Busto Arsizio, Saronno, VA, Italy|Divisione di Oncologia Medica, U.S.L.L. 13, Noale, VE, Italy|Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B, Napoli, Italy",C07H19/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00268151,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"James Graham Brown Cancer Center, Louisville, Kentucky, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT02423954,ADVANCED CANCER|PANCREATIC CANCER|RENAL CELL CANCER|NON SMALL CELL LUNG CANCER|COLORECTAL CARCINOMA|ENDOMETRIAL|UTERINE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States",C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT03169738,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT00095641,RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,DB01114,__CHLORPHENIRAMINE,6383471,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,114.0,37.0274543625125,1611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.74,274.788,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
Nc1ccc2cc3ccc(N)cc3nc2c1,0,DB01123,__PROFLAVINE,4189423,Terminated,NCT01456143,SQUAMOUS CELL CARCINOMA|NEOPLASIA|HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",C07D209/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,18.661574159633602,291.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,209.2465,64.93,3.0,2.0,3.0,23.17,65.46,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CN(C)CCC=C1c2ccccc2COc2ccccc21,0,DB01142,__DOXEPIN,6211229,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,0,DB01157,__TRIMETREXATE,6017922,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",C07D239/95,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,20.2714634797429,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,369.4176,117.54,8.0,3.0,3.0,40.24,107.7,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1
CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,0,DB01190,__CLINDAMYCIN,5266329,Withdrawn,NCT01715610,PERITONSILLAR ABSCESS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","London Health Sciences Center, St. Joseph's Hospital, London, Ontario, Canada",A61M31/002,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,24.1811946857225,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,424.983,102.26,6.0,4.0,2.0,44.65,105.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1
C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,0,DB01197,__CAPTOPRIL,5238924,Terminated,NCT00077064,LUNG CANCER|PULMONARY COMPLICATIONS|RADIATION FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|Mobile Infirmary Medical Center, Mobile, Alabama, United States|Arizona Oncology Services Foundation, Phoenix, Arizona, United States|Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center, Pomona, California, United States|General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Baptist-South Miami Regional Cancer Program, Miami, Florida, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Saint John's Cancer Center at Saint John's Medical Center, Anderson, Indiana, United States|Methodist Cancer Center at Methodist Hospital, Indianapolis, Indiana, United States|Cancer Treatment Center for Southern Kentucky, Bowling Green, Kentucky, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Central Maine Comprehensive Cancer Center at Central Maine Medical Center, Lewiston, Maine, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Great Lakes Cancer Institute at McLaren Regional Medical Center, Flint, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Haematology-Oncology Associates of Ohio and Michigan, PC, Lambertville, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Cape Girardeau, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton, Marlton, New Jersey, United States|J. Phillip Citta Regional Cancer Center at Community Medical Center, Toms River, New Jersey, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Fitzpatrick Cancer Center at Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|Highland Hospital of Rochester, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Wayne Radiation Oncology, Goldsboro, North Carolina, United States|Cancer Centers of North Carolina - Raleigh, Raleigh, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Wilmed Radiation Oncology Services, Wilson, North Carolina, United States|Trinity CancerCare Center, Minot, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fremont Memorial Hospital, Fremont, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Luke's Hospital, Maumee, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Firelands Regional Medical Center, Sandusky, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|CCOP - Greenville, Greenville, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Columbia Saint Mary's Hospital - Ozaukee, Mequon, Wisconsin, United States|Columbia-Saint Mary's Cancer Care Center, Milwaukee, Wisconsin, United States|Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|All Saints Cancer Center at Wheaton Franciscan Healthcare, Racine, Wisconsin, United States|West Allis Memorial Hospital, West Allis, Wisconsin, United States",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,21.3556746545103,1584.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,217.285,57.61,3.0,2.0,1.0,21.72,54.63,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,0,DB01201,__RIFAPENTINE,5306715,Terminated,NCT00728507,TUBERCULOSIS,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ, Curicica, Rio de Janeiro, Brazil|Posto de Saude Albert Sabin, Rio de Janeiro, RJ, Brazil|Hospital Universitario Clementio Fraga Filho, Rio de Janeiro, Brazil",C07D498/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,39.5572804369699,300.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.83,877.0307,220.15,14.0,6.0,6.0,93.14,242.0,6.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,0,DB01217,__ANASTROZOLE,RE36617,Terminated,NCT00932152,NON-SMALL CELL LUNG CANCER|POSTMENOPAUSAL WOMEN,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",C07D239/26,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,0,DB01249,__IODIXANOL,5366722,Terminated,NCT01188486,LUNG CANCER|LUNG CANCER NON-SMALL CELL CANCER (NSCLC)|LUNG CANCER SMALL CELL LUNG CANCER (SCLC)|MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"Stanford University School of Medicine, Stanford, California, United States",A61K49/0447,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,11.9263229224419,154.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1550.1819,339.09,15.0,13.0,2.0,111.56,277.16,22.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT00787852,NON SMALL CELL LUNG CANCER,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lifespan Hospitals, Providence, Rhode Island, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT01514864,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, S?o Paulo, Sao Paulo, Brazil|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Local Institution, Frankfurt, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Koeln, Germany|Local Institution, Koeln, Germany|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Taipei, Taiwan|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Gwent, United Kingdom",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT00564876,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT00858403,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,0,DB01254,__DASATINIB,6596746,Terminated,NCT01491633,SQUAMOUS CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT01257464,CYSTIC FIBROSIS,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of British Columbia Gerontology & Diabetes Reserach Centre (ViTALITY), Vancouver, British Columbia, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,0,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT00967798,CYSTIC FIBROSIS|PREDIABETES,All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Emory University and Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States|Nationwide Children's Hospital, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,0,DB01329,__CEFOPERAZONE,4427678,Suspended,NCT01601093,RESPIRATORY TRACT INFECTIONS|URINARY TRACT INFECTIONS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"the First Affiliated Hospital With Medical University, Nanjing, Jiangsu, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.3515267253947,889.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.11,645.67,220.26,11.0,4.0,5.0,60.97,169.06,9.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,1,0,1
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,0,DB01394,__COLCHICINE,7619004,Withdrawn,NCT00000577,ASTHMA|LUNG DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of California at San Diego, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|National Jewish Medical & Research Center, Denver, Colorado, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Wisconsin at Madison, Madison, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,0,DB01609,__DEFERASIROX,6465504,Terminated,NCT01892644,HEMOCHROMATOSIS|MYELODYSPLASTIC SYNDROMES,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haukeland University Hospital, Clinical Trial Unit, Bergen, Norway",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,0,DB01645,__GENISTEIN,5213971,Terminated,NCT00590538,CYSTIC FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",C12N15/76,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,0,DB01645,__GENISTEIN,5213971,Withdrawn,NCT00769990,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA|METASTATIC CANCER|PAIN|PROSTATE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12N15/76,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(O)CO,0,DB01839,__PROPYLENE_GLYCOL,,Terminated,NCT02585791,HEALTHY LIFETIME NON-SMOKERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other,"University of Miami School of Medicine, Miami, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00251589,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00503971,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Instituto Universitario Dexeus, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Institut Catalá d'Oncologia, Centre Sanitari i Universitari de Bellvitge (CSUB), Barcelona, Spain|Institut Catalá d'Oncología, Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital La Paz, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00697476,SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Clinico Humanitas, Rozzano, Milan, Italy",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01249443,"HIV INFECTION|RECURRENT ANAL CANCER|RECURRENT BREAST CANCER|RECURRENT ESOPHAGEAL CANCER|RECURRENT GASTRIC CANCER|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE IV ANAL CANCER|STAGE IV BREAST CANCER|STAGE IV ESOPHAGEAL CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01413750,STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Southern Illinois University School of Medicine - Obstetrics and Oncology, Springfield, Illinois, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00662311,STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00473889,STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00126451,BREAST CANCER|COLORECTAL CANCER|NON-SMALL-CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00565227,NON-SMALL-CELL LUNG CARCINOMA|PROSTATE CANCER|BLADDER CANCER|UROTHELIAL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00424775,NEOPLASMS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
NC(=O)c1cccnc1,0,DB02701,__NICOTINAMIDE,3931207,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",C07D207/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB02772,__SUCROSE,,Terminated,NCT00161694,APNEA OF PREMATURITY|RETINOPATHY OF PREMATURITY|PAIN,All,"5 Weeks and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,"NYPH - Weill Cornell Medical Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB02772,__SUCROSE,,Withdrawn,NCT00960921,"HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,0,DB02901,__STANOLONE,4071623,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,20.5014476683299,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,290.4403,37.3,2.0,1.0,4.0,34.69,83.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC(=O)OCC[N+](C)(C)C,0,DB03128,__ACETYLCHOLINE,6261546,Terminated,NCT00327080,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,26.6124561079282,4066.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.9,146.2074,26.3,1.0,0.0,0.0,16.69,51.35,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0
O=C(O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB03156,__BETA-D-GLUCURONIC_ACID,4058621,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.1811946857225,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.3,194.1394,127.45,7.0,5.0,1.0,16.37,35.79,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,0,DB03336,__BIA,,Suspended,NCT03740698,"DIABETES MELLITUS, TYPE 1",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"Imperial College Clinical Research Facility, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O,0,DB03424,__UBENIMEX,4029547,Terminated,NCT02736149,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Heart Center Foundation, An Affiliate of Cedars-Sinai Heart Institute, Cedars-Sinai Medical Care Foundation, Beverly Hills, California, United States|UCSD Medical Center, La Jolla, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Cleveland Clinic, Florida, Weston, Florida, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Chest Medicine Associates, South Portland, Maine, United States|Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic College of Medicine, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Weill Cornell Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Respiratory Institute, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pennsylvania Medical Center, Pittsburgh, Pennsylvania, United States|Alpert Medical School of Brown University Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University Texas Health Science Center, San Antonio, Texas, United States|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",C12P13/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,12.5834206041191,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,308.3728,112.65,5.0,4.0,1.0,33.09,82.05,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0
Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1,0,DB04786,__SURAMIN,4218535,Terminated,NCT01038752,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States",C12Q1/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,20.4028830160783,297.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,1297.28,483.75,23.0,12.0,8.0,120.22,314.9,16.0,1.0,0.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,0,DB04845,__IXABEPILONE,6605599,Terminated,NCT01012362,BREAST CANCER|LUNG CANCER|COLON CANCER|PANCREATIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|SARCOMA|HEPATOCELLULAR CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,62.5556992956734,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,506.7,112.05,6.0,3.0,3.0,56.86,136.71,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,0,DB04845,__IXABEPILONE,6605599,Terminated,NCT01057212,NON-SQUAMOUS NSCLC,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Portland Medical Center, Portland, Oregon, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,62.0,62.5556992956734,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,506.7,112.05,6.0,3.0,3.0,56.86,136.71,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1
C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1,0,DB04845,__IXABEPILONE,6605599,Withdrawn,NCT00998101,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,62.0,62.5556992956734,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.28,506.7,112.05,6.0,3.0,3.0,56.86,136.71,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,0,DB04849,__CEDIRANIB,WO-2001074360-A1,Terminated,NCT00937482,MALE BREAST CANCER|STAGE IV BREAST CANCER|STAGE IV MELANOMA|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV RENAL CELL CANCER|STAGE IVA COLON CANCER|STAGE IVA RECTAL CANCER|STAGE IVB COLON CANCER|STAGE IVB RECTAL CANCER|TUMORS METASTATIC TO BRAIN,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,0,DB04849,__CEDIRANIB,WO-2001074360-A1,Terminated,NCT02899728,EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1,0,DB04849,__CEDIRANIB,WO-2001074360-A1,Terminated,NCT01262612,MALIGNANT ASCITES|MALIGNANT PLEURAL EFFUSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,26.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,450.5053,72.5,5.0,1.0,5.0,48.77,125.16,8.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC,0,DB04851,__BIRICODAR,5620971,Terminated,NCT00003847,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fallon Clinic Inc., Worcester, Massachusetts, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,36.6989055216739,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.54,603.716,117.15,8.0,0.0,4.0,64.13,164.5,16.0,1.0,0.0,0.0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0,DB04868,__NILOTINIB,7169791,Terminated,NCT01179737,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Zurich, Switzerland",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Nc1nc(/C(=N/O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(/C=C4\CCN([C@@H]5CCNC5)C4=O)CS[C@H]23)ns1,0,DB04918,__CEFTOBIPROLE,5981519,Terminated,NCT00771719,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/572,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,65.0,23.0312737427873,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,534.57,203.44,11.0,5.0,5.0,51.22,131.04,6.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1
CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21,0,DB04942,__TAMIBAROTENE,4703110,Terminated,NCT01337154,STAGE IIIB NON-SMALL CELL LUNG CANCER WITH PLEURAL EFFUSION|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Kansas City Cancer Center, Kansas City, Kansas, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Department of Medical Oncology, Specialized Hospital for Active Treatment of Oncological Diseases, Sofia, Bulgaria|Medical Oncology Clinic, Multiprofile Hospital for Active Treatment, Varna, Bulgaria|Department of Medical Oncology, Complex Oncology Center, Veliko Tarnovo, Bulgaria|NIZAM's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|M S Patel Cancer Centre, Shree Krishna Hospital, Anand, Gujarat, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|Dr. Kamakshi Memorial Hospital, Chennai, Pallikaranai, India|G Kuppuswamy Naidu Memorial Hospital, Valvadi Narayanaswamy Cancer Centre, Coimbatore, Pappanaickenpalayam, India|Orchid Nursing Home, Kolkata, West Bengal, India|Instituto Nacional de Cancerologia, Mexico City, Mexico|State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk, Russian Federation|State Therapeutical and Prophylatic Institution: Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|State Medical Instituion Kursk Regional Oncology Center, Kursk, Russian Federation|Non-State Medical Institution: Central Clinical Hospital #2, Moscow, Russian Federation|St. Petersburg State Healthcare Institution: City Clinical Oncology Center, Saint-Pertersburg, Russian Federation|Public Institution: Dnipropetrovsk City Multispeciality Clinical Hospital #4, Dnipropetrovsk, Ukraine|Public Clinical Treatment and Prophylaxis Instituion: Donetsk Regional Antitumor Center, Donetsk, Ukraine|Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine|Public Healthcare Instituion: Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kyiv City Clinical Oncology Center, Kyiv, Ukraine|Zakarpattia Regional Clinical Oncology Center, Uzhhorod, Ukraine",C07C233/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,27.630957514528,59.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,351.4388,66.4,3.0,2.0,3.0,39.16,104.38,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,0,DB04967,__LUCANTHONE,5277912,Withdrawn,NCT02014545,BRAIN METASTASES|NON-SMALL CELL LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",A61K9/0068,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,21.191400234091,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.72,340.48199999999997,32.34,3.0,1.0,3.0,39.6,106.01,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0
CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12,0,DB04967,__LUCANTHONE,5277912,Withdrawn,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0068,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,21.191400234091,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.72,340.48199999999997,32.34,3.0,1.0,3.0,39.6,106.01,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,0,DB04982,__TALAMPANEL,6288057,Terminated,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,77.50467155383059,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.97,337.3725,77.15,5.0,1.0,4.0,36.34,94.65,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1,0,DB04983,__DENUFOSOL,,Terminated,NCT00425165,CYSTIC FIBROSIS,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,773.323,382.6,18.0,9.0,4.0,60.36,145.31,14.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,NCT00093132,"CARCINOMA, NON-SMALL CELL LUNG|LUNG CANCER",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southwestern Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
NC1=NC(=O)N2CC12,0,DB05003,__IMEXON,,Withdrawn,NCT00697060,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Cotton Cancer Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mary Crowley Research Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,111.102,58.46,3.0,1.0,2.0,9.98,25.7,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
NC1=NC(=O)N2CC12,0,DB05003,__IMEXON,,Withdrawn,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,111.102,58.46,3.0,1.0,2.0,9.98,25.7,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT01188707,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept of Oncology Copenhagen University Hospital Herlev, Herlev, Copenhagen, Denmark",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT01090830,NON-SMALL-CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Holy Cross Hospital, Inc, Fort Lauderdale, Florida, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1,0,DB05025,__ARIMOCLOMOL,,Withdrawn,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.45,313.78,70.52,5.0,1.0,2.0,32.93,83.13,6.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1
S=[Mo](=S)([S-])[S-],0,DB05088,__TETRATHIOMOLYBDATE,,Withdrawn,NCT00560495,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.57,224.19,0.0,0.0,0.0,0.0,14.29,37.74,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,DB05109,__TRABECTEDIN,8895557,Terminated,NCT00027508,MALIGNANT MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Industry|NIH,Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,DB05109,__TRABECTEDIN,8895557,Withdrawn,NCT03496519,"SOLID TUMOR, ADULT",All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT02367352,ADVANCED SOLID TUMORS|OVARIAN CANCER|SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chiba, Japan|Shizuoka, Japan|Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,0,DB05239,__COBIMETINIB,7803839,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,0,DB05255,__RONACALERET,7514473,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C217/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,64.3955728043697,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,447.523,78.79,5.0,3.0,3.0,47.78,118.36,11.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,0,DB05294,__VANDETANIB,RE42353,Terminated,NCT00720083,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Winship Cancer Institute of Emory University, Altanta, Georgia, United States|Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States|Cancer Institute at St. John's Hospital, Springfield, Illinois, United States|Saint John's Cancer Center at Saint John's Medical Center, Anderson, Indiana, United States|Methodist Cancer Center at Methodist Hospital, Indianapolis, Indiana, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Charach Cancer Center at Huron Valley - Sinai Hospital, Commerce, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|Saint Elizabeth Cancer Institute at Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States|Memorial Sloan-Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Radiation Oncology Associates, PA, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, Commack, New York, United States|Highland Hospital of Rochester, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Memorial Sloan-Kettering Cancer Center - Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|Barberton Citizens Hospital, Barberton, Ohio, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Lake/University Ireland Cancer Center, Mentor, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Fox Chase Cancer Center Buckingham, Furlong, Pennsylvania, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Sentara Cancer Institute at Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Schiffler Cancer Center at Wheeling Hospital, Wheeling, West Virginia, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee, Milwaukee, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,0,DB05294,__VANDETANIB,RE42353,Withdrawn,NCT00937417,"BREAST CANCER|HEAD AND NECK CANCER|LUNG CANCER|PROSTATE CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,163.518758085381,548.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,475.35400000000004,59.51,6.0,1.0,4.0,47.1,118.63,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Lu+3],0,DB05296,__MOTEXAFIN_LUTETIUM,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,1166.136,178.75,15.0,2.0,5.0,106.08,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,NCT00874497,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UAB Lung Health Center, Birmingham, Alabama, United States|Los Angeles Biomedical Institute, Torrance, California, United States|Pulmonary Disease Specialist/PDS Research, Kissimmee, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Florida Premier Research Institute, Winter Park, Florida, United States|Georgia Clinical Research, Austell, Georgia, United States|Illinios Lung Institute, Peoria, Illinois, United States|University of Louisville, Pulmonary Division, Louisville, Kentucky, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Texas Institute of Chest and Sleep Disorders, PA, Houston, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Pulmonary Associates of Richmond, Richmond, Virginia, United States|Multicare Pulmonary Specialist, Tacoma, Washington, United States",C07D417/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT01777464,HOUSE DUST MITE ALLERGY,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"uz leuven ORL, Leuven, Vlaams Brabant, Belgium",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT00387738,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Center Of Research Excellence, Oxford, Alabama, United States|Atlanta Allergy & Asthma Clinic, Stockbridge, Georgia, United States|Clinical Research of Atlanta, Stockbridge, Georgia, United States|Sneeze, Wheeze, and Itch Associates, Normal, Illinois, United States|Research Center of Indiana, Indianapolis, Indiana, United States|Asthma and Allergy Research Center, Minneapolis, Minnesota, United States|Clinical Research Institute, Plymouth, Minnesota, United States|Clinical Research of the Ozarks, Columbia, Missouri, United States|Clinical Research of The Ozarks, Rolla, Missouri, United States|Clinical Research Center, Saint Louis, Missouri, United States|Clinical Research of the Ozarks, Warrensburg, Missouri, United States|Midwest Allergy & Asthma Clinic, Omaha, Nebraska, United States|Creighton University, Omaha, Nebraska, United States|Asthma & Allergy Center, Papillion, Nebraska, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy & Asthma Center, High Point, North Carolina, United States|Allergy & Respiratory Center, Canton, Ohio, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States|Asthma & Allergy Research Associates, Upland, Pennsylvania, United States|AARA Research Center, Dallas, Texas, United States|Pharmaceutical Research & Consulting, Dallas, Texas, United States|Kerrville Allergy and Asthma Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research, San Antonio, Texas, United States|Asthma, Allergy & Sinus Center, Greenfield, Wisconsin, United States|University of Wisconsin Madison Medical School, Madison, Wisconsin, United States|Advanced Healthcare, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00121420,NEOPLASM METASTASIS|BRAIN NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix, Arizona, United States|Aurora, Colorado, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Sherbrooke, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00080028,HEAD AND NECK CANCER|OROPHARYNX CANCER|LARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States|University of Texas, San Antonio Health Science Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00365183,NON-SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntington Beach, California, United States|Long Beach, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Armonk, New York, United States|Columbus, Ohio, United States|Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00373204,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wilshire Oncology Medical Group, La Verne, California, United States|University of Rochester, Rochester, New York, United States|Tri-County Hematology & Oncology Associates, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Cancer Specialists of Tidewater, Chesapeake, Virginia, United States|Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada|Hospital Charles Lemoyne, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation|Blokhin Cancer Research Center (Dept. of Chemotherapy), Moscow, Russian Federation|Blokhin Cancer Research Center (Dept. of Clinical Pharmacology and Chemotherapy), Moscow, Russian Federation|Central Clinical Hospital, Moscow, Russian Federation|Moscow Oncology Hospital #62, Moscow, Russian Federation|Samara Regional Oncology Center, Samara, Russian Federation|St. Petersburg City Oncology Center, St. Petersburg, Russian Federation|Regional Oncology Dispensary, Yaroslavl, Russian Federation|Clinic for Pulmonary Diseases, Military Medical Academy, Belgrade, Serbia|Clinic for Pulmonary Diseases, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN(C)C(C)=O)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC)[C@@H](C)CC,0,DB05434,__ABT-510,,Terminated,NCT00061646,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology-Hematology Group of South Florida, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|The West Cancer Clinic, Memphis, Tennessee, United States|University of Wisconsin, Madison,, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,994.2317,358.05,14.0,11.0,1.0,107.34,257.8,30.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,1,0
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1,0,DB05460,__EZATIOSTAT,,Terminated,NCT00701870,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Central Hematology Oncology Medical Group, Alhambra, California, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|UCLA Medical Center, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Samsum Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Ormand Beach, Florida, United States|Suburban Hematology-Oncology Associates, PC, Lawrenceville, Georgia, United States|Medical & Surgical Specialists, Galesburg, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Case Medical Center-University Hospitals, Cleveland, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.39,529.648,136.82,5.0,3.0,2.0,57.5,141.82,17.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CS(=O)(=O)O.O=c1[nH]c2c(c3ccccc13)Cc1cc(S(=O)(=O)NCCCN3CCOCC3)ccc1-2,0,DB05549,__INO-1001,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.22,535.63,87.74,5.0,2.0,5.0,47.65,121.05,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,NCT02629848,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,ADVANCED NON-SQUAMOUS NSCLC,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F.O=C(O)/C=C/C(=O)O,0,DB05607,__PRX-08066,,Terminated,NCT00677872,COPD|PULMONARY HYPERTENSION,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Pulmonary and Critical Care Unit, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.19,517.96,64.84,5.0,1.0,4.0,40.92,106.49,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1
Cc1oc(=O)oc1COC(=O)C1=C([C@H]2CCCO2)S[C@@H]2[C@@H]([C@@H](C)O)C(=O)N12,0,DB05659,__FAROPENEM_MEDOXOMIL,US-20050169984-A1,Terminated,NCT00255983,CHRONIC BRONCHITIS,All,"35 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Multicenter, New Hope, Pennsylvania, United States",A61K9/4808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.64,397.4,111.6,6.0,1.0,4.0,38.63,95.39,6.0,0.0,1.0,0.0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Terminated,NCT01515969,"NON-SMALL CELL LUNG CANCER (NSCLC), RECURRENT|NON-SMALL CELL LUNG CANCER (NSCLC), STAGE IV",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,0,DB05943,__RESATORVID,US-20110184034-A1,Terminated,NCT00633477,SEPSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nagasaki, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,361.81,72.47,3.0,1.0,2.0,33.37,85.5,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2,0,DB05983,__BARDOXOLONE_METHYL,US-20130303797-A1,Terminated,NCT02657356,CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|Regents of The University of California, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Pacific Pulmonary Research, Inc., San Diego, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|NYU Langone Health, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|Integris Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fundación Favaloro, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Hospital Británico de Buenos Aires, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Instituto De Enfermedades Respiratorias E Investigacion Medica, Buenos Aires, Villa Vatteone, Argentina|Hospital Cordoba, Cordoba, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Hospital de Alta Complejidad ""Pte. J. D. Perón"", Formosa, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hôpital Erasme, Brussels, Belgium|Hospital de Messejana, Fortaleza, Ceara, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Universitatsklinkum Erlangen, Erlangen, Bayern, Germany|Universität Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Gunma University School of Medicine, Gunma, Japan|Kobe University Hospital, Kobe, Japan|Nagoya Medical Center, Nagoya, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Fujita Health University Hospital, Toyoake, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Nuevo Leon, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Angeles University Foundation Medical Center (AUFMC), Angeles City, Philippines|Mary Mediatrix Medical Center (MMMC), Lipa, Philippines|Makati Medical Center (MMC), Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Philippine Heart Center (PHC), Quezon City, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",C07J75/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.2676440994681,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.29,505.699,84.23,4.0,0.0,5.0,58.23,144.36,2.0,1.0,0.0,0.0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O,0,DB05992,__PLINABULIN,,Terminated,NCT02846792,ALK GENE TRANSLOCATION|EGFR ACTIVATING MUTATION|RECURRENT NON-SMALL CELL LUNG CARCINOMA|ROS1 GENE TRANSLOCATION|STAGE IIIB NON-SMALL CELL LUNG CANCER AJCC V7|STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.12,336.395,86.88,3.0,3.0,3.0,37.16,98.02,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,0,DB06013,__ALDOXORUBICIN,,Withdrawn,NCT03574649,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,750.758,267.84,15.0,7.0,6.0,75.89,189.86,12.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0
CC(C)CCCCCCC/C=C\CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@@H]([C@H](C)C(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H]([C@@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H]1C,0,DB06087,__FRIULIMICIN_B,,Terminated,NCT00492271,COMMUNITY ACQUIRED PNEUMONIA|STAPHYLOCOCCAL SKIN INFECTIONS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Swiss Pharma Contract Ltd, Basel, Switzerland",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.5,1303.48,512.63,20.0,15.0,3.0,134.16,321.78,23.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,NCT00435578,"CARCINOMA, SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Cancer Center, Greenbrae, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",C07C291/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C291/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,,SMALL CELL LUNG CANCER (SCLC),,,,,"FISABIO, Elche, Alicante, Spain",C07C291/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,DB06182,__TALABOSTAT,,Terminated,NCT00243204,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Marshall Schreeder, MD, Huntsville, Alabama, United States|James P. Daugherty, MD, Muscle Shoals, Alabama, United States|Alaska Cancer Research, Anchorage, Alaska, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Veena Charu, MD, Anaheim, California, United States|Lalita Pandit, MD, Inc, Fountain Valley, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Warren Paroly, MD, Oceanside, California, United States|Swarna S. Chanduri, MD, Pomona, California, United States|Southwest Cancer Care Medical Group, Poway, California, United States|Mile High Oncology, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Pasco Hernando Oncology Associates PA, Brooksville, Florida, United States|Lucio Gordan, MD, Gainesville, Florida, United States|Citrus Hematology and Oncology Center, Inverness, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Jorge G. Otoya, MD, Kissimmee, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Joliet Oncology Hematology Associates, Joliet, Illinois, United States|Indiana Hematology Oncology Consultants, Indianapolis, Indiana, United States|Northern Indiana Oncology Associates, South Bend, Indiana, United States|Kansas City Cancer Centers, Southwest, Overland Park, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Medical Oncology, LLC, Baton Rouge, Louisiana, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Chesapeake Oncology Hematology Associates (Tate Center), Glen Burnie, Maryland, United States|Josephine Ford Cancer Center -- Downriver, Brownstown, Michigan, United States|Michael McKenzie, DO, Clinton Township, Michigan, United States|Henry Ford Medical Center -- Fairlane, Dearborn, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Youssef Hanna, MD, Port Huron, Michigan, United States|Cancer and Transplant Consultants, PLC, Rochester Hills, Michigan, United States|Cancer Care Associates, Rochester Hills, Michigan, United States|Cancer Care Associates, PC, Royal Oak, Michigan, United States|Hematology Oncology Consultants, Royal Oak, Michigan, United States|Jeffrey H. Margolis, MD, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Hematology and Oncology Institute, Southgate, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|Mitchell Folbe, MD, PC, Troy, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Henry Ford Medical Center, West Bloomfield, Michigan, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Arch Medical Services, Inc., St. Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|George A. Zervos, MD, Glen Head, New York, United States|Northwestern Carolina Oncology Hematology, Hickory, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|Dayton Hematology and Oncology, Kettering, Ohio, United States|Mukesh C. Bhatt, MD, Medina, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Northwest Cancer Specialists, Northrup, Portland, Oregon, United States|Shatish A. Shah, MD, Gettysburg, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Rittenhouse Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|Chester County Hematology / Oncology Services, West Chester, Pennsylvania, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|Palmetto Hematology Oncology, PC, Spartanburg, South Carolina, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Cancer Center / Denton, Denton, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology, PA, Ft. Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Ft. Worth, Texas, United States|Texas Cancer Center of Mesquite, Mesquite, Texas, United States|Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Oncology Cancer Center--Sugar Land, Sugar Land, Texas, United States|Annandale-Fairfax Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|Peninsula Cancer Institute, Gloucester, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Peninsula Cancer Institute, Williamsburg, Virginia, United States|Masoom Kandahari, MD, PC, Woodbridge, Virginia, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Jay L. Wittenkeller, MD, Spokane, Washington, United States|Cancer Care Northwest Research, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,214.07,86.79,4.0,3.0,1.0,23.37,52.34,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,DB06182,__TALABOSTAT,,Terminated,NCT00290017,"CARCINOMA, NON-SMALL-CELL LUNG|LUNG CANCER|NEOPLASMS, LUNG|NEOPLASMS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Marshall Schreeder, MD, Huntsville, Alabama, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Heritage Physician Group-Oncology, Hot Springs, Arkansas, United States|Raul R. Mena, MD, Burbank, California, United States|Pacific Coast Hematology / Oncology Medical Group, Inc., Fountain Valley, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Antelope Valley Cancer Center, Lancaster, California, United States|Warren Paroly, MD, Oceanside, California, United States|Southwest Cancer Care Medical Group, Poway, California, United States|Mile High Oncology, Denver, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Northwestern Connecticut Oncology Hematology Associates, LLP, Torrington, Connecticut, United States|Lucio Gordan, MD, Gainesville, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|North Idaho Cancer Center, Coeur d'Alene, Idaho, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|American Health Network of Indiana--Hematology/Oncology, Indianapolis, Indiana, United States|Arnett Cancer Center, Lafayette, Indiana, United States|Northern Indiana Oncology Associates, South Bend, Indiana, United States|Associated Physicians and Surgeons, LLC, Terre Haute, Indiana, United States|HUX Cancer Center/Union Hospital, Terre Haute, Indiana, United States|Kansas City Cancer Center, LLC, Overland Park, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Chesapeake Oncology Hematology Associates (Tate Center), Glen Burnie, Maryland, United States|Carroll County Cancer Center, Westminster, Maryland, United States|Fallon Clinic, Inc. at Worcester Medical Center, Worcester, Massachusetts, United States|Michael McKenzie, DO, Clinton Township, Michigan, United States|Youssef Hanna, MD, Port Huron, Michigan, United States|Cancer and Transplant Consultants, PLC, Rochester Hills, Michigan, United States|Cancer Care Associates, Rochester Hills, Michigan, United States|Cancer Care Associates, PC, Royal Oak, Michigan, United States|Hematology Oncology Consultants, Royal Oak, Michigan, United States|Jeffrey H. Margolis, MD, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Dr. Folbe, MD/PC, Troy, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Minnesota Oncology Hematology, PA, Burnsville, Minnesota, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Hunterdon Regional Cancer Center, Flemington, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Hematology Oncology Associates, SJ, PA, Mount Holly, New Jersey, United States|Capital Health System, Trenton, New Jersey, United States|Mercer Bucks Oncology/Hematology, Trenton, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|Northwestern Carolina Oncology & Hematology, PA, Hickory, North Carolina, United States|Eugene Paschold, MD, Winston Salem, North Carolina, United States|Piedmont Hematology Oncology / Winston-Salem, Winston-Salem, North Carolina, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|Dayton Oncology & Hematology, PA, Kettering, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Satish A. Shah, MD, Gettysburg, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Hematology-Oncology Group, PC, Langhorne, Pennsylvania, United States|St. Mary Medical Center--Research Center, Langhorne, Pennsylvania, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Rittenhouse Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|Pottstown Memorial Medical Center, Pottstown, Pennsylvania, United States|Bux-Mont Oncology-Hematology, Sellersville, Pennsylvania, United States|Grandview Hospital, Sellersville, Pennsylvania, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|Palmetto Hematology Oncology PC, Spartanburg, South Carolina, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|McLeod Cancer and Blood Center, Johnson City, Tennessee, United States|University of Tennessee, Knoxville, Tennessee, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Cancer Center / Denton, Denton, Texas, United States|El Paso Cancer Treatment Center--East, El Paso, Texas, United States|Texas Oncology, PA, El Paso, Texas, United States|Texas Oncology, PA, Ft. Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Ft. Worth, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Texas Oncology, PA, Mesquite, Texas, United States|Texas Oncology, PA / Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Oncology Cancer Center--Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Cancer Outreach Associates, PC / Outreach Clinical Trial Consortium LLC, Abingdon, Virginia, United States|Fairfax Northern Virginia Hematology / Oncology, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Physicians, Inc., Richmond, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Salem, Virginia, United States|Luke Walker, MD, Everett, Washington, United States|Cascade Cancer Center, Kirkland, Washington, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Medical Consultants, Ltd., Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,214.07,86.79,4.0,3.0,1.0,23.37,52.34,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,DB06182,__TALABOSTAT,,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,214.07,86.79,4.0,3.0,1.0,23.37,52.34,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Terminated,NCT00372073,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Arizona Cancer Center, Tucson, Arizona, United States|Pacific Coast Hematology Oncology Group, Fountain Valley, California, United States|Pasco Hernando Oncology, New Port Richey, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Maryland, Greenebaun Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Columbia Presbyterian Medical Center, New York, New York, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburg Cancer Institute, Pittsburgh, Pennsylvania, United States|The Family Cancer Center, Collierville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Center for Oncology Research and Treatment, Dallas, Texas, United States|East Texas Medical Center, Tyler, Texas, United States|Danville Hematology Oncology, Danville, Virginia, United States",A61P17/00 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Terminated,,CYSTIC FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06233,__RIDAFOROLIMUS,,Terminated,NCT01212627,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"memorial Hospital of Rhode island, Pawtucket, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,990.222,201.5,12.0,2.0,4.0,107.25,267.98,8.0,1.0,0.0,0.0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2,0,DB06240,__TARIQUIDAR,WO-2005013947-A2,Terminated,NCT00042302,STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Masking: Double,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,646.744,111.25,8.0,2.0,6.0,70.07,188.12,11.0,1.0,0.0,0.0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O,0,DB06263,__AMRUBICIN,4673668,Terminated,NCT01904253,SMALL CELL LUNG CANCER (SCLC),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Baden-Württemberg, Germany|Lungenklinik Heckeshorn- HELIOS Kliniken GmbH, Berlin, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Germany|Klinikum Koeln-Merheim, Koplin, Germany|St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz, Mainz, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Turin, Italy|IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A, Aviano, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico, Catania, Italy|Azienda Ospedaliera Instituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera San Gerardo U.O Oncologia Medica, Monza, Italy|Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|A.O.V.V. Ospedale Eugenio Morelli-Sondalo, Sondalo, Italy|National Cancer Center Hospital East, Chiba, Japan|National Kyushi Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Hyogo, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Nippon Medical School Hospital, Tokyo, Japan|Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,26.185342614838,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.4,483.473,176.61,10.0,5.0,5.0,48.75,122.01,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O,0,DB06263,__AMRUBICIN,4673668,Terminated,NCT00286169,SMALL-CELL LUNG CANCER,All,70 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region Site, Chubu, Japan|Chugoku Region Site, Chugoku, Japan|Hokkaido Region Site, Hokkaido, Japan|Kanto Region Site, Kanto, Japan|Kinki Region Site, Kinki, Japan|Kyushu Region Site, Kyushu, Japan|Shikoku Region Site, Shikoku, Japan|Tohoku Region Site, Tohoku, Japan",C07D413/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,26.185342614838,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.4,483.473,176.61,10.0,5.0,5.0,48.75,122.01,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,0,DB06268,__SITAXENTAN,,Terminated,NCT01204853,"HYPERTENSION, PULMONARY",All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Shinjyuku-ku, Tokyo, Japan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,454.905,107.73,6.0,1.0,4.0,43.12,105.8,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,0,DB06268,__SITAXENTAN,,Terminated,NCT01050491,EFFECT OF SITAXSENTAN ON AIRWAY REMODELING IN SEVERE ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Clinical Investigation center 07, Hopital Bichat, Paris, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,454.905,107.73,6.0,1.0,4.0,43.12,105.8,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06287,__TEMSIROLIMUS,5362718,Terminated,NCT02423954,ADVANCED CANCER|PANCREATIC CANCER|RENAL CELL CANCER|NON SMALL CELL LUNG CANCER|COLORECTAL CARCINOMA|ENDOMETRIAL|UTERINE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB06287,__TEMSIROLIMUS,5362718,Terminated,NCT00921310,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,0,DB06309,__REFAMETINIB,US-20090082457-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,19.7786402184849,30.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.11,572.337,107.89,6.0,4.0,3.0,46.34,116.29,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCNCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06333,__TRODUSQUEMINE,,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,685.07,145.94,8.0,6.0,4.0,84.8,192.01,20.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
COc1cc(Cc2cnc(N)nc2N)c2c(c1OC)OC(C1CC1)C=C2,0,DB06358,__ICLAPRIM,5773446,Terminated,NCT00543608,HOSPITAL-ACQUIRED PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA|HEALTH-CARE-ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D239/49,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,18.8915583482207,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,354.41,105.51,7.0,2.0,4.0,37.53,101.99,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,NCT00084487,EXTENSIVE STAGE SMALL CELL LUNG CANCER|LIMITED STAGE SMALL CELL LUNG CANCER|RECURRENT SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,,EXTENSIVE STAGE SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,0,DB06365,__SAPACITABINE,US-20050014716-A1,Terminated,NCT00885963,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush University Medical Center, Chicago, Illinois, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,0,DB06370,__INDISULAM,6060498,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.4357379001622,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.21,385.846,122.12,4.0,3.0,3.0,35.23,90.94,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,0,DB06448,__LONAFARNIB,WO-2004022559-A1,Terminated,NCT00288444,LUNG CANCER|SOFT TISSUE SARCOMA|COLORECTAL CARCINOMA|BREAST CANCER|PROSTATE CANCER,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University Winship Cancer Institute, Atlanta, Georgia, United States",A61P19/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.34,638.822,79.53,3.0,1.0,5.0,60.09,149.31,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,0,DB06448,__LONAFARNIB,WO-2004022559-A1,Terminated,NCT00539968,PROSTATE CANCER|BREAST CANCER|OVARIAN CANCER|LUNG CANCER|GASTRIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61P19/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.34,638.822,79.53,3.0,1.0,5.0,60.09,149.31,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1,0,DB06448,__LONAFARNIB,WO-2004022559-A1,Terminated,NCT00050336,"CARCINOMA, NON-SMALL-CELL LUNG|METASTASES, NEOPLASM",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,A61P19/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.34,638.822,79.53,3.0,1.0,5.0,60.09,149.31,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1
Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,0,DB06486,__ENZASTAURIN,EP-0817627-B1,Withdrawn,NCT00469976,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Masking: None (Open Label)|Primary Purpose: Treatment,,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,122.811556705476,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,515.617,72.16,4.0,1.0,7.0,56.74,151.61,5.0,0.0,1.0,0.0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1,0,DB06532,__PAFURAMIDINE,WO-2005086754-A2,Terminated,NCT00302341,"PNEUMONIA, INTERSTITIAL PLASMA CELL|PNEUMOCYSTIS CARINII PNEUMONIA|PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California, San Francisco, California, United States|The University of Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|NYU School of Medicine, New York, New York, United States|UNC AIDS Clinical Trials, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Medical University of SC, Charleston, South Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,32.7488,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.65,364.405,103.36,6.0,4.0,3.0,40.58,145.42,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/65,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=c1[nH]oc2c1CCNC2,0,DB06554,__GABOXADOL,4278676,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,36.8303250580094,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,140.1399,50.36,3.0,2.0,2.0,13.31,35.5,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO,0,DB06558,__TEZOSENTAN,6004965,Terminated,NCT00458276,"HEART DISEASES|HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University School of Medicine, Stanford, California, United States|Columbia University Medical Center, New York, New York, United States|Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Baylor University Medical Center, Dallas, Texas, United States|Texas Heart Institute/St. Luke's Episcopal Hospital/Baylor College, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Medical University of Innsbruck, Innsbruck, Austria|AKH University of Vienna, Vienna, Austria|University of Alberta Hospital, Edmonton, Alberta, Canada|London Health Sciences Centre-University Hospital, London, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|Quebec Heart Institute/Hopital Laval, Quebec, Canada|Institute for Clinical and Experimental Medicine (IKEM), Prague, Czechia|Hopital Pitie Salpetriere, Paris, France|Deutches Herzzentrum, Berlin, Germany|Dresden Universitatsklinik/Cardiology Center, Dresden, Germany|Zentrum der Chirugie-Zchir-des Universitatsklinikums, Frankfurt, Germany|Narayana Hrudayalaya, Bangalore, India|Nizam's Institute of Medical Sciences, Hyderabaad, India|Shaare Zedek Medical Center, Jerusalem, Israel|Fondazione IRCCS San Matteo Hospital, Cardiac Surgery, Pavia, Italy|Azienda Sanitaria Ospedaliera ""San Giovanni Battista"", Cardiac Surgery Division, Torino, Italy|Medical University of Silesia, 2nd Dept of Cardiac Surgery, Katowice, Poland|Klinika Chirurgii Serca, Naczyn I Transplantologii, Szpital Jana Pawla II, Krakow, Poland|Dedinje Cardiovascular Institute, Belgrade, Serbia|National Institute of Cardiovascular Diseases, Clinic of Heart Surgery, Bratislava, Slovakia|Sahlgrenska University Hospital, Goteborg, Sweden|Papworth Hospital, Cambridge, United Kingdom|Northern General Hospital, Sheffield, United Kingdom",C07D403/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,86.0,28.1894905439536,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,605.625,200.11,12.0,3.0,5.0,61.25,178.23,11.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nn[nH]n3)c2)nc1OCCO,0,DB06558,__TEZOSENTAN,6004965,Terminated,NCT01077297,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States|Baylor College of Medicine, Houston, Texas, United States|Hopital Antoine Béclère, Paris, Clamart, France|University Hospital of Basel, Clinic of Pneumology, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland",C07D403/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,86.0,28.1894905439536,148.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,605.625,200.11,12.0,3.0,5.0,61.25,178.23,11.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01208064,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitair Ziekenhuis Gent, Gent, Belgium|Centre Hospitalier Regional De La Citadelle, Liege, Belgium|Clinique et Maternité Sainte Elisabeth, Namur, Belgium|National Cancer Institute, Cairo, Egypt|Centre Georges-Francois-Leclerc, Dijon, France|Assistance Publique - Hôpitaux de Marseille - Assistance Publique - Hôpitaux de Marseille - Hopital Nord, Marseille, France|Klinik Loewenstein, Loewenstein, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|University General Hospital Heraklion, Heraklion, Greece|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Isala Klinieken, Zwolle, Netherlands|University Clinic Golnik, Golnik, Slovenia|Royal Marsden - Surrey, Sutton, England, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Guy's and St Thomas' NHS, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|King's Mill Hospital, Sutton-in-Ashfield, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01012362,BREAST CANCER|LUNG CANCER|COLON CANCER|PANCREATIC CANCER|HEAD AND NECK CANCER|KIDNEY CANCER|SARCOMA|HEPATOCELLULAR CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01313663,"LUNG CANCER, SMALL CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Ames, Iowa, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Pikeville, Kentucky, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Latham, New York, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Fargo, North Dakota, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Bedford, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Garland, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Mesquite, Texas, United States|GSK Investigational Site, San Marcos, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Everett, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01060514,METASTATIC NON SMALL CELL LUNG CANCER|METASTATIC BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01392352,RENAL CELL CARCINOMA|SOFT TISSUE SARCOMA|GLIOBLASTOMA|OVARIAN CANCER|CERVICAL CANCER|BREAST CANCER|NON-SMALL CELL LUNG CANCER|SMALL CELL LUNG CANCER|PANCREATIC CANCER|MELANOMA|GASTROINTESTINAL CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT02193152,"CARCINOMA, NON-SMALL CELL LUNG|NON-SMALL CELL LUNG CANCER|NONSMALL CELL LUNG CANCER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT01049776,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Illinois CancerCare, P.C., Bloomington, Illinois, United States|Illinois CancerCare, P.C., Canton, Illinois, United States|Illinois CancerCare, P.C., Carthage, Illinois, United States|Illinois CancerCare, P.C., Eureka, Illinois, United States|Illinois CancerCare, P.C., Galesburg, Illinois, United States|Illinois CancerCare, P.C., Macomb, Illinois, United States|Illinois CancerCare, P.C., Monmouth, Illinois, United States|Illinois CancerCare, P.C., Normal, Illinois, United States|Illinois CancerCare, P.C., Ottawa, Illinois, United States|Illinois CancerCare, P.C., Pekin, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Illinois CancerCare, P.C., Peru, Illinois, United States|Illinois CancerCare, P.C., Princeton, Illinois, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,0,DB06589,__PAZOPANIB,7105530,Terminated,NCT00549328,"LUNG CANCER, NON-SMALL CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Duluth, Minnesota, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Sayre, Pennsylvania, United States|GSK Investigational Site, Corpus Christi, Texas, United States|GSK Investigational Site, Newport News, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,0,DB06603,__PANOBINOSTAT,6552065,Withdrawn,NCT01160731,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,0,DB06603,__PANOBINOSTAT,6552065,Withdrawn,NCT03982134,MELANOMA|NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1
CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1,0,DB06634,__CASOPITANT,WO-2004091616-A1,Withdrawn,NCT00891761,CANCER|CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING|NAUSEA AND VOMITING|SOLID TUMOR CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,"GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Robbinsdale, Minnesota, United States|GSK Investigational Site, Sherbrooke, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.73,616.625,47.1,3.0,0.0,4.0,57.87,149.02,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,0,DB06641,__PERIFOSINE,EP-1135193-B1,Terminated,NCT00062387,HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|LaGrange Memorial Hospital, LaGrange, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Oncology Care Associates, P.L.L.C., Saint Joseph, Michigan, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,34.7933222448099,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.82,461.668,58.59,2.0,0.0,1.0,58.14,142.15,20.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2nc(=O)n(P(=O)(O)O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB06717,__FOSAPREPITANT,5691336,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,26.5796012238444,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.89,614.4066,123.93,9.0,3.0,4.0,49.92,138.63,9.0,0.0,1.0,0.0,0,1,1,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1
[Al+3].[OH-].[OH-].[OH-],0,DB06723,__ALUMINUM_HYDROXIDE,,Withdrawn,NCT00533741,CORONAVIRUS (SARS-COV),All,18 Years to 40 Years   (Adult),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.45,78.0036,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Al+3].[OH-].[OH-].[OH-],0,DB06723,__ALUMINUM_HYDROXIDE,,Withdrawn,NCT01376765,SARS,All,18 Years to 40 Years   (Adult),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.45,78.0036,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,0,DB07101,__PD-0325901,WO-2002006213-A2,Terminated,NCT00174369,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Greenbrae, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, LaJolla, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Mateo, California, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Coon Rapids, Minnesota, United States|Pfizer Investigational Site, Fridley, Minnesota, United States|Pfizer Investigational Site, Robbinsdale, Minnesota, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States",A61P17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,73.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.64,482.19300000000004,90.82,5.0,4.0,2.0,37.56,96.14,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0
O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F,0,DB07101,__PD-0325901,WO-2002006213-A2,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,73.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.64,482.19300000000004,90.82,5.0,4.0,2.0,37.56,96.14,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Terminated,NCT01282333,ADVANCED ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|REGIONAL TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|STAGE III BLADDER CANCER|STAGE III PANCREATIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV BLADDER CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV PANCREATIC CANCER|TRANSITIONAL CELL CARCINOMA OF THE BLADDER|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
C[C@]1(c2nc3cccc(C(N)=O)c3[nH]2)CCCN1,0,DB07232,__VELIPARIB,US-20060229289-A1,Terminated,NCT02412371,NON-SMALL CELL LUNG CANCER STAGE III,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ucsd /Id# 133037, La Jolla, California, United States|Christiana Care Health Service /ID# 133486, Newark, Delaware, United States|University of Chicago /ID# 133828, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States|Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States|SUNY Upstate Medical University - Downtown /ID# 133492, Syracuse, New York, United States|Unc /Id# 133496, Chapel Hill, North Carolina, United States|Duke University Medical Center /ID# 133497, Durham, North Carolina, United States|Wake Forest Univ HS /ID# 134608, Winston-Salem, North Carolina, United States|Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States|The Miriam Hospital /ID# 133910, Providence, Rhode Island, United States|University of Virginia /ID# 133495, Charlottesville, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,38.40735949403471,48.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.1,244.2923,83.8,3.0,3.0,3.0,26.31,68.62,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,0,DB08079,__AMG-208,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,383.4027,74.43,6.0,0.0,5.0,40.72,119.54,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1,0,DB08486,__EFAPROXIRAL,5122539,Withdrawn,NCT00055887,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|North Idaho Cancer Center, Coeur d'Alene, Idaho, United States|Cancer Center at Lexington Clinic, Lexington, Kentucky, United States|Willis - Knighton Cancer Center, Shreveport, Louisiana, United States|St. Agnes Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Providence Everett Medical Center - Pacific Campus, Everett, Washington, United States|Schiffler Cancer Center, Wheeling, West Virginia, United States|Algemeen Ziekenhuis Middelheim, Antwerp, Belgium|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Hopital Notre- Dame du CHUM, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel",C07C271/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,12.9119694449578,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.12,341.4009,75.63,4.0,2.0,2.0,37.38,97.48,6.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
NCCc1c[nH]c2ccccc12,0,DB08653,__TRYPTAMINE,3930948,Terminated,,QUALITY OF LIFE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.21,160.2157,41.81,1.0,2.0,2.0,18.34,50.37,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Withdrawn,NCT02168530,IDIOPATHIC PULMONARY FIBROSIS,All,"40 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,0,DB08834,__TAUROURSODEOXYCHOLIC_ACID,5260074,Terminated,NCT03878654,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vermont Lung Center, Colchester, Vermont, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,16.591716462350302,243.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.38,499.71,123.93,6.0,4.0,4.0,56.75,130.68,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,0,DB08842,__ACETYLCARNITINE,4268524,Terminated,NCT01379976,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Istituto Oncologico del Mediterraneo, Viagrande, CT, Italy|Azienda Ospedaliera Ospedale S. Anna, Como, Italy|Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy|Azienda Ospedaliera di Desio e Vimercate - Presidio Ospedaliero di Desio, Desio, Italy|Ospedale Civile, Guastalla, Italy|Ospedale Alessandro Manzoni, Lecco, Italy|Azienda Ospedaliera Ospedale Civile di Legnano, Legnano, Italy|Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milano, Italy|Istituto Europeo Di Oncologia, Milano, Italy|Azienda Ospedaliera San Paolo, Milano, Italy|Azienda Ospedaliera Ospedale San Carlo Borromeo, Milano, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Azienda Ospedaliera Perugia, Perugia, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|IRCCS di Reggio Emilia, Reggio Emilia, Italy|Azienda Ospedaliera Busto Arsizio - Presidio Ospedaliero di Saronno, Saronno, Italy|Ospedale SS Annunziata - ASL1, Sassari, Italy|Azienda Ospedaliera Valtellina e Valchiavenna , Presidio Ospedaliero di Sondrio, Sondrio, Italy|Azienda Ospedaliera di Pavia, Ospedale Civile di Vigevano, Vigevano, Italy|Azienda Ospedaliera di Desio e Vimercate - Presidio Ospedaliero di Vimercate, Vimercate, Italy",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,10.5464177909197,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.4,203.238,66.43,3.0,0.0,0.0,20.89,72.64,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,0,DB08869,__TESAMORELIN,5861379,Terminated,NCT01388920,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,0,DB08869,__TESAMORELIN,5861379,Withdrawn,NCT01788462,LIPODYSTROPHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Johns Hopkins Sleep Disorders Center, Baltimore, Maryland, United States",C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,0,DB08875,__CABOZANTINIB,7579473,Terminated,NCT02132598,NON SMALL CELL LUNG CANCER (NSCLC)|METASTASES TO THE BRAIN,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,0,DB08877,__RUXOLITINIB,7598257,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,0,DB08877,__RUXOLITINIB,7598257,Terminated,NCT02119650,NSCLC (NON-SMALL CELL LUNG CARCINOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix, Arizona, United States|Fayetteville, Arkansas, United States|Fresno, California, United States|La Jolla, California, United States|San Diego, California, United States|San Francisco, California, United States|Lone Tree, Colorado, United States|Norwich, Connecticut, United States|Southington, Connecticut, United States|Augusta, Georgia, United States|Joliet, Illinois, United States|Indianapolis, Indiana, United States|Lafayette, Indiana, United States|Kansas City, Kansas, United States|Detroit, Michigan, United States|Saint Louis, Missouri, United States|Reno, Nevada, United States|Lebanon, New Hampshire, United States|Mount Kisco, New York, United States|New York, New York, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Portland, Oregon, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Ogden, Utah, United States|Leesburg, Virginia, United States|Kennewick, Washington, United States|Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1,0,DB08896,__REGORAFENIB,7351834,Terminated,NCT01187615,SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New Haven, Connecticut, United States|Las Vegas, Nevada, United States|New York, New York, United States|Chapel Hill, North Carolina, United States",C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,98.630362019754,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.53,482.815,92.35,3.0,3.0,3.0,41.23,114.73,6.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Terminated,NCT01761747,"NON-SMALL CELL LUNG CANCER, HEAD AND NECK CANCER",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,0,DB08903,__BEDAQUILINE,7498343,Withdrawn,,MULTI-DRUG RESISTANT TUBERCULOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,50.79365079365071,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.37,555.505,45.59,4.0,1.0,5.0,57.29,154.02,8.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0
COC(=O)/C=C/C(=O)OC,0,DB08908,__DIMETHYL_FUMARATE,6509376,Terminated,NCT02981082,SYSTEMIC SCLEROSIS|PULMONARY; HYPERTENSION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","National Jewish, Denver, Colorado, United States|John Hopkins, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT00537511,"CARCINOMA, SMALL CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States|Pennsylvania State University, Hershey, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Juranvinski Cancer Center - Medical Oncology, Hamilton, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Mc Gill University - Department of Oncology - Clinical Research Program, Montreal, Quebec, Canada",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Terminated,NCT01559129,"SCLERODERMA, SYSTEMIC|SCLEROSIS, SYSTEMIC|SYSTEMIC SCLERODERMA|SYSTEMIC SCLEROSIS|INTERSTITIAL LUNG DISEASE",All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCLA Division of Rheumatology, Los Angeles, California, United States|Advances in Medicine, Rancho Mirage, California, United States|Delaware Medical Care Associates, LLC, Newark, Delaware, United States|Georgetown University School of Medicine, Washington, District of Columbia, United States|USF Health Faculty Office Building-FOB, Tampa, Florida, United States|Arthritis Research and Treatment Center, Stockbridge, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|LaPorte County Institute for Clinical Research, Inc, Michigan City, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Louisiana State University, Shreveport, Louisiana, United States|Boston University of Medicine BUMC, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|UMDNJ-Robert Wood Johnson Medical School Clinical Research Center, New Brunswick, New Jersey, United States|North Shore-LIJ Health System-Division of Rheumatology, Great Neck, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Toledo College of Medicine, Toledo, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Monash Medical Centre, Clayton, Victoria, Australia|The Prince Charles Hospital, Chermside, Australia|The Queen Elizabeth Hospital, Woodville South, Australia|CHRU de Lille FR, Lille, France|Hopital Saint Louis, Paris, France|Groupe Hospitalier Saint Vincent de Paul, Paris, France|Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|University of Erlangen-Nuremberg, Erlangen, Germany|Klinikum der J.W. Gothe-Universitat Frankfurt, Frankfurt, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|University Hospital of Ulm, Ulm, Germany|Azienda Ospedaliera Universitaria S. Martino di Genova, Genova, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Policlinico Umberto I, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Centrum Miriada Prywatny Gabinet Specjalistyczny Profesora Dra Stanislawa Sierakowskiego, Bialystok, Poland|Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|SPSK Nr 7 Slaskiego Uniwersytetu Medycznego, Oddzial Chorob Wewnetrznych i Reumatologii, Katowice, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 im. prof.Tadeusza Sokolowskiego Pomorskiego UM w Szczec, Szczecin, Poland|Instytut Reumatologii, Klinika i Poliklinika Ukladowych Chorób Tkanki Lacznej, Warszawa, Poland|Akademicki Szpital Kliniczny Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Institution of the Russian Academy of Medical Sciences Research Institute of Rheumatology of the Ru, Moscow, Russian Federation|Penza Regional Clinical Hospital n.a. N.N. Burdenko, Penza, Russian Federation|St. Petersburg State Healthcare Institution ""Clinical Rheumatology Hospital # 25"", St. Petersburg, Russian Federation|Hospital Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario de Santiago, Santiago de Compostela, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Chapel Allerton Hospital, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Brompton Hospital - Interstitial Lung Disease Unit, London, United Kingdom",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,0,DB08910,__POMALIDOMIDE,5635517,Withdrawn,NCT01135199,PULMONARY FIBROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,10.3164336023326,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.02,273.2441,109.57,5.0,2.0,3.0,25.81,69.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,0,DB09053,__IBRUTINIB,7514444,Withdrawn,NCT02950038,"LUNG CANCER, NONSMALL CELL, STAGE I",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,DB09073,__PALBOCICLIB,6936612,Terminated,NCT02349633,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Medical Center - La Jolla, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center - Hillcrest, San Diego, California, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Prince Charles Hospital, Cancer Care Services, Chermside, Queensland, Australia|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital / Department of Internal Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,0,DB09074,__OLAPARIB,7151102,Terminated,NCT02899728,EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,0,DB09074,__OLAPARIB,7151102,Terminated,NCT03251872,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"IUCPQ-UL, Quebec City, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],0,DB09146,__IRON_SUCROSE,6174442,Withdrawn,NCT00960921,"HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Institute of Molecular Biology and Medicine, Bishkek, Kyrgyzstan",A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
NC(=O)CN1CCCC1=O,0,DB09210,__PIRACETAM,4115579,Withdrawn,,POSTPOLIOMYELITIS SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.006386168093801,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.6,142.1558,63.4,2.0,1.0,1.0,13.96,35.06,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)c1ccc2nc3ccc(N(C)C)cc3[s+]c2c1.[Cl-],0,DB09241,__METHYLENE_BLUE,3933788,Terminated,NCT00159510,SEPSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital #1, Arkhangelsk, Russia, Russian Federation",C12P21/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,30.817881270662603,2914.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,319.85,19.37,3.0,0.0,3.0,33.1,86.98,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,0,DB09308,__SOLITHROMYCIN,,Terminated,NCT02605122,COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA,All,2 Months to 17 Years   (Child),Industry|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Little Rock, Arkansas, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Washington, District of Columbia, United States|Tampa, Florida, United States|Louisville, Kentucky, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Memphis, Tennessee, United States|Amarillo, Texas, United States|Houston, Texas, United States|Splendora, Texas, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Vratsa, Bulgaria|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Cegléd, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Mosdós, Hungary|Nagykanizsa, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Torokbalint, Hungary|Veszprém, Hungary|Caloocan City, Philippines|Cebu City, Philippines|Davao City, Philippines|Iloilo, Philippines|Manila, Philippines|Muntinlupa, Philippines|Quezon City, Philippines|Quezon City, Philippines|Esplugues de Llobregat, Barcelona, Spain|San Sebastian, Guipuzcoa, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|London, United Kingdom|London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,845.0088,197.87,12.0,2.0,5.0,90.81,230.73,11.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,0,DB09308,__SOLITHROMYCIN,,Terminated,NCT02628769,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"45 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Muscle Lab, Respiratory Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,845.0088,197.87,12.0,2.0,5.0,90.81,230.73,11.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1
[133Xe],0,DB09315,__XENON-133,,Terminated,NCT01458639,PULMONARY EMBOLISM,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,"Barnes-Jewish Hospital, Washington University, St. Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,132.9059,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,0,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Withdrawn,NCT02570958,NON-SMALL CELL LUNG CANCER|THORACIC SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,0,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Withdrawn,NCT02423148,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
[K+].[O-][Cl+3]([O-])([O-])[O-],0,DB09418,__POTASSIUM_PERCHLORATE,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.97,138.549,74.27,4.0,0.0,0.0,5.23,11.91,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
OCC(O)CO,0,DB09462,__GLYCERIN,9034300,Terminated,NCT02585791,HEALTHY LIFETIME NON-SMOKERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other,"University of Miami School of Medicine, Miami, Florida, United States",A61K49/226,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,55.0976406086367,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,92.0938,60.69,3.0,3.0,0.0,8.93,20.52,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
C[Se]CC[C@H](N)C(=O)O,0,DB11142,__SELENOMETHIONINE,,Terminated,NCT00526890,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,196.11,63.32,3.0,2.0,0.0,14.64,42.91,4.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
C[Se]CC[C@H](N)C(=O)O,0,DB11142,__SELENOMETHIONINE,,Terminated,NCT01682031,CHEMOTHERAPEUTIC AGENT TOXICITY|MUCOSITIS|RADIATION TOXICITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|XEROSTOMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,"Roswell Park Cancer Institute, Buffalo, New York, United States|Waikato Hospital, Hamilton, New Zealand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,196.11,63.32,3.0,2.0,0.0,14.64,42.91,4.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],0,DB11246,__COPPER_GLUCONATE,4112066,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61Q11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1ccccc1O,0,DB11359,__GUAIACOL,3947570,Terminated,NCT02581397,COUGH,All,2 Years to 6 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"L.A.L. Clínica Centro de Pesquisa e Desenvolvimento Ltda., Valinhos, São Paulo, Brazil",A61K8/416,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,16.2303127374278,1524.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.32,124.139,29.46,2.0,1.0,1.0,12.69,34.5,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O,0,DB11363,__ALECTINIB,9126931,Terminated,NCT03131206,ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)|RET-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)|RET-POSITIVE THYROID CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Irvine, Irvine, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,29.0,62.9828127887636,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.59,482.6166,72.36,5.0,1.0,6.0,56.56,155.11,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F,0,DB11633,__ISAVUCONAZOLE,EP-1757609-A1,Terminated,NCT03327727,INVASIVE ASPERGILLOSIS|INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States|Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|DMC Harper University Hospital, Detroit, Michigan, United States|University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Infectious Disease, Saint Louis, Missouri, United States|The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium|General Hospital Saint-Jan, Department of Hematology, Brugge, Belgium|Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium|UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir, Belgium|Hamilton Health Sciences, Infectious Disease Research, Hamilton, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Division of Infectios Diseases, Montréal, Quebec, Canada|Grenoble University Hospital Center, Department of Hematology, Grenoble, France|South Lyon Hospital Center, Pierre-Bénite, France|Hautepierre Hospital, Strasbourg, France|University Hospital Jena, Jena, Germany|Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich, Germany|Chonnam National University, Hwasun, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,102.277254153062,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.46,437.47,87.62,5.0,1.0,4.0,42.74,123.94,6.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32,0,DB11641,__VINFLUNINE,,Terminated,NCT00519831,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alamance Oncology/Hematology Associates, LLP, Burlington, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.5,816.944,133.87,8.0,2.0,9.0,85.68,216.53,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,0
Clc1ccc(CCCOCCCN2CCCCC2)cc1,0,DB11642,__PITOLISANT,7169928,Withdrawn,NCT02978651,EXCESSIVE DAYTIME SLEEPINESS|OBSTRUCTIVE SLEEP APNEA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Laboratoire du sommeil Clinique de Physiologie, Sommeil et Exercice Pôle Thorax et Vaisseaux CHU de Grenoble, Grenoble, France|Hôpital Gui de Chauliac, CHU Montpellier, Unité des Troubles du Sommeil et de l'Eveil, Montpellier, France",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,31.967802213597803,39.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.47,295.85,12.47,2.0,0.0,2.0,35.5,86.81,8.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1
Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21,0,DB11651,__DACTOLISIB,WO-2006122806-A2,Withdrawn,NCT04139915,CLINICALLY SYMPTOMATIC RESPIRATORY ILLNESS,All,65 Years and older   (Older Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,32.7488,55.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.65,469.548,73.12,4.0,0.0,6.0,51.35,138.35,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,1
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,NCT01103037,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","West Coast Clinical Trials, Cypress, California, United States|American Health Research, Charlotte, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Moscow, Russian Federation",A61K45/06 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,NCT01820325,NON-SMALL CELL LUNCH CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Highlands Oncology Group, Fayetteville, Arkansas, United States|Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,NCT01911325,SQUAMOUS NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Highlands Oncology Group SC-1, Fayetteville, Arkansas, United States|H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Tampa, Florida, United States|Reliant Medical Group Reliant Medical Group, Worcester, Massachusetts, United States|Virginia Oncology Associates Virginia Oncology Assoc. (2), Norfolk, Virginia, United States|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Stockholm, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Withdrawn,NCT01971489,ADULT SOLID NEOPLASM|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12,0,DB11679,__FRUQUINTINIB,,Withdrawn,NCT03684967,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.12,393.399,95.71,5.0,1.0,4.0,40.64,106.25,5.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,DB11682,__DAPRODUSTAT,,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.48,393.44,124.09,6.0,2.0,3.0,40.18,96.89,5.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Withdrawn,NCT03004105,MALIGNANT NEOPLASM OF RESPIRATORY AND INTRATHORACIC ORGAN CARCINOMA|ADVANCED LUNG CANCER|RECURRENT NONSMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,NCT02342353,"NON-SMALL CELL LUNG CANCER|NONSMALL CELL LUNG CANCER|CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Terminated,NCT00441701,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"41 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Terminated,NCT03348904,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Cancer Center of Kansas, Wichita, Kansas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Terminated,NCT02298153,NSCLC (NON-SMALL CELL LUNG CARCINOMA)|UC (UROTHELIAL CANCER),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Yale University, New Haven, Connecticut, United States|Harvard-Mass General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Washington, Seattle, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Terminated,NCT03361228,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|The University of Chicago Medicine, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1,0,DB11717,__EPACADOSTAT,WO-2010005958-A2,Withdrawn,NCT03402880,EXTENSIVE STAGE SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,174.0,32.7488,30.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.43,438.23,167.76,9.0,5.0,2.0,35.25,93.53,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)C(C)C)C(N)=O,0,DB11724,__BOMBESIN,,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,1619.87,686.13,22.0,23.0,4.0,166.6,418.43,51.0,1.0,0.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0
CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21,0,DB11736,__PF-00489791,US-20050245544-A1,Terminated,NCT00853112,"HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pulmonary Associates, PA, Phoenix, Arizona, United States|John C. Lincoln Hospital, North Mountain, Phoenix, Arizona, United States|Pulmonary Associates, PA, Phoenix, Arizona, United States|Shands at University of Florida, Gainesville, Florida, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center - Department of Internal Medicine Pulmonary, Dallas, Texas, United States|UT Southwestern St. Paul Hospital, Dallas, Texas, United States|Lawson Health Research Institute, London, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada|Thoraxklinik am Universitaetsklinikum, Heidelberg, Germany|Department Of Cardiology, MediCiti Hospital,, Hyderabad, Andhra Pardesh, India|Department Of Cardiology, Sri Venkateswara Institute Of Medical Sciences, Tirupati, Andhra Pardesh, India|Bankers Heart Institute, Vadodara, Gujarat, India|Omega Hospital, Mangalore, Karnataka, India|Moscow Healthcare Institution ""City Clinical Hospital No. 57"", Moscow, Russian Federation|Institute of Cardiosurgery n.a. V.I.Burakovsky, Moscow, Russian Federation|Hospital General Universitari Vall D´Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Universitetssjukhuset i Lund, Hjart- och Lungdivisionen, Lund, Sweden|Norrlands Universitetssjukhus, Kliniskt Forsknings Centrum, Umea, Sweden|Akademiska Sjukhuset, Kardiologen 50F/Forskningsenheten, Uppsala, Sweden|Universitaetsspittal Zuerich, Medizinische Klinik A, Zuerich, Switzerland",A61P11/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,91.0,56.543255508326595,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,476.56,144.23,10.0,2.0,3.0,51.09,136.37,9.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,0
CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O,0,DB11741,__FAMITINIB,WO-2007085188-A1,Suspended,NCT02356991,NON SMALL CELL LUNG CANCER,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China|Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,410.49300000000005,68.44,3.0,2.0,4.0,46.14,119.31,6.0,0.0,1.0,0.0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,0,DB11760,__TALAZOPARIB,8012976,Withdrawn,NCT02537561,"SOLID TUMORS|CARCINOMA, NON-SMALL CELL LUNG|NON-SMALL CELL LUNG CANCER|NON-SMALL-CELL LUNG CARCINOMA|NONSMALL CELL LUNG CANCER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1
Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,0,DB11760,__TALAZOPARIB,8012976,Withdrawn,NCT02567396,ESTROGEN RECEPTOR NEGATIVE|HEAD AND NECK SQUAMOUS CELL CARCINOMA|HER2/NEU NEGATIVE|HORMONE-RESISTANT PROSTATE CANCER|METASTATIC PANCREATIC ADENOCARCINOMA|PROGESTERONE RECEPTOR NEGATIVE|SOLID NEOPLASM|STAGE III MESOTHELIOMA|STAGE IIIA GASTRIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIA OVARIAN CANCER|STAGE IIIA SMALL CELL LUNG CARCINOMA|STAGE IIIB GASTRIC CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IIIB OVARIAN CANCER|STAGE IIIB SMALL CELL LUNG CARCINOMA|STAGE IIIC GASTRIC CANCER|STAGE IIIC OVARIAN CANCER|STAGE IV MESOTHELIOMA|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN CANCER|STAGE IV SMALL CELL LUNG CARCINOMA|TRIPLE-NEGATIVE BREAST CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,25.331115628657603,10.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,380.35900000000004,84.2,5.0,2.0,5.0,35.82,111.27,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,0,DB11763,__MOMELOTINIB,WO-2008109943-A1,Terminated,NCT02206763,EGFR MUTATED EGFR TKI NAIVE METASTATIC NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duarte, California, United States|Palo Alto, California, United States|Whittier, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,414.469,103.17,7.0,2.0,4.0,44.23,118.46,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0
N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1,0,DB11763,__MOMELOTINIB,WO-2008109943-A1,Terminated,NCT02258607,RELAPSED METASTATIC KRAS-MUTATED NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duarte, California, United States|Sacramento, California, United States|Boston, Massachusetts, United States|Fairfax, Virginia, United States|Spokane, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,414.469,103.17,7.0,2.0,4.0,44.23,118.46,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0
O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,0,DB11798,__TANZISERTIB,US-20120100213-A1,Terminated,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2866,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,25.692519353580106,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.77,448.4415,97.12,7.0,3.0,5.0,44.11,111.52,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,1,0,1
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,0,DB11800,__TIVOZANIB,US-20040229876-A1,Withdrawn,NCT01728181,NON-SMALL CELL LUNG CANCER|STAGE IV DISEASE|EGFR UNKNOWN OR WILD-TYPE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,84.0,34.760467360726,23.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.25,454.86300000000006,107.74,5.0,2.0,4.0,44.26,120.85,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C[C@](C)(OC(C)=O)[C@H]2[C@@H]1OC(=O)CCCCCCC,0,DB11813,__MIPSAGARGIN,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,1409.5410000000006,529.98,23.0,13.0,3.0,148.12,339.89,50.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,DB11816,__OMECAMTIV_MECARBIL,US-20060014761-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01935947,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01886573,STAGE IA NON-SMALL CELL LUNG CARCINOMA|STAGE IB NON-SMALL CELL LUNG CARCINOMA|STAGE IIA NON-SMALL CELL LUNG CARCINOMA|STAGE IIB NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01207726,STAGE IA NON-SMALL CELL LUNG CARCINOMA|STAGE IB NON-SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12,0,DB11845,__LUCITANIB,US-20080227812-A1,Terminated,NCT02109016,NON-SMALL CELL LUNG CANCER|SQUAMOUS NON-SMALL CELL LUNG CANCER|NSCLC|SMALL CELL LUNG CANCER|SCLC|LUNG CANCER|ADVANCED LUNG CANCER|METASTATIC LUNG CANCER|STAGE IV LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, Los Angeles, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Associates in Oncology and Hematology, Rockville, Maryland, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Nashville, Tennessee, United States|CHU Caen, Hôpital de la Côte de Nacre, Caen, France|CHRU Lille, Hôpital Albert Calmette, Lille, France|Hôpital Nord, Marseille, France|Institut Gustave-Roussy, Villejuif, France|Universität Duisburg-Essen, Essen, Germany|Hospital Grosshansdorf, Grosshansdorf, Germany|Pius Hospital Oldenburg, Oldenburg, Germany|Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy|AOU San Luigi Gonzaga, Orbassano, Italy|Ospedale S. Maria della Misericordia, Perugia, Italy|Hospital Universitari Vall d'Hebrón, Barcelona, Cataluña, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,50.005133575638105,15.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.24,443.50300000000004,95.7,5.0,2.0,5.0,47.84,124.62,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,0,DB11871,__PF-00610355,US-20050182091-A1,Withdrawn,NCT00830427,"ASTHMA, BRONCHIAL|LUNG DISEASES, OBSTRUCTIVE|RESPIRATORY TRACT DISEASES|BRONCHIAL DISEASES",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,29.8650896322306,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.38,617.76,147.99,7.0,6.0,4.0,67.4,172.11,12.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,NCT01646125,ADVANCED NON SMALL CELL LUNG CANCER (NSCLC),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr., Los Angeles, California, United States|Maryland Oncology Hematology, P.A. SC, Rockville, Maryland, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5, Madison, Wisconsin, United States|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Leicester, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(=O)O)=C[C@H](NC(=N)N)[C@H]1NC(C)=O,0,DB11888,__LANINAMIVIR_OCTANOATE,,Terminated,NCT02014649,INFLUENZA,All,5 Years to 17 Years   (Child),Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Precision Trials LLC, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|SoCal Clinical Research Med Group, Bellflower, California, United States|Sherif Khamis MD Inc, Canoga Park, California, United States|Advanced Medical Research, Lakewood, California, United States|Madera Family Medical Group, Madera, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.G.A Clinical Trials, Hialeah, Florida, United States|Lafayette Clinical Research Group, Lafayette, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Dr Haidar's Clinic, Carriere, Mississippi, United States|DePaul Health Center, Bridgeton, Missouri, United States|Blue Ridge Pediatric and Adolescent Medicine Group, Boone, North Carolina, United States|Dayton Children's Hospital, Dayton, Ohio, United States|The University of Toledo Medical Center, Toledo, Ohio, United States|Dr Santiago Reyes, Oklahoma, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Sanford Research University of South Dakota, Sioux Falls, South Dakota, United States|Avant Research Assoc., Houston, Texas, United States|West Houston Clinical Research Service, Houston, Texas, United States|Foothill Family Clinic, Salt Lake City, Utah, United States|First Med, Salt Lake City, Utah, United States|Foothill Family Clinic South, Salt Lake City, Utah, United States|Copperview Medical Center, South Jordan, Utah, United States|Dixie Pediatrics, St. George, Utah, United States|Rockwood Clinic, Spokane, Washington, United States|Rockwood North Clinic, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.86,472.5325,193.29,10.0,6.0,1.0,49.12,128.02,15.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0
CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1,0,DB11896,__GEDATOLISIB,WO-2009143313-A1,Terminated,NCT02920450,NON SMALL CELL LUNG CANCER,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UF Health Cancer Center, Gainesville, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,26.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.68,615.739,128.29,10.0,2.0,6.0,67.18,189.15,7.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,0,DB11901,__APALUTAMIDE,8445507,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,73.82492453643809,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,477.44,89.33,4.0,1.0,4.0,43.44,113.6,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,0,DB11907,__ROCILETINIB,,Terminated,NCT02186301,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|East Valley Hematology and Oncology Medical Group, Inc., Burbank, California, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sutter Medical Group, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|Sansum Clinic, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Medical Center, Santa Monica, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Cancer Specialists of North Florida, Fleming Island, Florida, United States|Florida Cancer Specialists and Research Institute, Fort Myers, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Harry and Jeanette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Walter Reed Army Institute of Research, Bethesda, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Regional Cancer Care Associates, LLC, East Brunswick, New Jersey, United States|Regional Cancer Care Associates, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|USC/Norris Comprehensive Cancer Center, Nashville, Tennessee, United States|Texas Oncology, PA, Austin, Texas, United States|Texas Oncology-Beaumont, Beaumont, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington, Seattle, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States|Yakima Valley Memorial Hospital, North Star Lodge, Yakima, Washington, United States|Asklepios Fachkliniken München-Gauting, Gauting, Bayern, Germany|Pius Hospital Oldenburg, Oldenburg, Niedersachsen, Germany|Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany|Katholisches Klinikum Mainz, Sankt Hildegardis-Krankenhaus, Mainz, Rheinland-Pfalz, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Prince of Wales Hospital, Hong Kong, New Territories, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Ospedale Civile di Livorno, Livorno, Italy|Dong-A University Hospital, Busan, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Saint Vincent's Hospital, Suwon, Korea, Republic of|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.42,555.562,111.72,8.0,3.0,4.0,54.66,146.65,9.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,0,DB11907,__ROCILETINIB,,Terminated,NCT01526928,LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States|Samuel Oschin Cancer Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|University of California Davis Medical Center, Sacramento, California, United States|UCLA Health System, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|East Valley Hematology and Oncology Medical Group, Inc., Whittier, California, United States|The Oncology Institute of Hope and Innovations, Whittier, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Sylvester Comprehensive Cancer Center/UMHC, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|University Cancer & Blood Center, Athens, Georgia, United States|University of Chicago Medical Center, The Duchossois Center for Advanced Medicine, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Mass General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Karmanos Cancer Care Institute, Detroit, Michigan, United States|Regional Cancer Care Associates, Morristown, New Jersey, United States|Regional Cancer Center, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Monter Cancer Center, Lake Success, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Ohio State University, Comprehensive Cancer Center, Columbus, Ohio, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Providence CancerCenter Oncology and Hematology Care Clinic-Eastside Portland, Portland, Oregon, United States|Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPMC), Div. of Medical Oncology, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Peter MacCallum Cancer Centre, East Melbourne, Australia|Centre Antoine Lacassagne, Nice Cedex 2, Provence Alpes COTE D'azur, France|Centre Hospitalier Universitaire de Grenoble, Grenoble Cedex 9, Rhone-alpes, France|Centre Léon Bérard, Lyon Cedex 04, Rhone-alpes, France|Centre François Baclesse, Caen Cedex 05, France|Centre Hospitalier Intercommunal Créteil, Creteil cedex, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Institut Gustave Roussy, Villejuif, France|Med University Gdansk, Gdansk, Poland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.42,555.562,111.72,8.0,3.0,4.0,54.66,146.65,9.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1,0,DB11907,__ROCILETINIB,,Withdrawn,NCT02705339,"CARCINOMA, NON-SMALL-CELL LUNG|NON-SMALL CELL LUNG CANCER|NONSMALL CELL LUNG CANCER",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.42,555.562,111.72,8.0,3.0,4.0,54.66,146.65,9.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1
CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1,0,DB11909,__VARESPLADIB,5155118,Terminated,NCT01522196,SICKLE CELL DISEASE|VASO-OCCLUSIVE CRISIS,All,"5 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Investigator Site 101, Atlanta, Georgia, United States",C07D403/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,54.0,34.9904515493131,46.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.4,380.4,111.62,5.0,2.0,3.0,39.03,102.9,8.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0
Cc1nc(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)c(F)c(N2CCN3CCOC[C@@H]3C2)n1,0,DB11912,__LANOPEPDEN,WO-2009061879-A1,Terminated,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61P11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,199.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.6,479.55699999999996,123.16,9.0,3.0,4.0,50.61,126.0,8.0,0.0,1.0,0.0,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0
Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O,0,DB11922,__DANIRIXIN,US-20070249672-A1,Terminated,NCT02927431,VIRUS DISEASES,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSK Investigational Site, Stamford, Connecticut, United States|GSK Investigational Site, Council Bluffs, Iowa, United States|GSK Investigational Site, Natchitoches, Louisiana, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Salem, Virginia, United States|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, Lund, Sweden",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,46.128257253742284,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,441.9,107.53,5.0,4.0,3.0,41.94,111.66,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1
Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O,0,DB11922,__DANIRIXIN,US-20070249672-A1,Terminated,NCT03170232,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 76 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Houston, Texas, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,46.128257253742284,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,441.9,107.53,5.0,4.0,3.0,41.94,111.66,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1
CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1,0,DB11925,__VISTUSERTIB,US-20090099174-A1,Terminated,NCT03106155,SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,32.7488,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.22,462.55400000000003,92.71,8.0,1.0,5.0,51.35,133.06,4.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Terminated,NCT02351505,RECURRENT SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02536495,RECURRENT SQUAMOUS CELL LUNG CARCINOMA|STAGE IV SQUAMOUS CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21,0,DB11967,__BINIMETINIB,7777050,Withdrawn,NCT02451865,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",C07D235/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,28.9780077619663,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,441.233,88.41,5.0,3.0,3.0,38.55,98.02,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0
Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,0,DB11968,__MK-7145,US-20100286123-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,46.686790283168,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.33,466.534,99.54,6.0,2.0,5.0,49.95,128.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1,0,DB11970,__BURIXAFOR,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,566.732,151.9,11.0,6.0,4.0,65.83,161.18,14.0,1.0,0.0,0.0,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,0,DB11977,__GOLVATINIB,EP-1889836-A1,Terminated,,ADVANCED OR METASTATIC SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61P35/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,81.710096716565,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.19,633.701,119.14,6.0,3.0,6.0,64.23,172.48,8.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,0,DB12011,__FEVIPIPRANT,7666878,Terminated,NCT03650400,ASTHMA,All,6 Years to 11 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Boerne, Texas, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,56.280416435655695,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.87,426.41,89.26,5.0,1.0,3.0,38.66,100.88,6.0,0.0,1.0,0.0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0
C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,0,DB12036,__NAQUOTINIB,US-20140323463-A1,Terminated,NCT02588261,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site US10029, Beverly Hills, California, United States|Site US10025, Fountain Valley, California, United States|Site US10036, La Jolla, California, United States|Site US10051, Loma Linda, California, United States|Site US10033, Los Angeles, California, United States|Site US10031, Oxnard, California, United States|Site US10052, Redondo Beach, California, United States|Site US10003, Santa Monica, California, United States|Site US10018, Whittier, California, United States|Site US10047, Glenwood Springs, Colorado, United States|Site US10013, Aventura, Florida, United States|Site US10048, Saint Petersburg, Florida, United States|Site US10050, Atlanta, Georgia, United States|Site US10042, Baton Rouge, Louisiana, United States|Site US10037, Scarborough, Maine, United States|Site US10034, Boston, Massachusetts, United States|Site US10030, Minneapolis, Minnesota, United States|Site US10027, Rochester, Minnesota, United States|Site US10045, Albuquerque, New Mexico, United States|Site US10012, Mount Kisco, New York, United States|Site US10021, Bethlehem, Pennsylvania, United States|Site US10009, Nashville, Tennessee, United States|Site US10023, Nashville, Tennessee, United States|Site US10011, Lacey, Washington, United States|Site US10046, Milwaukee, Wisconsin, United States|Site AU61003, Randwick, New South Wales, Australia|Site AU61007, Woolloongabba, Queensland, Australia|Site AU61005, Adelaide, South Australia, Australia|Site AU61008, East Melbourne, Victoria, Australia|Site AU61002, Fitzroy, Victoria, Australia|Site AU61004, Footscray, Victoria, Australia|Site BE32002, Gent, West-Vlaanderen, Belgium|Site CA15006, Toronto, Ontario, Canada|Site CA15002, Montreal, Quebec, Canada|Site CL56001, Santiago, Región Metropolitana De Santia, Chile|Site CL56002, Vina del Mar, Valparaíso, Chile|Site CL56007, Vina del Mar, Valparaíso, Chile|Site FR33010, Pessac, Gironde, France|Site FR33011, Suresnes, Hauts-de-Seine, France|Site FR33003, Creteil, Ilej-de-France, France|Site FR33004, Tours, Indre-et-Loire, France|Site FR33006, Grenoble, Isère, France|Site FR33009, Saint Priest en Jarez, Loire, France|Site FR33012, Bayonne, Pyrénées-Atlantiques, France|Site FR33007, Pierre Benite, Rhône, France|Site DE49008, Freiburg, Baden-Württemberg, Germany|Site DE49005, Karlsruhe, Baden-Württemberg, Germany|Site DE49003, Gauting, Bayern, Germany|Site DE49006, Wurzburg, Bayern, Germany|Site DE49007, Kassel, Hessen, Germany|Site DE49004, Köln, Nordrhein-Westfalen, Germany|Site HU36002, Szekesfehervar, Fejér, Hungary|Site HU36003, Tatabanya, Tatabánya, Hungary|Site HU36006, Szombathely, Vas, Hungary|Site HU36004, Farkasgyepu, Veszprém, Hungary|Site HU36007, Budapest, Hungary|Site HU36001, Budapest, Hungary|Site IT39004, Monza, Lombardia, Italy|Site IT39009, Rozzano, Lombardia, Italy|Site IT39011, Aviano, Pordenone, Italy|Site IT39003, Bergamo, Italy|Site IT39015, Brescia, Italy|Site IT39002, Cremona, Italy|Site IT39013, Lucca, Italy|Site IT39014, Milano, Italy|Site IT39012, Piacenza, Italy|Site IT39008, Roma, Italy|Site JP81018, Matsuyama, Ehime, Japan|Site JP81013, Hiroshima, Hirosima [Hiroshima], Japan|Site JP81014, Sapporo, Hokkaidô, Japan|Site JP81017, Osakasayama-shi, Hukuoka [Fukuoka], Japan|Site JP81008, Kurume, Hukuoka, Japan|Site JP81024, Kobe, Hyogo, Japan|Site JP81015, Kanazawa, Isikawa [Ishikawa], Japan|Site JP81010, Yokohama, Kanagawa, Japan|Site JP81025, Yokohama, Kanagawa, Japan|Site JP81012, Sendai, Miyagi, Japan|Site JP81016, Kurashiki, Okayama, Japan|Site JP81005, Miyakojima-ku, Osaka, Japan|Site JP81020, Osakasayama-shi, Osaka, Japan|Site JP81019, Sunto-gun, Shizuoka, Japan|Site JP81001, Sunto-gun, Sizuoka [Shizuoka], Japan|Site JP81004, Tokyo, Tôkyô [Tokyo], Japan|Site JP81022, Niigata, Japan|Site JP81006, Okayama, Japan|Site JP81023, Wakayama, Japan|Site JP81021, Hirakata, Ôsaka [Osaka], Japan|Site JP81002, Osaka-sayama, Ôsaka [Osaka], Japan|Site KR82005, Cheongiu, Chungcheongbugdo, Korea, Republic of|Site KR82004, Suwon-si, Gyeonggi-do, Korea, Republic of|Site KR82016, Suwon-si, Gyeonggido [Kyonggi-do], Korea, Republic of|Site KR82017, Bundang, Gyeonggido, Korea, Republic of|Site KR82009, Jinju-si, Gyeongsangnamdo, Korea, Republic of|Site KR82003, Jeonju, Jeonrabugdo[Chollabuk-do], Korea, Republic of|Site KR82002, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82001, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82013, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82007, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82008, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82006, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82015, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp], Korea, Republic of|Site KR82014, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Site KR82011, Ulsan, Ulsan Gwang'yeogsi, Korea, Republic of|Site KR82010, Busan Gwang'yeogsi, Korea, Republic of|Site MY60001, Kuantan Pahang, Pahang, Malaysia|Site MY60002, Georgetown, Pulau Pinang, Malaysia|Site MY60004, Kuching, Sarawak, Malaysia|Site NL31001, Arnhem, Gelderland, Netherlands|Site NL31006, Alkmaar, Noord-Holland, Netherlands|Site PE51001, Cercado De Lima, Arequipa, Peru|Site PE51008, Miraflores, Lima, Peru|Site PE51004, San Isidro, Lima, Peru|Site PT35101, Amadora, Lisboa, Portugal|Site PT35104, Lisbon, Lisboa, Portugal|Site PT35103, Coimbra, Portugal|Site PT35102, Lisboa, Portugal|Site RO40004, Floresti, Cluj, Romania|Site RO40001, Craiova, Dolj, Romania|Site RO40010, Craiova, Dolj, Romania|Site RO40007, Ploiesti, Prahova, Romania|Site RO40008, Timisoara, Timis, Romania|Site RO40012, Bucuresti, Romania|Site RO40006, Sibiu, Romania|Site RU70012, Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation|Site RU70017, Ufa, Bashkortostan, Russian Federation|Site RU70009, Magnitogorsk, Chelyabinskaya Oblast', Russian Federation|Site RU70016, Nalchik, Kabardino-Balkarskaya Respublika, Russian Federation|Site RU70008, Pyatigorsk, Stavropol'skiy Kray, Russian Federation|Site RU70001, Saint Petersburg, Russian Federation|Site SG65001, Singapore, Central Singapore, Singapore|Site SG65002, Singapore, Central Singapore, Singapore|Site ES34003, Barcelona, Catalunya, Spain|Site ES34008, San Sebastian, Guipuzcoa, Guipúzcoa, Spain|Site ES34010, Malaga, Málaga, Spain|Site ES34006, Madrid, Spain|Site ES34016, Madrid, Spain|Site ES34004, Ourense, Spain|Site ES34005, Sevilla, Spain|Site ES34015, Valencia, Spain|Site ES34017, Valencia, Spain|Site ES34002, Valencia, Spain|Site TW88605, Taichung City, Taichung, Taiwan|Site TW88607, Taoyuan Hsien, Taoyuan, Taiwan|Site TW88606, Kaohsiung, Taiwan|Site TW88603, Taichung, Taiwan|Site TW88601, Tainan, Taiwan|Site TW88604, Tainan, Taiwan|Site TW88608, Taipei, Taiwan|Site TW88609, Taipei, Taiwan|Site TW88611, Taipei, Taiwan|Site TH66011, Chom Thong, Chiang Mai, Thailand|Site TH66001, Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand|Site TH66012, Bangkok, Krung Thep Maha Nakhon [Bangkok], Thailand|Site TH66002, Chiang Rai, Thailand|Site TH66004, Khon Kaen, Thailand|Site TH66006, Songkla, Thailand|Site UA38006, Chernivtsi, Chernivets'ka Oblast', Ukraine|Site UA38001, Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine|Site UA38005, Kryvyi Rih, Dnipropetrovs'ka Oblast', Ukraine|Site UA38008, Ivano-Frankivsk, Ivano-Frankivs'ka Oblast', Ukraine|Site UA38004, Lviv, L'vivs'ka Oblast', Ukraine|Site UA38007, Lutsk, Volyns'ka Oblast', Ukraine|Site UA38009, Uzhgorod, Zakarpats'ka Oblast', Ukraine|Site UA38003, Uzhgorod, Zakarpats'ka Oblast', Ukraine|Site GB44002, Middlesex, Hertfordshire, United Kingdom|Site GB44001, Liverpool, Wirral, United Kingdom|Site GB44003, Sheffield, United Kingdom",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,30.1279287049015,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,562.719,120.16,9.0,2.0,5.0,63.57,160.68,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,0
C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1,0,DB12036,__NAQUOTINIB,US-20140323463-A1,Terminated,NCT03082300,NON-SMALL CELL LUNG CANCER (NSCLC)|EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beverly Hills Cancer Center, Beverly Hills, California, United States|Renovatio Clinical, The Woodlands, Texas, United States|US Oncology - Virginia Cancer Specialists, P.C. (VCS), Fairfax, Virginia, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,30.1279287049015,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,562.719,120.16,9.0,2.0,5.0,63.57,160.68,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,0
Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@H](O)C2,0,DB12039,__EPICATECHIN,4166861,Withdrawn,NCT01880866,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF, San Francisco, California, United States",C07D311/62,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,29.437976139140396,1177.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,290.2681,110.38,6.0,5.0,3.0,28.13,74.0,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT02261805,CANCER|SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT02192541,NEOPLASMS,All,"18 Years to 120 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT01348126,NON-SMALL CELL LUNG CANCER STAGE IIIB|NON-SMALL CELL LUNG CANCER STAGE IV|NON-SMALL CELL LUNG CANCER METASTATIC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Synta Pharmaceuticals Investigative Site, Tucson, Arizona, United States|Synta Pharmaceuticals Investigative Site, Santa Monica, California, United States|Synta Pharmaceuticals Investigative Site, Atlanta, Georgia, United States|Synta Pharmaceuticals Investigative Site, Chicago, Illinois, United States|Synta Pharmaceutials Investigative Site, Boston, Massachusetts, United States|Synta Pharmaceuticals Investigative Site, Winston-Salem, North Carolina, United States|Synta Pharmaceuticals Investigative Site, Kettering, Ohio, United States|Synta Pharmaceuticals Investigative Site, Portland, Oregon, United States|Synta Pharmaceuticals Investigative Site, Brussels, Belgium|Synta Pharmaceuticals Investigative Site, Jette, Belgium|Synta Pharmaceuticals Investigative Site, Yvoir, Belgium|Synta Pharmaceuticals Investigative Site, Banja Luka, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Mostar, Bosnia and Herzegovina|Synta Pharmaceuticals Investgative Site, Sarajevo, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Sarajevo, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Tuzla, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Hamilton, Canada|Synta Pharmaceuticals Investigative Site, Montreal, Canada|Synta Pharmaceuticals Investigative Site, Montreal, Canada|Synta Pharmaceuticals Investigative Site, Ottawa, Canada|Synta Pharmaceuticals Investigative Site, Pula, Croatia|Synta Pharmaceuticals Investigative Site, Split, Croatia|Synta Pharmaceuticals Investigative Site, Zagreb, Croatia|Synta Pharmaceuticals Investigative Site, Prague, Czech Republic|Synta Pharmaceuticals Investigative Site, Halle, Germany|Synta Pharmaceuticals Investigative Site, Hamburg, Germany|Synta Pharmaceuticals Investigative Site, Mainz, Germany|Synta Pharmaceuticals Investigative Site, Mannheim, Germany|Synta Pharmaceuticals Investigative Site, Offenbach, Germany|Synta Pharmaceuticals Investigative Site, Krakow, Poland|Synta Pharmaceuticals Investigative Site, Olsztyn, Poland|Synta Pharmaceuticals Investigative Site, Prabuty, Poland|Synta Pharmaceuticals Investigative Site, Szczecin, Poland|Synta Pharmaceuticals Investigative Site, Cluj - Napoca, Romania|Synta Pharmaceuticals Investigative Site, Cluj - Napoca, Romania|Synta Pharmaceuticals Investigative Site, Craiova, Romania|Synta Pharmaceuticals Investigative Site, Suceava, Romania|Synta Pharmaceuticals Investigative Site, Kazan, Russian Federation|Synta Pharmaceuticals Investigative Site, Moscow, Russian Federation|Synta Pharmaceuticals Investigative Site, Moscow, Russian Federation|Synta Pharmaceuticals Investigative Site, Saint-Petersburg, Russian Federation|Synta Pharmaceuticals Investigative Site, Saint-Petersburg, Russian Federation|Synta Pharmaceuticals Investigative Site, Sochi, Russian Federation|Synta Pharmaceuticals Investigative Site, Voronezh, Russian Federation|Synta Pharmaceuticals Investigative Site, Belgrade, Serbia|Synta Pharmaceuticals Investigative Site, Sremska Kamenica, Serbia|Synta Pharmaceuticals Investigative Site, Badalona, Spain|Synta Pharmaceuticals Investigative Site, Barcelona, Spain|Synta Pharmaceuticals Investigative Site, Madrid, Spain|Synta Pharmaceuticals Investigational Site, Leicester, United Kingdom|Synta Pharmaceuticals Investigative Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, Sutton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O,0,DB12047,__GANETESPIB,WO-2006055760-A1,Terminated,NCT01798485,NON-SMALL-CELL LUNG ADENOCARCINOMA|NON-SMALL CELL LUNG CANCER STAGE IIIB|NON-SMALL CELL LUNG CANCER STAGE IV|NON-SMALL CELL LUNG CANCER METASTATIC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates PC- NAHOA, Flagstaff, Arizona, United States|Arizona Oncology Associates, PC- NAHOA, Prescott Valley, Arizona, United States|Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Comprehensive Blood & Cancer Center, Bakersfield, California, United States|City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|St. Joseph Hospital, Center for Cancer Prevention and Treatment, Orange, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|UC Davis Medical Center - UC Davis Comprehensive Cancer, Sacramento, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|City of Hope- South Pasadena, South Pasadena, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology Associates, Norwich, Connecticut, United States|Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States|Lynn Cancer Institute Center for Hematology Oncology, Boca Raton, Florida, United States|Halifax Health - Medical Center, Daytona Beach, Florida, United States|University of Miami Health System Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Baptist Health Medical Group Oncology, LLC, Miami, Florida, United States|University of South Florida - H. Lee Moffitt, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States|Saint Anthony Medical Center, Rockford, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc, Fort Wayne, Indiana, United States|AAMC Oncology and Hematology, Annapolis, Maryland, United States|The Center for Cancer and Blood Disorders (CCBD) - Bethesda, Bethesda, Maryland, United States|The John R Marsh Cancer Center, Hagerstown, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Luke's Hospital Duluth, Duluth, Minnesota, United States|Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|St. Louis Cancer Care, LLP - North County, Bridgeton, Missouri, United States|Renown Regional Medical Center, Reno, Nevada, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|New Mexico Cancer Center, Albuquerque, New Mexico, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|New Hanover Regional Medical Center - Zimmer Cancer Center, Wilmington, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Tulsa Cancer Institute, PLLC, Tulsa, Oklahoma, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Prairie Lakes Healthcare System, Watertown, South Dakota, United States|Erlanger Institute for Clinical Research, Chattanooga, Tennessee, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Texas Oncology-Arlington North, Arlington, Texas, United States|Texas Oncology - Arlington South, Arlington, Texas, United States|Texas Oncology, P.A., Beaumont, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Houston Methodist Hospital Research Institute, Houston, Texas, United States|Millennium Oncology, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Cancer Care Centers Of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology - Sherman, Sherman, Texas, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Cancer Care Northwest, Spokane Valley, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Mary Babb Cancer Center, Morgantown, West Virginia, United States|Green Bay Oncology, Ltd. - St. Mary's Site, Green Bay, Wisconsin, United States|Green Bay Oncology, Green Bay, Wisconsin, United States|Landesklinikum Krems, Krems, Niederösterreich, Austria|Krankenhaus Der Barmherzigen Schwestern, Linz, Oberösterreich, Austria|Klinikum Wels-Grieskirchen, Wels, Oberösterreich, Austria|Bezirkskrankenhaus Kufstein [Onkologie], Kufstein, Tirol, Austria|Allgemeines Krankenhaus Linz, Linz, Austria|Elisabeth Linz Hospital, Linz, Austria|Otto Wagner Spital, Wien, Austria|Sozialmedizinisches Zentrum Baumgartner Höhe, Wien, Austria|AZ Sint-Maarten - Campus Leopoldstraat, Mechelen, Antwerpen, Belgium|Clinique Saint-Pierre Ottignies, Ottignies, Brabant Wallon, Belgium|Grand Hôpital de Charleroi - Site Notre-Dame, Charleroi, Hainaut, Belgium|INDC Entité Jolimontoise - Polyclinique de Jolimont, Haine St. Paul, Hainaut, Belgium|CHU Dinant Godinne UCL Namur, Yvoir, Namur, Belgium|Algemeen Stedelijk Ziekenhuis - Campus Aalst, Roeselaere, West-Vlaanderen, Belgium|Cliniques Universitaire Saint-Luc, Bruxelles, Belgium|CHR de la Citadelle - Site Citadelle, Liège, Belgium|Clinical Centre Banja Luka, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, Tuzlanski kanton, Bosnia and Herzegovina|Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Clinic of Oncology, Sarajevo, Bosnia and Herzegovina|University Clinical Centre Sarajevo, Sarajevo, Bosnia and Herzegovina|University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina|Kantonalna bolnica Zenica, Zenica, Bosnia and Herzegovina|Princess Margaret Hospital, Toronto, Ontario, Canada|Mc Gill University-MUHC, Montreal, Quebec, Canada|University Hospital Center Zagreb, Zagreb, Grad Zagreb, Croatia|Opca bolnica Pula, Pula, Istarska županija, Croatia|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czech Republic|Vseobecna fakultni nemocnice v Praze, Prague, Czech Republic|Nemocnice Na Bulovce, Prague, Czech Republic|CHI des Alpes du Sud, Gap, Hautes-Alpes, France|Centre D'Oncologie Du Pays Basque, Bayonne, Pyrénées-Atlantiques, France|Centre Hosptalier De Villefranche-Sur-Saone, Villefranche Sur Saone, Rhône, France|Chi creteil, Creteil, Val-de-Marne, France|Chu De Grenoble - Hopital Michallon, Grenoble, France|Centre Léon Bérard, Lyon, France|Groupe Hospitalier Cochin, Paris, France|Centre Hospitalier Universitaire de Rennes - Hopital d, Rennes, France|Hôpital Charles Nicolle, Rouen, France|CHRU de Strasbourg, Strasbourg, France|Universitätsklinikum Freiburg, Freiburg, Baden-Württemberg, Germany|Universiaetsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Baden-Württemberg, Germany|Asklepios Fachklinik München-Gauting, Gauting, Bayern, Germany|Klinikum Bogenhausen, Muenchen, Bayern, Germany|Gesundheitszentrum Wetterau, Bad Nauheim, Hessen, Germany|Johann Wolfgang Goethe University Clinic Frankfurt, Frankfurt, Hessen, Germany|Johann Wolfgang Goethe University Clinic Frankfurt, Frankfurt, Hessen, Germany|Klinikum Kassel, Kassel, Hessen, Germany|Kliniken der Stadt Köln gGmbH, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum des Saarlandes, Homburg, Saarland, Germany|Universitätsklinikum Leipzig [Pneumologie], Leipzig, Sachsen, Germany|Pneumologisches Forschungsinstitut an der Lungenclinic Gross, Großhansdorf, Schleswig-Holstein, Germany|MVZ Äerzteforum Seestraße, Berlin, Germany|Ev. Krankenhaus Bielefeld, Bielefeld, Germany|Klinikum Frankfurt An Der Oder, Frankfurt/Oder, Germany|Practice Laack, Hamburg, Germany|Unikl. Schleswig-Holstein - Lübeck, Lübeck, Germany|J. Gutenberg Uni.Mainz, Mainz, Germany|Medizinische Fakultät Mannheim Uni Heidelberg, Mannheim, Germany|Gemeinschaftspraxis fuer Haematologie und Onkologie, Muenster, Germany|Klinikum Offenbach GmbH, Offenbach, Germany|Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkó, Deszk, Csongrád, Hungary|Fejér Megyei Szent György Egyetemi Oktató Kórház, Székesfehérvár, Fejér, Hungary|Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Pest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary|Békés Megyei Pándy Kálmán Kórház, Gyula, Hungary|CRU Hungary Kft., Miskolc, Hungary|Irccs Irst, Meldola, Forli, Italy|Presidio Ospedaliero Centrale Belcolle, AUSL Viterbo, Viterbo, Lazio, Italy|Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy|CRO, IRCCS, Istituto Nazionale Tumori, Aviano, Pordenone, Italy|Azienda Policlinico Umberto I, Rome, Roma, Italy|Policlinico S.Orsola Malpighi, AOU di Bologna, Bologna, Italy|AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can, Genova, Italy|Istituto Europeo di Oncologia, Istituto di Ricovero e Cura a, Milano, Italy|Iov-Irccs, Padova, Italy|Ospedale S.Maria della Misericordia, AO di Perugia, Universi, Perugia, Italy|Ospedale Guglielmo da Saliceto, AUSL Piacenza, Piacenza, Italy|Istituti Fisioterapici Ospitalieri Regina Elena, Roma, Italy|Borgo Roma, Policlinico G.Rossi, AOU Integrata Verona, Verona, Italy|Ziekenhuis Assen, Assen, Drenthe, Netherlands|Ziekenhuis St Jansdal, Harderwijk, Gelderland, Netherlands|Gelre Ziekenhuis Zutphen, Zutphen, Gelderland, Netherlands|academisch ziekenhuis Maastricht, Maastricht, Limburg, Netherlands|Isala Klinieken Zwolle, Zwolle, Overijssel, Netherlands|Sint Antoniusziekenhuis, location Utrecht, Utrecht, Netherlands|Wojewodzki Szpital Specjalistyczny im. M.Kopernika, Lodz, Lodzkie, Poland|Medica Pro Familia Sp. z o.o. S.K.A., Krakow, Malopolskie, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Mazowieckie, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie, Warszawa, Mazowieckie, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Podlaskie, Poland|Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego, Lomza, Podlaskie, Poland|Szpital Wojewodzki Zespolony, Elblag, Warminsko-mazurskie, Poland|NZOZ Med Polonia, Poznan, Wielkopolskie, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan, Wielkopolskie, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn, Poland|Szpital Chorob Pluc im. Sw. Jozefa w Pilchowicach, Pilchowice, Poland|Szpital Specjalistyczny, Prabuty, Poland|Institutul Oncologic ""Prof. Dr. Alex. Trestioreanu"", Bucharest, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucharest, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Institutul Oncologic ""Prof.Dr.I.Chiricuta"" Cluj Napoca, Cluj Napoca, Romania|Medisprof, Cluj Napoca, Romania|Institutul Oncologic ""Prof.Dr.I.Chiricuta"" Cluj Napoca, Cluj-Napoca, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Oncomed, Timisoara, Romania|Synta Pharmaceuticals Investigational Site, Chelyabinsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Ekaterinburg, Russian Federation|Synta Pharmaceuticals Investigational Site, Ivanovo, Russian Federation|Synta Pharmaceuticals Investigational Site, Izhevsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Kemerovo, Russian Federation|Synta Pharmaceuticals Investigational Site, Krasnoyarsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Kursk, Russian Federation|Synta Pharmaceuticals Investigational Site, Lipetsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Moscow, Russian Federation|Synta Pharmaceuticals Investigational Site, Nizhny Novgorod, Russian Federation|Synta Pharmaceuticals Investigational Site, Novosibirsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Omsk, Russian Federation|Synta Pharmaceuticals Investigational Site, Orel, Russian Federation|Synta Pharmaceuticals Investigational Site, Rostov-on-Don, Russian Federation|Synta Pharmaceuticals Investigational Site, Samara, Russian Federation|Synta Pharmaceuticals Investigational Site, Saransk, Russian Federation|Synta Pharmaceuticals Investigational Site, Sochi, Russian Federation|Synta Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Synta Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Synta Pharmaceuticals Investigational Site, St. Petersburg, Russian Federation|Synta Pharmaceuticals Investigational Site, Stavropol, Russian Federation|Synta Pharmaceuticals Investigational Site, Ufa, Russian Federation|Synta Pharmaceuticals Investigational Site, Ufa, Russian Federation|Clinical Centre of Serbia, Beograd, Belgrade, Serbia|Clinical Centre Nis, Nis, Nišavski okrug, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Institute for pulmonary diseases of Vojvodine, Sremska Kamenica, Serbia|Clinical Center Kragujevac, Kragujevac, Šumadijski okrug, Serbia|Univerzitetna klinika za pljucne bolesti in alergijo Golnik, Golnik, Slovenia|Onkoloski institut Ljubljana, Ljubljana, Slovenia|Xerencia de Xestión Integrada A Coruña Hospital Teresa Herrera, La Coruña, A Coruña, Spain|Synta Pharmaceuticals Investigational Site, Málaga, Andalucía, Spain|Synta Pharmaceuticals Investigational Site, Oviedo, Asturias, Spain|H. Son Llàtzer, Palma de Mallorca, Baleares, Spain|Hospital de Mataró, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain|Synta Pharmaceuticals Investigational Site, Santander, Cantabria, Spain|Onkologikoa, San Sebastian, Guipuzcoa, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|H.U. Vall d'Hebrón, Barcelona, Spain|Synta Pharmaceuticals Investigational Site, Barcelona, Spain|H.U. Reina Sofía, Córdoba, Spain|Synta Pharmaceuticals Investigational Site, Girona, Spain|Synta Pharmaceuticals Investigational Site, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Synta Pharmaceuticals Investigational Site, Madrid, Spain|F. Jiménez Diaz, Madrid, Spain|Synta Pharmaceuticals Investigational Site, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Synta Pharmaceuticals Investigational Site, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Synta Pharmaceuticals Investigational Site, Cherkasy, Ukraine|Synta Pharmaceuticals Investigational Site, Chernivtsi, Ukraine|Synta Pharmaceuticals Investigational Site, Dnepropetrovsk, Ukraine|Synta Pharmaceuticals Investigational Site, Donetsk, Ukraine|Synta Pharmaceuticals Investigational Site, Donetsk, Ukraine|Synta Pharmaceuticals Investigational Site, Ivano-Frankivsk, Ukraine|Synta Pharmaceuticals Investigative Site, Kharkiv, Ukraine|Synta Pharmaceuticals Investigational Site, Khmelnytskyi, Ukraine|Synta Pharmaceuticals Investigational Site, Kirovohrad, Ukraine|Synta Pharmaceuticals Investigational Site, Kryvyi Rih, Ukraine|Synta Pharmaceuticals Investigational Site, Kyiv, Ukraine|Synta Pharmaceuticals Investigational Site, Makiivka, Ukraine|Synta Pharmaceuticals Investigational Site, Poltava, Ukraine|Synta Pharmaceuticals Investigational Site, Simferopol, Ukraine|Synta Pharmaceuticals Investigational Site, Sumy, Ukraine|Synta Pharmaceuticals Investigational Site, Uzhhorod, Ukraine|Synta Pharmaceuticals Investigational Site, Vinnytsia, Ukraine|Synta Pharmaceuticals Investigational Site, Truro, Cornwall, United Kingdom|Synta Pharmaceuticals Investigational Site, Shrewsbury, Shropshire, United Kingdom|Synta Pharmaceuticals Investigational Site, Sutton, Surrey, United Kingdom|Synta Pharmaceuticals Investigational Site, Swindon, Wiltshire, United Kingdom|Synta Pharmaceuticals Investigational Site, Cardiff, United Kingdom|Synta Pharmaceuticals Investigational Site, Edinburgh, United Kingdom|Synta Pharmaceuticals Investigational Site, Leicester, United Kingdom|Synta Pharmaceuticals Investigational Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, Nottingham, United Kingdom|Synta Pharmaceuticals Investigational Site, Southampton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,59.0,32.7488,69.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.81,364.3978,90.09,4.0,3.0,4.0,37.83,102.65,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,0,DB12064,__BMS-777607,,Withdrawn,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,512.893,106.78,5.0,2.0,4.0,49.23,132.8,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,0,DB12072,__ORANTINIB,6395734,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,36.0089529559128,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,310.3471,82.19,3.0,3.0,3.0,34.37,90.47,4.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0
C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,0,DB12078,__ENOBOSARM,WO-2009036206-A1,Terminated,,STRESS URINARY INCONTINENCE (SUI),,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.82,389.32800000000003,106.14,5.0,2.0,2.0,35.87,95.05,6.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0
O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1,0,DB12100,__ABEDITEROL,US-20090042933-A1,Terminated,NCT04199598,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,Male,18 Years to 45 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Research Site, Berlin, Germany",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,61.1429392800673,17.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.14,460.522,90.82,5.0,4.0,3.0,48.29,125.51,13.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
O=C(O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,DB12109,__CPI-613,US-20100190858-A1,Terminated,NCT01832857,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eastchester Center for Cancer Care, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,34.629047824390604,2.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.59,388.58,37.3,2.0,1.0,2.0,45.88,114.56,13.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,NCT02219048,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Center of Alabama, Birmingham, Alabama, United States|Pulmonary Associates, Pa, Phoenix, Arizona, United States|Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States|California Research Medical Group, Inc, Fullerton, California, United States|California Allergy and Asthma Medical Group, Inc., Los Angeles, California, United States|Jonathan Corren MD, Inc., Los Angeles, California, United States|Integrated Research Group, Incorporated, Riverside, California, United States|Peninsula Research Associates, Rolling Hills Estates, California, United States|Allergy Associates Medical Group, San Diego, California, United States|Asthma and Allergy Associates, PC, Colorado Springs, Colorado, United States|Colorado Allergy and Asthma Centers, PC, Denver, Colorado, United States|University of South Florida - Asthma, Allergy and Immunology Clinical Research Unit, Tampa, Florida, United States|Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States|Chesapeake Clinical Research, Inc., Baltimore, Maryland, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Associated Specialists in Medicine, PC, Saint Louis, Missouri, United States|The Clinical Research Center, L.L.C., Saint Louis, Missouri, United States|The Asthma and Allergy Center, Bellevue, Nebraska, United States|North Shore Long Island Jewish Health System, New Hyde Park, New York, United States|American Health Research, Charlotte, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|University of Pittsburgh Asthma Institute, Pittsburgh, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|The Allergy & Asthma Clinic of Central Texas, Killeen, Texas, United States|University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,NCT02366637,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medicines Evaluation Unit Ltd, Wythenshawe, Manchester, United Kingdom|Nottingham University Hospital NHS Trust, Nottingham, Nottinghamshire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Respiratory Medicine, Bradford Institute of Health Research, Bradford, United Kingdom",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1,0,DB12141,__GILTERITINIB,8969336,Terminated,NCT02495233,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site JP81004, Fukuoka Minami-ku, Fukuoka, Japan|Site JP81005, Osakasayama, Osaka, Japan|Site JP81003, Suntogun Nagaizumicho,Shizuoka, Japan|Site JP81002, Tokyo, Japan",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,57.890305755765,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.51,552.724,121.11,10.0,3.0,5.0,62.92,159.84,9.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0
Cc1cccc([C@H](C)c2c[nH]c(=S)[nH]2)c1C,0,DB12143,__REZATOMIDINE,US-20100029659-A1,Terminated,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,38.900182755292704,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.74,232.35,24.06,0.0,2.0,2.0,26.53,73.33,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB12144,__BMS-275183,,Terminated,NCT00359450,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Burlington, Massachusetts, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Morganton, North Carolina, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Montreal, Ontario, Canada|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, St. Jerome, Quebec, Canada|Local Institution, Belfort, France|Local Institution, Besancon, France|Local Institution, Poitiers, France|Local Institution, Saint-Herblain Cedex, France|Local Institution, Strasbourg, France|Local Institution, Tours, France|Local Institution, Napoli, Italy|Local Institution, Orbassano Torino, Italy|Local Institution, Perugia, Italy|Local Institution, Roma, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Maastricht, Netherlands|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Glasgow, Central, United Kingdom|Local Institution, Plymouth, Devon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,845.936,239.75,11.0,4.0,5.0,86.51,208.21,16.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0
COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB12144,__BMS-275183,,Terminated,,TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,845.936,239.75,11.0,4.0,5.0,86.51,208.21,16.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Terminated,NCT02257619,NSCLC (NON-SMALL CELL LUNG CARCINOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hot Springs, Arizona, United States|Los Angeles, California, United States|Washington, District of Columbia, United States|Orlando, Florida, United States|Detroit, Michigan, United States|Pascagoula, Mississippi, United States|Kansas City, Missouri, United States|Omaha, Nebraska, United States|Lebanon, New Hampshire, United States|Goldsboro, North Carolina, United States|Cleveland, Ohio, United States|Gettysburg, Pennsylvania, United States|Hershey, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Spartanburg, South Carolina, United States|Round Rock, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Withdrawn,NCT02355431,SOLID TUMORS AND HEMATOLOGIC MALIGNANCY|NSCLC (NON-SMALL CELL LUNG CARCINOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ogden, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,0,DB12155,__NAPABUCASIN,EP-1134216-B1,Terminated,NCT02826161,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beverly Hills, California, United States|Santa Rosa, California, United States|Aventura, Florida, United States|Gettysburg, Pennsylvania, United States|Arlington, Texas, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,43.2370274543625,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,240.21400000000003,64.35,3.0,0.0,3.0,23.91,63.82,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O,0,DB12155,__NAPABUCASIN,EP-1134216-B1,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,43.2370274543625,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,240.21400000000003,64.35,3.0,0.0,3.0,23.91,63.82,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
Cc1cn2nc([C@@H]3CCCCN3C(=O)c3cc(Cl)ccc3NS(C)(=O)=O)cc2nc1N1CC[C@H](N)C1,0,DB12165,__PRESATOVIR,,Withdrawn,,"INFECTIONS, RESPIRATORY SYNCYTIAL VIRUS",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.1,532.06,125.93,7.0,2.0,5.0,55.64,150.41,4.0,0.0,1.0,0.0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0
CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21,0,DB12167,__LY-3023414,US-20120184577-A1,Terminated,,METASTATIC NON-SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,16.0660383170085,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.36,406.486,78.79,5.0,1.0,4.0,44.34,114.46,5.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C([C@H]3CCCO3)S[C@H]12,0,DB12190,__FAROPENEM,6531508,Terminated,NCT00255983,CHRONIC BRONCHITIS,All,"35 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Multicenter, New Hope, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,20.468592784246,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.24,285.316,87.07,5.0,2.0,3.0,28.16,69.26,3.0,0.0,1.0,0.0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Withdrawn,NCT01563601,EXTENSIVE-STAGE SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12,0,DB12200,__TIVANTINIB,US-20060223760-A1,Terminated,NCT01861301,EPITHELIOID MESOTHELIOMA|RECURRENT MALIGNANT MESOTHELIOMA|SARCOMATOID MESOTHELIOMA|STAGE II PLEURAL MESOTHELIOMA|STAGE III PLEURAL MESOTHELIOMA|STAGE IV PLEURAL MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,50.9907800981539,15.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.04,369.42400000000004,66.89,2.0,2.0,6.0,39.51,106.6,2.0,0.0,1.0,0.0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0
CC(C)(C)N/C(=N/c1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1)NC#N,0,DB12204,__TERBOGREL,EP-0547517-A1,Terminated,NCT02223494,"HYPERTENSION, PULMONARY",All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,29.14228218238561,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,405.50199999999995,110.4,7.0,3.0,2.0,44.61,128.67,8.0,0.0,1.0,0.0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,0,DB12228,__TELCAGEPANT,EP-2007764-B1,Terminated,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,28.68231380521161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,566.523,97.88,4.0,2.0,5.0,52.43,134.6,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,0,DB12254,__ABT-751,5250549,Terminated,NCT00354562,LUNG CANCER|NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Site Ref # / Investigator 3572, Birmingham, Alabama, United States|Site Ref # / Investigator 4771, Burbank, California, United States|Site Ref # / Investigator 3574, Orange, California, United States|Site Ref # / Investigator 3567, Rancho Mirage, California, United States|Site Ref # / Investigator 3512, Gurnee, Illinois, United States|Site Ref # / Investigator 3565, Hackensack, New Jersey, United States|Site Ref # / Investigator 3569, Buffalo, New York, United States|Site Ref # / Investigator 3511, Cleveland, Ohio, United States|Site Ref # / Investigator 5237, Ravenna, Ohio, United States|Site Ref # / Investigator 3551, Crossville, Tennessee, United States|Site Ref # / Investigator 3549, Knoxville, Tennessee, United States|Site Ref # / Investigator 3571, Nashville, Tennessee, United States|Site Ref # / Investigator 3510, Weston, Wisconsin, United States|Site Ref # / Investigator 3563, Sydney, Nova Scotia, Canada|Site Ref # / Investigator 3559, Barrie, Ontario, Canada|Site Ref # / Investigator 3561, Sudbury, Ontario, Canada|Site Ref # / Investigator 3560, Greenfield Park, Quebec, Canada|Site Ref # / Investigator 3562, Montreal, Quebec, Canada|Site Ref # / Investigator 2222, Montreal, Quebec, Canada|Site Ref # / Investigator 3558, Regina, Saskatchewan, Canada|Site Ref # / Investigator 5097, Cork, Ireland|Site Ref # / Investigator 4986, Dublin 24, Ireland|Site Ref # / Investigator 4999, Dublin 4, Ireland|Site Ref # / Investigator 5158, Dublin 7, Ireland|Site Ref # / Investigator 4971, Dublin 8, Ireland|Site Ref # / Investigator 5270, Barming, United Kingdom|Site Ref # / Investigator 5259, Belfast, United Kingdom|Site Ref # / Investigator 5271, Edinburgh, United Kingdom|Site Ref # / Investigator 5017, Glasgow, United Kingdom|Site Ref # / Investigator 5274, Hull, United Kingdom|Site Ref # / Investigator 5273, Surrey, United Kingdom|Site Ref # / Investigator 5268, Surrey, United Kingdom",C07H15/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,25.9225035421671,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.4,371.41,100.55,6.0,3.0,3.0,38.29,97.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0
COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,0,DB12254,__ABT-751,5250549,Terminated,NCT00735878,NON SMALL CELL LUNG CANCER|LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States",C07H15/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,25.9225035421671,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.4,371.41,100.55,6.0,3.0,3.0,38.29,97.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,0,DB12255,__VADADUSTAT,US-20070299086-A1,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,39.5572804369699,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.53,306.7,99.52,5.0,3.0,2.0,29.63,75.51,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CC(C)OP(=O)(OC(C)C)C(Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OC(C)C)OC(C)C,0,DB12276,__APOMINE,6048995,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/404,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,19.7129304503172,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.53,562.665,91.29,3.0,1.0,1.0,61.56,151.23,14.0,1.0,0.0,0.0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0
COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1,0,DB12307,__FORETINIB,US-20070054928-A1,Withdrawn,NCT02034097,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,168.0,108.256843056325,14.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.78,632.6538,111.25,7.0,2.0,6.0,64.65,168.3,12.0,1.0,0.0,0.0,1,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1
CC(=C/C=C/C(C)=C/C(=O)O)/C=C1\CCCc2ccccc21,0,DB12316,__9CUAB30,,Terminated,,"HEALTHY, NO EVIDENCE OF DISEASE",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.6,294.3875,37.3,2.0,1.0,2.0,33.81,94.7,4.0,0.0,1.0,0.0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,0,DB12332,__RUCAPARIB,6495541,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1,0,DB12378,__APRICOXIB,5908858,Terminated,NCT01532362,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",C07D207/333,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,26.185342614838,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.95,356.44,74.32,3.0,1.0,3.0,38.33,109.24,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O,0,DB12391,__SAGOPILONE,US-20040167083-A1,Terminated,NCT00299390,SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K47/6809,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,70.506581243968,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.42,543.72,109.25,6.0,2.0,4.0,59.69,145.71,3.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1
O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1,0,DB12394,__ELECLAZINE,WO-2013006485-A1,Terminated,NCT02291237,HYPERTROPHIC CARDIOMYOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cedars-Sinai Heart Institute, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Athens Regional Medical Center, Athens, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Morristown Medical Center, Morristown, New Jersey, United States|Columbia University Medical Center/ New York Presbyterian, New York, New York, United States|NYU School of Medicine Pediatrics, New York, New York, United States|Duke Health Center at Southpoint, Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|St. Thomas Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Heart Institute, Houston, Texas, United States|UT Southwestern Medical Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Marshfield Clinic Research Institute, Marshfield, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Alfred Hospital, Melbourne, Victoria, Australia|Hôpital Européen Georges Pompidou, Paris, France|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Ein Kerem-Hadassah Medical Organization, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat-Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Madonna del Soccorso Hospital, San Benedetto del Tronto, Ascoli Piceno, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliero Universitaria Di Bologna, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Florence, Italy|Ospedale San Raffaele S.r.l., Milan, Italy|Azienda Ospedaliera Monaldi, Naples, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Academisch Medisch Centrum Amsterdam, Amsterdam, Noord-Holland, Netherlands|Erasmus MC, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|University Hospital of Wales, Cardiff, South Glamergon, United Kingdom|Northern General Hospital, Sheffield, Yorkshire, United Kingdom", A61K31/5513,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,67.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,415.37199999999996,64.55,5.0,0.0,4.0,39.47,98.42,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0
Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,0,DB12405,__TRICIRIBINE,5633235,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,34.7276124766422,177.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,320.309,144.47,8.0,4.0,4.0,31.22,90.56,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB12406,__LISOFYLLINE,5281731,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/1804,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,14.1604550401445,245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.78,280.328,78.67,4.0,1.0,2.0,30.03,74.65,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,0,DB12415,__GALETERONE,WO-2008154382-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0
CON=C1CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2,0,DB12479,__ZABOFLOXACIN,,Terminated,NCT01081964,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Huntsville, Alabama, United States|Toney, Alabama, United States|Ft. Myers, Florida, United States|Eagle, Idaho, United States|Evansville, Indiana, United States|Keego Harbor, Michigan, United States|Belvidere, New Jersey, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Springfield, Ohio, United States|Gresham, Oregon, United States|Warminster, Pennsylvania, United States|Tyler, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,401.398,107.36,9.0,2.0,5.0,40.29,102.53,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
O=C1NC(O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,DB12484,__TETRAHYDROURIDINE,,Terminated,NCT01479348,HEAD AND NECK NEOPLASMS|LUNG NEOPLASMS|URINARY BLADDER NEOPLASMS|BREAST NEOPLASMS,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,248.235,122.49,6.0,5.0,2.0,23.59,53.04,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,0,DB12485,__PIMONIDAZOLE,5674693,Withdrawn,NCT00374517,REFRACTORY PULMONARY TUBERCULOSIS,All,"20 Years and older   (Adult, Older Adult)",NIH|Other,Primary Purpose: Treatment,"International Tuberculosis Research Center, Masan, Korea, Republic of|National Masan Tuberculosis Hospital, Masan, Korea, Republic of",G01N33/57492,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,42.678494424936794,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,254.29,84.43,5.0,1.0,2.0,25.32,65.83,5.0,0.0,1.0,0.0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,,DIASTOLIC HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,0,DB12511,__IMIGLITAZAR,6251926,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,19.3515267253947,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.16,470.525,94.15,6.0,1.0,4.0,52.47,141.78,11.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNCc1ccc([123I])cc1)C(=O)O)C(=O)O,0,DB12514,__IOFOLASTAT_I-123,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,531.337,165.06,8.0,6.0,1.0,46.59,114.95,14.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,0,DB12522,__TOREFORANT,WO-2007117399-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,392.551,69.73,5.0,2.0,4.0,48.0,131.1,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,0,DB12594,__AZD-9056,WO-2001044170-A1,Withdrawn,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61P1/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.33,419.01,61.36,3.0,3.0,4.0,47.83,118.78,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,0,DB12602,__PENTETREOTIDE,6180082,Terminated,NCT00002947,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHILDHOOD LANGERHANS CELL HISTIOCYTOSIS|GASTROINTESTINAL CARCINOID TUMOR|HEAD AND NECK CANCER|INTRAOCULAR MELANOMA|ISLET CELL TUMOR|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|NEOPLASTIC SYNDROME|NEUROENDOCRINE CARCINOMA OF THE SKIN|PHEOCHROMOCYTOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Yale Comprehensive Cancer Center, New Haven, Connecticut, United States",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,57.0,26.2510523830058,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1394.58,494.22,23.0,17.0,5.0,140.9,353.02,34.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0
CC1(C)CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1,0,DB12651,__BARDOXOLONE,,Terminated,NCT02657356,CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Banner University Medical Center, Phoenix Advanced Lung Disease Institute, Phoenix, Arizona, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Beverly Hills, California, United States|Regents of The University of California, Fresno, California, United States|University of California San Diego, La Jolla, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Pacific Pulmonary Research, Inc., San Diego, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States|Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Augusta University, Augusta, Georgia, United States|Piedmont-Georgia Lung, Austell, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University of New Mexico, Albuquerque, New Mexico, United States|NYU Langone Health, New York, New York, United States|University of Rochester - University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|Integris Nazih Zuhdi Transplant Institute, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fundación Favaloro, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Hospital Británico de Buenos Aires, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Centro Médico Dra de Salvo, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina|Instituto de Investigaciones Clínicas Mar Del Plata, Buenos Aires, Mar Del Plata, Argentina|Instituto De Enfermedades Respiratorias E Investigacion Medica, Buenos Aires, Villa Vatteone, Argentina|Hospital Cordoba, Cordoba, Argentina|Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina|Instituto de Cardiologia de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Hospital de Alta Complejidad ""Pte. J. D. Perón"", Formosa, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|UZ Leuven, Leuven, Vlaams Brabant, Belgium|Hôpital Erasme, Brussels, Belgium|Hospital de Messejana, Fortaleza, Ceara, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão, Blumenau, Santa Catarina, Brazil|Hospital São Paulo, Sao Paulo, Brazil|Instituto do Coração - HCFMUSP, São Paulo, Brazil|Peter Lougheed Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Centre Hospitalier de l'Université Laval, Sainte Foy, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Prague, Czechia|Institut klinicke a experimentalni mediciny, Prague, Czechia|Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Universitatsklinkum Erlangen, Erlangen, Bayern, Germany|Universität Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany|DRK Kliniken Berlin Westend, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Thorax Klinik, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|National Hospital Organization Okayama Medical Center, Okayama-shi, Okayama, Japan|Chiba University Hospital, Chiba, Japan|Gunma University School of Medicine, Gunma, Japan|Kobe University Hospital, Kobe, Japan|Nagoya Medical Center, Nagoya, Japan|Hokkaido University Hospital, Sapporo, Japan|Kurume University Medical Center, Sendai-shi, Japan|National Cerebral and Cardiovascular Center, Suita, Japan|Fujita Health University Hospital, Toyoake, Japan|Instituto Nacional de Cardiologia Dr. Ignacio Chavez, Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Nuevo Leon, Mexico|Unidad de Investigación Clínica En Medicina SC, Monterrey, Nuevo Leon, Mexico|Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, Netherlands|Angeles University Foundation Medical Center (AUFMC), Angeles City, Philippines|Mary Mediatrix Medical Center (MMMC), Lipa, Philippines|Makati Medical Center (MMC), Makati, Philippines|Philippine General Hospital (PGH), Manila, Philippines|Philippine Heart Center (PHC), Quezon City, Philippines|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Virgen de La Salud, Toledo, Spain|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.39,491.67199999999997,95.23,5.0,1.0,5.0,56.02,139.59,1.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0
NC(=O)CNC1Cc2ccccc2C1,0,DB12664,__INDANTADOL,US-20040082543-A1,Terminated,NCT01401673,COUGH,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Manchester University Hospital, Manchester, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,32.7488,18.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.79,190.24599999999998,55.12,2.0,2.0,2.0,21.07,54.95,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O,0,DB12668,__METENKEFALIN,EP-0415470-A2,Terminated,,TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",C12Y304/11011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.126347563605,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.28,573.67,199.95,8.0,7.0,2.0,58.85,149.01,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C,0,DB12677,__SOBLIDOTIN,US-20030138864-A1,Withdrawn,,"UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,48.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.36,701.9939999999997,120.52,7.0,2.0,2.0,80.46,197.97,20.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,0,DB12678,__RELAMORELIN,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NCC(c4ccccc4)c4ccccc4)nc(C(=O)NCCNC(=O)NC4CCN(c5ccccn5)CC4)nc32)[C@H](O)[C@@H]1O,0,DB12691,__UK-432097,US-20030013675-A1,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.08,777.8713,220.78,12.0,7.0,7.0,83.68,212.67,14.0,1.0,0.0,0.0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1
N=C(N)NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCCN,0,DB12692,__GUSPERIMUS,4518532,Terminated,NCT01446211,WEGENERS GRANULOMATOSIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Všeobecná fakultní nemocnice v Praze, Praha, Czech Republic",C07D209/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,31.7049631409269,614.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,387.529,178.38,8.0,8.0,0.0,44.43,115.75,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCCN,0,DB12692,__GUSPERIMUS,4518532,Terminated,,GRANULOMATOSIS WITH POLYANGIITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/48,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,31.7049631409269,614.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,387.529,178.38,8.0,8.0,0.0,44.43,115.75,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1
O=C(Cn1ccnc1[N+](=O)[O-])NCCO,0,DB12736,__ETANIDAZOLE,5192784,Terminated,NCT00028782,ADVANCED MALIGNANT MESOTHELIOMA|LOCALIZED MALIGNANT MESOTHELIOMA|MALIGNANT ASCITES|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT MALIGNANT MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,8.41085032546869,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.4,214.18099999999998,110.29,5.0,2.0,1.0,19.04,48.8,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Withdrawn,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
Cc1ncc2c(c1O)COC2c1ccc(Cl)cc1,0,DB12766,__CICLETANINE,5026855,Terminated,NCT00832507,PULMONARY ARTERIAL HYPERTENSION,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama, Mobile, Alabama, United States|Arizona Pulmonary Specialists, Phoenix, Arizona, United States|VA Greater LA Healthcare System, Los Angeles, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Harish H. K. Murthy, MD, San Jose, California, United States|UCLA Medical Center, Torrance, California, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Cleveland Clinic, Ft. Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|University of Chicago Hospital, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Louisiana State University, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Lindner Clinical Trial Center, Cincinnati, Ohio, United States|Case Medical Center, Cleveland, Ohio, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University Of Virginia, Charlottesville, Virginia, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|University Klinik Graz, Graz, Austria|University Klinik Wien, Wien, Austria|ULB Hôpital Erasme, Bruxelles, Belgium|Peter Lougheed Centre, Calgary, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Ludwig-Maximilians-Universitaet, Muenchen, BY, Germany|Universitaetsklinikum Giessen und Marburg, Giessen, HE, Germany|Rabin Medical Center, Petach Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Unidad de Investigación Clínica en Medicina S.C., Monterrey, NL, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico|H Clinic i Provincial, Barcelona, Spain|HU 12 de Octubre, Madrid, Spain|Royal Free Hospital, London, Gt Lon, United Kingdom",C07D491/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,18.858703464136802,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.8,261.71,42.35,3.0,1.0,3.0,26.49,69.68,1.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO,0,DB12774,__AZD-8055,US-20090099174-A1,Withdrawn,,ADVANCED SOLID TUMOURS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.87,465.55400000000003,93.07,9.0,1.0,5.0,51.7,132.36,5.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](NC(=O)c3cc(=O)[nH]c(=O)[nH]3)C[C@@H](C(=O)NCCNC(=O)COCCOCC(=O)Nc3cc(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(S(=O)(=O)O)c34)C[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2OC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O,0,DB12778,__RIVIPANSEL,,Terminated,,PAIN CRISIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1447.42,567.07,30.0,15.0,8.0,140.15,328.37,30.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
CO[C@H]([C@H](O)CO)[C@@H]1OC(C(=O)O)=C[C@H](NC(=N)N)[C@H]1NC(C)=O,0,DB12791,__LANINAMIVIR,,Terminated,NCT02014649,INFLUENZA,All,5 Years to 17 Years   (Child),Industry|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Precision Trials LLC, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|SoCal Clinical Research Med Group, Bellflower, California, United States|Sherif Khamis MD Inc, Canoga Park, California, United States|Advanced Medical Research, Lakewood, California, United States|Madera Family Medical Group, Madera, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.G.A Clinical Trials, Hialeah, Florida, United States|Lafayette Clinical Research Group, Lafayette, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Dr Haidar's Clinic, Carriere, Mississippi, United States|DePaul Health Center, Bridgeton, Missouri, United States|Blue Ridge Pediatric and Adolescent Medicine Group, Boone, North Carolina, United States|Dayton Children's Hospital, Dayton, Ohio, United States|The University of Toledo Medical Center, Toledo, Ohio, United States|Dr Santiago Reyes, Oklahoma, Oklahoma, United States|Cyn3rgy Research, Gresham, Oregon, United States|Sanford Research University of South Dakota, Sioux Falls, South Dakota, United States|Avant Research Assoc., Houston, Texas, United States|West Houston Clinical Research Service, Houston, Texas, United States|Foothill Family Clinic, Salt Lake City, Utah, United States|First Med, Salt Lake City, Utah, United States|Foothill Family Clinic South, Salt Lake City, Utah, United States|Copperview Medical Center, South Jordan, Utah, United States|Dixie Pediatrics, St. George, Utah, United States|Rockwood Clinic, Spokane, Washington, United States|Rockwood North Clinic, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,346.3364,187.22,10.0,7.0,1.0,33.07,91.23,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,1,0,0
O[C@H]([C@@H]1CO1)[C@@H](O)[C@H]1CO1,0,DB12873,__DIANHYDROGALACTITOL,US-20020037328-A1,Withdrawn,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,11.663483849771,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,146.142,62.22,4.0,2.0,2.0,13.67,31.38,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT03213665,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III HODGKIN LYMPHOMA|ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV HODGKIN LYMPHOMA|ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA|EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|LOW GRADE GLIOMA|RECURRENT EPENDYMOMA|RECURRENT EWING SARCOMA|RECURRENT GLIOMA|RECURRENT HEPATOBLASTOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT LANGERHANS CELL HISTIOCYTOSIS|RECURRENT MALIGNANT GERM CELL TUMOR|RECURRENT MALIGNANT GLIOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT MEDULLOBLASTOMA|RECURRENT NEUROBLASTOMA|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT OSTEOSARCOMA|RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT RHABDOID TUMOR|RECURRENT RHABDOMYOSARCOMA|RECURRENT SOFT TISSUE SARCOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY LANGERHANS CELL HISTIOCYTOSIS|REFRACTORY MALIGNANT GERM CELL TUMOR|REFRACTORY MALIGNANT GLIOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY MEDULLOBLASTOMA|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY OSTEOSARCOMA|REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|REFRACTORY RHABDOID TUMOR|REFRACTORY SOFT TISSUE SARCOMA|RHABDOID TUMOR|STAGE III SOFT TISSUE SARCOMA AJCC V7|STAGE IV SOFT TISSUE SARCOMA AJCC V7|WILMS TUMOR,All,"12 Months to 21 Years   (Child, Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
C[C@@H]([C@H](N)C(=O)N[C@H](C(=O)O)[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](O)[C@@H]1O)[C@H](O)c1ccc(O)cn1,0,DB12939,__NIKKOMYCIN_Z,,Terminated,NCT00614666,COCCIDIOIDOMYCOSIS,All,18 Years to 50 Years   (Adult),Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Clinical & Translational Research Center - University of Arizona, Tucson, Arizona, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.2,495.445,244.87,12.0,8.0,3.0,46.27,111.84,8.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1
CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1,0,DB12966,__FALNIDAMOL,WO-1997032880-A1,Suspended,,"UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",,,,,"FISABIO, Elche, Alicante, Spain",A61P17/06 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,387.85,78.86,7.0,2.0,4.0,39.41,104.5,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1
C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,0,DB12974,__RONICICLIB,8735412,Terminated,NCT01573338,SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Saint Louis, Missouri, United States|Buffalo, New York, United States|Cleveland, Ohio, United States|Caen Cedex, France|Lyon Cedex, France|Marseille, France|Villejuif Cedex, France|Seoul, Korea, Republic of|Seoul, Korea, Republic of",C07D239/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,55.5576089858107,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,430.45,108.19,7.0,3.0,3.0,39.89,101.21,8.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,0,DB12974,__RONICICLIB,8735412,Terminated,,SMALL CELL LUNG CANCER (SCLC),,,,,"FISABIO, Elche, Alicante, Spain",C07D239/47,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,55.5576089858107,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,430.45,108.19,7.0,3.0,3.0,39.89,101.21,8.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,0,DB12974,__RONICICLIB,8735412,Withdrawn,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/47,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,55.5576089858107,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,430.45,108.19,7.0,3.0,3.0,39.89,101.21,8.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,DB12978,__PEXIDARTINIB,7893075,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,39.064457175712,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.64,417.82,66.49,4.0,2.0,4.0,39.33,105.89,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1
N#CN/C(=N\c1ccncc1)NCCCCCCOc1ccc(Cl)cc1,0,DB12980,__CHS-828,5696140,Withdrawn,,"UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,14.193309924228402,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,371.87,82.33,6.0,2.0,2.0,40.84,104.55,9.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,0,DB12986,__VS-5584,,Terminated,NCT02372227,RELAPSED MALIGNANT MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Chicago Medical Center, Chicago, Illinois, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University of Leicester, Leicester, United Kingdom|The Institute of Cancer Research, Sutton Surrey, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.96,354.418,107.87,8.0,1.0,4.0,38.53,99.61,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1
O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O,0,DB13029,__MK-0873,,Terminated,NCT00132730,"LUNG DISEASES|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.82,422.444,89.24,5.0,1.0,5.0,45.46,115.36,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,0,DB13036,__RAMATROBAN,6362214,Withdrawn,NCT00311051,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Center Borstel, Borstel, Germany",C07D209/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,21.0928355818394,30.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,416.47,88.4,4.0,2.0,4.0,42.28,107.08,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0
O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,0,DB13053,__CP-195543,WO-2001034134-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.41,428.407,66.76,4.0,2.0,4.0,41.92,109.38,5.0,0.0,1.0,0.0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,,ADVANCED MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1,0,DB13062,__ME-344,,Terminated,NCT02100007,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|University of WA Seattle Cancer Care Alliance, Seattle, Washington, United States|The Bays St Mary's Hospital, London, England, United Kingdom|Sarah Cannon Research Instititute UK, London, England, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,348.398,69.92,4.0,3.0,4.0,36.89,100.63,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1,0,DB13164,__OLMUTINIB,US-20130116213-A1,Terminated,NCT04510415,NON SMALL CELL LUNG CANCER,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center, Gyeonggi-do, Korea, Republic of|The Catholic Univ. of Korea Bucheon St.Mary's Hospital, Gyeonggi-do, Korea, Republic of|The Catholic Univ. of Korea St.Vincent's Hospital, Gyeonggi-do, Korea, Republic of|The Catholic Univ. of Korea Uijeongbu St.Mary's Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|The Catholic Univ. of Korea Incheon St.Mary's Hospital, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic Univ. of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,43.95983490420741,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.22,486.59,82.62,6.0,2.0,5.0,53.21,140.67,7.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0
N=C(N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](NCC(=O)O)C2CCCCC2)cc1,0,DB13616,__MELAGATRAN,6174855,Terminated,,THROMBOEMBOLISM,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/55,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,30.357912893488496,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.51,429.5126,148.61,7.0,5.0,3.0,46.84,125.7,9.0,0.0,1.0,0.0,1,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1
CN1C(=O)C(O)N=C(c2ccccc2Cl)c2cc(Cl)ccc21,0,DB13872,__LORMETAZEPAM,4065451,Terminated,,SLEEP INITIATION AND MAINTENANCE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,70.736565432555,105.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.92,335.185,52.9,3.0,1.0,3.0,32.21,85.82,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,0,DB13994,__AZD-7325,US-20070142328-A1,Suspended,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC1=C(C)C(=O)C(CC[C@](C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C1=O,0,DB14094,__TOCOPHERYLQUINONE,US-20100063161-A1,Terminated,,NEUROMUSCULAR DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,38.40735949403471,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.09,446.7055,54.37,3.0,1.0,1.0,56.76,137.43,15.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0
F[B-](F)(F)F.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Cu+],0,DB14106,__TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I)_TETRAFLUOROBORATE,,Terminated,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.94,602.99,13.59,1.0,0.0,0.0,12.7,41.61,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)[O-],0,DB14511,__ACETATE,,Terminated,NCT00637728,ANOREXIA|CACHEXIA|WEIGHT LOSS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Innovative Medical Research of South Florida, Inc, Miami, Florida, United States|Western Maryland Health System, Cumberland, Maryland, United States|Lowcountry Hematology & Oncology, PA, Mt. Pleasant, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],0,DB14511,__ACETATE,,Terminated,NCT01257802,"LUPUS ERYTHEMATOSUS, SYSTEMIC|SYSTEMIC VASCULITIS|ISOLATED ANGIITIS OF CENTRAL NERVOUS SYSTEM|LUNG DISEASE WITH SYSTEMIC SCLEROSIS|LUNG DISEASE INTERSTITIAL DIFFUSE",Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Michigan, Ann Arbor, Michigan, United States|The Ohio State University, Columbus, Ohio, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,0,DB14539,__HYDROCORTISONE_ACETATE,3956349,Terminated,,INFLUENZA IN HUMANS,,,,,"FISABIO, Elche, Alicante, Spain",C07J5/0053,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.718988069570198,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,404.4966,100.9,5.0,2.0,4.0,43.82,106.55,4.0,0.0,1.0,0.0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O,0,DB00781,__POLYMYXIN_B,,Withdrawn,NCT02134106,BACTEREMIA|HEALTHCARE-ASSOCIATED PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA,All,"21 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,1203.499,490.66,18.0,18.0,2.0,127.4,313.22,29.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1,0,DB14768,__PF-06459988,US-20130079324-A1,Withdrawn,NCT02297425,ADVANCED EGFRM (DEL 19 OR L858R +/- T790M) NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.3292059385202,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.38,431.88,110.19,7.0,2.0,4.0,44.34,122.92,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,1,1,1
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O,0,DB14777,__MUREPAVADIN,,Terminated,NCT03409679,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research site, Chicago, Illinois, United States|Research site, Springfield, Missouri, United States|Research site, Greensboro, North Carolina, United States|Research Site 1, Belo Horizonte, Brazil|Research Site 2, Belo Horizonte, Brazil|Research Site, Itaquaquecetuba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, São José Do Rio Preto, Brazil|Research site 1, Zagreb, Croatia|Research site 2, Zagreb, Croatia|Research site, Tallinn, Estonia|Reasearch site, Tartu, Estonia|Reasearch site, Võru, Estonia|Research site, Lille, France|Reasearch site, Limoges, France|Research site, Lyon, France|Reasearch site, Nice, France|Research site 1, Paris, France|Research site 2, Paris, France|Research site 3, Paris, France|Research site, Pierre-Bénite, France|Research Site, Athens, Greece|Research Site, Ioánnina, Greece|Research Site 1, Larissa, Greece|Research Site 2, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloníki, Greece|Reasearch site, Budapest, BU, Hungary|Research site, Budapest, BU, Hungary|Reasearch site, Ózd, BZ, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Vác, Hungary|Research site, Jerusalem, JM, Israel|Research site, Nahariya, Z, Israel|Research site, Tiberias, Z, Israel|Research site, Petah Tiqva, Israel|Research site, Tel HaShomer, Israel|Research site, Zefat, Israel|Research Site, Ansansi Danweongu, Korea, Republic of|Research Site, Gangwon-do, Korea, Republic of|Research site, Gyeongsang, Korea, Republic of|Research site, Incheon, Korea, Republic of|Research site 1, Seoul, Korea, Republic of|Research site 2, Seoul, Korea, Republic of|Research Site 3, Seoul, Korea, Republic of|Research site, Seoul, Korea, Republic of|Research Site 1, Guadalajara, Mexico|Research Site 2, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research site 1, Tshwane, Gauteng, South Africa|Research Site, Cape Town, South Africa|Research Site, Pretoria, South Africa|Research Site 2, Tshwane, South Africa|Research site, Barcelona, B, Spain|Research site, Terrassa, B, Spain|Research site, Girona, Spain|Research Site 1, Bangkok, Thailand|Research Site 2, Bangkok, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Nonthaburi, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,1553.8370000000002,617.98,22.0,22.0,7.0,161.06,403.1,21.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O,0,DB14777,__MUREPAVADIN,,Terminated,,BRONCHIECTASIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,1553.8370000000002,617.98,22.0,22.0,7.0,161.06,403.1,21.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0
C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,0,DB14785,__FENEBRUTINIB,8716274,Terminated,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,18.070186246124106,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,664.811,119.3,9.0,2.0,8.0,75.41,192.2,7.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1
CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C,0,DB14808,__LUMICITABINE,,Terminated,,RESPIRATORY SYNCYTIAL VIRUS (RSV),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,433.86,120.52,6.0,1.0,2.0,41.59,98.79,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0
CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1,0,DB14814,__LANABECESTAT,8415483,Withdrawn,,HEPATIC IMPAIRMENT,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,15.6389248239183,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.46,412.537,72.86,5.0,1.0,5.0,48.22,120.18,3.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,1
Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1,0,DB14822,__SB-649868,,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.64,477.55,75.44,3.0,1.0,5.0,49.12,128.06,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[N+]([O-])c1nccn1CC(O)C[18F],0,DB14830,__FLUOROMISONIDAZOLE_F-18,,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,188.149,81.19,4.0,1.0,1.0,15.65,40.27,4.0,0.0,1.0,0.0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O,0,DB14879,__CEFIDEROCOL,9238657,Terminated,NCT03862040,BACTERIAL PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Anschutz Medical Campus, Aurora, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|University of Florida, Jacksonville, Florida, United States|U Miami Health Tower, Miami, Florida, United States|North Western University, Chicago, Illinois, United States|Creighton University, Omaha, Nebraska, United States|Weill Cornell Medical College, New York, New York, United States",C07D505/24,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,74.7448612907862,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,752.21,256.9,13.0,6.0,5.0,72.74,204.1,13.0,1.0,0.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,1
COc1cc(OCc2csc(-c3ccc(C(=O)N(C)C)cc3)n2)c2cc(-c3cn4nc(OC)sc4n3)oc2c1,0,DB14942,__BMS-986141,,Withdrawn,,HEPATIC IMPAIRMENT,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.9,561.63,104.22,7.0,0.0,6.0,60.17,177.23,8.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,1,0,1,0,0
Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1,0,DB14944,__TARLOXOTINIB,,Terminated,,NON SMALL CELL LUNG CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,601.87,140.76,8.0,2.0,4.0,56.17,161.76,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21,0,DB14945,__FLORBENAZINE_F-18,,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,364.49199999999996,41.93,4.0,1.0,3.0,42.07,101.86,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0
Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1,0,DB14948,__BMS-986020,US-20100311799-A1,Withdrawn,,SCLERODERMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,17.4130885644469,12.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.63,482.536,101.66,5.0,2.0,5.0,51.69,136.34,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,0,DB14969,__GTX-758,US-20070265296-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,181.0,60.0587281052999,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.09,341.314,60.77,3.0,2.0,3.0,32.11,88.88,3.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,0,DB14974,__PIMODIVIR,,Terminated,,INFLUENZA A VIRUS INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,399.402,103.79,6.0,3.0,5.0,38.46,112.27,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,0,DB14975,__VOXELOTOR,9018210,Terminated,,HYPOXEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,27.95950635536661,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.02,337.379,77.24,5.0,1.0,3.0,35.37,106.25,6.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Terminated,NCT04053543,PAH,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|Anaheim Clinical Trials, LLC, Anaheim, California, United States|University of California San Diego, La Jolla, California, United States|University of California San Francisco, San Francisco, California, United States|National Jewish Health, Denver, Colorado, United States|Washington Hospital (Medstar), Washington, District of Columbia, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Health, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Minnesotta, Minneapolis, Minnesota, United States|Washington University and Barnes Jewish Hospital, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Christ Hospital-Lindner Research Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Vanderbuilt University, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|Texas Tech, El Paso, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Virginia School of Medicine, Charlottesville, Virginia, United States|Inova Medical Campus, Falls Church, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Froedert Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Golden Jubilee National Hospital, Glasgow, United Kingdom|Royal Free, London, United Kingdom|Royal Brompton, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,NCT03680976,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H]1[C@H]2N(C(=O)CN(C)N2C(=O)NCc2ccccc2)[C@@H](Cc2ccc(OP(=O)(O)O)cc2)C(=O)N1Cc1cccc2cccnc12,0,DB15034,__PRI-724,WO-2014061828-A1,Terminated,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.09,658.6519999999998,155.85,8.0,3.0,6.0,65.6,171.76,8.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
NS(=O)(=O)c1cncc(-c2nc(NCc3ccccn3)c3c(-c4ccccc4)cccc3n2)c1,0,DB15047,__BMS-919373,US-20120232068-A1,Terminated,,PAROXYSMAL ATRIAL FIBRILLATION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,38.1445204213638,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.65,468.54,123.75,7.0,2.0,5.0,47.97,141.79,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,0,DB15057,__NUC-1031,,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.43,580.482,162.01,7.0,3.0,4.0,53.24,134.78,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,0,DB15097,__GEFAPIXANT,7858632,Terminated,NCT03569033,ACUTE COUGH,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hvivo Service Limited. Queen Mary BioEnterprises ( Site 0003), London, United Kingdom",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,69.8494835622907,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.87,353.4,156.44,7.0,3.0,2.0,34.62,91.44,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,0,DB15170,__EVOBRUTINIB,WO-2012170976-A2,Terminated,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.94,429.524,93.37,5.0,2.0,4.0,45.68,128.81,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@@H]1CN(c2nc(-n3ccc(OCCC4(C(F)(F)F)CC4)n3)ccc2C(=O)NS(=O)(=O)c2ccccc2)C(C)(C)C1,0,DB15177,__VX-659,,Terminated,NCT03633526,CYSTIC FIBROSIS,All,6 Years to 11 Years   (Child),Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Clinical Research of Charlotte, Charlotte, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Texas Children's Hospital, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.81,591.65,106.42,7.0,1.0,5.0,60.42,149.59,9.0,1.0,0.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0
CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2,0,DB15195,__MIBENRATIDE,,Withdrawn,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,2097.27,940.67,37.0,32.0,5.0,203.7,528.21,32.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,1,1
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,0,DB15205,__CAPROMORELIN,6107306,Terminated,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0202,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,17.7416374052855,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,505.619,117.33,6.0,2.0,4.0,54.59,140.17,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,0,DB15219,__TOMIVOSERTIB,,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C,0,DB15245,__OLOROFIM,,Withdrawn,,INVASIVE ASPERGILLOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,498.56199999999995,83.36,6.0,1.0,5.0,52.99,144.16,6.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,0,DB15266,__TAK-580,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,506.29,135.78,7.0,3.0,3.0,43.95,114.04,6.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)[C@@H](C)CC)C(=O)NCC(=O)O,0,DB15272,__EDRATIDE,,Terminated,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.6,2309.574,883.21,33.0,31.0,10.0,242.59,603.24,67.0,1.0,0.0,0.0,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,1
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,0,DB15273,__VS-4718,,Terminated,,METASTATIC CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.55,501.51,87.75,7.0,3.0,4.0,50.39,131.1,8.0,1.0,0.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1
CCCCCCC(=O)N[C@@H]1CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2C[C@H](C(N)=O)NC(=O)[C@@H]2CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CCCC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O,0,DB15355,__PL-3994,,Withdrawn,NCT01304628,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cranbury, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,1875.21,762.94,30.0,28.0,5.0,190.05,507.91,36.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(=O)C3CCCC3)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)C)c4cccs4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB15384,__SIMOTAXEL,,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,896.01,230.52,10.0,4.0,7.0,91.58,221.91,16.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1,0,DB15412,__LB-100,,Withdrawn,,EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.97,268.313,70.08,5.0,1.0,3.0,27.89,67.27,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,0,DB15418,__AZD-9977,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,399.37800000000004,96.97,5.0,2.0,4.0,38.12,101.36,3.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,0,DB15440,__GSK-3117391,,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,403.523,100.55,5.0,3.0,3.0,45.52,108.98,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1
CCCCCc1cccc(CC(=O)O)c1,0,DB15447,__SETOGEPRAM,WO-2010127448-A1,Terminated,,CYSTIC FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.84,206.285,37.3,2.0,1.0,1.0,24.07,60.81,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1,0,DB15490,__ZURANOLONE,,Suspended,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.03,409.574,78.91,4.0,1.0,5.0,47.55,127.19,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1
Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Fe+3],0,DB15598,__FERRIC_MALTOL,9248148,Terminated,NCT03371173,"HYPERTENSION, PULMONARY|ANEMIA, IRON DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hannover Medical School, Hannover, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,80.6587404258814,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.62,431.154,49.36,3.0,0.0,3.0,11.25,44.27,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CS(=O)(=O)CCCn1c(Cn2c(=O)n(CC(F)(F)F)c3ccncc32)cc2cc(Cl)ccc21,0,DB15672,__RILEMATOVIR,,Terminated,,"INFECTIONS, RESPIRATORY SYNCYTIAL VIRUS",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,500.92,75.51,4.0,0.0,4.0,46.71,118.14,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1
CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,,_NELFINAVIR_MESYLATE,5925759,Suspended,NCT03050060,METASTATIC KIDNEY CARCINOMA|RECURRENT LUNG NON-SMALL CELL CARCINOMA|STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7|STAGE IV RENAL CELL CANCER AJCC V7|STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,22.439885829277802,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,,_VASOPRESSIN,4150149,Suspended,NCT02975999,PLEURAL EFFUSION|SINGLE-VENTRICLE,All,18 Months to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Advocate Children's Hospital, Oak Lawn, Illinois, United States",G01N33/74,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,28.5508942688761,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,,_VASOPRESSIN,4150149,Terminated,NCT01370096,PULMONARY HYPERTENSION,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stollery Children's Hospital, Edmonton, Alberta, Canada",G01N33/74,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,28.5508942688761,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,0,,_MORPHINE_SULFATE,4083982,Suspended,NCT03564548,CANCER|BREAKTHROUGH CANCER PAIN,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HRI, Berlin, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,0,,_MORPHINE_SULFATE,4083982,Withdrawn,NCT02455362,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|DYSPNEA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1.C[C@H](O)C(=O)O.O,0,,_DOVITINIB_LACTATE,,Terminated,NCT01515969,"NON-SMALL CELL LUNG CANCER (NSCLC), RECURRENT|NON-SMALL CELL LUNG CANCER (NSCLC), STAGE IV",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT01515969,"NON-SMALL CELL LUNG CANCER (NSCLC), RECURRENT|NON-SMALL CELL LUNG CANCER (NSCLC), STAGE IV",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT02134886,HIV INFECTION|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT01193881,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00042835,ADENOCARCINOMA OF THE LUNG|BRONCHOALVEOLAR CELL LUNG CANCER|LARGE CELL LUNG CANCER|SQUAMOUS CELL LUNG CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT02926638,MET POSITIVE|RECURRENT SQUAMOUS CELL LUNG CARCINOMA|STAGE IV SQUAMOUS CELL LUNG CARCINOMA AJCC V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States|Kaiser Permanente-Bellflower, Bellflower, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Sutter Davis Hospital, Davis, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Kaiser Permanente Hospital, Fontana, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Washington Hospital, Fremont, California, United States|Kaiser Permanente, Fresno, California, United States|Saint Jude Medical Center, Fullerton, California, United States|Kaiser Permanente - Harbor City, Harbor City, California, United States|Kaiser Permanente-Irvine, Irvine, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|City of Hope Antelope Valley, Lancaster, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Cadillac, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Kaiser Permanente - Panorama City, Panorama City, California, United States|Feather River Cancer Center, Paradise, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Riverside, Riverside, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Saint Helena Hospital, Saint Helena, California, United States|Kaiser Permanente-San Diego Mission, San Diego, California, United States|Kaiser Permanente-San Diego Zion, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Marcos, San Marcos, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Kaiser Permanente, Woodland Hills, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Medical Oncology and Hematology Group PC-Guilford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale-New Haven Hospital Saint Raphael Campus, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|University of Florida Health Science Center ?? Gainesville, Gainesville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Memorial University Medical Center, Savannah, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|South Georgia Medical Center/Pearlman Cancer Center, Valdosta, Georgia, United States|Hawaii Oncology Inc-Pali Momi, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Leeward, 'Ewa Beach, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Hawaii Oncology Inc-Kuakini, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Joseph Regional Medical Center, Lewiston, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Advocate Sherman Hospital, Elgin, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Saint Francis Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Hematology Oncology Consultants Limited, Naperville, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|IU Health Central Indiana Cancer Centers-Fishers, Fishers, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers-East, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|IU Health Arnett Cancer Care, Lafayette, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Woodland Cancer Care Center, Michigan City, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Hardin Memorial Hospital, Elizabethtown, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Hematology/Oncology Clinic LLP, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States|Ochsner Medical Center Kenner, Kenner, Louisiana, United States|Robert Veith MD LLC, Metairie, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|LSU Healthcare Network/Saint Charles, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Mercy Hospital, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|York Hospital, York, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|MedStar Union Memorial Hospital, Baltimore, Maryland, United States|MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Beverly Hospital, Beverly, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mid-Michigan Medical Center - Midland, Midland, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Providence Hospital-Southfield Cancer Center, Southfield, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Baptist Cancer Center-Golden Triangle, Columbus, Mississippi, United States|Boston Baskin Cancer Center-Grenada, Grenada, Mississippi, United States|Family Cancer Center-Oxford, Oxford, Mississippi, United States|Family Cancer Center-Southhaven, Southaven, Mississippi, United States|Baptist Memorial Hospital-Desoto, Southhaven, Mississippi, United States|Baptist Cancer Institute-Starkville, Starkville, Mississippi, United States|Central Care Cancer Center-Carrie J Babb Cancer Center, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|CoxHealth Cancer Center, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital-Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Faith Regional Medical Offices West, Norfolk, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Regional West Medical Center, Scottsbluff, Nebraska, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada - Henderson, Henderson, Nevada, United States|Las Vegas Cancer Center-Henderson, Henderson, Nevada, United States|21st Century Oncology - Henderson, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada-Southeast Henderson, Henderson, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Central, Las Vegas, Nevada, United States|21st Century Oncology, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Radiation Oncology Centers of Nevada Southeast, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Northwest, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada-Summerlin, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Las Vegas Cancer Center-Medical Center, Las Vegas, Nevada, United States|21st Century Oncology - Fort Apache, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|21st Century Oncology - Vegas Tenaya, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Alpine Hematology-Oncology, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Radiation Oncology Associates, Reno, Nevada, United States|Reno Oncology Consultants, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Arnot Ogden Medical Center/Falck Cancer Center, Elmira, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Cancer Care of Western North Carolina, Asheville, North Carolina, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Oncology Specialists of Charlotte, Charlotte, North Carolina, United States|Southern Oncology Specialists-Charlotte, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Park Ridge Hospital Breast Health Center, Hendersonville, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Southern Oncology Specialists-Huntersville, Huntersville, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Matthews Radiation Oncology Center, Matthews, North Carolina, United States|Novant Health Cancer Specialists-Matthews, Matthews, North Carolina, United States|Lake Norman Hematology Oncology Specialists-Mooresville, Mooresville, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lancaster Radiation Oncology, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|PinnacleHealth Cancer Center-Community Campus, Harrisburg, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC-Coraopolis/Heritage Valley Radiation Oncology, Moon, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC Jefferson Regional Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates-Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Charleston Hematology Oncology Associates PA-St. Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Georgetown Hospital System, Georgetown, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Carolina Blood and Cancer Care Associates PA-Lancaster, Lancaster, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Boston Baskin Cancer Center-Bartlett, Bartlett, Tennessee, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|Baptist Memorial Hospital for Women, Memphis, Tennessee, United States|Family Cancer Center-Memphis, Memphis, Tennessee, United States|The Don and Sybil Harrington Cancer Center, Amarillo, Texas, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|The Methodist Hospital System, Houston, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg, Virginia, United States|Lynchburg Hematology-Oncology Clinic, Lynchburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|VCU Community Memorial Health Center, South Hill, Virginia, United States|Shenandoah Oncology Associates PC, Winchester, Virginia, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Providence - Saint Peter Hospital, Olympia, Washington, United States|Capital Medical Center, Olympia, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|MultiCare Allenmore Hospital, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Northwest NCI Community Oncology Research Program, Tacoma, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Fox Valley Hematology and Oncology SC-Appleton, Appleton, Wisconsin, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Aurora Cancer Care-Kenosha South, Kenosha, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Vince Lombardi Cancer Clinic-Marinette, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Marshfield Clinic at James Beck Cancer Center, Rhinelander, Wisconsin, United States|Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Lakeview Medical Center-Marshfield Clinic, Rice Lake, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Marshfield Clinic Cancer Care at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care-Waukesha, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Saint Clare's Hospital, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT01857271,STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albert Einstein College of Medicine, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00976677,RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Saint Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States|Porubcin, Michael MD (UIA Investigator), Moline, Illinois, United States|Sharis, Christine M MD (UIA Investigator), Moline, Illinois, United States|Spector, David MD (UIA Investigator), Moline, Illinois, United States|Stoffel, Thomas J MD (UIA Investigator), Moline, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|McFarland Clinic, Ames, Iowa, United States|Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium Community Clinical Oncology Program, Ann Arbor, Michigan, United States|Oakwood Hospital, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Essentia Health Duluth Clinic CCOP, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Orange Village, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazelton, Hazleton, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States|Lankenau Hospital, Wynnewood, Pennsylvania, United States|Mainline Health CCOP, Wynnewood, Pennsylvania, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Zale Lipshy University Hospital, Dallas, Texas, United States|Saint Paul Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Dean Hematology and Oncology Clinic, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00087269,STAGE IA NON-SMALL CELL LUNG CANCER|STAGE IB NON-SMALL CELL LUNG CANCER|STAGE IIA NON-SMALL CELL LUNG CANCER|STAGE IIB NON-SMALL CELL LUNG CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Eastern Cooperative Oncology Group, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT01192815,STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00096265,METASTATIC MALIGNANT NEOPLASM IN THE BRAIN|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7,All,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Scottsdale Health Care-Osborn, Scottsdale, Arizona, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Integrated Community Oncology Network-Florida Cancer Center Beaches, Jacksonville Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Integrated Community Oncology Network-Southside Cancer Center, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|21st Century Oncology-Orange Park, Orange Park, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|21st Century Oncology-Palatka, Palatka, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States|Tallahassee Memorial HealthCare, Tallahassee, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Saint John's Hospital, Springfield, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Franciscan Saint Margaret Health-Hammond Campus, Hammond, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Finley Hospital, Dubuque, Iowa, United States|Norton Suburban Hospital and Medical Campus, Louisville, Kentucky, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Sparta Cancer Treatment Center, Sparta, New Jersey, United States|University of Rochester, Rochester, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Wheaton Franciscan Cancer Care - All Saints, Racine, Wisconsin, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Ottawa Hospital-Civic Campus, Ottawa, Ontario, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00738881,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Valley Care Health System - Pleasanton, Pleasanton, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Bristol Hospital, Bristol, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Lynn Regional Cancer Center - West, Boca Raton, Florida, United States|Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|MacNeal Hospital and Cancer Center, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Cottage, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|NorthShore Hematology Oncology-Libertyville, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|DuPage Medical Group-Ogden, Naperville, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Franciscan St. Francis Health-Beech Grove, Beech Grove, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Hematology Oncology Associates-Quad Cities, Bettendorf, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Medical Center - West Campus, Davenport, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Shawnee Mission Medical Center-KCCC, Shawnee Mission, Kansas, United States|Stormont-Vail Regional Health Center, Topeka, Kansas, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|The Memorial Hospital at Easton, Easton, Maryland, United States|Cancer Trials Support Unit, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Minnesota Cooperative Group Outreach Program, Minneapolis, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Center for Cancer Care and Research, Saint Louis, Missouri, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Syracuse Veterans Administration Medical Center, Syracuse, New York, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Cancer Consortium-Upstate NCORP, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Mercy Hospital, Scranton, Pennsylvania, United States|Scranton Hematology Oncology, Scranton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Memorial Hospital Of Martinsville, Martinsville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT00554775,LUNG CANCER|METASTATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Charing Cross Hospital, London, England, United Kingdom|University College of London Hospitals, London, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom|South West Wales Cancer Institute, Swansea, Wales, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Withdrawn,NCT01332279,RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|TONGUE CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Withdrawn,NCT01928160,RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.O=C(O)C(O)C(O)C(=O)O,0,,_LEVALBUTEROL_TARTRATE,,Terminated,NCT02150499,ASTHMA,All,up to 48 Months   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Score Physician Alliance, LLC, Saint Petersburg, Florida, United States|Northern Illinios Research Associates, Dekalb, Illinois, United States|Northern Illinois Associates, Dekalb, Illinois, United States|Michael W. Simon, MD, PSC, Nicholasville, Kentucky, United States|Willis-Knighton Physician Network / Portico Pediatrics, Shreveport, Louisiana, United States|Mid Michigan Sleep Center, Grand Blanc, Michigan, United States|Craig Spiegel, MD, Bridgeton, Missouri, United States|St. Peter's University Hospital, New Brunswick, New Jersey, United States|Capital Pediatrics & Adolescent Center PLLC, Raleigh, North Carolina, United States|Capitol Pediatric & Adolescent Center PLLC, Raleigh, North Carolina, United States|Dayton Clinical Research, Dayton, Ohio, United States|Charleston Allergy & Asthma Research, Summerville, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|TTS Research, Boerne, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|PI-Coor Clinical Research, Burke, Virginia, United States|Advanced Pediatrics, Vienna, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
O=C([O-])[C@@H]1CCC(O)=N1.O=C([O-])[C@@H]1CCC(O)=N1.[Mg+2],0,,_MAGNESIUM_PIDOLATE,WO-1997038701-A1,Terminated,NCT00532883,HEMOGLOBIN SC DISEASE,All,"5 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hospital and Research Center, Oakland, California, United States|University of California Davis, Sacramento, California, United States|University of Colorado, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Saint Christopher's Hospital, Philadelphia, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Medical Center, Dallas, Texas, United States",A61K33/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl,0,,_EZATIOSTAT_HYDROCHLORIDE,,Terminated,NCT00701870,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Central Hematology Oncology Medical Group, Alhambra, California, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|UCLA Medical Center, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|North Valley Hematology/Oncology Medical Group, Northridge, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Samsum Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital Cancer Institute, Ormand Beach, Florida, United States|Suburban Hematology-Oncology Associates, PC, Lawrenceville, Georgia, United States|Medical & Surgical Specialists, Galesburg, Illinois, United States|Joliet Oncology/Hematology Associates, Ltd., Joliet, Illinois, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Case Medical Center-University Hospitals, Cleveland, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1
CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1.O,0,,_NAVARIXIN,,Terminated,NCT00441701,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"41 Years to 75 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,0,,_VEDOTIN,,Terminated,NCT02713828,SQUAMOUS CELL CARCINOMA OF THE LUNG,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Hospital, Miami, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Stony Brook University, Stony Brook, New York, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O.CS(=O)(=O)O,0,,_TALABOSTAT_MESYLATE,,Terminated,NCT00243204,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Marshall Schreeder, MD, Huntsville, Alabama, United States|James P. Daugherty, MD, Muscle Shoals, Alabama, United States|Alaska Cancer Research, Anchorage, Alaska, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Veena Charu, MD, Anaheim, California, United States|Lalita Pandit, MD, Inc, Fountain Valley, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Warren Paroly, MD, Oceanside, California, United States|Swarna S. Chanduri, MD, Pomona, California, United States|Southwest Cancer Care Medical Group, Poway, California, United States|Mile High Oncology, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Pasco Hernando Oncology Associates PA, Brooksville, Florida, United States|Lucio Gordan, MD, Gainesville, Florida, United States|Citrus Hematology and Oncology Center, Inverness, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Jorge G. Otoya, MD, Kissimmee, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Joliet Oncology Hematology Associates, Joliet, Illinois, United States|Indiana Hematology Oncology Consultants, Indianapolis, Indiana, United States|Northern Indiana Oncology Associates, South Bend, Indiana, United States|Kansas City Cancer Centers, Southwest, Overland Park, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Medical Oncology, LLC, Baton Rouge, Louisiana, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Chesapeake Oncology Hematology Associates (Tate Center), Glen Burnie, Maryland, United States|Josephine Ford Cancer Center -- Downriver, Brownstown, Michigan, United States|Michael McKenzie, DO, Clinton Township, Michigan, United States|Henry Ford Medical Center -- Fairlane, Dearborn, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Youssef Hanna, MD, Port Huron, Michigan, United States|Cancer and Transplant Consultants, PLC, Rochester Hills, Michigan, United States|Cancer Care Associates, Rochester Hills, Michigan, United States|Cancer Care Associates, PC, Royal Oak, Michigan, United States|Hematology Oncology Consultants, Royal Oak, Michigan, United States|Jeffrey H. Margolis, MD, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Hematology and Oncology Institute, Southgate, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|Mitchell Folbe, MD, PC, Troy, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Henry Ford Medical Center, West Bloomfield, Michigan, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Arch Medical Services, Inc., St. Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|George A. Zervos, MD, Glen Head, New York, United States|Northwestern Carolina Oncology Hematology, Hickory, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|Dayton Hematology and Oncology, Kettering, Ohio, United States|Mukesh C. Bhatt, MD, Medina, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Northwest Cancer Specialists, Northrup, Portland, Oregon, United States|Shatish A. Shah, MD, Gettysburg, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Rittenhouse Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|Chester County Hematology / Oncology Services, West Chester, Pennsylvania, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|Palmetto Hematology Oncology, PC, Spartanburg, South Carolina, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Cancer Center / Denton, Denton, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology, PA, Ft. Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Ft. Worth, Texas, United States|Texas Cancer Center of Mesquite, Mesquite, Texas, United States|Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Oncology Cancer Center--Sugar Land, Sugar Land, Texas, United States|Annandale-Fairfax Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|Peninsula Cancer Institute, Gloucester, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Peninsula Cancer Institute, Williamsburg, Virginia, United States|Masoom Kandahari, MD, PC, Woodbridge, Virginia, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Jay L. Wittenkeller, MD, Spokane, Washington, United States|Cancer Care Northwest Research, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0
CC[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,,_TALABOSTAT,,Terminated,NCT00243204,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Marshall Schreeder, MD, Huntsville, Alabama, United States|James P. Daugherty, MD, Muscle Shoals, Alabama, United States|Alaska Cancer Research, Anchorage, Alaska, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Veena Charu, MD, Anaheim, California, United States|Lalita Pandit, MD, Inc, Fountain Valley, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Warren Paroly, MD, Oceanside, California, United States|Swarna S. Chanduri, MD, Pomona, California, United States|Southwest Cancer Care Medical Group, Poway, California, United States|Mile High Oncology, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Pasco Hernando Oncology Associates PA, Brooksville, Florida, United States|Lucio Gordan, MD, Gainesville, Florida, United States|Citrus Hematology and Oncology Center, Inverness, Florida, United States|Nature Coast Clinical Research, LLC, Inverness, Florida, United States|Jorge G. Otoya, MD, Kissimmee, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Joliet Oncology Hematology Associates, Joliet, Illinois, United States|Indiana Hematology Oncology Consultants, Indianapolis, Indiana, United States|Northern Indiana Oncology Associates, South Bend, Indiana, United States|Kansas City Cancer Centers, Southwest, Overland Park, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Medical Oncology, LLC, Baton Rouge, Louisiana, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Chesapeake Oncology Hematology Associates (Tate Center), Glen Burnie, Maryland, United States|Josephine Ford Cancer Center -- Downriver, Brownstown, Michigan, United States|Michael McKenzie, DO, Clinton Township, Michigan, United States|Henry Ford Medical Center -- Fairlane, Dearborn, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Youssef Hanna, MD, Port Huron, Michigan, United States|Cancer and Transplant Consultants, PLC, Rochester Hills, Michigan, United States|Cancer Care Associates, Rochester Hills, Michigan, United States|Cancer Care Associates, PC, Royal Oak, Michigan, United States|Hematology Oncology Consultants, Royal Oak, Michigan, United States|Jeffrey H. Margolis, MD, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Michigan Hematology and Oncology Institute, Southgate, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|Mitchell Folbe, MD, PC, Troy, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Henry Ford Medical Center, West Bloomfield, Michigan, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Arch Medical Services, Inc., St. Louis, Missouri, United States|Billings Clinic, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|George A. Zervos, MD, Glen Head, New York, United States|Northwestern Carolina Oncology Hematology, Hickory, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|Gabrail Cancer Center, Dover, Ohio, United States|Dayton Hematology and Oncology, Kettering, Ohio, United States|Mukesh C. Bhatt, MD, Medina, Ohio, United States|Trilogy Cancer Center, Wooster, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Northwest Cancer Specialists, Northrup, Portland, Oregon, United States|Shatish A. Shah, MD, Gettysburg, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Rittenhouse Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|Chester County Hematology / Oncology Services, West Chester, Pennsylvania, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|Palmetto Hematology Oncology, PC, Spartanburg, South Carolina, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Cancer Center / Denton, Denton, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology, PA, Ft. Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Ft. Worth, Texas, United States|Texas Cancer Center of Mesquite, Mesquite, Texas, United States|Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Oncology Cancer Center--Sugar Land, Sugar Land, Texas, United States|Annandale-Fairfax Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|Peninsula Cancer Institute, Gloucester, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Peninsula Cancer Institute, Williamsburg, Virginia, United States|Masoom Kandahari, MD, PC, Woodbridge, Virginia, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Jay L. Wittenkeller, MD, Spokane, Washington, United States|Cancer Care Northwest Research, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CC[C@H](N)C(=O)N1CCC[C@H]1B(O)O,0,,_TALABOSTAT,,Terminated,NCT00290017,"CARCINOMA, NON-SMALL-CELL LUNG|LUNG CANCER|NEOPLASMS, LUNG|NEOPLASMS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Marshall Schreeder, MD, Huntsville, Alabama, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Heritage Physician Group-Oncology, Hot Springs, Arkansas, United States|Raul R. Mena, MD, Burbank, California, United States|Pacific Coast Hematology / Oncology Medical Group, Inc., Fountain Valley, California, United States|Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States|Antelope Valley Cancer Center, Lancaster, California, United States|Warren Paroly, MD, Oceanside, California, United States|Southwest Cancer Care Medical Group, Poway, California, United States|Mile High Oncology, Denver, Colorado, United States|Medical Specialists of Fairfield, Fairfield, Connecticut, United States|Northwestern Connecticut Oncology Hematology Associates, LLP, Torrington, Connecticut, United States|Lucio Gordan, MD, Gainesville, Florida, United States|Cancer and Blood Disease Center, Lecanto, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Center of Florida, Ocoee, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|North Idaho Cancer Center, Coeur d'Alene, Idaho, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|American Health Network of Indiana--Hematology/Oncology, Indianapolis, Indiana, United States|Arnett Cancer Center, Lafayette, Indiana, United States|Northern Indiana Oncology Associates, South Bend, Indiana, United States|Associated Physicians and Surgeons, LLC, Terre Haute, Indiana, United States|HUX Cancer Center/Union Hospital, Terre Haute, Indiana, United States|Kansas City Cancer Center, LLC, Overland Park, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Chesapeake Oncology Hematology Associates (Tate Center), Glen Burnie, Maryland, United States|Carroll County Cancer Center, Westminster, Maryland, United States|Fallon Clinic, Inc. at Worcester Medical Center, Worcester, Massachusetts, United States|Michael McKenzie, DO, Clinton Township, Michigan, United States|Youssef Hanna, MD, Port Huron, Michigan, United States|Cancer and Transplant Consultants, PLC, Rochester Hills, Michigan, United States|Cancer Care Associates, Rochester Hills, Michigan, United States|Cancer Care Associates, PC, Royal Oak, Michigan, United States|Hematology Oncology Consultants, Royal Oak, Michigan, United States|Jeffrey H. Margolis, MD, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Dr. Folbe, MD/PC, Troy, Michigan, United States|William Beaumont Hospital, Troy, Michigan, United States|Minnesota Oncology Hematology, PA, Burnsville, Minnesota, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|St. Joseph Oncology, Inc., St. Joseph, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Hunterdon Regional Cancer Center, Flemington, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Hematology Oncology Associates, SJ, PA, Mount Holly, New Jersey, United States|Capital Health System, Trenton, New Jersey, United States|Mercer Bucks Oncology/Hematology, Trenton, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|Northwestern Carolina Oncology & Hematology, PA, Hickory, North Carolina, United States|Eugene Paschold, MD, Winston Salem, North Carolina, United States|Piedmont Hematology Oncology / Winston-Salem, Winston-Salem, North Carolina, United States|Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States|Dayton Oncology & Hematology, PA, Kettering, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Satish A. Shah, MD, Gettysburg, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Hematology-Oncology Group, PC, Langhorne, Pennsylvania, United States|St. Mary Medical Center--Research Center, Langhorne, Pennsylvania, United States|Paoli Hospital, Paoli, Pennsylvania, United States|Rittenhouse Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|Pottstown Memorial Medical Center, Pottstown, Pennsylvania, United States|Bux-Mont Oncology-Hematology, Sellersville, Pennsylvania, United States|Grandview Hospital, Sellersville, Pennsylvania, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Charleston Hematology Oncology, PA, Charleston, South Carolina, United States|Palmetto Hematology Oncology PC, Spartanburg, South Carolina, United States|Associates in Oncology and Hematology, Chattanooga, Tennessee, United States|McLeod Cancer and Blood Center, Johnson City, Tennessee, United States|University of Tennessee, Knoxville, Tennessee, United States|Texas Cancer Center, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Texas Cancer Center / Denton, Denton, Texas, United States|El Paso Cancer Treatment Center--East, El Paso, Texas, United States|Texas Oncology, PA, El Paso, Texas, United States|Texas Oncology, PA, Ft. Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Ft. Worth, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Texas Oncology, PA, Mesquite, Texas, United States|Texas Oncology, PA / Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Texas Oncology Cancer Center--Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Cancer Outreach Associates, PC / Outreach Clinical Trial Consortium LLC, Abingdon, Virginia, United States|Fairfax Northern Virginia Hematology / Oncology, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Physicians, Inc., Richmond, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Salem, Virginia, United States|Luke Walker, MD, Everett, Washington, United States|Cascade Cancer Center, Kirkland, Washington, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Medical Consultants, Ltd., Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00953459,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00906360,METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER|UNTREATED METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC.O=C(O)CC(O)(CC(=O)O)C(=O)O.O=C(O)CC(O)(CC(=O)O)C(=O)O,0,,_BIRICODAR_DICITRATE,WO-2003080171-A1,Terminated,NCT00003847,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fallon Clinic Inc., Worcester, Massachusetts, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",A61K51/0476,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DOXORUBICIN_HYDROCHLORIDE,4003996,Terminated,NCT00003847,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fallon Clinic Inc., Worcester, Massachusetts, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00003847,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Fallon Clinic Inc., Worcester, Massachusetts, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O,0,,_ESUBERAPROST,US-20120190637-A1,Terminated,NCT03657095,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Beverly Hills, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of California Los Angeles UCLA, Los Angeles, California, United States|West Los Angeles VA Healthcare Center, Los Angeles, California, United States|Santa Barbara Pulmonary Associates, Santa Barbara, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Allianz Research Institute, Westminster, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Aurora Denver Cardiology Associates, Denver, Colorado, United States|South Denver Cardiology Associates, Littleton, Colorado, United States|Bay Area Cardiology Research, Brandon, Florida, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Florida Hospital, Orlando, Florida, United States|South Miami Heart Specialists, South Miami, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Emory University, Atlanta, Georgia, United States|Pulmonary & Critical Care of Atlanta, Atlanta, Georgia, United States|Georgia Clinical Research, Austell, Georgia, United States|Indiana University Health North Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Louisville Research Foundation, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beaumont Health, Troy, Michigan, United States|Albany Medical Center, Albany, New York, United States|The Mount Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The University of Toledo, Toledo, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Anderson Pharmaceutical Research, LLC, Anderson, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Scott & White Memorial Hospital, Temple, Texas, United States|Sentara Cardiovascular Research Institute, Norfolk, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,32.7488,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C(O)[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,,_TRIMETREXATE_GLUCURONATE,,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Terminated,NCT00227617,GASTROINTESTINAL CARCINOID TUMOR|ISLET CELL TUMOR|LUNG CANCER|NEOPLASTIC SYNDROME|NEUROENDOCRINE TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Univeristy of California, San Francisco, San Francisco, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,,_LEUCOVORIN,4148999,Withdrawn,NCT03169738,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1.O=S(=O)(O)CCO,0,,_PENTAMIDINE_ISETHIONATE,,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],0,,_LEUCOVORIN_CALCIUM,4500711,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
CC(O)C(=O)O.Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,0,,_MILRINONE_LACTATE,WO-2000066123-A1,Terminated,NCT01088997,PERSISTENT FETAL CIRCULATION SYNDROME,All,up to 10 Days   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Children's Hospital of Michigan/Hutzel Women's Hospital, Detroit, Michigan, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,32.7488,238.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O,0,,_IRINOTECAN_HYDROCHLORIDE,,Terminated,NCT01935947,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT01935947,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00049608,BREAST CANCER|COLORECTAL CANCER|LUNG CANCER|PANCREATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Masking: None (Open Label)|Primary Purpose: Treatment,"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT02145078,RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00619021,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT01282333,ADVANCED ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|REGIONAL TRANSITIONAL CELL CANCER OF THE RENAL PELVIS AND URETER|STAGE III BLADDER CANCER|STAGE III PANCREATIC CANCER|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV BLADDER CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV PANCREATIC CANCER|TRANSITIONAL CELL CARCINOMA OF THE BLADDER|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT02607423,STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT01971489,ADULT SOLID NEOPLASM|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT01935947,RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Medical University of South Carolina, Charleston, South Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT00573989,HEAD AND NECK CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT02145078,RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT00438204,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT00280748,LUNG CANCER|METASTATIC CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alamance Oncology/Hematology Associates, LLP, Burlington, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Terminated,NCT02134912,ADENOCARCINOMA OF THE LUNG|LARGE CELL LUNG CANCER|RECURRENT NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Memorial Hospital Colorado Springs, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer, Sandpoint, Idaho, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Reid Health, Richmond, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Central Care Cancer Center-Carrie J Babb Cancer Center, Bolivar, Missouri, United States|CoxHealth Cancer Center, Branson, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital-Joplin, Joplin, Missouri, United States|Phelps County Regional Medical Center, Rolla, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Hematology and Oncology, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Faith Regional Medical Offices West, Norfolk, Nebraska, United States|Great Plains Regional Medical Center, North Platte, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hemotology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Regional West Medical Center, Scottsbluff, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire, United States|Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire, United States|Orange Regional Medical Center, Middletown, New York, United States|Asheville Hematology-Oncology Associates, Asheville, North Carolina, United States|Park Ridge Hospital Breast Health Center, Hendersonville, North Carolina, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Miami Valley Hospital South, Centerville, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Cancer Center, Springfield, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|SWOG, Portland, Oregon, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Withdrawn,NCT02607423,STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+],0,,_PEMETREXED_DISODIUM,WO-2001062760-A2,Withdrawn,NCT01105390,ADVANCED MALIGNANT MESOTHELIOMA|EPITHELIAL MESOTHELIOMA|RECURRENT MALIGNANT MESOTHELIOMA|SARCOMATOUS MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)C[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,0,,_SOLITHROMYCIN,,Terminated,NCT02605122,COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA,All,2 Months to 17 Years   (Child),Industry|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Little Rock, Arkansas, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Washington, District of Columbia, United States|Tampa, Florida, United States|Louisville, Kentucky, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Toledo, Ohio, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Memphis, Tennessee, United States|Amarillo, Texas, United States|Houston, Texas, United States|Splendora, Texas, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Roanoke, Virginia, United States|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Vratsa, Bulgaria|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Cegléd, Hungary|Debrecen, Hungary|Gyor, Hungary|Gyula, Hungary|Mosdós, Hungary|Nagykanizsa, Hungary|Nyiregyhaza, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Torokbalint, Hungary|Veszprém, Hungary|Caloocan City, Philippines|Cebu City, Philippines|Davao City, Philippines|Iloilo, Philippines|Manila, Philippines|Muntinlupa, Philippines|Quezon City, Philippines|Quezon City, Philippines|Esplugues de Llobregat, Barcelona, Spain|San Sebastian, Guipuzcoa, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|London, United Kingdom|London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1
CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)C[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C,0,,_SOLITHROMYCIN,,Terminated,NCT02628769,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"45 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Muscle Lab, Respiratory Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1
CO/N=C1\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2,0,,_ZABOFLOXACIN,WO-2008127060-A1,Terminated,NCT01081964,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Huntsville, Alabama, United States|Toney, Alabama, United States|Ft. Myers, Florida, United States|Eagle, Idaho, United States|Evansville, Indiana, United States|Keego Harbor, Michigan, United States|Belvidere, New Jersey, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Springfield, Ohio, United States|Gresham, Oregon, United States|Warminster, Pennsylvania, United States|Tyler, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,0,,_INSULIN_DETEMIR,,Terminated,NCT00639626,CYSTIC FIBROSIS RELATED DIABETES,All,"16 Years to 45 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nationwide Children's Hospital, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,0,,_INSULIN_DETEMIR,,Terminated,NCT00322257,"DIABETES|DIABETES MELLITUS, TYPE 1",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Tuscaloosa, Alabama, United States|Novo Nordisk Investigational Site, Concord, California, United States|Novo Nordisk Investigational Site, Encino, California, United States|Novo Nordisk Investigational Site, Escondido, California, United States|Novo Nordisk Investigational Site, Fresno, California, United States|Novo Nordisk Investigational Site, Inglewood, California, United States|Novo Nordisk Investigational Site, La Jolla, California, United States|Novo Nordisk Investigational Site, Mission Viejo, California, United States|Novo Nordisk Investigational Site, Poway, California, United States|Novo Nordisk Investigational Site, San Mateo, California, United States|Novo Nordisk Investigational Site, Santa Barbara, California, United States|Novo Nordisk Investigational Site, Tustin, California, United States|Novo Nordisk Investigational Site, Vista, California, United States|Novo Nordisk Investigational Site, Walnut Creek, California, United States|Novo Nordisk Investigational Site, Aurora, Colorado, United States|Novo Nordisk Investigational Site, Colorado Springs, Colorado, United States|Novo Nordisk Investigational Site, New Britain, Connecticut, United States|Novo Nordisk Investigational Site, Norwalk, Connecticut, United States|Novo Nordisk Investigational Site, Waterbury, Connecticut, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Hollywood, Florida, United States|Novo Nordisk Investigational Site, Lake Mary, Florida, United States|Novo Nordisk Investigational Site, Melbourne, Florida, United States|Novo Nordisk Investigational Site, Merritt Island, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, West Palm Beach, Florida, United States|Novo Nordisk Investigational Site, Athens, Georgia, United States|Novo Nordisk Investigational Site, Atlanta, Georgia, United States|Novo Nordisk Investigational Site, Savannah, Georgia, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, United States|Novo Nordisk Investigational Site, Idaho Falls, Idaho, United States|Novo Nordisk Investigational Site, Chicago, Illinois, United States|Novo Nordisk Investigational Site, Peoria, Illinois, United States|Novo Nordisk Investigational Site, Springfield, Illinois, United States|Novo Nordisk Investigational Site, Lafayette, Indiana, United States|Novo Nordisk Investigational Site, New Albany, Indiana, United States|Novo Nordisk Investigational Site, Des Moines, Iowa, United States|Novo Nordisk Investigational Site, Shawnee Mission, Kansas, United States|Novo Nordisk Investigational Site, Topeka, Kansas, United States|Novo Nordisk Investigational Site, Lexington, Kentucky, United States|Novo Nordisk Investigational Site, Baton Rouge, Louisiana, United States|Novo Nordisk Investigational Site, Scarborough, Maine, United States|Novo Nordisk Investigational Site, Hyattsville, Maryland, United States|Novo Nordisk Investigational Site, Springfield, Massachusetts, United States|Novo Nordisk Investigational Site, Waltham, Massachusetts, United States|Novo Nordisk Investigational Site, Bloomington, Minnesota, United States|Novo Nordisk Investigational Site, Duluth, Minnesota, United States|Novo Nordisk Investigational Site, Minneapolis, Minnesota, United States|Novo Nordisk Investigational Site, Tupelo, Mississippi, United States|Novo Nordisk Investigational Site, Jefferson City, Missouri, United States|Novo Nordisk Investigational Site, Kansas City, Missouri, United States|Novo Nordisk Investigational Site, Saint Louis, Missouri, United States|Novo Nordisk Investigational Site, Butte, Montana, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Dover, New Hampshire, United States|Novo Nordisk Investigational Site, Hampton, New Hampshire, United States|Novo Nordisk Investigational Site, Lawrenceville, New Jersey, United States|Novo Nordisk Investigational Site, Albany, New York, United States|Novo Nordisk Investigational Site, New Hyde Park, New York, United States|Novo Nordisk Investigational Site, Rochester, New York, United States|Novo Nordisk Investigational Site, Asheville, North Carolina, United States|Novo Nordisk Investigational Site, Greenville, North Carolina, United States|Novo Nordisk Investigational Site, Cincinnati, Ohio, United States|Novo Nordisk Investigational Site, Cleveland, Ohio, United States|Novo Nordisk Investigational Site, Dayton, Ohio, United States|Novo Nordisk Investigational Site, Kettering, Ohio, United States|Novo Nordisk Investigational Site, Mentor, Ohio, United States|Novo Nordisk Investigational Site, Medford, Oregon, United States|Novo Nordisk Investigational Site, Hershey, Pennsylvania, United States|Novo Nordisk Investigational Site, Norristown, Pennsylvania, United States|Novo Nordisk Investigational Site, Philadelphia, Pennsylvania, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Chattanooga, Tennessee, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Midland, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Ogden, Utah, United States|Novo Nordisk Investigational Site, Olympia, Washington, United States|Novo Nordisk Investigational Site, Renton, Washington, United States|Novo Nordisk Investigational Site, Spokane, Washington, United States|Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States|Novo Nordisk Investigational Site, Victoria, British Columbia, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Laval, Quebec, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Gatineau, Canada|Novo Nordisk Investigational Site, Mississauga, Canada|Novo Nordisk Investigational Site, Penticton, Canada|Novo Nordisk Investigational Site, Red Deer, Canada|Novo Nordisk Investigational Site, St John's, Canada|Novo Nordisk Investigational Site, Vancouver, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,0,,_INSULIN_DETEMIR,,Terminated,NCT00331604,"DIABETES|DIABETES MELLITUS, TYPE 2",All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Campinas, Brazil|Novo Nordisk Investigational Site, Higienopolis, Brazil|Novo Nordisk Investigational Site, Porto Alegre, Brazil|Novo Nordisk Investigational Site, Sao Paulo, Brazil|Novo Nordisk Investigational Site, Hillerød, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, Århus C, Denmark|Novo Nordisk Investigational Site, Brest, France|Novo Nordisk Investigational Site, GRENOBLE cedex, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, France|Novo Nordisk Investigational Site, Nanterre, France|Novo Nordisk Investigational Site, Narbonne, France|Novo Nordisk Investigational Site, NEVERS cedex, France|Novo Nordisk Investigational Site, Strasbourg, France|Novo Nordisk Investigational Site, TOULOUSE cedex, France|Novo Nordisk Investigational Site, Bad Harzburg, Germany|Novo Nordisk Investigational Site, Bad Kreuznach, Germany|Novo Nordisk Investigational Site, Bad Lauterberg, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Dresden, Germany|Novo Nordisk Investigational Site, Friedrichsthal, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Hamburg, Germany|Novo Nordisk Investigational Site, Herrenberg, Germany|Novo Nordisk Investigational Site, Hohenmölsen, Germany|Novo Nordisk Investigational Site, Neumünster, Germany|Novo Nordisk Investigational Site, Neuwied, Germany|Novo Nordisk Investigational Site, Schkeuditz, Germany|Novo Nordisk Investigational Site, Speyer, Germany|Novo Nordisk Investigational Site, St. Ingbert, Germany|Novo Nordisk Investigational Site, Völklingen, Germany|Novo Nordisk Investigational Site, Warburg, Germany|Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong|Novo Nordisk Investigational Site, Beer Sheva, Israel|Novo Nordisk Investigational Site, Holon, Israel|Novo Nordisk Investigational Site, Jerusalem, Israel|Novo Nordisk Investigational Site, Bari, Italy|Novo Nordisk Investigational Site, Catania, Italy|Novo Nordisk Investigational Site, Catanzaro, Italy|Novo Nordisk Investigational Site, Milano, Italy|Novo Nordisk Investigational Site, Perugia, Italy|Novo Nordisk Investigational Site, Pescara, Italy|Novo Nordisk Investigational Site, Pisa, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, Roma, Italy|Novo Nordisk Investigational Site, San Giovanni Rotondo, Italy|Novo Nordisk Investigational Site, Verona, Italy|Novo Nordisk Investigational Site, Singapore, Singapore|Novo Nordisk Investigational Site, Singapore, Singapore|Novo Nordisk Investigational Site, Almería, Spain|Novo Nordisk Investigational Site, Cáceres, Spain|Novo Nordisk Investigational Site, Elche, Spain|Novo Nordisk Investigational Site, Granada, Spain|Novo Nordisk Investigational Site, Lugo, Spain|Novo Nordisk Investigational Site, Mostoles - Madrid -, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valladolid, Spain|Novo Nordisk Investigational Site, Xátiva, Spain|Novo Nordisk Investigational Site, Taichung City, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Aberdeen, United Kingdom|Novo Nordisk Investigational Site, Ayr, United Kingdom|Novo Nordisk Investigational Site, Bristol, United Kingdom|Novo Nordisk Investigational Site, Cosham, United Kingdom|Novo Nordisk Investigational Site, Edgbaston, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Livingstone, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Plymouth, United Kingdom|Novo Nordisk Investigational Site, Salford, United Kingdom|Novo Nordisk Investigational Site, Sheffield, United Kingdom|Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2.Cl,0,,_ISEGANAN_HYDROCHLORIDE,,Terminated,NCT00118781,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Barnes-Jewish Hospital, St. Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,1,1
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2,0,,_ISEGANAN,,Terminated,NCT00118781,PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Barnes-Jewish Hospital, St. Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,1,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1.O=C(O)/C=C\C(=O)O,0,,_CEDIRANIB_MALEATE,EP-1699782-B1,Terminated,NCT00937482,MALE BREAST CANCER|STAGE IV BREAST CANCER|STAGE IV MELANOMA|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV RENAL CELL CANCER|STAGE IVA COLON CANCER|STAGE IVA RECTAL CANCER|STAGE IVB COLON CANCER|STAGE IVB RECTAL CANCER|TUMORS METASTATIC TO BRAIN,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,66.1368816608144,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1.O=C(O)/C=C\C(=O)O,0,,_CEDIRANIB_MALEATE,EP-1699782-B1,Terminated,NCT02899728,EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,66.1368816608144,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl,0,,_AMRUBICIN_HYDROCHLORIDE,6376469,Terminated,NCT00286169,SMALL-CELL LUNG CANCER,All,70 Years and older   (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chubu Region Site, Chubu, Japan|Chugoku Region Site, Chugoku, Japan|Hokkaido Region Site, Hokkaido, Japan|Kanto Region Site, Kanto, Japan|Kinki Region Site, Kinki, Japan|Kyushu Region Site, Kyushu, Japan|Shikoku Region Site, Shikoku, Japan|Tohoku Region Site, Tohoku, Japan",C07H15/252,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,22.965563974619602,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,,_FOSAPREPITANT_DIMEGLUMINE,,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,1
Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,0,,_PALONOSETRON_HYDROCHLORIDE,5202333,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,50.0,22.7355797860325,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,,_FOSAPREPITANT,,Terminated,NCT00895245,NAUSEA AND VOMITING|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00121420,NEOPLASM METASTASIS|BRAIN NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix, Arizona, United States|Aurora, Colorado, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Sherbrooke, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00080028,HEAD AND NECK CANCER|OROPHARYNX CANCER|LARYNX CANCER|HYPOPHARYNX CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States|University of Texas, San Antonio Health Science Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00365183,NON-SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntington Beach, California, United States|Long Beach, California, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Armonk, New York, United States|Columbus, Ohio, United States|Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00373204,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wilshire Oncology Medical Group, La Verne, California, United States|University of Rochester, Rochester, New York, United States|Tri-County Hematology & Oncology Associates, Canton, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Cancer Specialists of Tidewater, Chesapeake, Virginia, United States|Cancer Centre of Southeastern Ontario, Kingston, Ontario, Canada|Hospital Charles Lemoyne, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation|Blokhin Cancer Research Center (Dept. of Chemotherapy), Moscow, Russian Federation|Blokhin Cancer Research Center (Dept. of Clinical Pharmacology and Chemotherapy), Moscow, Russian Federation|Central Clinical Hospital, Moscow, Russian Federation|Moscow Oncology Hospital #62, Moscow, Russian Federation|Samara Regional Oncology Center, Samara, Russian Federation|St. Petersburg City Oncology Center, St. Petersburg, Russian Federation|Regional Oncology Dispensary, Yaroslavl, Russian Federation|Clinic for Pulmonary Diseases, Military Medical Academy, Belgrade, Serbia|Clinic for Pulmonary Diseases, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1.O=C(O)/C=C\C(=O)O,0,,_PAFURAMIDINE_MALEATE,,Terminated,NCT00302341,"PNEUMONIA, INTERSTITIAL PLASMA CELL|PNEUMOCYSTIS CARINII PNEUMONIA|PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California, San Francisco, California, United States|The University of Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|NYU School of Medicine, New York, New York, United States|UNC AIDS Clinical Trials, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Medical University of SC, Charleston, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl,0,,_PAZOPANIB_HYDROCHLORIDE,US-20070292513-A1,Terminated,NCT01208064,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universitair Ziekenhuis Gent, Gent, Belgium|Centre Hospitalier Regional De La Citadelle, Liege, Belgium|Clinique et Maternité Sainte Elisabeth, Namur, Belgium|National Cancer Institute, Cairo, Egypt|Centre Georges-Francois-Leclerc, Dijon, France|Assistance Publique - Hôpitaux de Marseille - Assistance Publique - Hôpitaux de Marseille - Hopital Nord, Marseille, France|Klinik Loewenstein, Loewenstein, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|University General Hospital Heraklion, Heraklion, Greece|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Isala Klinieken, Zwolle, Netherlands|University Clinic Golnik, Golnik, Slovenia|Royal Marsden - Surrey, Sutton, England, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Guy's and St Thomas' NHS, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|King's Mill Hospital, Sutton-in-Ashfield, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom",A61P27/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,54.539107579211,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,0,,_CO-TRIMOXAZOLE,WO-2001079554-A1,Terminated,NCT02759120,IDIOPATHIC PULMONARY FIBROSIS,All,"40 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|University of California David Medical Center, Sacramento, California, United States|Stanford, Stanford, California, United States|Loyola University Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Kansas, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Columbia University, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University of Rochester, Rochester, New York, United States|Mayo Clinic, Rochester, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State, Columbus, Ohio, United States|Pennsylvania State University, Hershey, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas at San Antonio, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|INOVA, Falls Church, Virginia, United States|Washington University, Seattle, Washington, United States",C12Q1/6883 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,38.0,32.7488,32.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,,_FULVESTRANT,,Terminated,NCT00592007,NON SMALL CELL LUNG CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Moores UCSD Cancer Center, La Jolla, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,,_FULVESTRANT,,Terminated,NCT00932152,NON-SMALL CELL LUNG CANCER|POSTMENOPAUSAL WOMEN,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0
C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,0,,_FULVESTRANT,,Withdrawn,NCT03169738,NON SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,1,0
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.O=S(=O)(O)O,0,,_GENTAMICIN_SULFATE,,Terminated,NCT01570192,BACTERIAL PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","InClin, Inc., San Mateo, California, United States|UFL Department of Medicine: Pulmonary, Critical Care and Sleep Medicine, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|JMI Laboratories, North Liberty, Iowa, United States|Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical Center of Cornell University, New York, New York, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere, Paris, France|Hannover Clinical Trial Center GmbH, Hannover, Germany|Hospital Vall d'Hebron, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O,0,,_AMIKACIN_SULFATE,5620865,Terminated,NCT01570192,BACTERIAL PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","InClin, Inc., San Mateo, California, United States|UFL Department of Medicine: Pulmonary, Critical Care and Sleep Medicine, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|JMI Laboratories, North Liberty, Iowa, United States|Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical Center of Cornell University, New York, New York, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|Institut de Cardiologie, Groupe Hospitalier Pitie-Salpetriere, Paris, France|Hannover Clinical Trial Center GmbH, Hannover, Germany|Hospital Vall d'Hebron, Barcelona, Spain",C12Q1/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,29.3394114868888,120.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,0,,_IMATINIB_MESYLATE,WO-2002018368-A1,Terminated,NCT00323362,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,0,,_VINORELBINE_TARTRATE,5994409,Terminated,NCT00863512,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Regional Medical Center, Anniston, Alabama, United States|UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States|Glendale Memorial Hospital Comprehensive Cancer Center, Glendale, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Pismo Beach, California, United States|Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center, Pomona, California, United States|Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ella Milbank Foshay Cancer Center at Jupiter Medical Center, Jupiter, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States|Resurrection Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States|Maine Center for Cancer Medicine and Blood Disorders - Scarborough, Scarborough, Maine, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Cancer Institute at St. Joseph Medical Center, Towson, Maryland, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Michiana Hematology Oncology PC - Niles, Niles, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, St. Joseph, Michigan, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Saint Francis Hospital Cancer Center, Poughkeepsie, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Faxton Regional Cancer Center, Utica, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Mercy Cancer Center at Mercy Medical Center, Canton, Ohio, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|St. Luke's Cancer Network at St. Luke's Hospital, Bethlehem, Pennsylvania, United States|Easton Regional Cancer Center at Easton Hospital, Easton, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Jameson Memorial Hospital - North Campus, New Castle, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Lynchburg Hematology-Oncology Clinic, Lynchburg, Virginia, United States|Providence Centralia Hospital, Centralia, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Providence St. Peter Hospital Regional Cancer Center, Olympia, Washington, United States|Good Samaritan Cancer Center, Puyallup, Washington, United States|Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|St. Vincent's Hospital - Melbourne, Fitzroy, Victoria, Australia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,40.0,23.688371424464503,559.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,0,,_OXYTOCIN,3943246,Terminated,NCT02999100,POSTPARTUM HAEMORRHAGE,Female,18 Years to 40 Years   (Adult),Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Clayton, Victoria, Australia|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom",A61K38/095,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl,0,,_DOXEPIN_HYDROCHLORIDE,4370324,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,28.2552003121213,135.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
O=C([O-])c1ccccc1.[Na+],0,,_SODIUM_BENZOATE,3932316,Terminated,NCT01349205,OBSTRUCTIVE SLEEP APNEA|ENLARGEMENT OF TONSIL OR ADENOID,All,2 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Memorial Hermann Hospital, Houston, Texas, United States",C11D3/2079,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.996180619725196,2725.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cc2c(cc1O)CCN[C@]21CS[C@H]2c3c(OC(C)=O)c(C)c4c(c3[C@@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,,_TRABECTEDIN,,Terminated,NCT00027508,MALIGNANT MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Industry|NIH,Primary Purpose: Treatment,"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
COc1cc2c(cc1O)CCN[C@]21CS[C@H]2c3c(OC(C)=O)c(C)c4c(c3[C@@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,,_TRABECTEDIN,,Withdrawn,NCT03496519,"SOLID TUMOR, ADULT",All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT01803269,EXTENSIVE STAGE SMALL CELL LUNG CANCER|RECURRENT SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Ingalls Park, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00087048,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl,0,,_VERAPAMIL_HYDROCHLORIDE,4753802,Terminated,NCT03102190,SINUSITIS|NASAL POLYPS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts Eye and Ear, Boston, Massachusetts, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,27.3352635577732,466.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,0,,_ESCITALOPRAM_OXALATE,WO-2003011278-A1,Terminated,NCT00387348,COLORECTAL CANCER|DEPRESSION|ESOPHAGEAL CANCER|EXTRAHEPATIC BILE DUCT CANCER|FATIGUE|GALLBLADDER CANCER|GASTRIC CANCER|LIVER CANCER|LUNG CANCER|PANCREATIC CANCER,All,"35 Years to 85 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Massachusetts General Hospital, Boston, Massachusetts, United States",A61P25/24 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1,0,,_NEMIRALISIB,US-20100280045-A1,Terminated,NCT03345407,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Daytona Beach, Florida, United States|GSK Investigational Site, Saint Petersburg, Florida, United States|GSK Investigational Site, Adairsville, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Columbia, Maryland, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Gastonia, North Carolina, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Rapid City, South Dakota, United States|GSK Investigational Site, Abingdon, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Morgantown, West Virginia, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Florida, Buenos Aires, Argentina|GSK Investigational Site, Mar del Plata, Buenos Aires, Argentina|GSK Investigational Site, San Rafael, Mendoza, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Santo Tome, Santa Fe, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Mendoza, Argentina|GSK Investigational Site, Tucuman, Argentina|GSK Investigational Site, Gosford, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, Woodville South, South Australia, Australia|GSK Investigational Site, Clayton, Victoria, Australia|GSK Investigational Site, Murdoch, Western Australia, Australia|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Windsor, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Quebec City, Quebec, Canada|GSK Investigational Site, St-Charles-Borromée, Quebec, Canada|GSK Investigational Site, Brest cedex, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Montpellier cedex 5, France|GSK Investigational Site, Rennes Cedex 9, France|GSK Investigational Site, Vandoeuvre-lès-Nancy cedex, France|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Bamberg, Bayern, Germany|GSK Investigational Site, Rosenheim, Bayern, Germany|GSK Investigational Site, Potsdam, Brandenburg, Germany|GSK Investigational Site, Darmstadt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Rheine, Nordrhein-Westfalen, Germany|GSK Investigational Site, Warendorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Geesthacht, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Schleswig, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Reggio Emilia, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Tradate (VA), Lombardia, Italy|GSK Investigational Site, Catania, Sicilia, Italy|GSK Investigational Site, Messina, Sicilia, Italy|GSK Investigational Site, Negrar, Veneto, Italy|GSK Investigational Site, Daejon, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|GSK Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Zapopan, Jalisco, Mexico|GSK Investigational Site, Monterrey, Nuevo León, Mexico|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Breda, Netherlands|GSK Investigational Site, Eindhoven, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Harderwijk, Netherlands|GSK Investigational Site, Hoorn, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Elblag, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lubin, Poland|GSK Investigational Site, Olawa, Poland|GSK Investigational Site, Ruda Slaska, Poland|GSK Investigational Site, Slupsk, Poland|GSK Investigational Site, Sosnowiec, Poland|GSK Investigational Site, Tarnow, Poland|GSK Investigational Site, Bucarest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Bucharest, Romania|GSK Investigational Site, Cluj Napoca, Romania|GSK Investigational Site, Comuna Alexandru Cel Bun, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Oradea, Romania|GSK Investigational Site, Ramnicu Valcea, Romania|GSK Investigational Site, Suceava, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Barnaul, Russian Federation|GSK Investigational Site, Belgorod, Russian Federation|GSK Investigational Site, Blagoveshchensk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Ivanovo, Russian Federation|GSK Investigational Site, Kemerovo, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Novgorod, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, Perm, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, Saratov, Russian Federation|GSK Investigational Site, Tomsk, Russian Federation|GSK Investigational Site, Ulyanovsk, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Laredo, Cantabria, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Basurto/Bilbao, Spain|GSK Investigational Site, Cartagena (Murcia), Spain|GSK Investigational Site, Cáceres, Spain|GSK Investigational Site, Elda (Alicante), Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Logroño, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Mérida (Badajoz), Spain|GSK Investigational Site, Orihuela (Alicante), Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Pama de Mallorca, Spain|GSK Investigational Site, Ponferrada (León), Spain|GSK Investigational Site, Pozuelo De Alarcón/Madrid, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Chesterfield, Derbyshire, United Kingdom|GSK Investigational Site, Wishaw, Lanarkshire, United Kingdom|GSK Investigational Site, Blackburn, United Kingdom|GSK Investigational Site, Bradford, United Kingdom|GSK Investigational Site, Edgbaston, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Stockton-on-Tees, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,42.5142200045175,9.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,1,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_CHLORPHENIRAMINE_MALEATE,4256763,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,29.897944516314503,544.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,0,,_DESMOPRESSIN,4613500,Terminated,NCT01530451,NOCTURIA|OBSTRUCTIVE SLEEP APNOEA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Prince of Wales Hospital, Shatin, Hong Kong",A61K9/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,30.489332429824,674.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00726986,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia Presbyterian, New York, New York, United States|Lake/University Ireland Cancer Center, Cleveland, Ohio, United States|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|CCF-Fairview Hospital, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States|UHHS Westlake Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|UH-Monarch, Mayfield Heights, Ohio, United States|UH-Firelands, Sandusky, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Nc1ccc2cc3ccc(N)cc3nc2c1.Nc1ccc2cc3ccc(N)cc3nc2c1.O=S(=O)(O)O,0,,_PROFLAVINE_HEMISULFATE,,Terminated,NCT01456143,SQUAMOUS CELL CARCINOMA|NEOPLASIA|HEAD AND NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Icahn School of Medicine at Mount Sinai, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(C)CCCCCCC/C=C\CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]1C(=O)N2CCCC[C@@H]2C(=O)N[C@@H]([C@H](C)C(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H]([C@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H]1C,0,,_FRIULIMICIN_B,,Terminated,NCT00492271,COMMUNITY ACQUIRED PNEUMONIA|STAPHYLOCOCCAL SKIN INFECTIONS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Swiss Pharma Contract Ltd, Basel, Switzerland",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1
O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,,_TETRAHYDROURIDINE,,Terminated,NCT01479348,HEAD AND NECK NEOPLASMS|LUNG NEOPLASMS|URINARY BLADDER NEOPLASMS|BREAST NEOPLASMS,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Terminated,NCT00800150,CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Terminated,NCT00618540,"HISTIOCYTOSIS, LANGERHANS-CELL",All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Terminated,NCT01212887,"BREAST CANCER|COLORECTAL CANCER|GASTRIC CANCER|LUNG CANCER|OVARIAN CANCER|PANCREATIC CANCER|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Masking: None (Open Label)|Primary Purpose: Treatment,"Christie Hospital, Manchester, England, United Kingdom",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,0,,_FLUDARABINE_PHOSPHATE,4357324,Withdrawn,NCT00006126,BREAST CANCER|KIDNEY CANCER|LUNG CANCER|MELANOMA (SKIN)|TESTICULAR GERM CELL TUMOR,All,"up to 59 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,0,,_CATECHIN,4094969,Terminated,NCT00611650,LUNG CANCER|PRECANCEROUS CONDITION|TOBACCO USE DISORDER,All,"45 Years to 74 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada",A01N25/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,35.9103883036612,1741.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,0,,_PROCALCITONIN,,Terminated,NCT00498121,VENTILATOR ASSOCIATED PNEUMONIA,All,"18 Years and older   (Adult, Older Adult)",Other,Time Perspective: Prospective,"McGill University Health Centre, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1
Cc1cccn2c(=O)c(-c3nnn[nH]3)cnc12,0,,_PEMIROLAST,,Terminated,NCT03119714,ALLERGIC ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Lung and Allergy Research Unit C2-88 Karolinska University Hospital Huddinge, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O,0,,_QUININE_SULFATE,,Terminated,NCT02630472,RHINITIS|SINUSITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,0,,_VERTEPORFIN,,Terminated,NCT02702700,"PLEURAL EFFUSION, MALIGNANT",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Vaud (VD), Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
Cc1occc(=O)c1O,0,,_MALTOL,3940499,Terminated,NCT03371173,"HYPERTENSION, PULMONARY|ANEMIA, IRON DEFICIENCY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hannover Medical School, Hannover, Germany",A23G4/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,17.183104375859802,881.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+],0,,_DENUFOSOL_TETRASODIUM,,Terminated,NCT00425165,CYSTIC FIBROSIS,All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0
CN(C)c1ccc2nc3ccc(=[N+](C)C)cc-3sc2c1.O.O.O.[Cl-],0,,_METHYLENE_BLUE,,Terminated,NCT00159510,SEPSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital #1, Arkhangelsk, Russia, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,0,,_TETRAXETAN,4508625,Terminated,NCT03773133,SMALL CELL LUNG CANCER AND BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"MD Anderson Cancer Center, Houston, Texas, United States|Medical University of Innsbruck, Innsbruck, Austria|University Hospital (UZ) Leuven, Leuven, Belgium|CHU de Marseille - Hôpital la Timone, Marseille, France|CHU de Bordeaux - Hôpital Haut Lévêque, Pessac, France|Universitaetsklinikum Essen, Essen, Germany|University Hospital Basel, Basel, Switzerland|Royal Marsden Hospital - Surrey, Sutton, United Kingdom",B03C1/01,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,17.8730569416209,1632.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,,_LEUPROLIDE_ACETATE,4851211,Terminated,NCT01257802,"LUPUS ERYTHEMATOSUS, SYSTEMIC|SYSTEMIC VASCULITIS|ISOLATED ANGIITIS OF CENTRAL NERVOUS SYSTEM|LUNG DISEASE WITH SYSTEMIC SCLEROSIS|LUNG DISEASE INTERSTITIAL DIFFUSE",Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Michigan, Ann Arbor, Michigan, United States|The Ohio State University, Columbus, Ohio, United States",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,0,,_PIOGLITAZONE_HYDROCHLORIDE,5356913,Terminated,NCT01342770,STAGE IA NON-SMALL CELL LUNG CARCINOMA|STAGE IB NON-SMALL CELL LUNG CARCINOMA|STAGE IIA NON-SMALL CELL LUNG CARCINOMA|STAGE IIB NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,17.8730569416209,190.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,0,,_PIOGLITAZONE_HYDROCHLORIDE,5356913,Withdrawn,NCT00604578,ASTHMA|AIRWAY INFLAMMATION|AIRFLOW OBSTRUCTION|AIRWAY HYPERACTIVITY,All,"18 Years to 75 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Fairfax Hospital, Falls Church, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,17.8730569416209,190.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+],0,,_CROMOLYN_SODIUM,4161516,Terminated,NCT01841307,GASTROESOPHAGEAL REFLUX|RESPIRATORY ASPIRATION|IDIOPATHIC PULMONARY FIBROSIS|LUNG TRANSPLANTATION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"UCSF Airway Clinical Research Center, San Francisco, California, United States",A61K9/1688,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,30.0293640526499,1596.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)(C)/N=C(\NC#N)Nc1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1,0,,_TERBOGREL,EP-0547517-A1,Terminated,NCT02223494,"HYPERTENSION, PULMONARY",All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,29.14228218238561,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1
O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21,0,,_VS-5584,,Terminated,NCT02372227,RELAPSED MALIGNANT MESOTHELIOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Chicago Medical Center, Chicago, Illinois, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University of Leicester, Leicester, United Kingdom|The Institute of Cancer Research, Sutton Surrey, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21,0,,_PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
[C-]#[O+],0,,_CARBON_MONOXIDE,,Terminated,NCT01050712,ILEUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[C-]#[O+],0,,_CARBON_MONOXIDE,,Withdrawn,NCT00180622,HEALTHY NON-SMOKERS|CURRENT SMOKERS|COPD PATIENTS,All,"30 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Observational Model: Other|Time Perspective: Prospective,"Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[C-]#[O+],0,,_CARBON_MONOXIDE,,Withdrawn,NCT01523548,"HYPERTENSION, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Illinois at Chicago Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[C-]#[O+],0,,_CARBON_MONOXIDE,,Withdrawn,NCT00531856,KIDNEY TRANSPLANTATION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Universtiy of CA, San Francisco, San Francisco, California, United States|Northwestern University, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],0,,_INDOCYANINE_GREEN,3959455,Withdrawn,NCT02570958,NON-SMALL CELL LUNG CANCER|THORACIC SURGERY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],0,,_INDOCYANINE_GREEN,3959455,Withdrawn,NCT02423148,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
Cl.Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21,0,,_ENZASTAURIN_HYDROCHLORIDE,,Withdrawn,NCT00469976,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1
CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O,0,,_POLYMYXIN_B,,Withdrawn,NCT02134106,BACTEREMIA|HEALTHCARE-ASSOCIATED PNEUMONIA|VENTILATOR-ASSOCIATED PNEUMONIA,All,"21 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O,0,,_THYMALFASIN,,Withdrawn,NCT02542930,NON-SMALL CELL LUNG CANCER|METASTATIC NON-SMALL CELL LUNG CANCER|RADIOTHERAPY|THYMALFASIN,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O,0,,_THYMALFASIN,,Withdrawn,NCT02542137,SMALL CELL LUNG CANCER|RADIOTHERAPY|THYMALFASIN,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0
CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O,0,,_DALBAVANCIN,,Withdrawn,NCT02269644,COMMUNITY ACQUIRED PNEUMONIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mercury Street Medical Group, Butte, Montana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,1
NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,0,,_FAMOTIDINE,,Withdrawn,NCT02700087,LARYNGOMALACIA|ACID REFLUX|STRIDOR,All,up to 4 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1,0,,_CEFUROXIME_AXETIL,,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,0,,_PSEUDOEPHEDRINE_HYDROCHLORIDE,4181719,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,19.220107189059306,39.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,0,,_PSEUDOEPHEDRINE_HYDROCHLORIDE,4181719,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,19.220107189059306,39.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12,0,,_FLUORESCEIN,US-20100159613-A1,Withdrawn,NCT02628496,LARYNGEAL DYSPLASIA|LARYNGEAL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,, G01N33/582 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,41.5942832501694,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0
CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_PHENIRAMINE_MALEATE,4631284,Withdrawn,NCT02730364,"INFECTIONS, RESPIRATORY TRACT",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.2488141440275,86.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl,0,,_DILTIAZEM_HYDROCHLORIDE,4292068,Withdrawn,NCT01645826,IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION|PRIMARY PULMONARY HYPERTENSION|PULMONARY ARTERIAL HYPERTENSION|FAMILIAL PRIMARY PULMONARY HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of South Florida, Tampa, Florida, United States",A01N43/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.8484979157682,429.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,0,,_CURCUMIN,WO-2002069910-A2,Withdrawn,NCT01048983,NON SMALL CELL LUNG CANCER,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,A61K8/315,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,0,,_ETOPOSIDE_PHOSPHATE,,Withdrawn,NCT01160731,LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_BROMPHENIRAMINE_MALEATE,4269835,Withdrawn,NCT01177852,INFLAMMATION|COUGH|RHINITIS,All,2 Years to 12 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,17.4130885644469,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,0,,_COLCHICINE,4008719,Withdrawn,NCT00000577,ASTHMA|LUNG DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of California at San Diego, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|National Jewish Medical & Research Center, Denver, Colorado, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Wisconsin at Madison, Madison, Wisconsin, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Withdrawn,NCT00198328,HEAD NECK CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inovio Biomedical Corporation, San Diego, California, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,0,,_CLINDAMYCIN,3957983,Withdrawn,NCT01715610,PERITONSILLAR ABSCESS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","London Health Sciences Center, St. Joseph's Hospital, London, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.226164808312195,1162.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Withdrawn,NCT01563601,EXTENSIVE-STAGE SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
Oc1cccc(-c2c3nc(c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4ccc([nH]4)c(-c4cccc(O)c4)c4nc2CC4)C=C3)c1,0,,_TEMOPORFIN,,Withdrawn,NCT01637376,"CARCINOMA, NON-SMALL-CELL-LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
O=c1ncnc2[nH][nH]cc1-2,0,,_ALLOPURINOL,,Withdrawn,NCT00214084,OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"University of Wisconsin, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H]2CSSC[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](CO)NC2=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@H](C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O)[C@@H](C)CC,0,,_ENDOTHELIN,,Withdrawn,NCT02309463,PULMONARY ARTERIAL HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1
N=C1NC(=O)N2CC12,0,,_IMEXON,,Withdrawn,NCT00697060,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC Norris Cotton Cancer Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mary Crowley Research Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=N[O-].[Na+],0,,_SODIUM_NITRITE,,Withdrawn,NCT04401527,COVID-19|ACUTE RESPIRATORY DISTRESS SYNDROME|ACUTE RESPIRATORY FAILURE,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Participating Research Facility, Tampa, Florida, United States|Participating Research Facility, Fort Worth, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
